326552

STIC-EIC1600/2900

From: STIC-EIC1600/2900@uspto.gov
Sent: Monday, March 29, 2010 9:14 AM
To: Underdahl, Thane E. (AU1651)
Cc: STIC-EIC1600/2900
Subject: Confirmation Receipt: 1600 Search Request - 10597378

This is an automated email confirming that your 1600 Search Request has been received by STIC's EIC1600.

Thank you for using STIC services.

Requester

Name: UNDERDAHL, THANE E
Organization: TC 1600
Art Unit: 1651
Employee Num
Office Locatio
Phone Numbe
Email: thane.u

Request Detail

Attachment: CoQ10 Pic.png

Case/Application number: **10597378** PALM
Priority App. Filing Date: **10597378**
Format for Search Results: **SCORE**

Meaning of unusual acronyms or initialisms:
CoQ10= Coenzyme Q10=ubiquinone=ubidecarenone or simply coenzyme Q. It has a CAS number of 303-98-0, the chemical structure is well known and the IUPAC name is HUGE.

Identify the novelty:
a composition of 0.01-30% w/w of CoQ10 can treat cancer, any cancer (See Claim 1). They also claim that a CoQ10 composition fo 1.5-4mg per kg body wt applied topically can treat cancer.

Additional Comments:
I'd like any art that has CoQ10 directly treating cancer in any species. Since CoQ10 compositions are well known (as sunscreens, food, culture media) the big point to search is how well they treat cancer. Thanks for doing this! This Application was published as US 2008/0299100 on Dec 4, 2008

3/29/2010

48

```
=> file registry
FILE 'REGISTRY' ENTERED AT 12:14:21 ON 29 MAR 2010
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2010 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
```

provided by InfoChem.

STRUCTURE FILE UPDATES: 28 MAR 2010 HIGHEST RN 1214990-69-8
DICTIONARY FILE UPDATES: 28 MAR 2010 HIGHEST RN 1214990-69-8

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 8, 2010.

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

Uploading L15.str



chain nodes :
1 2 3 4 5 6 7 8 9 16 17 18 19 20 21 22 23 24 25 26 27 28 29
30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50
51 52 53 54
55 56 57 58 59 60 61
ring nodes :
10 11 12 13 14 15
chain bonds :
1-12 2-18 3-22 4-26 5-30 6-14 7-15 8-11 9-13 10-16 16-17 17-18 18-19
19-20 20-21 21-22 22-23 23-24 24-25 25-26 26-27 27-28 28-29 29-30 30-55
31-37 32-41
33-45 34-49 35-53 36-37 36-56 37-38 38-39 39-40 40-41 41-42 42-43 43-44
44-45 45-46 46-47
47-48 48-49 49-50 50-51 51-52 52-53 53-54 54-57 55-56 57-59 58-59 58-60
58-61
ring bonds :
10-11 10-12 11-13 12-14 13-15 14-15
exact/norm bonds :
6-14 8-11 10-11 10-12 11-13 12-14 13-15 14-15
exact bonds :
1-12 2-18 3-22 4-26 5-30 7-15 9-13 10-16 16-17 17-18 18-19 19-20 20-21
21-22 22-23 23-24 24-25 25-26 26-27 27-28 28-29 29-30 30-55 31-37 32-41
33-45 34-49
35-53 36-37 36-56 37-38 38-39 39-40 40-41 41-42 42-43 43-44 44-45 45-46
46-47 47-48
48-49 49-50 50-51 51-52 52-53 53-54 54-57 55-56 57-59 58-59 58-60 58-61

Match level :

```
1:CLASS  2:CLASS  3:CLASS  4:CLASS  5:CLASS  6:CLASS  7:CLASS  8:CLASS  9:CLASS
10:Atom  11:Atom  12:Atom  13:Atom  14:Atom  15:Atom  16:CLASS  17:CLASS  18:CLASS
19:CLASS  20:CLASS
21:CLASS  22:CLASS  23:CLASS  24:CLASS  25:CLASS  26:CLASS  27:CLASS  28:CLASS
29:CLASS  30:CLASS
31:CLASS  32:CLASS  33:CLASS  34:CLASS  35:CLASS  36:CLASS  37:CLASS  38:CLASS
39:CLASS  40:CLASS
41:CLASS  42:CLASS  43:CLASS  44:CLASS  45:CLASS  46:CLASS  47:CLASS  48:CLASS
49:CLASS  50:CLASS
51:CLASS  52:CLASS  53:CLASS  54:CLASS  55:CLASS  56:CLASS  57:CLASS  58:CLASS
59:CLASS  60:CLASS
61:CLASS



=> file zcaplus
FILE 'ZCAPLUS' ENTERED AT 12:14:24 ON 29 MAR 2010
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2010 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS is
strictly prohibited.

FILE COVERS 1907 - 29 Mar 2010  VOL 152 ISS 14
FILE LAST UPDATED: 28 Mar 2010  (20100328/ED)
REVISED CLASS FIELDS (/NCL) LAST RELOADED:  Dec 2009
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE:  Dec 2009

ZCAplus now includes complete International Patent Classification (IPC)
reclassification data for the first quarter of 2010.

CAS Information Use Policies apply and are available at:

http://www.cas.org/legal/infopolicy.html

This file contains CAS Registry Numbers for easy and accurate
substance identification.
'OBI' IS DEFAULT SEARCH FIELD FOR 'ZCAPLUS' FILE

=> d stat que L60
L48         228 SEA FILE=ZCAPLUS SPE=ON  ABB=ON  PLU=ON  HSIA S?/AU,AUTH
L49          89 SEA FILE=ZCAPLUS SPE=ON  ABB=ON  PLU=ON  NARAIN N?/AU,AUTH
L50       81413 SEA FILE=ZCAPLUS SPE=ON  ABB=ON  PLU=ON  LI J?/AU,AUTH
L51         704 SEA FILE=ZCAPLUS SPE=ON  ABB=ON  PLU=ON  RUSSELL K?/AU,AUTH
L52           5 SEA FILE=ZCAPLUS SPE=ON  ABB=ON  PLU=ON  WOAN K?/AU,AUTH
L53           9 SEA FILE=ZCAPLUS SPE=ON  ABB=ON  PLU=ON  PERSAUD I?/AU,AUTH
L55           2 SEA FILE=ZCAPLUS SPE=ON  ABB=ON  PLU=ON  L48 AND (L49 OR L50
                OR L51 OR L52 OR L53)
L56           6 SEA FILE=ZCAPLUS SPE=ON  ABB=ON  PLU=ON  L49 AND (L50 OR L51
                OR L52 OR L53)
```

```
L57             6 SEA FILE=ZCAPLUS SPE=ON  ABB=ON  PLU=ON  L50 AND (L51 OR L52
                  OR L53)
L58             1 SEA FILE=ZCAPLUS SPE=ON  ABB=ON  PLU=ON  L51 AND (L52 OR L53)
L59             1 SEA FILE=ZCAPLUS SPE=ON  ABB=ON  PLU=ON  L52 AND L53
L60            11 SEA FILE=ZCAPLUS SPE=ON  ABB=ON  PLU=ON  L55 OR L56 OR L57 OR
                  L58 OR L59


=> d stat que L83
L15             STR
```




```
Structure attributes must be viewed using STN Express query preparation.
L17            83 SEA FILE=REGISTRY FAM FUL L15
L48           228 SEA FILE=ZCAPLUS SPE=ON  ABB=ON  PLU=ON  HSIA S?/AU,AUTH
L49            89 SEA FILE=ZCAPLUS SPE=ON  ABB=ON  PLU=ON  NARAIN N?/AU,AUTH
L50         81413 SEA FILE=ZCAPLUS SPE=ON  ABB=ON  PLU=ON  LI J?/AU,AUTH
L51           704 SEA FILE=ZCAPLUS SPE=ON  ABB=ON  PLU=ON  RUSSELL K?/AU,AUTH
L52             5 SEA FILE=ZCAPLUS SPE=ON  ABB=ON  PLU=ON  WOAN K?/AU,AUTH
L53             9 SEA FILE=ZCAPLUS SPE=ON  ABB=ON  PLU=ON  PERSAUD I?/AU,AUTH
L83            18 SEA FILE=ZCAPLUS SPE=ON  ABB=ON  PLU=ON  (L48 OR L49 OR L50 OR
                  L51 OR L52 OR L53) AND L17


=> d stat que L84
L15             STR
```




```
Structure attributes must be viewed using STN Express query preparation.
L17          83 SEA FILE=REGISTRY FAM FUL L15
L21        2380 SEA FILE=ZCAPLUS SPE=ON  ABB=ON  PLU=ON  L17 (L) (THU OR DMA
                OR BAC OR PKT OR PAC OR FFD)/RL
L22      139854 SEA FILE=ZCAPLUS SPE=ON  ABB=ON  PLU=ON  (?LEUKAEM?/BI OR
                ?LEUKEM?/BI)
L23      502215 SEA FILE=ZCAPLUS SPE=ON  ABB=ON  PLU=ON  ?CANCER?/BI
L24      781886 SEA FILE=ZCAPLUS SPE=ON  ABB=ON  PLU=ON  ?TUMOUR?/BI OR
                ?TUMOR?/BI
L25       62114 SEA FILE=ZCAPLUS SPE=ON  ABB=ON  PLU=ON  ?SARCOMA?/BI
L26      645501 SEA FILE=ZCAPLUS SPE=ON  ABB=ON  PLU=ON  ?NEOPLAS?/BI
L27      360843 SEA FILE=ZCAPLUS SPE=ON  ABB=ON  PLU=ON  ?CARCINO?/BI
L28       28213 SEA FILE=ZCAPLUS SPE=ON  ABB=ON  PLU=ON  ?MYELOM?/BI
L29       52342 SEA FILE=ZCAPLUS SPE=ON  ABB=ON  PLU=ON  ?LYMPHOMA?/BI
L30       46413 SEA FILE=ZCAPLUS SPE=ON  ABB=ON  PLU=ON  ?MELANOM?/BI
L31       66132 SEA FILE=ZCAPLUS SPE=ON  ABB=ON  PLU=ON  ?ANGIOGEN?/BI
L32      200452 SEA FILE=ZCAPLUS SPE=ON  ABB=ON  PLU=ON  CELL PROLIFER?/BI
L33         311 SEA FILE=ZCAPLUS SPE=ON  ABB=ON  PLU=ON  L21 AND (L22 OR L23
                OR L24 OR L25 OR L26 OR L27 OR L28 OR L29 OR L30 OR L31 OR
                L32)
L48         228 SEA FILE=ZCAPLUS SPE=ON  ABB=ON  PLU=ON  HSIA S?/AU,AUTH
L49          89 SEA FILE=ZCAPLUS SPE=ON  ABB=ON  PLU=ON  NARAIN N?/AU,AUTH
L50       81413 SEA FILE=ZCAPLUS SPE=ON  ABB=ON  PLU=ON  LI J?/AU,AUTH
L51         704 SEA FILE=ZCAPLUS SPE=ON  ABB=ON  PLU=ON  RUSSELL K?/AU,AUTH
L52           5 SEA FILE=ZCAPLUS SPE=ON  ABB=ON  PLU=ON  WOAN K?/AU,AUTH
L53           9 SEA FILE=ZCAPLUS SPE=ON  ABB=ON  PLU=ON  PERSAUD I?/AU,AUTH
L84           4 SEA FILE=ZCAPLUS SPE=ON  ABB=ON  PLU=ON  (L48 OR L49 OR L50 OR
                L51 OR L52 OR L53) AND L33


=> s L60 or L83 or L84
L85          24 L60 OR L83 OR L84

=> file medline embase biosis wpix
FILE 'MEDLINE' ENTERED AT 12:15:03 ON 29 MAR 2010

FILE 'EMBASE' ENTERED AT 12:15:03 ON 29 MAR 2010
Copyright (c) 2010 Elsevier B.V. All rights reserved.
```

```
FILE 'BIOSIS' ENTERED AT 12:15:03 ON 29 MAR 2010
Copyright (c) 2010 The Thomson Corporation

FILE 'WPIX' ENTERED AT 12:15:03 ON 29 MAR 2010
COPYRIGHT (C) 2010 THOMSON REUTERS

=> d stat que L78
L61          862 SEA HSIA S?/AU,AUTH
L62          107 SEA NARAIN N?/AU,AUTH
L63        92982 SEA LI J?/AU,AUTH
L64         1996 SEA RUSSELL K?/AU,AUTH
L65           16 SEA WOAN K?/AU,AUTH
L66           28 SEA PERSAUD I?/AU,AUTH
L68           11 SEA L61 AND (L62 OR L63 OR L64 OR L65 OR L66)
L69           19 SEA L62 AND (L63 OR L64 OR L65 OR L66)
L70           28 SEA L63 AND (L64 OR L65 OR L66)
L71           10 SEA L64 AND (L65 OR L66)
L72            8 SEA L65 AND L66
L74           11 SEA L68 AND (L69 OR L70 OR L71 OR L72)
L75           10 SEA L69 AND (L70 OR L71 OR L72)
L76            9 SEA L70 AND (L71 OR L72)
L77            8 SEA L71 AND L72
L78           11 SEA L74 OR L75 OR L76 OR L77


=> file medline embase biosis
FILE 'MEDLINE' ENTERED AT 12:16:16 ON 29 MAR 2010

FILE 'EMBASE' ENTERED AT 12:16:16 ON 29 MAR 2010
Copyright (c) 2010 Elsevier B.V. All rights reserved.

FILE 'BIOSIS' ENTERED AT 12:16:16 ON 29 MAR 2010
Copyright (c) 2010 The Thomson Corporation

=> d stat que L80
L15             STR
```




```
Structure attributes must be viewed using STN Express query preparation.
L17           83 SEA FILE=REGISTRY FAM FUL L15
```

```
L22      139854 SEA FILE=ZCAPLUS SPE=ON  ABB=ON  PLU=ON  (?LEUKAEM?/BI OR
                ?LEUKEM?/BI)
L23      502215 SEA FILE=ZCAPLUS SPE=ON  ABB=ON  PLU=ON  ?CANCER?/BI
L24      781886 SEA FILE=ZCAPLUS SPE=ON  ABB=ON  PLU=ON  ?TUMOUR?/BI OR
                ?TUMOR?/BI
L25       62114 SEA FILE=ZCAPLUS SPE=ON  ABB=ON  PLU=ON  ?SARCOMA?/BI
L26      645501 SEA FILE=ZCAPLUS SPE=ON  ABB=ON  PLU=ON  ?NEOPLAS?/BI
L27      360843 SEA FILE=ZCAPLUS SPE=ON  ABB=ON  PLU=ON  ?CARCINO?/BI
L28       28213 SEA FILE=ZCAPLUS SPE=ON  ABB=ON  PLU=ON  ?MYELOM?/BI
L29       52342 SEA FILE=ZCAPLUS SPE=ON  ABB=ON  PLU=ON  ?LYMPHOMA?/BI
L30       46413 SEA FILE=ZCAPLUS SPE=ON  ABB=ON  PLU=ON  ?MELANOM?/BI
L31       66132 SEA FILE=ZCAPLUS SPE=ON  ABB=ON  PLU=ON  ?ANGIOGEN?/BI
L32      200452 SEA FILE=ZCAPLUS SPE=ON  ABB=ON  PLU=ON  CELL PROLIFER?/BI
L38             SEL  PLU=ON  L17 1- CHEM :      120 TERMS
L39       10721 SEA L38
L40        1098 SEA L39 AND (L22 OR L23 OR L24 OR L25 OR L26 OR L27 OR L28 OR
                L29 OR L30 OR L31 OR L32)
L41          34 SEA L40 AND ?TOPICAL?
L61         862 SEA HSIA S?/AU,AUTH
L62         107 SEA NARAIN N?/AU,AUTH
L63       92982 SEA LI J?/AU,AUTH
L64        1996 SEA RUSSELL K?/AU,AUTH
L65          16 SEA WOAN K?/AU,AUTH
L66          28 SEA PERSAUD I?/AU,AUTH
L80           2 SEA L41 AND (L61 OR L62 OR L63 OR L64 OR L65 OR L66)


=> d stat que L82
L15             STR
```




```
Structure attributes must be viewed using STN Express query preparation.
L17             83 SEA FILE=REGISTRY FAM FUL L15
L22      139854 SEA FILE=ZCAPLUS SPE=ON  ABB=ON  PLU=ON  (?LEUKAEM?/BI OR
                ?LEUKEM?/BI)
L23      502215 SEA FILE=ZCAPLUS SPE=ON  ABB=ON  PLU=ON  ?CANCER?/BI
L24      781886 SEA FILE=ZCAPLUS SPE=ON  ABB=ON  PLU=ON  ?TUMOUR?/BI OR
                ?TUMOR?/BI
L25       62114 SEA FILE=ZCAPLUS SPE=ON  ABB=ON  PLU=ON  ?SARCOMA?/BI
L26      645501 SEA FILE=ZCAPLUS SPE=ON  ABB=ON  PLU=ON  ?NEOPLAS?/BI
```

```
L27      360843 SEA FILE=ZCAPLUS SPE=ON  ABB=ON  PLU=ON  ?CARCINO?/BI
L28       28213 SEA FILE=ZCAPLUS SPE=ON  ABB=ON  PLU=ON  ?MYELOM?/BI
L29       52342 SEA FILE=ZCAPLUS SPE=ON  ABB=ON  PLU=ON  ?LYMPHOMA?/BI
L30       46413 SEA FILE=ZCAPLUS SPE=ON  ABB=ON  PLU=ON  ?MELANOM?/BI
L31       66132 SEA FILE=ZCAPLUS SPE=ON  ABB=ON  PLU=ON  ?ANGIOGEN?/BI
L32      200452 SEA FILE=ZCAPLUS SPE=ON  ABB=ON  PLU=ON  CELL PROLIFER?/BI
L38             SEL  PLU=ON  L17 1- CHEM :     120 TERMS
L39       10721 SEA L38
L40        1098 SEA L39 AND (L22 OR L23 OR L24 OR L25 OR L26 OR L27 OR L28 OR
                 L29 OR L30 OR L31 OR L32)
L61         862 SEA HSIA S?/AU,AUTH
L62         107 SEA NARAIN N?/AU,AUTH
L63       92982 SEA LI J?/AU,AUTH
L64        1996 SEA RUSSELL K?/AU,AUTH
L65          16 SEA WOAN K?/AU,AUTH
L66          28 SEA PERSAUD I?/AU,AUTH
L82          12 SEA L40 AND (L61 OR L62 OR L63 OR L64 OR L65 OR L66)


=> s L80 or L82
L86          12 L80 OR L82

=> file medline embase biosis wpix
FILE 'MEDLINE' ENTERED AT 12:17:03 ON 29 MAR 2010

FILE 'EMBASE' ENTERED AT 12:17:03 ON 29 MAR 2010
Copyright (c) 2010 Elsevier B.V. All rights reserved.

FILE 'BIOSIS' ENTERED AT 12:17:03 ON 29 MAR 2010
Copyright (c) 2010 The Thomson Corporation

FILE 'WPIX' ENTERED AT 12:17:03 ON 29 MAR 2010
COPYRIGHT (C) 2010 THOMSON REUTERS

=> d stat que L78
L61          862 SEA HSIA S?/AU,AUTH
L62          107 SEA NARAIN N?/AU,AUTH
L63        92982 SEA LI J?/AU,AUTH
L64         1996 SEA RUSSELL K?/AU,AUTH
L65           16 SEA WOAN K?/AU,AUTH
L66           28 SEA PERSAUD I?/AU,AUTH
L68           11 SEA L61 AND (L62 OR L63 OR L64 OR L65 OR L66)
L69           19 SEA L62 AND (L63 OR L64 OR L65 OR L66)
L70           28 SEA L63 AND (L64 OR L65 OR L66)
L71           10 SEA L64 AND (L65 OR L66)
L72            8 SEA L65 AND L66
L74           11 SEA L68 AND (L69 OR L70 OR L71 OR L72)
L75           10 SEA L69 AND (L70 OR L71 OR L72)
L76            9 SEA L70 AND (L71 OR L72)
L77            8 SEA L71 AND L72
L78           11 SEA L74 OR L75 OR L76 OR L77


=> dup rem L85 L86 L78
FILE 'ZCAPLUS' ENTERED AT 12:17:18 ON 29 MAR 2010
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2010 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'BIOSIS' ENTERED AT 12:17:18 ON 29 MAR 2010
```

FILE 'WPIX' ENTERED AT 12:17:18 ON 29 MAR 2010
COPYRIGHT (C) 2010 THOMSON REUTERS
PROCESSING COMPLETED FOR L85
PROCESSING COMPLETED FOR L86
PROCESSING COMPLETED FOR L78
L87 37 DUP REM L85 L86 L78 (10 DUPLICATES REMOVED)
ANSWERS '1-24' FROM FILE ZCAPLUS
ANSWERS '25-37' FROM FILE BIOSIS

=> d ibib abs hitind hitstr L87 1-24; d iall L87 25-37

L87 ANSWER 1 OF 37 ZCAPLUS COPYRIGHT 2010 ACS on STN DUPLICATE 1
ACCESSION NUMBER: 2007:1303119 ZCAPLUS Full-text
DOCUMENT NUMBER: 147:528171
TITLE: Topical co-enzyme Q10 formulations and treatment of pain, fatigue and wounds
INVENTOR(S): Asia, Sung L.; Narain, Niven R.; Persaud, Indushekhar
PATENT ASSIGNEE(S): University of Miami, USA
SOURCE: PCT Int. Appl., 48pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007131047	A2	20071115	WO 2007-US68052	20070502
WO 2007131047	A3	20080724		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				
CA 2650825	A1	20071115	CA 2007-2650825	20070502
EP 2073819	A2	20090701	EP 2007-761758	20070502
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS				
JP 2009536215	T	20091008	JP 2009-510055	20070502
MX 2008013855	A	20090129	MX 2008-13855	20081029
US 20100062048	A1	20100311	US 2009-299354	20090903
PRIORITY APPLN. INFO.:			US 2006-797008P P	20060502
			WO 2007-US68052 W	20070502

AB CoQ10 has a stimulatory effect on fibroblasts and keratinocytes, increases ATP production, decreases pain. The formulations are useful for promoting acute wound healing, fatigue and treatment of acute and chronic pain. Q10 administration to human aortic smooth muscle cells increases ATP production and implies that the phospholipid vehicle (liposomes) is effective in delivering exogenous Q10 to cells.
CC 63-6 (Pharmaceuticals)

Section cross-reference(s): 13
IT 303-98-0, Coenzyme Q10
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(topical coenzyme Q10 formulations and treatment of pain, fatigue and wounds)
IT 303-98-0, Coenzyme Q10
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(topical coenzyme Q10 formulations and treatment of pain, fatigue and wounds)
RN 303-98-0 ZCAPLUS
CN 2,5-Cyclohexadiene-1,4-dione, 2-[(2E,6E,10E,14E,18E,22E,26E,30E,34E)-3,7,11,15,19,23,27,31,35,39-decamethyl-2,6,10,14,18,22,26,30,34,38-tetracontadecaen-1-yl]-5,6-dimethoxy-3-methyl- (CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A



PAGE 1-B



PAGE 1-C

L87 ANSWER 2 OF 37 ZCAPLUS COPYRIGHT 2010 ACS on STN DUPLICATE 4
ACCESSION NUMBER: 2005:696614 ZCAPLUS Full-text
DOCUMENT NUMBER: 143:159636
TITLE: Topical Coenzyme Q10 formulations
INVENTOR(S): Hsia, Sung Lan; Narain, Niven Rajin; Li, Jie; Russell, Kathryn J.; Woan, Karrune V.; Persaud, Indushekhar
PATENT ASSIGNEE(S): University of Miami, USA
SOURCE: PCT Int. Appl., 86 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent

LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005069916	A2	20050804	WO 2005-US1581	20050121
WO 2005069916	A3	20061019		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, SM				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2005206953	A1	20050804	AU 2005-206953	20050121
CA 2553690	A1	20050804	CA 2005-2553690	20050121
EP 1718283	A2	20061108	EP 2005-711599	20050121
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, BA, HR, IS, YU				
CN 1953743	A	20070425	CN 2005-80005626	20050121
BR 2005007039	A	20070605	BR 2005-7039	20050121
JP 2007518805	T	20070712	JP 2006-551208	20050121
MX 2006008293	A	20070611	MX 2006-8293	20060721
IN 2006KN02090	A	20070518	IN 2006-KN2090	20060725
NO 2006003439	A	20061023	NO 2006-3439	20060726
KR 2007012349	A	20070125	KR 2006-716800	20060822
US 20080299100	A1	20081204	US 2008-597378	20080821
PRIORITY APPLN. INFO.:			US 2004-538319P P	20040122
			WO 2005-US1581 W	20050121

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

AB Topical formulations of CoQ10 reduce the rate of tumor growth in an animal subject. In the expts. described herein, CoQ10 was shown to increase the rate of apoptosis in a culture of skin cancer cells but not normal cells. Moreover, treatment of tumor-bearing animals with a topical formulation of CoQ10 was shown to dramatically reduce the rate of tumor growth in the animals. Thus, a kit comprised Coenzyme Q10, Phospholipon-90, glycerol, BHT, ethanol, medium chain triglycerides and lavender.

IC ICM A61K
CC 63-6 (Pharmaceuticals)
Section cross-reference(s): 1
IT Antitumor agents
Apoptosis
Human
Lavandula
Neoplasm
(topical Coenzyme Q10 formulations)
IT 303-98-0, Coenzyme Q10
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(topical Coenzyme Q10 formulations)
IT 303-98-0, Coenzyme Q10
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(topical Coenzyme Q10 formulations)

RN 303-98-0 ZCAPLUS
CN 2,5-Cyclohexadiene-1,4-dione, 2-[(2E,6E,10E,14E,18E,22E,26E,30E,34E)-3,7,11,15,19,23,27,31,35,39-decamethyl-2,6,10,14,18,22,26,30,34,38-tetracontadecaen-1-yl]-5,6-dimethoxy-3-methyl- (CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A



PAGE 1-B



PAGE 1-C

OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)
REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L87 ANSWER 3 OF 37 ZCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2009:1402763 ZCAPLUS Full-text
DOCUMENT NUMBER: 151:537058
TITLE: Methods and compositions for the treatment or prevention of pathological cardiac remodeling and heart failure
INVENTOR(S): Yan, Chen; Li, Jian-Dong
PATENT ASSIGNEE(S): University of Rochester, USA
SOURCE: PCT Int. Appl., 50pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2009137465	A2	20091112	WO 2009-US42823	20090505

WO 2009137465 A3 20091230
W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA
PRIORITY APPLN. INFO.: US 2008-50308P P 20080505

AB The invention relates to methods of treating or preventing pathol. cardiac remodeling and/or preventing heart failure. These methods include the administration of a PDE1 inhibitor to a patient under conditions effective to treat or prevent pathol. cardiac remodeling, and therefore heart failure that occurs as a result of such remodeling. Pharmaceutical compns. and delivery vehicles that can be used in the methods of the present invention are also disclosed herein.

CC 63-6 (Pharmaceuticals)
Section cross-reference(s): 1

IT 53-57-6, NAD(P)H 56-65-5, ATP, biological studies 85-61-0, Coenzyme A, biological studies 303-98-0, Coenzyme Q10 318-98-9, Propranolol hydrochloride 525-66-6, Propranolol 1617-90-9D, Vincamine, derivs. 1951-25-3, Amiodarone 1980-45-6, AB 103 3930-20-9, Sotalol 4880-88-0, (-)-Eburnamonine 6452-71-7, Oxprenolol 7683-59-2, Isoproterenol 13392-18-2, Fenoterol 13523-86-9, Pindolol 18559-94-9, Salbutamol 22664-55-7, Metipranolol 23031-25-6, Terbutaline 26652-09-5, Ritodrine 26839-75-8, Timolol 27773-65-5, Apovincaminic acid 29122-68-7, Atenolol 34273-10-4, Saralasin 34368-04-2, Dobutamine 34441-14-0, Nicotianamine 36894-69-6, Labetalol 37148-27-9, Clenbuterol 37517-30-9, Acebutolol 38363-40-5, Penbutolol 39698-78-7, Saralasin acetate 42200-33-9, Nadolol 42971-09-5, (+)-Vinpocetine 43229-80-7, Formoterol fumarate 47141-42-4, Levobunolol 51384-51-1, Metoprolol 51781-06-7, Carteolol 52468-60-7, Flunarizine 54063-53-5, Propafenone 56290-94-9, Medroxalol 56392-17-7, Metoprolol tartrate 56980-93-9, Celiprolol 60719-84-8, Amrinone 62571-86-2, Captopril 62658-63-3, Bopindolol 63659-18-7, Betaxolol 64706-54-3, Bepridil 66722-44-9, Bisoprolol 67714-46-9, SA 291 67763-96-6, Insulin-like growth factor-1 71119-11-4, Bucindolol 72956-09-3, Carvedilol 73573-87-2, Formoterol 74258-86-9, Alacepril 75176-37-3, Zofenoprilat 75847-73-3, Enalapril 76420-72-9, Enalaprilat 76547-98-3, Lisinopril 76693-38-4, EU4865 77671-31-9, Enoximone 78415-72-2, Milrinone 78779-29-0, Wy 44221 80830-42-8, Rentiapril 80876-01-3, Indolapril 81045-50-3, Pivopril 81147-92-4, Esmolol 81161-17-3, Esmolol hydrochloride 81938-42-3, SQ26900 82768-85-2, Quinaprilat 82834-16-0, Perindopril 82924-03-6, Pentopril 83059-56-7, Zabicipril 83348-78-1, CGS-13928C 83435-66-9, Delapril 83602-05-5, Spiraprilat 83647-97-6, Spirapril 84768-09-2, BRL-36378 85441-61-8, Quinapril 85856-54-8, Moveltipril 86541-75-5, Benazepril 86541-78-8, Benazeprilat 86709-48-0, CL242817 87269-97-4, Ramiprilat 87333-19-5, Ramipril 87679-37-6, Trandolapril 87679-71-8, RU 44403 88201-41-6, Ancovenin 88768-40-5, Cilazapril 88874-29-7, Sarmesin 89371-37-9, Imidapril 90982-51-7, RS 2039 91273-47-1, EU 5476 91386-17-3, L681176 94818-84-5, Phenacein 95153-31-4, Perindoprilat 95399-71-6, Fosinoprilat 95508-61-5, Isoteoline 98048-97-6, Fosinopril 98418-47-4, Metoprolol succinate 100157-28-6, Foroxymithine 100277-62-1, CV 5975 103221-88-1, BW-A575C 103370-21-4, KS-619-1

103775-10-6, Moexipril 104344-23-2, Bisoprolol fumarate 105500-12-7, RGH-0537 106498-99-1, RGH-2981 109075-64-1, WF 10129 109214-55-3, Libenzapril 109683-61-6, Utibapril 110221-53-9, RS5139 111223-26-8, Ceranapril 111581-85-2, MDL-27088 111902-57-9, Temocapril 114773-44-3, EXP-6803 114785-12-5, PD 123177 114798-27-5, EXP-7711 114798-32-2, EXP-9270 118393-93-4, S8307 118457-14-0, Nebivolol 119256-78-9, s8308 121280-51-1, EXP-6155 123060-44-6, Hoe-065 124750-92-1, EXP-3174 124750-95-4, DuP-532 124750-99-8, Losartan potassium 127420-24-0, Idrapril 130663-39-7, PD 123319 133040-01-4, Eprosartan 133085-33-3, BIBS39 133240-46-7, L 158809 133240-72-9, L-158978 135015-84-8, ZD 8731 135038-57-2, Alatriopril 135070-05-2, E 4177 136284-47-4, CV 11194 137862-53-4, Valsartan 137882-98-5, CGP-49870 138402-11-6, Irbesartan 139481-59-7, Candesartan 139958-16-0, ME 3221 139964-19-5, DMP-811 141872-46-0, A-81282 141887-34-5, A 81988 142023-57-2, BIBS-222 142999-90-4, BMS-180560 143494-72-8, ICI-D8731 144701-48-4, Telmisartan 144756-71-8, SL-910102 145004-82-6, L 161177 145040-37-5, Candesartan cilexetil 145543-03-9, RG 13647 145733-36-4, Tasosartan 145781-32-4, Zolasartan 146623-69-0, Saprisartan 146709-78-6, ZD 7155 146948-75-6, L 162234 148504-51-2, UP-269-6 148564-47-0, LR-B081 149285-55-2, WAY-126227 149586-24-3, YM 31472 149968-26-3, HN 65021 150484-27-8, L 159689 150690-79-2, XH 148 150802-50-9, KW-3433 151127-13-8, Equaten 151127-78-5, Synecor 151127-87-6, Y 23785 151406-38-1, YM 358 152134-02-6, u96849 152134-03-7, u97018 153072-63-0, BMS-184698 153235-15-5, HR 720 153465-66-8, GA 0056 153804-05-8, KT3-671 154200-12-1, RWJ-46458 154512-46-6, L 162441 154668-27-6, LY 301875 156039-69-9, Mixanpril 157263-00-8, L 159282 159748-08-0, LY 285434 160135-56-8, BMS182657 160936-25-4, Prentyl 167298-74-0, SCH51866 169181-38-8, XR 510 169281-98-5, 1163017 172345-25-4, RWJ 38970 186537-37-1, L 162154 186615-80-5, BIBR 363 186615-83-8, CGP-63170 186615-84-9, DA 2079 186615-85-0, DE 3489 186615-89-4, EMD 73495 186615-91-8, EXP 929 186615-99-6, ICI-D 7155 186616-03-5, LR-B 087 186616-04-6, LY 235656 186616-06-8, LY 302289 186616-07-9, LY 315995 186616-16-0, UP-275-22 186616-18-2, WK 1360 186616-19-3, WK 1492.2K 186616-20-6, X 6803 211934-97-3, EMD-66397 847667-15-6, EU 4867 847667-16-7, FR 900456 847667-23-6, 15B2 847667-25-8, RG 5975 847667-26-9, RG 6134 847667-27-0, RG 6207 847667-28-1, RGH 0399 847667-29-2, ROO 911 847667-30-5, RS 86127 847667-31-6, SQ 28084 847667-32-7, SQ 28370 847667-33-8, SQ 28940 847667-34-9, P 0154 872039-03-7, KR 1-1177 1026784-27-9, L 163007 1026784-28-0, PD 150304 1193666-47-5, K 295-2 1193666-49-7, IC 86340 1193666-50-0, IC 295 1193667-16-1, C 1-996 1193668-13-1, KR 1-1230

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(methods and compns. for treatment or prevention of pathol. cardiac remodeling and heart failure)

IT 303-98-0, Coenzyme Q10

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(methods and compns. for treatment or prevention of pathol. cardiac remodeling and heart failure)

RN 303-98-0 ZCAPLUS

CN 2,5-Cyclohexadiene-1,4-dione, 2-[(2E,6E,10E,14E,18E,22E,26E,30E,34E)-3,7,11,15,19,23,27,31,35,39-decamethyl-2,6,10,14,18,22,26,30,34,38-tetracontadecaen-1-yl]-5,6-dimethoxy-3-methyl- (CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A



PAGE 1-B



PAGE 1-C

L87 ANSWER 4 OF 37 ZCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2009:1260432 ZCAPLUS Full-text
DOCUMENT NUMBER: 151:418146
TITLE: Methods and use of exogenous coenzyme Q10, or a metabolite thereof, for inducing apoptosis in cancer cells
INVENTOR(S): Narain, Niven Rajin; Persaud, Indushekhar; McCook, John Patrick
PATENT ASSIGNEE(S): Cytotech Labs, LLC, USA
SOURCE: PCT Int. Appl., 54pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2009126764	A1	20091015	WO 2009-US39992	20090409

W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN,

TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: US 2008-44085P P 20080411

AB The invention provides a method for inducing apoptosis in a cancer cell by delivery of exogenous coenzyme Q10 or metabolites thereof in a pharmaceutically acceptable carrier to effectuate cell contact of endogenous coenzyme Q10 or metabolites thereof in addition to but not limited to mevalonic acid and oleic acid to form an intracellular complex. The invention also provides a method for modulating the p53 pathway and Bcl-2 protein family in a manner that restores the apoptotic potential to a cancer cell by delivery of coenzyme Q10 in a pharmaceutically acceptable carrier. The invention further provides a method to specifically normalize the ratio of pro-apoptotic and anti-apoptotic members of the Bcl-2 gene family in a proportion to re-program a cancer cell to undergo apoptosis.

CC 1-6 (Pharmacology)

ST cancer apoptosis induction coenzyme Q10

IT Proteins
RL: ADV (Adverse effect, including toxicity); BSU (Biological study, unclassified); BIOL (Biological study)
(BIK (Bcl-2-interacting killer), BH3 binding domain; exogenous coenzyme Q10 or coenzyme Q10 metabolite for apoptosis induction in cancer cells)

IT Proteins
RL: ADV (Adverse effect, including toxicity); BSU (Biological study, unclassified); BIOL (Biological study)
(Bak; exogenous coenzyme Q10 or coenzyme Q10 metabolite for apoptosis induction in cancer cells)

IT Proteins
RL: ADV (Adverse effect, including toxicity); BSU (Biological study, unclassified); BIOL (Biological study)
(Bax; exogenous coenzyme Q10 or coenzyme Q10 metabolite for apoptosis induction in cancer cells)

IT Protein motifs
(Bcl-2 family BH3 binding domain; exogenous coenzyme Q10 or coenzyme Q10 metabolite for apoptosis induction in cancer cells)

IT Proteins
RL: ADV (Adverse effect, including toxicity); BSU (Biological study, unclassified); BIOL (Biological study)
(Bcl-2, Bsl-2 subfamily members; exogenous coenzyme Q10 or coenzyme Q10 metabolite for apoptosis induction in cancer cells)

IT Proteins
RL: ADV (Adverse effect, including toxicity); BSU (Biological study, unclassified); BIOL (Biological study)
(Bcl-2; exogenous coenzyme Q10 or coenzyme Q10 metabolite for apoptosis induction in cancer cells)

IT Proteins
RL: ADV (Adverse effect, including toxicity); BSU (Biological study, unclassified); BIOL (Biological study)
(Bcl-xL; exogenous coenzyme Q10 or coenzyme Q10 metabolite for apoptosis induction in cancer cells)

IT Proteins
RL: ADV (Adverse effect, including toxicity); BSU (Biological study, unclassified); BIOL (Biological study)
(Bid, BH3 binding domain; exogenous coenzyme Q10 or coenzyme Q10 metabolite for apoptosis induction in cancer cells)

IT Proteins
RL: ADV (Adverse effect, including toxicity); BSU (Biological study, unclassified); BIOL (Biological study)
(Bim, BH3 binding domain; exogenous coenzyme Q10 or coenzyme Q10 metabolite for apoptosis induction in cancer cells)

IT Transcription factors
RL: ADV (Adverse effect, including toxicity); BSU (Biological study, unclassified); BIOL (Biological study)
(HIF-1α (hypoxia-inducible factor 1α); exogenous coenzyme Q10 or coenzyme Q10 metabolite for apoptosis induction in cancer cells)
IT Proteins
RL: ADV (Adverse effect, including toxicity); BSU (Biological study, unclassified); BIOL (Biological study)
(Mcl-1 (myeloid cell leukemia sequence-1); exogenous coenzyme Q10 or coenzyme Q10 metabolite for apoptosis induction in cancer cells)
IT Angiogenesis
Angiogenesis inhibitors
Antitumor agents
Apoptosis
Cell cycle
Mammary gland, neoplasm
Melanoma
Neoplasm
Pharmaceutical aerosols
Pharmaceutical creams
Pharmaceutical foams
Pharmaceutical gels
Pharmaceutical liposomes
Pharmaceutical liquids
Pharmaceutical ointments
Pharmaceutical sprays
Pharmaceutical suppositories
Prostate gland, neoplasm
(exogenous coenzyme Q10 or coenzyme Q10 metabolite for apoptosis induction in cancer cells)
IT Angiogenic factors
Quinones
Transcription factor Smad
Transforming growth factor β
p53 (protein)
RL: ADV (Adverse effect, including toxicity); BSU (Biological study, unclassified); BIOL (Biological study)
(exogenous coenzyme Q10 or coenzyme Q10 metabolite for apoptosis induction in cancer cells)
IT Phospholipids
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(exogenous coenzyme Q10 or coenzyme Q10 metabolite for apoptosis induction in cancer cells)
IT Membrane, biological
(lipids; exogenous coenzyme Q10 or coenzyme Q10 metabolite for apoptosis induction in cancer cells)
IT Lipids
RL: ADV (Adverse effect, including toxicity); BSU (Biological study, unclassified); BIOL (Biological study)
(membrane; exogenous coenzyme Q10 or coenzyme Q10 metabolite for apoptosis induction in cancer cells)
IT Drug delivery systems
(mousse; exogenous coenzyme Q10 or coenzyme Q10 metabolite for apoptosis induction in cancer cells)
IT Pharmaceutical powders
(nebulized; exogenous coenzyme Q10 or coenzyme Q10 metabolite for apoptosis induction in cancer cells)
IT Drug delivery systems

(salve; exogenous coenzyme Q10 or coenzyme Q10 metabolite for apoptosis induction in cancer cells)

IT Pharmaceutical emulsions
Topical drug delivery systems
(topical lotions; exogenous coenzyme Q10 or coenzyme Q10 metabolite for apoptosis induction in cancer cells)

IT 112-80-1, Oleic acid, biological studies 150-97-0, Mevalonic acid 62031-54-3, FGF 86090-08-6, Angiostatin 115926-52-8, PI3 kinase 127464-60-2, VEGF 148640-14-6, Akt kinase 150428-23-2, Cyclin-dependent kinase 169592-56-7, Caspase 3
RL: ADV (Adverse effect, including toxicity); BSU (Biological study, unclassified); BIOL (Biological study)
(exogenous coenzyme Q10 or coenzyme Q10 metabolite for apoptosis induction in cancer cells)

IT 303-98-0, Coenzyme Q10
RL: ADV (Adverse effect, including toxicity); BSU (Biological study, unclassified); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(exogenous coenzyme Q10 or coenzyme Q10 metabolite for apoptosis induction in cancer cells)

IT 303-98-0D, Coenzyme Q10, metabolites
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(exogenous coenzyme Q10 or coenzyme Q10 metabolite for apoptosis induction in cancer cells)

IT 303-98-0, Coenzyme Q10
RL: ADV (Adverse effect, including toxicity); BSU (Biological study, unclassified); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(exogenous coenzyme Q10 or coenzyme Q10 metabolite for apoptosis induction in cancer cells)

RN 303-98-0 ZCAPLUS

CN 2,5-Cyclohexadiene-1,4-dione, 2-[(2E,6E,10E,14E,18E,22E,26E,30E,34E)-3,7,11,15,19,23,27,31,35,39-decamethyl-2,6,10,14,18,22,26,30,34,38-tetracontadecaen-1-yl]-5,6-dimethoxy-3-methyl- (CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A



PAGE 1-B



PAGE 1-C

IT 303-98-0D, Coenzyme Q10, metabolites
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(exogenous coenzyme Q10 or coenzyme Q10 metabolite for apoptosis induction in cancer cells)
RN 303-98-0 ZCAPLUS
CN 2,5-Cyclohexadiene-1,4-dione, 2-[(2E,6E,10E,14E,18E,22E,26E,30E,34E)-3,7,11,15,19,23,27,31,35,39-decamethyl-2,6,10,14,18,22,26,30,34,38-tetracontadecaen-1-yl]-5,6-dimethoxy-3-methyl- (CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A



PAGE 1-B



PAGE 1-C

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L87 ANSWER 5 OF 37 ZCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2009:918124 ZCAPLUS Full-text
DOCUMENT NUMBER: 151:166952
TITLE: Assay system for the assessment of oncogenicity, tumor progression, and treatment efficacy
INVENTOR(S): Narain, Niven Rajin; Persaud, Indushekhar
PATENT ASSIGNEE(S): Cytotech Labs, LLC, USA

SOURCE: PCT Int. Appl., 29pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2009094619	A1	20090730	WO 2009-US31957	20090126

W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: US 2008-23570P P 20080125

AB Systems and kits are provided which are capable of determining the oncogenicity of a cancer, tumor progression, and effectiveness of a cancer treatment. Such systems and kits utilize assays to examine the levels of apoptotic markers, angiogenesis markers, immunomodulation markers, and cell cycle markers and can compare samples from a patient taken at different times to determine the oncogenicity of a cancer, tumor progression, and effectiveness of a cancer treatment. Methods for determining the oncogenicity of a cancer, tumor progression, and effectiveness of a cancer treatment with such systems and kits are also provided.

CC 9-1 (Biochemical Methods)
Section cross-reference(s): 1, 14

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L87 ANSWER 6 OF 37 ZCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2009:710042 ZCAPLUS Full-text
DOCUMENT NUMBER: 151:64011
TITLE: Inhalable compositions having enhanced bioavailability
INVENTOR(S): Persaud, Indushekhar; Mccook, John Patrick; Narain, Niven Rajin
PATENT ASSIGNEE(S): Cytotech Labs, LLC, USA
SOURCE: PCT Int. Appl., 54pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2009073843	A1	20090611	WO 2008-US85669	20081205

W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ,

TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: US 2007-992787P P 20071206

AB The present disclosure provides methods and compns. suitable for delivering lipophilic bioactive agents, such as Coenzyme Q10 (CoQ10). The compns. may be utilized to treat numerous diseases and conditions that would benefit from the application of a lipophilic bioactive agent. In embodiments the compns. may be introduced by inhalation. Thus, particles and respirable aggregates of CoQ10 were prepared by a spray freezing into liquid method in presence of Polysorbate 80.

CC 63-6 (Pharmaceuticals)
Section cross-reference(s): 1

IT Absorbents
Analgesics
Anthelmintics
Anti-inflammatory agents
Antianginal agents
Antiarrhythmics
Antibacterial agents
Anticoagulants
Anticonvulsants
Antidepressants
Antidiabetic agents
Antifoaming agents
Antigout agents
Antihistamines
Antihypertensives
Antimalarials
Antimicrobial agents
Antimigraine agents
Antiobesity agents
Antiosteoporotic agents
Antioxidants
Antiparkinsonian agents
Antipsychotics
Antithyroid agents
Antitumor agents
Antiviral agents
Anxiolytics
Buffers
Cognition enhancers
Cyclooxygenase 2 inhibitors
Dietary supplements
Diuretics
Drug bioavailability
Drug toxicity
Encapsulation
Fungicides
Gastrointestinal agents
Human
Humectants
Hypnotics and Sedatives
Immunosuppressants
Inhalation drug delivery systems
Inotropics
Leukotriene antagonists

Lung
Muscarinic antagonists
Muscle relaxants
Nervous system stimulants
Particle size
Pharmaceutical liposomes
Pharmaceutical particles
Protozoacides
Solubilizers
Solvents
Thickening agents
Tranquilizers
β-Adrenoceptor antagonists
(inhalable compns. of lipophilic drugs having enhanced bioavailability)

IT Lung, neoplasm
Neoplasm
(treatment of; inhalable compns. of lipophilic drugs having enhanced bioavailability)

IT 50-14-6, Ergocalciferol 50-21-5D, Lactic acid, derivs. 50-24-8, Prednisolone 50-99-7D, Glucose, deoxy derivs., salts 51-48-9, L-Thyroxine, biological studies 52-01-7, Spironolactone 53-43-0, Dehydroepiandrosterone 55-98-1, Busulfan 57-50-1D, Saccharose, fatty acid esters 57-83-0, Progesterone, biological studies 66-76-2, Dicoumarol 67-20-9, Nitrofurantoin 67-45-8, Furazolidone 67-96-9, Dihydrotachysterol 67-97-0, Cholecalciferol 76-57-3, Codeine 76-99-3, Methadone 77-92-9D, Citric acid, derivs. 87-33-2, Isosorbide dinitrate 90-82-4, Pseudoephedrine 96-26-4, Dihydroxy acetone 104-31-4, Benzonatate 110-15-6D, Butanedioic acid, derivs. 110-17-8D, Fumaric acid, derivs. 110-94-1D, Glutaric acid, derivs. 113-15-5, Ergotamine 113-92-8 122-99-6, Phenoxyethanol 125-84-8, Aminoglutethimide 126-07-8, Griseofulvin 127-17-3D, Pyruvic acid, derivs. 127-40-2, Lutein 141-82-2D, Malonic acid, derivs. 143-19-1, Sodium oleate 151-21-3, Sodium dodecyl sulfate, biological studies 154-17-6, 2-Deoxyglucose 155-97-5, Pyridostigmine 298-46-4, 5H-Dibenz[b,f]azepine-5-carboxamide 298-57-7, Cinnarizine 298-81-7, Methoxsalen 300-62-9, Amphetamine 302-79-4, Tretinoin 303-49-1, Clomipramine 303-53-7, Cyclobenzaprine 303-98-0, Coenzyme Q 10 321-64-2, Tacrine 359-83-1, Pentazocine 378-44-9, Betamethasone 404-86-4, Capsaicin 437-38-7, Fentanyl 443-48-1, Metronidazole 502-65-8, Lycopene 511-12-6, Dihydroergotamine 520-85-4, Medroxyprogesterone 595-33-5 911-45-5, Clomiphene 1134-47-0, Baclofen 1397-89-3, Amphotericin B 1406-16-2, Vitamin D 1406-18-4, Vitamin E 1951-25-3, Amiodarone 1972-08-3, Tetrahydrocannabinol 3573-50-0, 6-Deoxyglucose phosphate 4419-39-0, Beclomethasone 4759-48-2, Isotretinoin 5104-49-4, Flurbiprofen 5343-92-0, Hydrolite 5 6915-15-7D, Malic acid, derivs. 7261-97-4, Dantrolene 7658-08-4, 6-Deoxyglucose 7689-03-4, Camptothecin 9003-39-8D, PVP, conjugates with phosphatidylethanolamine 9004-54-0D, Dextran, polyoxyalkylene derivs. 9004-65-3, Methocel E3 9004-98-2, Brij 98 9005-63-4D, Polyoxyethylene sorbitan, fatty acid esters 9005-65-6, Polysorbate 80 10540-29-1, Tamoxifen 11103-57-4, Vitamin A 12001-79-5, Vitamin K 15307-86-5, Diclofenac 15574-96-6, Pizotifen 15686-51-8, Clemastine 15687-27-1, Ibuprofen 17230-88-5, Danazol 18559-94-9, Albuterol 19356-17-3, Calcifediol 20594-83-6, Nalbuphine 20830-75-5, Digoxin 21256-18-8, Oxaprozin 21829-25-4, Nifedipine 22916-47-8, Miconazole 23288-49-5, Probucol 25322-68-3D, Polyethylene glycol, derivs. 25523-97-1, Dexchlorpheniramine 25812-30-0, Gemfibrozil 27203-92-5, Tramadol 29094-61-9, Glipizide 29767-20-2, Teniposide 32222-06-3, Calcitriol 33069-62-4, Paclitaxel 33419-42-0, Etoposide 34090-49-8, 2-Deoxyglucose phosphate 34911-55-2, Bupropion 38304-91-5, Minoxidil

41340-25-4, Etodolac 42924-53-8, Nabumetone 43200-80-2, Zopiclone
49562-28-9, Fenofibrate 49697-38-3, Rimexolone 51322-75-9, Tizanidine
51333-22-3, Budesonide 51481-61-9, Cimetidine 53123-88-9, Sirolimus
53179-11-6, Loperamide 53230-10-7, Mefloquine 54965-21-8, Albendazole
55079-83-9, Acitretin 55142-85-3, Ticlopidine 59467-70-8, Midazolam
59865-13-3, Cyclosporine 60142-96-3, Gabapentin 61379-65-5,
Rifapentine 61869-08-7, Paroxetine 62013-04-1, Dirithromycin
63590-64-7, Terazosin 63612-50-0, Nilutamide 63675-72-9, Nisoldipine
65271-80-9, Mitoxantrone 65277-42-1, Ketoconazole 68506-86-5,
Vigabatrin 69756-53-2, Halofantrine 70288-86-7, Ivermectin
72432-03-2, Miglitol 72559-06-9, Rifabutine 73590-58-6, Omeprazole
73963-72-1, Cilostazole 74103-06-3, Ketorolac 75330-75-5, Lovastatin
75706-12-6, Leflunomide 76547-98-3, Lisinopril 76824-35-6, Famotidine
76963-41-2, Nizatidine 79617-96-2, Sertraline 79794-75-5, Loratadine
79902-63-9, Simvastatin 81093-37-0, Pravastatin 81098-60-4, Cisapride
81103-11-9, Clarithromycin 82626-48-0, Zolpidem 83799-24-0,
Fexofenadine 83881-51-0, Cetirizine 83905-01-5, Azithromycin
84057-84-1, Lamotrigine 84371-65-3, Mifepristone 84449-90-1,
Raloxifene 84625-61-6, Itraconazole 85721-33-1, Ciprofloxacin
86386-73-4, Fluconazole 86541-75-5, Benazepril 88150-42-9, Amlodipine
89778-26-7, Toremifene 90357-06-5, Bicalutamide 91161-71-6,
Terbinafine 93390-81-9, Fosphenytoin 93413-69-5, Venlafaxine
93479-97-1, Glimepiride 93957-54-1, Fluvastatin 95233-18-4, Atovaquone
97240-79-4, Topiramate 97322-87-7, Troglitazone 97682-44-5, Irinotecan
98319-26-7, Finasteride 101828-21-1, Butenafine 103577-45-3,
Lansoprazole 103628-46-2, Sumatriptan 104987-11-3, Tacrolimus
106133-20-4, Tamsulosin 106392-12-5, Polyoxyethylene-polyoxypropylene
block copolymer 106650-56-0, Sibutramine 107753-78-6, Zafirlukast
111025-46-8, Pioglitazone 111406-87-2, Zileuton 112965-21-6,
Calcipotriene 113665-84-2, Clopidogrel 115103-54-3, Tiagabine
117976-89-3, Rabeprazole 118292-40-3, Tazarotene 120014-06-4,
Donepezil 121679-13-8, Naratriptan 122320-73-4, Rosiglitazone
123948-87-8, Topotecan 127779-20-8, Saquinavir 129497-78-5,
Verteporfin 131918-61-1, Paricalcitol 133040-01-4, Eprosartan
134523-00-5, Atorvastatin 135062-02-1, Repaglinide 137862-53-4,
Valsartan 138402-11-6, Irbesartan 139264-17-8, Zolmitriptan
139481-59-7, Candesartan 144034-80-0, Rizatriptan 144494-65-5,
Tirofiban 144701-48-4, Telmisartan 145599-86-6, Cerivastatin
145941-26-0, 2-178-Interleukin 11 (human clone pXM/IL-11) 147059-72-1,
Trovafloxacin 153559-49-0, Targretin 154598-52-4, Efavirenz
155213-67-5, Ritonavir 158747-02-5, Frovatriptan 158966-92-8,
Montelukast 159989-64-7, Nelfinavir 162011-90-7, Rofecoxib
169590-42-5, Celecoxib 171599-83-0, Sildenafil citrate 691397-13-4,
Pluronic F 127
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(inhalable compns. of lipophilic drugs having enhanced bioavailability)

IT 303-98-0, Coenzyme Q 10
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(inhalable compns. of lipophilic drugs having enhanced bioavailability)

RN 303-98-0 ZCAPLUS

CN 2,5-Cyclohexadiene-1,4-dione, 2-[(2E,6E,10E,14E,18E,22E,26E,30E,34E)-3,7,11,15,19,23,27,31,35,39-decamethyl-2,6,10,14,18,22,26,30,34,38-tetracontadecaen-1-yl]-5,6-dimethoxy-3-methyl- (CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A



PAGE 1-B



PAGE 1-C

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L87 ANSWER 7 OF 37 ZCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2009:470777 ZCAPLUS Full-text
DOCUMENT NUMBER: 150:497155
TITLE: Method and apparatus for obtaining ultrafine lipid, lipid-soluble substance or macromolecular particle by atomizing supercritical carbon dioxide saturated solution
INVENTOR(S): Li, Jun; Hong, Wei; Su, Yuzhong; Wang, Hongtao
PATENT ASSIGNEE(S): Xiamen University, Peop. Rep. China
SOURCE: Faming Zhuanli Shenqing Gongkai Shuomingshu, 10pp. CODEN: CNXXEV
DOCUMENT TYPE: Patent
LANGUAGE: Chinese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
CN 101406818	A	20090415	CN 2008-10072107	20081112
PRIORITY APPLN. INFO.:			CN 2008-10072107	20081112

AB The title apparatus comprises a carbon dioxide storage tank, a high pressure atomizing fluid storage tank, a condensing tank, a buffer tank, a high pressure mixing tank, a collecting chamber, a filter, a normal pressure material tank, two pressure-controlled pumps or compressors, a high pressure circulating pump, a high pressure liquid pump, a compressor, a valve, a pressure meter, and a temperature meter. The method comprises (1) melting a material to be treated, placing into the mixing tank, introducing carbon

dioxide into the mixing tank, and heating the mixing tank until the carbon dioxide reaches supercrit. state, and (2) starting the circulating pump to pump the material in the mixing tank from the bottom to the top for circulation until a carbon dioxide saturated solution is formed in the mixing tank, delivering into one passage of a coaxial dual-passage spray nozzle, adding atomizing fluid into the other passage to atomize the carbon dioxide saturated solution, and collecting solidified particles in the collecting chamber.

CC 48-3 (Unit Operations and Processes)
Section cross-reference(s): 49

IT 303-98-0, Coenzyme Q10 544-63-8, Myristic acid, uses
25322-68-3, Polyethylene glycol
RL: TEM (Technical or engineered material use); USES (Uses)
(method and apparatus for obtaining ultrafine lipid, lipid-soluble substance or
macromol. particle by atomizing supercrit. carbon dioxide saturated solution)

IT 303-98-0, Coenzyme Q10
RL: TEM (Technical or engineered material use); USES (Uses)
(method and apparatus for obtaining ultrafine lipid, lipid-soluble substance or
macromol. particle by atomizing supercrit. carbon dioxide saturated solution)

RN 303-98-0 ZCAPLUS

CN 2,5-Cyclohexadiene-1,4-dione, 2-[(2E,6E,10E,14E,18E,22E,26E,30E,34E)-3,7,11,15,19,23,27,31,35,39-decamethyl-2,6,10,14,18,22,26,30,34,38-tetracontadecaen-1-yl]-5,6-dimethoxy-3-methyl- (CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A



PAGE 1-B



PAGE 1-C

L87 ANSWER 8 OF 37 ZCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2008:1156621 ZCAPLUS Full-text
DOCUMENT NUMBER: 149:409737
TITLE: Topical formulations comprising lipophilic bioactive agents having enhanced bioavailability
INVENTOR(S): McCook, John Patrick; Narain, Niven Rajin; Persaud, Indushekhar
PATENT ASSIGNEE(S): Pathfinder Management, Inc., USA
SOURCE: PCT Int. Appl., 68pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008116135	A2	20080925	WO 2008-US57786	20080321
WO 2008116135	A3	20081224		
W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				
AU 2008228764	A1	20080925	AU 2008-228764	20080321
CA 2680825	A1	20080925	CA 2008-2680825	20080321
US 20080233183	A1	20080925	US 2008-52825	20080321
EP 2136787	A2	20091230	EP 2008-732635	20080321
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR				
NO 2009003032	A	20091022	NO 2009-3032	20090921
MX 2009010170	A	20091126	MX 2009-10170	20090922
PRIORITY APPLN. INFO.:			US 2007-919554P P	20070322
			WO 2008-US57786 W	20080321

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

AB The present disclosure provides compns. suitable for delivering lipophilic bioactive agents. The compns. may be utilized to treat numerous diseases and conditions that would benefit from the application of a lipophilic bioactive agent. Thus, a cream contained Polysorbate-80 25.000, ubidecarenone 21.000, propylene glycol 10.000, phenoxyethanol 0.500, water 35.500, and lecithin 8.000%.

CC 63-6 (Pharmaceuticals)
IT Absorbents
Analgesics
Anthelmintics
Anti-inflammatory agents
Antianginal agents
Antiarrhythmics
Antibacterial agents
Anticoagulants
Anticonvulsants

Antidepressants
Antidiabetic agents
Antifoaming agents
Antihistamines
Antihypertensives
Antimalarials
Antimicrobial agents
Antimigraine agents
Antiobesity agents
Antiosteoporotic agents
Antioxidants
Antiparkinsonian agents
Antipsychotics
Antithyroid agents
Antitumor agents
Antiviral agents
Anxiolytics
Buffers
Carcinoma
Chelating agents
Cognition enhancers
Cyclooxygenase 2 inhibitors
Diuretics
Emulsifying agents
Fungicides
Gastrointestinal agents
Human
Humectants
Hypnotics and Sedatives
Immunosuppressants
Inotropics
Leukemia
Leukotriene antagonists
Lymphoma
Melanoma
Muscarinic antagonists
Muscle relaxants
Neoplasm
Nervous system stimulants
Nutrition, animal
Permeation enhancers
Pharmaceutical creams
Pharmaceutical liposomes
Pigments, nonbiological
Protozoacides
Sarcoma
Skin emollients
Solubilizers
Solvents
Stabilizing agents
Surfactants
Thickening agents
Tranquilizers
β-Adrenoceptor antagonists
(topical formulations comprising lipophilic bioactive agents having enhanced bioavailability)

IT 50-14-6, Ergocalciferol 50-21-5, 2-Hydroxypropionic acid, biological studies 50-21-5D, Lactic acid, derivs. 50-24-8, Prednisolone 50-28-2, Estradiol, biological studies 51-48-9, L-Thyroxine, biological studies 52-01-7, Spironolactone 55-98-1, Busulphan 56-81-5,

Glycerin, biological studies 57-10-3D, Palmitic acid, derivs. 57-11-4D, Stearic acid, derivs. 57-13-6, Urea, biological studies 57-50-1D, Saccharose, fatty acid esters 57-55-6, Propylene glycol, biological studies 57-83-0, Progesterone, biological studies 60-33-3D, Linoleic acid, derivs. 64-17-5, Ethanol, biological studies 65-85-0D, Benzoic acid, C12-15 alkyl esters 66-76-2, Dicoumarol 67-20-9, Nitrofurantoin 67-45-8, Furazolidone 67-63-0, 2-Propanol, biological studies 67-64-1, Acetone, biological studies 67-68-5, Dimethyl sulfoxide, biological studies 67-71-0, Methyl sulfonyl methane 67-96-9, Dihydrotachysterol 67-97-0, Cholecalciferol 68-12-2, N,N-Dimethylformamide, biological studies 71-23-8, 1-Propanol, biological studies 72-17-3, Sodium lactate 75-65-0, 2-Methyl propan-2-ol, biological studies 76-57-3, Codeine 76-99-3, Methadone 77-92-9D, Citric acid, derivs. 84-74-2, Dibutyl phthalate 84-77-5, Didecyl phthalate 87-33-2, Isosorbide dinitrate 90-82-4, Pseudoephedrine 97-64-3, Ethyl 2-hydroxypropanoate 97-99-4 102-71-6, Triethanolamine, biological studies 103-23-1, Dioctyl adipate 103-24-2, Dioctyl azelate 104-31-4, Benzonatate 106-18-3, Butyl laurate 106-32-1, Ethyl caprylate 106-33-2, Ethyl laurate 106-79-6, Dimethyl sebacate 107-88-0, 1,3-Butylene glycol 108-27-0, 5-Methyl-2-pyrrolidone 109-43-3, Dibutyl sebacate 109-99-9, Tetrahydrofuran, biological studies 110-17-8D, Fumaric acid, derivs. 110-36-1, Butyl myristate 110-38-3, Ethyl caprate 110-40-7, Diethyl sebacate 110-63-4, 1,4-Butanediol, biological studies 110-98-5, Bis(2-hydroxypropyl)ether 111-20-6D, Sebacic acid, derivs. 111-46-6, Diglycol, biological studies 111-87-5, Octyl alcohol, biological studies 111-90-0 112-53-8, Lauryl alcohol 112-92-5, Stearyl alcohol 113-15-5, Ergotamine 113-92-8 118-58-1, Benzyl salicylate 118-61-6, Ethyl salicylate 120-51-4, Benzyl benzoate 122-62-3, Dioctyl sebacate 122-99-6, Phenoxyethanol 123-66-0, Ethyl caproate 123-91-1, 1,4-Dioxane, biological studies 123-95-5, Butyl stearate 124-06-1, Ethyl myristate 125-84-8, Aminoglutethimide 126-07-8, Griseofulvin 127-19-5, N,N-Dimethylacetamide 127-40-2, Lutein 134-62-3, Diethyl-m-toluamide 136-60-7, Butyl benzoate 140-24-9, Dibenzyl sebacate 141-03-7, Dibutyl succinate 142-91-6, Isopropyl palmitate 143-28-2, Oleyl alcohol 155-97-5, Pyridostigmine 298-46-4, 5H-Dibenz[b,f]azepine-5-carboxamide 298-57-7, Cinnarizine 298-81-7, Methoxsalen 300-62-9, Amphetamine 302-79-4, Tretinoin 303-49-1, Clomipramine 303-53-7, Cyclobenzaprine 303-98-0, Coenzyme Q10 321-64-2, Tacrine 334-48-5D, Decanoic acid, derivs. 359-83-1, Pentazocine 378-44-9, Betamethasone 404-86-4, Capsaicin 437-38-7, Fentanyl 443-48-1, Metronidazole 502-65-8, Lycopene 511-12-6, Dihydroergotamine 520-85-4, Medroxyprogesterone 595-33-5 616-45-5, 2-Pyrrolidone 617-73-2, 2-Hydroxyoctanoic acid 625-69-4, 2,4-Pentanediol 872-50-4, 1-Methyl-2-pyrrolidone, biological studies 911-45-5, Clomiphene 1134-47-0, Baclofen 1319-41-1, Laponite 1327-43-1, Aluminum magnesium silicate 1343-98-2, Silicic acid 1397-89-3, Amphotericin B 1406-16-2, Vitamin D 1406-18-4, Vitamin E 1732-10-1, Dimethyl azelate 1951-25-3, Amiodarone 1972-08-3, Tetrahydrocannabinol 2568-33-4, Isopentyl diol 2687-91-4, 1-Ethyl-2-pyrrolidone 2917-73-9, Dibutyl azelate 2935-44-6, 2,5-Hexanediol 3687-46-5, Decyl oleate 4419-39-0, Beclometasone 4759-48-2, Isotretinoin 5075-92-3, 1,5-Dimethyl-2-pyrrolidone 5104-49-4, Flurbiprofen 5343-92-0, Hydrolite 5 5343-92-0, 1,2-Pentanediol 6144-28-1D, Dilinoleic acid, derivs. 6938-94-9, Diisopropyl adipate 7261-97-4, Dantrolene 7491-02-3, Diisopropyl sebacate 7689-03-4, Camptothecin 9000-01-5, Acacia gum 9000-07-1, Carrageenin 9000-30-0, Guar gum 9000-36-6, Karaya gum 9000-40-2, Carob gum 9000-65-1, Tragacanth 9000-69-5, Pectin 9002-18-0, Agar 9002-89-5, Polyvinyl alcohol 9002-98-6 9003-01-4D, Acrylic acid

polymer, crosslinked 9003-04-7, Sodium polyacrylate 9003-05-8, Polyacrylamide 9003-32-1, Poly(ethyl acrylate) 9003-39-8, Polyvinylpyrrolidone 9003-39-8D, Polyvinylpyrrolidone, reaction products with phosphatidylethanolamines 9004-54-0, Dextran, biological studies 9004-54-0D, Dextran, alkoxylated 9004-74-4, Methoxy polyethylene glycol 9004-81-3, Polyethylene glycol laurate 9004-96-0, Polyoxyethylene oleate 9004-99-3, Polyethylene glycol stearate 9005-08-7, Polyethylene glycol distearate 9005-25-8, Starch, biological studies 9005-37-2, Propylene glycol Alginate 9005-38-3, Sodium alginate 9005-63-4D, Ethoxylated sorbitan, fatty acid esters 9005-65-6, Polysorbate 80 9014-37-3, Succinoglucan 9036-88-8, Mannan 9037-22-3, Amylopectin 9037-55-2, Galactan 9057-02-7, Pullulan 9057-06-1, Carboxymethyl starch 10238-21-8, Glibenclamide 10540-29-1, Tamoxifen 11099-07-3, Glyceryl stearate 11103-57-4, Vitamin A 11138-66-2, Xanthan gum 12001-79-5, Vitamin K 12173-47-6, Hectorite 13463-67-7, Titanium dioxide, biological studies 15307-86-5, Diclofenac 15574-96-6, Pizotifen 15686-51-8, Clemastine 15687-27-1, Ibuprofen 16090-77-0, Dibutyl suberate 17230-88-5, Danazol 18559-94-9, Albuterol 19356-17-3, Calcifediol 20594-83-6, Nalbuphine 20830-75-5, Digoxin 21256-18-8, Oxaprozin 21829-25-4, Nifedipine 22916-47-8, Miconazole 23288-49-5, Probucol 25231-21-4, Polyoxypropylene stearyl ether 25322-68-3D, esters or ethers 25523-97-1, Dexchlorpheniramine 25812-30-0, Gemfibrozil 27203-92-5, Tramadol 29094-61-9, Glipizide 29767-20-2, Teniposide 30399-84-9D, Isostearic acid, derivs. 32222-06-3, Calcitriol 33069-62-4, Paclitaxel 33419-42-0, Etoposide 34316-64-8, Hexyl laurate 34911-55-2, Bupropion 36653-82-4, Cetyl alcohol 38304-91-5, Minoxidil 39421-75-5, Hydroxypropyl guar gum 39464-87-4, Scleroglucan 41340-25-4, Etodolac 41395-83-9, Propylene glycol dipelargonate 42924-53-8, Nabumetone 43200-80-2, Zopiclone 49562-28-9, Fenofibrate 49697-38-3, Rimexolone 51333-22-3, Budesonide 51481-61-9, Cimetidine 53123-88-9, Sirolimus 53179-11-6, Loperamide 53230-10-7, Mefloquine 54965-21-8, Albendazole 55079-83-9, Acitretin 55142-85-3, Ticlopidine 58251-46-0, RitaPRO 165 59227-89-3, 1-Dodecylazacycloheptan-2-one 59467-70-8, Midazolam 59587-44-9, 2-Ethylhexyl pelargonate 60142-96-3, Gabapentin 61379-65-5, Rifapentine 61869-08-7, Paroxetine 62013-04-1, Dirithromycin 62356-64-3 63590-64-7, Terazosin 63612-50-0, Nilutamide 63675-72-9, Nisoldipine 65271-80-9, Mitoxantrone 65277-42-1, Ketoconazole
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(topical formulations comprising lipophilic bioactive agents having enhanced bioavailability)

IT 303-98-0, Coenzyme Q10
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(topical formulations comprising lipophilic bioactive agents having enhanced bioavailability)

RN 303-98-0 ZCAPLUS

CN 2,5-Cyclohexadiene-1,4-dione, 2-[(2E,6E,10E,14E,18E,22E,26E,30E,34E)-3,7,11,15,19,23,27,31,35,39-decamethyl-2,6,10,14,18,22,26,30,34,38-tetracontadecaen-1-yl]-5,6-dimethoxy-3-methyl- (CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A



PAGE 1-B



PAGE 1-C

OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)

L87 ANSWER 9 OF 37 ZCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2008:1095572 ZCAPLUS Full-text
DOCUMENT NUMBER: 150:279445
TITLE: Effects of coq10 supplementation and incremental load training on the activities of skeletal muscle mitochondrial respiratory chain complexes of rats with an exhaust exercise
AUTHOR(S): Li, Jie; Wang, Yuxia; Xing, Liangmei; Zhang, Yaobin
CORPORATE SOURCE: College of Physical Education, Northwest Normal University, Lanzhou, 730070, Peop. Rep. China
SOURCE: Zhongguo Yundong Yixue Zazhi (2008), 27(4), 475-477
CODEN: ZYYZAS; ISSN: 1000-6710
PUBLISHER: Zhongguo Tiyu Baoye Zongshe
DOCUMENT TYPE: Journal
LANGUAGE: Chinese

AB The effects of CoQ10 supplementation and incremental load training on the activities of skeletal muscle mitochondrial respiratory chain complexes I-III of rats with an exhaust exercise were studied. 36 Male Wistar rats (2-mo-old) were divided into 4 groups (n = 9): control group (NC), CoQ10 supplementation group (QC), training group , and CoQ10 supplementation + training group (QE). Rats were fed and trained for 7 wk. Rats in QC group and QE group were supplemented CoQ10 (2 mg/100 g body mass per day). Rats only in NE group and QE group were performed incremental load treadmill training. Rats in each group were performed an exhaust exercise and then sacrificed, and the activities of mitochondrial respiratory chain complexes were detected. The activity of complex I in QC group and QE group was significantly lower than that in NC group (P <0.05, P <0.01), and that in QE group was significantly

lower than that in NE group (P <0.05). The activity of complex II in QC group was significantly higher than that in NC group (P <0.01), that in QE group was significantly lower than that in QC group (P <0.01), and that in QE group was significantly higher than that in NE group (P <0.05). The activity of complex III in QC group and NE group was significantly higher than that in NC group (P <0.01). The results showed that single CoQ10 supplementation and incremental load training can increase instant function of skeletal muscle mitochondrial respiratory chain, preferably single CoQ10 supplementation, but there was no synergistic effect between both.

CC 13-6 (Mammalian Biochemistry)

IT 303-98-0, Coenzyme Q10 9028-04-0, NADH-CoQ reductase
9028-11-9, Succinate-CoQ reductase
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(effects of coq10 supplementation and incremental load training on the activities of skeletal muscle mitochondrial respiratory chain complexes of rats with an exhaust exercise)

IT 303-98-0, Coenzyme Q10
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(effects of coq10 supplementation and incremental load training on the activities of skeletal muscle mitochondrial respiratory chain complexes of rats with an exhaust exercise)

RN 303-98-0 ZCAPLUS

CN 2,5-Cyclohexadiene-1,4-dione, 2-[(2E,6E,10E,14E,18E,22E,26E,30E,34E)-3,7,11,15,19,23,27,31,35,39-decamethyl-2,6,10,14,18,22,26,30,34,38-tetracontadecaen-1-yl]-5,6-dimethoxy-3-methyl- (CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A



PAGE 1-B



PAGE 1-C

L87 ANSWER 10 OF 37 ZCAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2009:1376098 ZCAPLUS Full-text
DOCUMENT NUMBER: 152:117420
TITLE: Screening of coenzyme Q10 producing marine yeast and optimization of its culture conditions
AUTHOR(S): Li, Junfeng; Yao, Shumin; Li, Hongfang
CORPORATE SOURCE: Department of Bioengineering and Biotechnology, Qingdao University of Science and Technology, Qingdao, Shandong Province, 266043, Peop. Rep. China
SOURCE: Shipin Kexue (Beijing, China) (2008), 29(12), 426-430
CODEN: SPKHD5; ISSN: 1002-6630
PUBLISHER: Zhongguo Shipin Zazhishe
DOCUMENT TYPE: Journal
LANGUAGE: Chinese

AB Eleven coenzyme Q10 producing strains were isolated from 50 marine yeasts preliminarily. A high-producing strain, FH-8 was obtained through rescreening from those 11 yeasts. The fermentation conditions of CoQ10 by FH-08 were optimized. The optimal fermentation conditions were as following: carbon source of glucose 3%, nitrogen source of yeast extract 2%, initial pH 6.5, inoculum size 4%, filled volume of medium 50 mL/300 mL, temperature 30℃ and rotation speed 200 r/min. Under these fermentation conditions, the biomass reached 2.34 g/200 mL, and the CoQ10 concentration in broth reaches 28.6 mg/L.

CC 16-2 (Fermentation and Bioindustrial Chemistry)
IT 303-98-0P, Coenzyme Q10
RL: BMF (Bioindustrial manufacture); BIOL (Biological study); PREP (Preparation)
(screening of coenzyme Q10 producing marine yeast and optimization of its culture conditions)
IT 303-98-0P, Coenzyme Q10
RL: BMF (Bioindustrial manufacture); BIOL (Biological study); PREP (Preparation)
(screening of coenzyme Q10 producing marine yeast and optimization of its culture conditions)
RN 303-98-0 ZCAPLUS
CN 2,5-Cyclohexadiene-1,4-dione, 2-[(2E,6E,10E,14E,18E,22E,26E,30E,34E)-3,7,11,15,19,23,27,31,35,39-decamethyl-2,6,10,14,18,22,26,30,34,38-tetracontadecaen-1-yl]-5,6-dimethoxy-3-methyl- (CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A



PAGE 1-B



L87 ANSWER 11 OF 37 ZCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2009:499251 ZCAPLUS Full-text
DOCUMENT NUMBER: 151:196411
TITLE: Promotion of coenzyme Q10 productivity through tolerating high concentration of precursor and structure analogy
AUTHOR(S): Li, Jiyang; Ding, Yan; Zhou, Pei
CORPORATE SOURCE: Department of Biosynthesis Medicinal Chemistry, School of Pharmacy, Fudan University, Shanghai, 200032, Peop. Rep. China
SOURCE: Fudan Xuebao, Yixueban (2008), 35(3), 393-395, 400
CODEN: FXYUAO; ISSN: 1672-8467
PUBLISHER: Fudan Xuebao, Yixueban Bianji Weiyuanhui
DOCUMENT TYPE: Journal
LANGUAGE: Chinese

AB The coenzyme Q10 productivity of Candida tropicalis was promoted. Candida tropcalis was used as the starting strain and subjected to UV-radiation. On the basis of feedback regulation mechanism for coenzyme Q10 synthesis pathway, a high productivity coenzyme Q10 mutant screening method was set up. Mutants were specifically screened with high concentration coenzyme Q10 precursor p-hydroxybenzoic acid and benzonic acid. The final coenzyme Q10 yield of the mutant reached 120 μg/mL, which was 2.84 times higher than that of the original strain. The high concentration biosynthetic precursor can promote the coenzyme Q10 productivity.

CC 16-5 (Fermentation and Bioindustrial Chemistry)
Section cross-reference(s): 7, 10

IT 303-98-0P, Coenzyme Q10
RL: BMF (Bioindustrial manufacture); BSU (Biological study, unclassified); BIOL (Biological study); PREP (Preparation)
(promotion of coenzyme Q10 productivity through screening of UV radiation-induced Candida tropicalis mutant)

IT 303-98-0P, Coenzyme Q10
RL: BMF (Bioindustrial manufacture); BSU (Biological study, unclassified); BIOL (Biological study); PREP (Preparation)
(promotion of coenzyme Q10 productivity through screening of UV radiation-induced Candida tropicalis mutant)

RN 303-98-0 ZCAPLUS
CN 2,5-Cyclohexadiene-1,4-dione, 2-[(2E,6E,10E,14E,18E,22E,26E,30E,34E)-3,7,11,15,19,23,27,31,35,39-decamethyl-2,6,10,14,18,22,26,30,34,38-tetracontadecaen-1-yl]-5,6-dimethoxy-3-methyl- (CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A



PAGE 1-B



PAGE 1-C

L87 ANSWER 12 OF 37 ZCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2007:166267 ZCAPLUS Full-text
DOCUMENT NUMBER: 146:254492
TITLE: Nitrogen-assisted method and device for preparing microspheres
INVENTOR(S): Li, Jun; Su, Yuzhong; Wang, Hongtao
PATENT ASSIGNEE(S): Xiamen University, Peop. Rep. China
SOURCE: Faming Zhuanli Shenqing Gongkai Shuomingshu, 10pp. CODEN: CNXXEV
DOCUMENT TYPE: Patent
LANGUAGE: Chinese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
CN 1907553	A	20070207	CN 2006-10036589	20060720
CN 100478062	C	20090415		

PRIORITY APPLN. INFO.: CN 2006-10036589 20060720

AB The title method comprises pumping raw material to a high-pressure system, sending to a nozzle, atomizing with high-pressure nitrogen gas, and curing atomized particles in a particle collecting chamber. The title device comprises gas conveying part, liquid conveying part, particle forming/collecting part, and control/display part. By adopting supercrit. nitrogen gas and coaxial two-channel nozzle, the invention can conveniently treat liquid raw material with simplified operation and control to form uniform microspheres.

CC 48-4 (Unit Operations and Processes)
IT 303-98-0, Coenzyme Q10

RL: PEP (Physical, engineering or chemical process); TEM (Technical or engineered material use); PROC (Process); USES (Uses)
(nitrogen-assisted method and device for preparation of microspheres)
IT 303-98-0, Coenzyme Q10
RL: PEP (Physical, engineering or chemical process); TEM (Technical or engineered material use); PROC (Process); USES (Uses)
(nitrogen-assisted method and device for preparation of microspheres)
RN 303-98-0 ZCAPLUS
CN 2,5-Cyclohexadiene-1,4-dione, 2-[(2E,6E,10E,14E,18E,22E,26E,30E,34E)-3,7,11,15,19,23,27,31,35,39-decamethyl-2,6,10,14,18,22,26,30,34,38-tetracontadecaen-1-yl]-5,6-dimethoxy-3-methyl- (CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A



PAGE 1-B



PAGE 1-C

OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)

L87 ANSWER 13 OF 37 ZCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2008:293049 ZCAPLUS Full-text
DOCUMENT NUMBER: 150:144172
TITLE: Friedel-Crafts allylation of 2-(benzyloxy)-3,4,5-trimethoxytoluene catalyzed by a metal trifluoromethanesulfonate salt in synthesis of coenzyme Q10
AUTHOR(S): Zheng, Yun-Feng; Lin, Jing-Du; Li, Cheng-Ping; Li, Jing-Rua
CORPORATE SOURCE: College of Pharmaceutical Sciences, Zhejiang University of Technology, 310032, Peop. Rep. China
SOURCE: Journal of Chemical Research (2007), (12), 686-688
CODEN: JCROA4

PUBLISHER: Science Reviews
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 150:144172

GI



I



II

AB In the presence of a catalytic amount of scandium triflate, 2-(benzyloxy)-3,4,5-trimethoxytoluene reacted with allylic derivs., giving the key intermediate (E)-I, which was used for preparing coenzyme Q10 (II) in moderate to high yields.

CC 26-8 (Biomolecules and Their Synthetic Analogs)
Section cross-reference(s): 25

IT 303-98-0P, Coenzyme Q10
RL: SPN (Synthetic preparation); PREP (Preparation)
(Friedel-Crafts allylation of 2-(benzyloxy)-3,4,5-trimethoxytoluene catalyzed by scandium triflate in preparation of coenzyme Q10)

IT 303-98-0P, Coenzyme Q10
RL: SPN (Synthetic preparation); PREP (Preparation)
(Friedel-Crafts allylation of 2-(benzyloxy)-3,4,5-trimethoxytoluene catalyzed by scandium triflate in preparation of coenzyme Q10)

RN 303-98-0 ZCAPLUS

CN 2,5-Cyclohexadiene-1,4-dione, 2-[(2E,6E,10E,14E,18E,22E,26E,30E,34E)-3,7,11,15,19,23,27,31,35,39-decamethyl-2,6,10,14,18,22,26,30,34,38-tetracontadecaen-1-yl]-5,6-dimethoxy-3-methyl- (CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A



PAGE 1-B



PAGE 1-C

REFERENCE COUNT: 41 THERE ARE 41 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L87 ANSWER 14 OF 37 ZCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2008:482201 ZCAPLUS Full-text
DOCUMENT NUMBER: 149:124950
TITLE: Protecting myocardium by inhibiting activation of nuclear factor kappa B in open heart surgery
AUTHOR(S): Wang, Yun; Yi, Dinghua; Wan, Ronghua; Gu, Jiwei; Li, Junpeng
CORPORATE SOURCE: Department of Cardiothoracic Surgery, Ningxia Medical College Hospital, Yinchuan, Ningxia Province, 750004, Peop. Rep. China
SOURCE: Xi'an Jiaotong Daxue Xuebao, Yixueban (2007), 28(1), 43-46
CODEN: XJDXAS; ISSN: 1671-8259
PUBLISHER: Xi'an Jiaotong Daxue Xuebao, Yixueban Bianjibu
DOCUMENT TYPE: Journal
LANGUAGE: Chinese

AB The relationship of the activation of nuclear factor kappa B (NF-κB) with myocardial neutrophil infiltration and injury in human open heart surgery was investigated, and the inhibiting effect on the activation of NF-κB and protecting effect on myocardium of the Coenzyme Q10, a scavenger of oxygen free radicals, were observed Forty-seven adult patients undergoing open heart surgery were randomly divided into two groups, the control group and the treatment group. Coenzyme Q10 tablets were given to the treatment group 5 days before operation. Biopsy of right atrium for myocardial pathol., activated NF-κB detection and ultrastructure observation were done prior to cardiopulmonary bypass, 45 min of ischemia and 45 min of reperfusion. The dynamic indexes, vasomotor drug dosage and outcomes were observed postoperatively. Upon 45 min of ischemia and 45 min of reperfusion, in control group there were neutrophil accumulation and adhesion of vascular endothelium, ultrastructural damages, and pos. expression of NF-κB both in nuclei and cytoplasm, and in myocardium. In treatment group, there were only mild neutrophil infiltration and ultrastructural damages, and weak pos. expression of NF-κB both in nuclei and cytoplasm. However, the dynamic indexes, vasomotor drug dosage and outcomes of two groups were not significantly different. NF-κB plays an important role in pathophysiol. process of myocardial ischemia and reperfusion in open heart surgery. Coenzyme Q10 has obvious inhibiting effect on activation of NF-κB and protecting effect on myocardium.

CC 14-2 (Mammalian Pathological Biochemistry)
IT 303-98-0, Coenzyme Q10
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(protecting myocardium by inhibiting activation of nuclear factor kappa B in open heart surgery)
IT 303-98-0, Coenzyme Q10
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(protecting myocardium by inhibiting activation of nuclear factor kappa B in open heart surgery)
RN 303-98-0 ZCAPLUS
CN 2,5-Cyclohexadiene-1,4-dione, 2-[(2E,6E,10E,14E,18E,22E,26E,30E,34E)-3,7,11,15,19,23,27,31,35,39-decamethyl-2,6,10,14,18,22,26,30,34,38-tetracontadecaen-1-yl]-5,6-dimethoxy-3-methyl- (CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A



PAGE 1-B



PAGE 1-C

L87 ANSWER 15 OF 37 ZCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2009:67033 ZCAPLUS Full-text
DOCUMENT NUMBER: 151:6847
TITLE: Breeding of the analogue-resistant strains for high production of coenzyme Q10
AUTHOR(S): Qi, Wei; Li, Jing; Li, Jian; Wang, Jianling; Du, Lianxiang
CORPORATE SOURCE: Tianjin Key Laboratory of Industrial Microbiology, College of Biotechnology, Tianjin University of Science and Technology, Tianjin, 300457, Peop. Rep. China
SOURCE: Gongye Weishengwu (2007), 37(6), 12-15
CODEN: GOWEEK; ISSN: 1001-6678

PUBLISHER: Quanguo Gongye Weishengwu Xinxi Zhongxin
DOCUMENT TYPE: Journal
LANGUAGE: Chinese

AB Agrobacterium sp. TLY-4 was treated by NTG with the death-rate of 70%. Two vitamin K3-resistant mutants R-122 and R-015 with high production of Co Q10 were obtained. The CoQ10 yield of R-122 and R-015 reached 57.3 mg/L and 59.9 mg/L in shaking flask for 72 h. They were 35.7% and 41.6% higher than that of the original strain resp. The mutants R-122 and R-015 showed high genetic stability in subculture expts. The problem of the insoly. of vitamin K3 in the medium was solved by adding N, N-dimethylformamide (DMF) and Tween-80. And the minimal inhibitory concentration of vitamin K3 in ager plat was 0.15 mg/mL.

CC 16-2 (Fermentation and Bioindustrial Chemistry)

IT 303-98-0P, Coenzyme Q10
RL: BMF (Bioindustrial manufacture); BIOL (Biological study); PREP (Preparation)
(increase in fermentation of coenzyme Q10 by mutagenesis of Agrobacterium)

IT 303-98-0P, Coenzyme Q10
RL: BMF (Bioindustrial manufacture); BIOL (Biological study); PREP (Preparation)
(increase in fermentation of coenzyme Q10 by mutagenesis of Agrobacterium)

RN 303-98-0 ZCAPLUS

CN 2,5-Cyclohexadiene-1,4-dione, 2-[(2E,6E,10E,14E,18E,22E,26E,30E,34E)-3,7,11,15,19,23,27,31,35,39-decamethyl-2,6,10,14,18,22,26,30,34,38-tetracontadecaen-1-yl]-5,6-dimethoxy-3-methyl- (CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A



PAGE 1-B



PAGE 1-C

L87 ANSWER 16 OF 37 ZCAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2006:649839 ZCAPLUS Full-text
DOCUMENT NUMBER: 145:167431
TITLE: Synthesis of coenzyme Q10
INVENTOR(S): Li, Jinghua; Zheng, Yunfeng; Shen, Huafeng
PATENT ASSIGNEE(S): Zhejiang University of Technology, Peop. Rep. China
SOURCE: Faming Zhuanli Shenqing Gongkai Shuomingshu, 22 pp.
CODEN: CNXXEV
DOCUMENT TYPE: Patent
LANGUAGE: Chinese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
CN 1793100	A	20060628	CN 2005-10062381	20051230
PRIORITY APPLN. INFO.:			CN 2005-10062381	20051230

OTHER SOURCE(S): CASREACT 145:167431; MARPAT 145:167431
GI



I



II

AB The title preparation includes alkali metal reduction of 2,3,4-trimethoxy-5-R-oxy-6-methylphenyl polyisoprene (formula I, R = diphenylmethyl or benzyl or benzyl substituted with C1-6 hydrocarbyl or methoxy or ethoxy) at -80 to 40° in organic solvent (C1-6 alc., liquid ammonia, methylamine, dimethylamine, ethylamine, diethylamine, or their mixture) to generate 5-hydroxy-2,3,4-trimethoxy-6-methylphenyl polyisoprene, then oxidation with ferric salt to generate the coenzyme Q10, wherein the compound I was obtained by reduction/desulfonation 2-(4-solanesyl-4-arylsulfonyl-3-methyl-but-2-enyl)-3,4,5-trimethoxy-6-R- oxytoluene II with lithium triethylborohydride in the presence of Pd(DPPP)Cl2. The method has the advantage of high product yield and can be industrialized at lower cost.

CC 30-40 (Terpenes and Terpenoids)
IT 303-98-0P, Coenzyme Q10
RL: SPN (Synthetic preparation); PREP (Preparation)
(synthesis of coenzyme Q10 via reduction/desulfonation and oxidation)

IT 303-98-0P, Coenzyme Q10
RL: SPN (Synthetic preparation); PREP (Preparation)
(synthesis of coenzyme Q10 via reduction/desulfonation and oxidation)
RN 303-98-0 ZCAPLUS
CN 2,5-Cyclohexadiene-1,4-dione, 2-[(2E,6E,10E,14E,18E,22E,26E,30E,34E)-3,7,11,15,19,23,27,31,35,39-decamethyl-2,6,10,14,18,22,26,30,34,38-tetracontadecaen-1-yl]-5,6-dimethoxy-3-methyl- (CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A



PAGE 1-B



PAGE 1-C

L87 ANSWER 17 OF 37 ZCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2006:1033182 ZCAPLUS Full-text
DOCUMENT NUMBER: 146:323916
TITLE: Evaluation of uncertainty for determination the content of coenzyme Q10 capsules by HPLC.
AUTHOR(S): Lin, Huijing; Li, Jie
CORPORATE SOURCE: Dongguan Institute for Drug Control, Dongguan, GuangDong, 523109, Peop. Rep. China
SOURCE: Zhongguo Yaoshi (Wuhan, China) (2006), 9(6), 498-500
CODEN: ZYWCAH; ISSN: 1008-049X
PUBLISHER: Yaowu Liuxingbingxue Zazhishe
DOCUMENT TYPE: Journal
LANGUAGE: Chinese
AB A method was established for evaluation of uncertainty in content assaying of coenzyme Q10 capsules by HPLC. ODS was employed as stationary phase, MeOH-EtOH (1:1) was used as mobile phase and the detection wavelength was set to 275 nm. Uncertainty in each ponderance were analyzed and put forward combined standard uncertainty results of the method. It was concluded that the measures result is controllable under constant instrument environment.

CC 64-3 (Pharmaceutical Analysis)
IT 303-98-0, Coenzyme Q10
RL: ANT (Analyte); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(uncertainty evaluation for content assaying of coenzyme Q10 capsules by HPLC)
IT 303-98-0, Coenzyme Q10
RL: ANT (Analyte); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(uncertainty evaluation for content assaying of coenzyme Q10 capsules by HPLC)
RN 303-98-0 ZCAPLUS
CN 2,5-Cyclohexadiene-1,4-dione, 2-[(2E,6E,10E,14E,18E,22E,26E,30E,34E)-3,7,11,15,19,23,27,31,35,39-decamethyl-2,6,10,14,18,22,26,30,34,38-tetracontadecaen-1-yl]-5,6-dimethoxy-3-methyl- (CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A



PAGE 1-B



PAGE 1-C

L87 ANSWER 18 OF 37 ZCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2006:199505 ZCAPLUS Full-text
DOCUMENT NUMBER: 144:496293
TITLE: Binary solid-liquid-gas equilibrium of the tripalmitin/CO2 and ubiquinone/CO2 systems
AUTHOR(S): Li, Jun; Rodrigues, Miguel; Paiva, Alexandre; Matos, Henrique A.; Gomes de Azevedo, Edmundo
CORPORATE SOURCE: Department of Chemical Engineering, Instituto Superior Tecnico, Lisbon, 1049-001, Port.
SOURCE: Fluid Phase Equilibria (2006), 241(1-2), 196-204
CODEN: FPEQDT; ISSN: 0378-3812

PUBLISHER: Elsevier B.V.
DOCUMENT TYPE: Journal
LANGUAGE: English

AB A conventional method was used to measure the m.ps. of the natural lipid tripalmitin and of the coenzyme ubiquinone (coQ10) under high pressure carbon dioxide. The pressure-temperature behavior of the binary three-phase solid-liquid-gas (SLG) equilibrium for these and test systems, namely naphthalene and biphenyl with carbon dioxide, ethylene and ethane, were investigated using the Peng-Robinson equation of state (PR-EoS) with the van der Waals one fluid (vdw-1) mixing rules and with the NRTL equation to calculate the solute activity in the liquid phase. When the interaction parameter in the vdw-1 mixing rules could be determined by the PR-EoS through the correlation of the solid-fluid phase equilibrium data, the two NRTL parameters were used as adjustable parameters. The results showed that fairly good correlations could be achieved for the exptl. pressure-temperature data of all the asym. systems studied here, indicating that the NRTL parameters are crucial for describing the pressure-temperature behavior but have little effect on the phase compns. at the SLG equilibrium

CC 68-1 (Phase Equilibriums, Chemical Equilibriums, and Solutions)

IT 124-38-9, Carbon dioxide, properties 303-98-0, CoQ10
555-44-2, Glyceryl tripalmitate
RL: PEP (Physical, engineering or chemical process); PRP (Properties); PYP (Physical process); PROC (Process)
(solid-liquid-gas equilibrium in carbon dioxide binary mixts. with glyceryl tripalmitate and coQ10)

IT 303-98-0, CoQ10
RL: PEP (Physical, engineering or chemical process); PRP (Properties); PYP (Physical process); PROC (Process)
(solid-liquid-gas equilibrium in carbon dioxide binary mixts. with glyceryl tripalmitate and coQ10)

RN 303-98-0 ZCAPLUS

CN 2,5-Cyclohexadiene-1,4-dione, 2-[(2E,6E,10E,14E,18E,22E,26E,30E,34E)-3,7,11,15,19,23,27,31,35,39-decamethyl-2,6,10,14,18,22,26,30,34,38-tetracontadecaen-1-yl]-5,6-dimethoxy-3-methyl- (CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A



PAGE 1-B



OS.CITING REF COUNT: 6 THERE ARE 6 CAPLUS RECORDS THAT CITE THIS RECORD (6 CITINGS)
REFERENCE COUNT: 32 THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L87 ANSWER 19 OF 37 ZCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 1998:108411 ZCAPLUS Full-text
DOCUMENT NUMBER: 128:99936
ORIGINAL REFERENCE NO.: 128:19505a,19508a
TITLE: Kinetic Phases in the Electron Transfer from P+QA-QB to P+QAQB- and the Associated Processes in Rhodobacter sphaeroides R-26 Reaction Centers
AUTHOR(S): Li, Jiali; Gilroy, Dan; Tiede, David M.; Gunner, M. R.
CORPORATE SOURCE: Department of Physics, City College of New York, New York, NY, 10031, USA
SOURCE: Biochemistry (1998), 37(9), 2818-2829
CODEN: BICHAW; ISSN: 0006-2960
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Electron transfer from P+QA-QB to form P+QAQB- was measured in Rhodobacter sphaeroides R-26 reaction centers (RCs) where the native primary quinone, ubiquinone-10 (UQA), was replaced by 2-methyl-3-phytyl-1,4-naphthoquinone (MQA). The native secondary quinone, UQ-10, was retained as UQB. The difference spectrum of the semiquinone MQA- minus UQB- absorption is very similar to that of MQ- minus UQ- in solution (398-480 nm). Thus, the absorption change provides a direct monitor of the electron transfer from MQA- to UQB. In contrast, when both QA and QB are UQ-10 the spectral difference between UQA- and UQB- arises from electrochromic responses of RC chromophores. Three kinetic processes are seen in the near UV (390-480 nm) and near-IR (740-820 nm). Anal. of the time-correlated spectra support the conclusion that the changes at $\tau 1 \approx 3$ μs are mostly due to electron transfer, electron transfer and charge compensation are mixed in $\tau 2 \approx 80$ μs, while little or no electron transfer occurs at 200-600 μs ($\tau 3$) in MQAUQB RCs. The 80-μs rate has been previously observed, while the fast component has not. The fast phase represents 60% of the electron-transfer reaction (398 nm). The activation energy for electron transfer is $\Delta G \approx 3.5$ kcal/mol for both $\tau 1$ and $\tau 2$ between 0 and 30°C. In isolated RCs with UQA, if there is any fast component, it appears to be faster and less important than in the MQA reconstituted RCs.

CC 11-6 (Plant Biochemistry)
Section cross-reference(s): 10

IT 84-80-0 303-98-0, Ubiquinone-10
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(kinetic phases in electron transfer from P+QA-QB to P+QAQB- and the associated processes in Rhodobacter sphaeroides R-26 reaction centers)

IT 303-98-0, Ubiquinone-10
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(kinetic phases in electron transfer from P+QA-QB to P+QAQB- and the associated processes in Rhodobacter sphaeroides R-26 reaction centers)

RN 303-98-0 ZCAPLUS
CN 2,5-Cyclohexadiene-1,4-dione, 2-[(2E,6E,10E,14E,18E,22E,26E,30E,34E)-3,7,11,15,19,23,27,31,35,39-decamethyl-2,6,10,14,18,22,26,30,34,38-tetracontadecaen-1-yl]-5,6-dimethoxy-3-methyl- (CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A



PAGE 1-B



PAGE 1-C

OS.CITING REF COUNT: 87 THERE ARE 87 CAPLUS RECORDS THAT CITE THIS RECORD (87 CITINGS)
REFERENCE COUNT: 82 THERE ARE 82 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L87 ANSWER 20 OF 37 ZCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 1997:186974 ZCAPLUS Full-text
DOCUMENT NUMBER: 126:220276
ORIGINAL REFERENCE NO.: 126:42439a,42442a
TITLE: N-Aryl-3,3,3- trifluoro-2-hydroxy-2-methylpropanamides: KATP Potassium Channel Openers. Modifications on the Western Region. [Erratum to document cited in CA126:370]
AUTHOR(S): Ohnmacht, Cyrus J.; Russell, Keith; Empfield, James R.; Frank, Cathy A.; Gibson, Keith H.; Mayhugh, Daniel R.; McLaren, Frances M.; Shapiro, Howard S.; Brown, Frederick J.; Trainor, Diane A.; Ceccarelli, Christopher; Lin, Margaret M.; Masek, Brian B.; Forst, Janet M.; Harris, Robert J.; Hulsizer, James M.; Lewis, Joseph J.; Silverman, Stuart M.; Smith, Reed W.; Warwick, Paul J.; Kau, Sen T.; Chun, Alexa L.; Grant, Thomas L.; Howe, Burton B.; Li, Jack H.; Trivedi, Shephali; Halterman, Tracy J.; Yochim,

Christopher; Dyroff, Martin C.; Kirkland, M.; Neilson, Kathleen L.
CORPORATE SOURCE: Department of Medicinal Chemistry, Zeneca Pharmaceuticals, Wilmington, DE, 19897, USA
SOURCE: Journal of Medicinal Chemistry (1997), 40(6), 1048
CODEN: JMCMAR; ISSN: 0022-2623
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
AB The errors were not reflected in the abstract or the index entries.
CC 1-3 (Pharmacology)
Section cross-reference(s): 25

L87 ANSWER 21 OF 37 ZCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 1995:756145 ZCAPLUS Full-text
DOCUMENT NUMBER: 123:165777
ORIGINAL REFERENCE NO.: 123:29483a,29486a
TITLE: Calcium dependent K-channels in guinea pig and human urinary bladder
AUTHOR(S): Trivedi, S.; Potter-Lee, L.; Li, J. H.; Yasay, G. D.; Russell, K.; Ohnmacht, C. J.; Empfield, J. R.; Trainor, D. A.; Kau, S. T.
CORPORATE SOURCE: Dep. Pharmacol. Med. Chem., Zeneca Inc., Wilmington, DE, 19897, USA
SOURCE: Biochemical and Biophysical Research Communications (1995), 213(2), 404-9
CODEN: BBRCA9; ISSN: 0006-291X
PUBLISHER: Academic
DOCUMENT TYPE: Journal
LANGUAGE: English
AB This study provides evidence for the presence of large conductance Ca2+-dependent K-channels in guinea pig and human urinary bladder smooth muscle. A23187, a Ca2+-ionophore, increased charybdotoxin and iberiatoxin sensitive 42K efflux in human urinary bladder smooth muscle cells, suggesting that large conductance Ca2+-dependent K-channels are present in these cells. NS004, a large conductance Ca2+-dependent K-channel opener, relaxed guinea pig bladder strips precontracted with 15 mM KCl which is inhibited by iberiatoxin. In addition, NS004 also evoked an iberiatoxin sensitive increase in 86Rb/42K efflux in guinea pig and human urinary bladder smooth muscle cells, demonstrating that NS004 activates large conductance Ca2+-dependent K-channels to achieve its relaxation effect in the bladder.
CC 13-2 (Mammalian Biochemistry)
OS.CITING REF COUNT: 22 THERE ARE 22 CAPLUS RECORDS THAT CITE THIS RECORD (22 CITINGS)

L87 ANSWER 22 OF 37 ZCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 1995:688039 ZCAPLUS Full-text
DOCUMENT NUMBER: 123:132383
ORIGINAL REFERENCE NO.: 123:23233a,23236a
TITLE: Zeneca ZD6169 and its analogs from a novel series of anilide tertiary carbinols: in vitro KATP channel opening activity in bladder detrusor
AUTHOR(S): Li, J. H.; Yasay, G. D.; Zografos, P.; Kau, S. T.; Ohnmacht, C. J.; Russell, K.; Empfield, J. R.; Brown, F. J.; Trainor, D. A.; et al.
CORPORATE SOURCE: Department Pharmacology, Zeneca Pharmaceuticals Group, Wilmington, DE, USA
SOURCE: Pharmacology (1995), 51(1), 33-42
CODEN: PHMGBN; ISSN: 0031-7012
PUBLISHER: Karger

DOCUMENT TYPE: Journal
LANGUAGE: English
AB The potassium (K+) channel opening activity of Zeneca ZD6169 and one of its pyridylsulfonyl analogs from the anilide tertiary carbinol series was ascertained. Their mechanoinhibitory effects on the myogenic activity of the guinea pig bladder detrusor muscle were measured in a set of functional assays. Elevating the K+ concentration in the tissue bath from 15 to 80 mmol/L increased the IC50 value of ZD6169 from 1.61 ± 0.22 to 223 ± 37 μmol/L. This result suggest that ZD6169 may act as a K+ channel opener. Similar to the prototypic ATP-sensitive K+ (KATP) channel opener cromakalim, the K+ channel openers from the anilide tertiary carbinol series displayed stereoselective mechanoinhibitory activity only in the test protocol in which the detrusor was stimulated with 15 mmol/L KCl. Being the active enantiomer, ZD6169 has an activity more than 30-fold higher than the less active enantiomer. ZD6169 at 10 μmol/L hyperpolarized the guinea pig detrusor membrane potential by 6.1 ± 1.2 mV and increased the whole cell KATP current in isolated guinea pig smooth muscle cells by 34.9 ± 7.9 pA. This is comparable to the increase of 26.8 ± 5.0 pA obtained with 10 μmol/L of lemakalim, the active enantiomer of cromakalim. The K+ channel opening activity of ZD6169 and the pyridylsulfonyl analog was competitively antagonized by the KATP channel blocker glibenclamide in the guinea pig detrusor with a pA2 value of 7.2. This activity, however, was unaffected by blockers of small and large conductance Ca-dependent K+ channels, such as apamin and charybdotoxin, resp. The present study showed that Zeneca ZD6169 and its analog from the anilide tertiary carbinol series are K+ channel openers that activate KATP channels in vitro to relax bladder detrusors.
CC 1-8 (Pharmacology)
OS.CITING REF COUNT: 18 THERE ARE 18 CAPLUS RECORDS THAT CITE THIS RECORD (18 CITINGS)

L87 ANSWER 23 OF 37 ZCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 1994:315448 ZCAPLUS Full-text
DOCUMENT NUMBER: 120:315448
ORIGINAL REFERENCE NO.: 120:55197a,55200a
TITLE: A highly potent series of fluoroalkyl benzoxazine pyridine-N-oxide potassium channel openers
AUTHOR(S): Russell, K.; Brown, F. J.; Warwick, P.; Forst, J.; Grant, T.; Howe, B.; Kau, S. T.; Li, J. H.; McLaren, F. M.; et al.
CORPORATE SOURCE: Med. Chem. Dep., ZENECA Pharm. Group, Wilmington, DE, 19897, USA
SOURCE: Bioorganic & Medicinal Chemistry Letters (1993), 3(12), 2727-8
CODEN: BMCLE8; ISSN: 0960-894X
DOCUMENT TYPE: Journal
LANGUAGE: English
AB A new structural class of fluoroalkyl benzoxazine pyridine-N-oxide potassium channel openers with antihypertensive properties is described.
CC 1-8 (Pharmacology)
OS.CITING REF COUNT: 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD (4 CITINGS)

L87 ANSWER 24 OF 37 ZCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 1994:315769 ZCAPLUS Full-text
DOCUMENT NUMBER: 120:315769
ORIGINAL REFERENCE NO.: 120:55277a,55280a
TITLE: Anilide tertiary carbinols: a new structural class of potent potassium channel openers
AUTHOR(S): Grant, T.; Frank, C. A.; Kau, S. T.; Li, J. H.;

McLaren, F. M.; Ohnmacht, C. J.; Russell, K.; Shapiro, H. S.; Trivedi, S.
CORPORATE SOURCE: Med. Chem. Dep., ZENECA Pharm. Group, Wilmington, DE, 19897, USA
SOURCE: Bioorganic & Medicinal Chemistry Letters (1993), 3(12), 2723-4
CODEN: BMCLE8; ISSN: 0960-894X
DOCUMENT TYPE: Journal
LANGUAGE: English
AB A new structural class of anilide tertiary carbinol potassium channel openers (PCOs) is described, particularly with respect to drugs with possible therapeutic effects for the treatment of urinary incontinence. These carbinol potassium channel openers interact with the KATP channel in guinea pig detrusor smooth muscle.
CC 1-12 (Pharmacology)
OS.CITING REF COUNT: 9 THERE ARE 9 CAPLUS RECORDS THAT CITE THIS RECORD (9 CITINGS)

L87 ANSWER 25 OF 37 BIOSIS COPYRIGHT (c) 2010 The Thomson Corporation on STN DUPLICATE 2
ACCESSION NUMBER: 2006:584351 BIOSIS Full-text
DOCUMENT NUMBER: PREV200600594977
TITLE: Attenuation of tumor angiogenesis in routine melanoma model using liposomal formulation of Coenzyme Q10.
AUTHOR(S): Persaud, Indushekhar [Reprint Author]; Narain, Niven R.; Woan, Winston; Russell, Kathryn J.; Malik, Lindsey J.; Ricotti, Carlos A.; Li, Jie; Elgart, George; Hsia, Sung L.
CORPORATE SOURCE: Univ Miami, Miami, FL 33152 USA
SOURCE: Proceedings of the American Association for Cancer Research Annual Meeting, (APR 2006) Vol. 47, pp. 230.
Meeting Info.: 97th Annual Meeting of the American-Association-for-Cancer-Research (AACR). Washington, DC, USA. April 01 -05, 2006. Amer Assoc Canc Res.
ISSN: 0197-016X.
DOCUMENT TYPE: Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)
LANGUAGE: English
ENTRY DATE: Entered STN: 8 Nov 2006
Last Updated on STN: 8 Nov 2006
CONCEPT CODE: General biology - Symposia, transactions and proceedings 00520
Cytology - Animal 02506
Cytology - Human 02508
Biochemistry studies - Proteins, peptides and amino acids 10064
Pathology - Therapy 12512
Integumentary system - Physiology and biochemistry 18504
Integumentary system - Pathology 18506
Pharmacology - General 22002
Pharmacology - Clinical pharmacology 22005
Neoplasms - Pathology, clinical aspects and systemic effects 24004
Neoplasms - Therapeutic agents and therapy 24008
INDEX TERMS: Major Concepts
Pharmacology; Integumentary System (Chemical

Ordered 4/22/10

Coordination and Homeostasis); Tumor Biology
INDEX TERMS: Parts, Structures, & Systems of Organisms
skin: integumentary system; epithelial cell; fibroblast; mitochondrion; squamous cell
INDEX TERMS: Diseases
melanoma: neoplastic disease, integumentary system disease, drug therapy
Melanoma (MeSH)
INDEX TERMS: Diseases
squamous cell carcinoma: neoplastic disease, integumentary system disease, drug therapy
Carcinoma, Squamous Cell (MeSH)
INDEX TERMS: Chemicals & Biochemicals
Bcl-2; coenzyme Q10: antineoplastic-drug, topical administration
INDEX TERMS: Miscellaneous Descriptors
angiogenesis
ORGANISM: Classifier
Hominidae 86215
Super Taxa
Primates; Mammalia; Vertebrata; Chordata; Animalia
Organism Name
SKMEL 28 cell line (cell_line): human melanoma cells
Taxa Notes
Animals, Chordates, Humans, Mammals, Primates, Vertebrates
ORGANISM: Classifier
Muridae 86375
Super Taxa
Rodentia; Mammalia; Vertebrata; Chordata; Animalia
Organism Name
mouse (common)
Taxa Notes
Animals, Chordates, Mammals, Nonhuman Vertebrates, Nonhuman Mammals, Rodents, Vertebrates
REGISTRY NUMBER: 303-98-0 (coenzyme Q10)

L87 ANSWER 26 OF 37 BIOSIS COPYRIGHT (c) 2010 The Thomson Corporation on STN DUPLICATE 3
ACCESSION NUMBER: 2006:584165 BIOSIS Full-text
DOCUMENT NUMBER: PREV200600594791
TITLE: Coenzyme Q10: A novel bcl-2 drug target for the treatment of melanoma.
AUTHOR(S): Narain, Niven R. [Reprint Author]; Persaud, Indushekhar; Russell, Kathryn J.; Wean, Karrune V.; Malik, Lindsey H.; Ricotti, Carlos A. Jr.; Nassiri, Mehdi; Barrientos, Antoni; Hsia, Sung L.
CORPORATE SOURCE: Univ Miami, Miller Sch Med, Miami, FL 33152 USA
SOURCE: Proceedings of the American Association for Cancer Research Annual Meeting, (APR 2006) Vol. 47, pp. 187.
Meeting Info.: 97th Annual Meeting of the American-Association-for-Cancer-Research (AACR). Washington, DC, USA. April 01 -05, 2006. Amer Assoc Canc Res.
ISSN: 0197-016X.
DOCUMENT TYPE: Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)
LANGUAGE: English
ENTRY DATE: Entered STN: 8 Nov 2006
Last Updated on STN: 8 Nov 2006

Ordered 4/22/10

CONCEPT CODE: General biology - Symposia, transactions and proceedings 00520
Cytology - Animal 02506
Genetics - General 03502
Genetics - Animal 03506
Pathology - Therapy 12512
Metabolism - General metabolism and metabolic pathways 13002
Integumentary system - Physiology and biochemistry 18504
Pharmacology - General 22002
Neoplasms - Pathology, clinical aspects and systemic effects 24004
Neoplasms - Therapeutic agents and therapy 24008
INDEX TERMS: Major Concepts
Pharmacology; Metabolism; Molecular Genetics (Biochemistry and Molecular Biophysics); Integumentary System (Chemical Coordination and Homeostasis); Tumor Biology
INDEX TERMS: Parts, Structures, & Systems of Organisms
skin cell: integumentary system
INDEX TERMS: Diseases
melanoma: neoplastic disease, drug therapy, etiology
Melanoma (MeSH)
INDEX TERMS: Chemicals & Biochemicals
bcl-2: drug target, expression, downregulation;
coenzyme Q10: antineoplastic-drug, pharmacodynamics
INDEX TERMS: Miscellaneous Descriptors
skin cell metabolism
ORGANISM: Classifier
Animalia 33000
Super Taxa
Animalia
Organism Name
animal (common)
Taxa Notes
Animals
REGISTRY NUMBER: 303-98-0 (coenzyme Q10)
GENE NAME: animal livin gene (Animalia): expression, downregulation; animal survivin gene (Animalia): expression, downregulation

L87 ANSWER 27 OF 37 BIOSIS COPYRIGHT (c) 2010 The Thomson Corporation on STN DUPLICATE 5
ACCESSION NUMBER: 2007:263904 BIOSIS Full-text
DOCUMENT NUMBER: PREV200700273971
TITLE: Coenzyme Q10 inhibits proliferation of breast cancer cells while stabilizing growth in primary cells in vitro.
AUTHOR(S): Malik, Lindsey H. [Reprint Author]; Narain, Niven R.; Russell, Kathryn J.; Woan, Karrune V.; Persaud, Indushekhar; Li, Jie; Hsia, Sung L.
CORPORATE SOURCE: Univ Miami, Sch Med, Miami, FL USA
SOURCE: Proceedings of the American Association for Cancer Research Annual Meeting, (APR 2005) Vol. 46, pp. 1384-1385. Meeting Info.: 96th Annual Meeting of the American-Association-for-Cancer-Research. Anaheim, CA, USA. April 16 -20, 2005. Amer Assoc Canc Res.
ISSN: 0197-016X.
DOCUMENT TYPE: Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)
LANGUAGE: English
ENTRY DATE: Entered STN: 25 Apr 2007

Ordered 4/22/10

Last Updated on STN: 11 Jul 2007
CONCEPT CODE: General biology - Symposia, transactions and proceedings 00520
Cytology - Animal 02506
Cytology - Human 02508
Pathology - Therapy 12512
Reproductive system - Pathology 16506
Integumentary system - Physiology and biochemistry 18504
Pharmacology - General 22002
Pharmacology - Clinical pharmacology 22005
Neoplasms - Pathology, clinical aspects and systemic effects 24004
Neoplasms - Carcinogens and carcinogenesis 24007
Neoplasms - Therapeutic agents and therapy 24008
INDEX TERMS: Major Concepts
Pharmacology; Tumor Biology
INDEX TERMS: Parts, Structures, & Systems of Organisms
keratinocyte: integumentary system
INDEX TERMS: Diseases
breast cancer: neoplastic disease, reproductive system disease/female
Breast Neoplasms (MeSH)
INDEX TERMS: Chemicals & Biochemicals
MUC-1: expression; coenzyme Q10: antineoplastic-drug
INDEX TERMS: Miscellaneous Descriptors
apoptosis; cell proliferation; carcinogenesis; serum
ORGANISM: Classifier
Hominidae 86215
Super Taxa
Primates; Mammalia; Vertebrata; Chordata; Animalia
Organism Name
MDA-MB-468 cell line (cell_line): human breast cancer cells
BT-20 cell line (cell_line): human breast cancer cells
ZR-75 cell line (cell_line): human breast cancer cells
MCF 7 cell line (cell_line): human breast cancer cells
SK-BR3 cell line (cell_line): human breast cancer cells
Taxa Notes
Animals, Chordates, Humans, Mammals, Primates, Vertebrates
ORGANISM: Classifier
Muridae 86375
Super Taxa
Rodentia; Mammalia; Vertebrata; Chordata; Animalia
Organism Name
mouse (common)
Taxa Notes
Animals, Chordates, Mammals, Nonhuman Vertebrates, Nonhuman Mammals, Rodents, Vertebrates
REGISTRY NUMBER: 303-98-0 (coenzyme Q10)

L87 ANSWER 28 OF 37 BIOSIS COPYRIGHT (c) 2010 The Thomson Corporation on STN DUPLICATE 6
ACCESSION NUMBER: 2007:258312 BIOSIS Full-text
DOCUMENT NUMBER: PREV200700268379
TITLE: Coenzyme Q10 induces apoptosis in human prostate and osteosarcoma cells.
AUTHOR(S): Persaud, Indushekhar [Reprint Author]; Narain, Niven R.; Woan, Karrune V.; Russell, Kathryn J.; Malik, Lindsey H.; Li, Jie; Lokeshwar, Balakrishna L.; Hsia,

Sung L.
CORPORATE SOURCE: Univ Miami, Sch Med, Miami, FL 33152 USA
SOURCE: Proceedings of the American Association for Cancer Research Annual Meeting, (APR 2005) Vol. 46, pp. 65.
Meeting Info.: 96th Annual Meeting of the American-Association-for-Cancer-Research. Anaheim, CA, USA. April 16 -20, 2005. Amer Assoc Canc Res.
ISSN: 0197-016X.
DOCUMENT TYPE: Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)
LANGUAGE: English
ENTRY DATE: Entered STN: 25 Apr 2007
Last Updated on STN: 11 Jul 2007
CONCEPT CODE: General biology - Symposia, transactions and proceedings 00520
Cytology - Animal 02506
Cytology - Human 02508
Biochemistry studies - Nucleic acids, purines and pyrimidines 10062
Pathology - Therapy 12512
Urinary system - Pathology 15506
Reproductive system - Physiology and biochemistry 16504
Reproductive system - Pathology 16506
Bones, joints, fasciae, connective and adipose tissue - Physiology and biochemistry 18004
Bones, joints, fasciae, connective and adipose tissue - Pathology 18006
Integumentary system - Physiology and biochemistry 18504
Pharmacology - General 22002
Pharmacology - Clinical pharmacology 22005
Neoplasms - Pathology, clinical aspects and systemic effects 24004
Neoplasms - Therapeutic agents and therapy 24008
INDEX TERMS: Major Concepts
Pharmacology; Skeletal System (Movement and Support); Reproductive System (Reproduction); Tumor Biology
INDEX TERMS: Parts, Structures, & Systems of Organisms
bone: skeletal system; prostate: reproductive system; fibroblast; keratinocyte: integumentary system; mitochondrion
INDEX TERMS: Diseases
osteosarcoma: neoplastic disease, bone disease
Bone Neoplasms (MeSH); Osteosarcoma (MeSH)
INDEX TERMS: Diseases
prostate cancer: urologic disease, reproductive system disease/male, neoplastic disease, drug therapy
Prostatic Neoplasms (MeSH)
INDEX TERMS: Chemicals & Biochemicals
ATP; JC-1; coenzyme Q10: antineoplastic-drug
INDEX TERMS: Miscellaneous Descriptors
apoptosis; mitochondrial polarity
ORGANISM: Classifier
Hominidae 86215
Super Taxa
Primates; Mammalia; Vertebrata; Chordata; Animalia
Organism Name
143B cell line (cell_line): human osteosarcoma cells
PC3 cell line (cell_line): human prostate cancer cells
Taxa Notes
Animals, Chordates, Humans, Mammals, Primates,

Ordered 4/22/10

Vertebrates
REGISTRY NUMBER: 111839-44-2 (ATP)
303-98-0 (coenzyme Q10)

L87 ANSWER 29 OF 37 BIOSIS COPYRIGHT (c) 2010 The Thomson Corporation on STN DUPLICATE 7
ACCESSION NUMBER: 2005:405818 BIOSIS Full-text
DOCUMENT NUMBER: PREV200510197637
TITLE: Coenzyme Q10 attenuates angiogenesis in melanoma.
AUTHOR(S): Narain, N. R. [Reprint Author]; Elgart, G. W.; Persaud, I.; Woan, K. V.; Russell, K. J.; Malik, L. H.; Li, J.; Hsia, S. L.
CORPORATE SOURCE: Univ Miami, Miller Sch Med, Miami, FL 33152 USA
SOURCE: Journal of Investigative Dermatology, (APR 2005) Vol. 124, No. 4, Suppl. S, pp. A24.
Meeting Info.: 66th Annual Meeting of the Society-for-Investigative-Dermatology. St Louis, MO, USA. May 04 -07, 2005. Soc Investigat Dermatol.
CODEN: JIDEAE. ISSN: 0022-202X.
DOCUMENT TYPE: Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)
LANGUAGE: English
ENTRY DATE: Entered STN: 12 Oct 2005
Last Updated on STN: 12 Oct 2005
CONCEPT CODE: General biology - Symposia, transactions and proceedings 00520
Cytology - Animal 02506
Cytology - Human 02508
Biochemistry studies - General 10060
Biochemistry studies - Proteins, peptides and amino acids 10064
Endocrine - General 17002
Neoplasms - Pathology, clinical aspects and systemic effects 24004
INDEX TERMS: Major Concepts
Biochemistry and Molecular Biophysics; Tumor Biology
INDEX TERMS: Diseases
melanoma: neoplastic disease
Melanoma (MeSH)
INDEX TERMS: Chemicals & Biochemicals
vascular endothelial growth factor [VEGF]; coenzyme Q10; HIF-1 alpha: regulation
INDEX TERMS: Methods & Equipment
pathological analysis: laboratory techniques
INDEX TERMS: Miscellaneous Descriptors
apoptosis; angiogenesis
ORGANISM: Classifier
Hominidae 86215
Super Taxa
Primates; Mammalia; Vertebrata; Chordata; Animalia
Organism Name
SKMEL-28 cell line (cell_line): human melanoma cells
Taxa Notes
Animals, Chordates, Humans, Mammals, Primates, Vertebrates
ORGANISM: Classifier
Muridae 86375
Super Taxa
Rodentia; Mammalia; Vertebrata; Chordata; Animalia
Organism Name

Ordered 4/22/10

mouse (common)
Taxa Notes
Animals, Chordates, Mammals, Nonhuman Vertebrates, Nonhuman Mammals, Rodents, Vertebrates
REGISTRY NUMBER: 127464-60-2 (vascular endothelial growth factor)
127464-60-2 (VEGF)
303-98-0 (coenzyme Q10)

L87 ANSWER 30 OF 37 BIOSIS COPYRIGHT (c) 2010 The Thomson Corporation on STN DUPLICATE 8

Ordered 4/22/10

ACCESSION NUMBER: 2005:319513 BIOSIS Full-text
DOCUMENT NUMBER: PREV200510114908
TITLE: Coenzyme Q10 induces apoptosis in human melanoma cells.
AUTHOR(S): Narain, N. R. [Reprint Author]; Li, J.; Woan, K. V.; Russell, K. J.; Ochoa, M. S.; Persaud, I.; Fenjves, E. S.; Hsia, S. L.
CORPORATE SOURCE: Univ Miami, Sch Med, Diabet Res Inst, Miami, FL USA
SOURCE: Journal of Investigative Dermatology, (MAR 2004) Vol. 122, No. 3, pp. A160.
Meeting Info.: 65th Annual Meeting of the Society-for-Investigative-Dermatology. Providence, RI, USA. April 28 -May 01, 2004. Soc Investigat Dermatol.
CODEN: JIDEAE. ISSN: 0022-202X.
DOCUMENT TYPE: Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)
LANGUAGE: English
ENTRY DATE: Entered STN: 25 Aug 2005
Last Updated on STN: 25 Aug 2005
CONCEPT CODE: General biology - Symposia, transactions and proceedings 00520
Cytology - Animal 02506
Cytology - Human 02508
Biochemistry studies - Proteins, peptides and amino acids 10064
Pathology - Therapy 12512
Integumentary system - Physiology and biochemistry 18504
Pharmacology - General 22002
Pharmacology - Clinical pharmacology 22005
Neoplasms - Pathology, clinical aspects and systemic effects 24004
Neoplasms - Therapeutic agents and therapy 24008
INDEX TERMS: Major Concepts
Pharmacology; Integumentary System (Chemical Coordination and Homeostasis); Tumor Biology
INDEX TERMS: Parts, Structures, & Systems of Organisms
fibroblasts
INDEX TERMS: Diseases
melanoma: neoplastic disease
Melanoma (MeSH)
INDEX TERMS: Chemicals & Biochemicals
annexin V; 7-AAD; coenzyme Q10: antineoplastic-drug
INDEX TERMS: Methods & Equipment
flow cytometry: laboratory techniques, histology and cytology techniques
INDEX TERMS: Miscellaneous Descriptors
apoptotic pathway
ORGANISM: Classifier
Hominidae 86215
Super Taxa
Primates; Mammalia; Vertebrata; Chordata; Animalia

Organism Name
SKMEL28 cell line (cell_line)
Taxa Notes
Animals, Chordates, Humans, Mammals, Primates, Vertebrates
REGISTRY NUMBER: 303-98-0 (coenzyme Q10)

L87 ANSWER 31 OF 37 BIOSIS COPYRIGHT (c) 2010 The Thomson Corporation on STN DUPLICATE 9
ACCESSION NUMBER: 2005:319512 BIOSIS Full-text
DOCUMENT NUMBER: PREV200510114907
TITLE: Topical formulation of coenzyme Q10 inhibits the growth of melanoma tumors.
AUTHOR(S): Narain, N. R. [Reprint Author]; Li, J.; He, J.; Malik, L. H.; Russell, K. J.; Woan, K. V.; Persaud, T.; Hsia, S. L.
CORPORATE SOURCE: Univ Miami, Sch Med, Miami, FL USA
SOURCE: Journal of Investigative Dermatology, (MAR 2004) Vol. 122, No. 3, pp. A160.
Meeting Info.: 65th Annual Meeting of the Society-for-Investigative-Dermatology. Providence, RI, USA. April 28 -May 01, 2004. Soc Investigat Dermatol.
CODEN: JIDEAE. ISSN: 0022-202X.
DOCUMENT TYPE: Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)
LANGUAGE: English
ENTRY DATE: Entered STN: 25 Aug 2005
Last Updated on STN: 25 Aug 2005
CONCEPT CODE: General biology - Symposia, transactions and proceedings 00520
Cytology - Animal 02506
Cytology - Human 02508
Pathology - Therapy 12512
Pharmacology - General 22002
Pharmacology - Clinical pharmacology 22005
Neoplasms - Pathology, clinical aspects and systemic effects 24004
Neoplasms - Therapeutic agents and therapy 24008
INDEX TERMS: Major Concepts
Pharmacology; Tumor Biology
INDEX TERMS: Diseases
melanoma: neoplastic disease
Melanoma (MeSH)
INDEX TERMS: Chemicals & Biochemicals
coenzyme Q10; liposome-encapsulated Q10 cream: antineoplastic-drug, topical administration
INDEX TERMS: Methods & Equipment
transfection: laboratory techniques, genetic techniques; histological examination: laboratory techniques, histology and cytology techniques
ORGANISM: Classifier
Hominidae 86215
Super Taxa
Primates; Mammalia; Vertebrata; Chordata; Animalia
Organism Name
SKMEL28 cell line (cell_line)
Taxa Notes
Animals, Chordates, Humans, Mammals, Primates, Vertebrates
ORGANISM: Classifier

Muridae 86375
Super Taxa
Rodentia; Mammalia; Vertebrata; Chordata; Animalia
Organism Name
mouse (common)
Taxa Notes
Animals, Chordates, Mammals, Nonhuman Vertebrates, Nonhuman Mammals, Rodents, Vertebrates
REGISTRY NUMBER: 303-98-0 (coenzyme Q10)

L87 ANSWER 32 OF 37 BIOSIS COPYRIGHT (c) 2010 The Thomson Corporation on STN DUPLICATE 10
ACCESSION NUMBER: 2004:390480 BIOSIS Full-text
DOCUMENT NUMBER: PREV200400390557
TITLE: Coenzyme Q10 inhibits the proliferation of oncogenic cells while stabilizing growth in primary cells in vitro.
AUTHOR(S): Narain, N. R. [Reprint Author]; Li, J.; Russell, K. J.; Woan, K. V.; He, I.; Persaud, I.; Ricotti, C. A.; Fenjves, E. S.; Hsia, S. L.
CORPORATE SOURCE: Sch MedDiabet Res Inst, Univ Miami, Miami, FL, 33152, USA
SOURCE: Journal of Investigative Dermatology, (March 2004) Vol. 122, No. 3, pp. A28. print.
Meeting Info.: The 65th Annual Meeting of the Society for Investigative Dermatology. Providence, Rhode Island, USA. April 28-May 01, 2004. Society for Investigative Dermatology.
ISSN: 0022-202X (ISSN print).
DOCUMENT TYPE: Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)
LANGUAGE: English
ENTRY DATE: Entered STN: 6 Oct 2004
Last Updated on STN: 6 Oct 2004
CONCEPT CODE: General biology - Symposia, transactions and proceedings 00520
Cytology - General 02502
Cytology - Animal 02506
Cytology - Human 02508
Biochemistry studies - General 10060
Biochemistry studies - Nucleic acids, purines and pyrimidines 10062
Pathology - Therapy 12512
Integumentary system - Physiology and biochemistry 18504
Integumentary system - Pathology 18506
Pharmacology - General 22002
Pharmacology - Clinical pharmacology 22005
Pharmacology - Integumentary system, dental and oral biology 22020
Neoplasms - Pathology, clinical aspects and systemic effects 24004
Neoplasms - Therapeutic agents and therapy 24008
Pediatrics 25000
INDEX TERMS: Major Concepts
Biochemistry and Molecular Biophysics; Cell Biology; Integumentary System (Chemical Coordination and Homeostasis); Pharmacology; Tumor Biology
INDEX TERMS: Parts, Structures, & Systems of Organisms
fibroblast; keratinocyte: integumentary system; oncogenic cell, growth stabilization, proliferation
INDEX TERMS: Diseases
malignant melanoma: integumentary system disease,

neoplastic disease
Melanoma (MeSH)
INDEX TERMS: Diseases
squamous cell carcinoma: integumentary system disease, neoplastic disease
Carcinoma, Squamous Cell (MeSH)
INDEX TERMS: Chemicals & Biochemicals
ATp; coenzyme Q10: antineoplastic-drug, dermatological-drug, pharmacodynamics
ORGANISM: Classifier
Hominidae 86215
Super Taxa
Primates; Mammalia; Vertebrata; Chordata; Animalia
Organism Name
human (common): neonate
Taxa Notes
Animals, Chordates, Humans, Mammals, Primates, Vertebrates
REGISTRY NUMBER: 56-65-5Q (ATp)
42530-29-0Q (ATp)
94587-45-8Q (ATp)
111839-44-2Q (ATp)
303-98-0 (coenzyme Q10)

L87 ANSWER 33 OF 37 BIOSIS COPYRIGHT (c) 2010 The Thomson Corporation on STN
ACCESSION NUMBER: 2009:494884 BIOSIS Full-text
DOCUMENT NUMBER: PREV200900495987
TITLE: Apoptotic affect of Ubiquinone precursors in melanoma.
AUTHOR(S): Persaud, Indushekhar [Reprint Author]; McCook, John P.; Alarcon, Maria E.; Bhangu, Thara; Cepero, Maria; Narain, Niven R.
CORPORATE SOURCE: Univ Miami, Miami, FL USA
SOURCE: Proceedings of the American Association for Cancer Research Annual Meeting, (APR 2009) Vol. 50, pp. 794.
Meeting Info.: 100th Annual Meeting of the American-Association-for-Cancer-Research. Denver, CA, USA. April 18 -22, 2009. Amer Assoc Canc Res.
ISSN: 0197-016X.
DOCUMENT TYPE: Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)
LANGUAGE: English
ENTRY DATE: Entered STN: 19 Aug 2009
Last Updated on STN: 19 Aug 2009
CONCEPT CODE: General biology - Symposia, transactions and proceedings 00520
Biochemistry studies - General 10060
Biochemistry studies - Vitamins 10063
Biochemistry studies - Proteins, peptides and amino acids 10064
Enzymes - General and comparative studies: coenzymes 10802
Integumentary system - Physiology and biochemistry 18504
Integumentary system - Pathology 18506
Neoplasms - Pathology, clinical aspects and systemic effects 24004
INDEX TERMS: Major Concepts
Integumentary System (Chemical Coordination and Homeostasis); Tumor Biology; Biochemistry and Molecular Biophysics

INDEX TERMS: Diseases
melanoma: neoplastic disease, integumentary system disease, etiology
Melanoma (MeSH)
INDEX TERMS: Chemicals & Biochemicals
Bcl-2: expression; L-phenylalanine; pyridoxine; mevalonic acid; L-tyrosine; phenylacetate; ubiquinone-10; 4-hydroxyphenylpyruvate; caspase-3 [EC 3.4.22.56]; ubiquinone precursor
INDEX TERMS: Miscellaneous Descriptors
apoptotic affect
ORGANISM: Classifier
Animalia 33000
Super Taxa
Animalia
Organism Name
animal (common)
Taxa Notes
Animals
REGISTRY NUMBER: 63-91-2 (L-phenylalanine)
65-23-6 (pyridoxine)
150-97-0 (mevalonic acid)
60-18-4 (L-tyrosine)
7631-42-7 (phenylacetate)
606-06-4 (ubiquinone-10)
169592-56-7 (caspase-3)
169592-56-7 (EC 3.4.22.56)

L87 ANSWER 34 OF 37 BIOSIS COPYRIGHT (c) 2010 The Thomson Corporation on STN
ACCESSION NUMBER: 2009:431590 BIOSIS Full-text
DOCUMENT NUMBER: PREV200900432693
TITLE: NORMALIZATION OF BCL-2 FAMILY MEMBERS IN BREAST CANCER BY COENZYME Q10.
AUTHOR(S): Pinto, Lizbeth [Reprint Author]; Sloan, Alexis; Persaud, Indushekhar; Narain, Niven R.
CORPORATE SOURCE: Univ Miami, Miller Sch Med, Dept Dermatol and Cutaneous Surg, Miami, FL 33136 USA
SOURCE: Ethnicity & Disease, (SUM 2009) Vol. 19, No. 2, Suppl. 3, pp. S17-S18.
ISSN: 1049-510X.
DOCUMENT TYPE: Article
LANGUAGE: English
ENTRY DATE: Entered STN: 22 Jul 2009
Last Updated on STN: 22 Jul 2009
ABSTRACT:Cancer is second only to heart disease as the leading cause of death in the United States. Indeed, it is estimated that approximately 178,000 new breast cancer cases were diagnosed in 2007 anti 40,000 women will succumb to the disease. The nature of the disease makes it very resistant to chemotherapeutic intervention and radiation. The balance of the Bcl-2 protein family has been implicated as the major contributing factor to conferral of resistance to cancer therapy. Previous work from our research group has demonstrated that Coenzyme Q10 (Q10) is able to significantly decrease Bcl-2 and thereby induce apoptosis in melanoma and prostate cancer. Hence, we postulated that Q10 may have a pro-apoptotic effect in breast cancer. To investigate this hypothesis, we employed the Sk-Br3 and MCF-7 breast cancer lines which exhibit a mutation Her-2/neu and p53 respectively. We examined the effect of Coenzyme Q10 on various members of the Bcl-2 family (bcl-2, bcl-xl, bid, bad, bak, mcl-1, bim, and bax), p53, and caspases 3, 6, 9. All cells were treated for 0-24 hours in the presence and absence of 50 mu M and

100 mu M Q10 under physiologic conditions after which total protein was isolated and subjected to Western blot analysis to measure the aforementioned protein products.The results of our study may provide a template for further investigation into the mechanism of action of mammary oncogenesis while providing support for the use of Coenzyme Q10 as an adjuvant breast cancer therapy. The results showed that there was an upregulation in protein expression of proapoptotic members and BH3 subfamily members such as bid, bad, bax, bim, and bak whereas the anti-apototic members bcl-xl, mcl-1, and bcl-2 significantly decreased in total protein expression between 4 and 12 hours. Commitment to apoptosis was confirmed by activation of caspase 3, 6 and 9. Conversely, administration of Coenzyme Q10 to mammary fibroblasts did not elicit a significant response on any of the aforementioned intracellular proteins involved in programmed cell death. The data herein suggest that Coenzyme Q10 is able to modulate the various subfamilies of the Bcl-2 family in a manner that restores the apoptotic potential in breast cancer without presenting any adverse effects to normal breast tissue. This provides a template for further investigation into the mechanism of action of mammary oncogenesis while providing support for the use of Coenzyme Q10 as an adjuvant in breast cancer therapy.

CONCEPT CODE: Cytology - Animal 02506
Cytology - Human 02508
Biochemistry studies - General 10060
Biochemistry studies - Proteins, peptides and amino acids 10064
Pathology - Diagnostic 12504
Cardiovascular system - Heart pathology 14506
Urinary system - Pathology 15506
Reproductive system - Pathology 16506
Integumentary system - Pathology 18506
Neoplasms - Diagnostic methods 24001
Neoplasms - Pathology, clinical aspects and systemic effects 24004

INDEX TERMS: Major Concepts
Oncology (Human Medicine, Medical Sciences); Biochemistry and Molecular Biophysics; Gynecology (Human Medicine, Medical Sciences)

INDEX TERMS: Parts, Structures, & Systems of Organisms
fibroblast

INDEX TERMS: Diseases
prostate cancer: urologic disease, reproductive system disease/male, neoplastic disease
Prostatic Neoplasms (MeSH)

INDEX TERMS: Diseases
breast cancer: neoplastic disease, reproductive system disease/female, diagnosis, mortality
Breast Neoplasms (MeSH)

INDEX TERMS: Diseases
heart disease: heart disease
Heart Diseases (MeSH)

INDEX TERMS: Diseases
melanoma: neoplastic disease, integumentary system disease
Melanoma (MeSH)

INDEX TERMS: Chemicals & Biochemicals
bcl-2; coenzyme Q-10; p53 protein: mutation; bcl-xl; mcl-1; caspase 3 [EC 3.4.22.56]: activation; caspase 9 [EC 3.4.22.62]: activation; caspase 6 [EC 3.4.22.59]: activation; Her-2/neu: mutation; bak protein: upregulation; bim: upregulation; bid: upregulation; bad: upregulation; bax protein: upregulation

INDEX TERMS: Methods & Equipment
chemotherapy: therapeutic and prophylactic techniques, clinical techniques; radiation therapy: therapeutic and prophylactic techniques, clinical techniques; cancer therapy: therapeutic and prophylactic techniques, clinical techniques; Western blot analysis: laboratory techniques, genetic techniques; adjuvant breast cancer therapy: therapeutic and prophylactic techniques, clinical techniques
INDEX TERMS: Miscellaneous Descriptors
apoptosis
GEOGRAPHICAL TERMS: USA (North America, Nearctic region)
ORGANISM: Classifier
Hominidae 86215
Super Taxa
Primates; Mammalia; Vertebrata; Chordata; Animalia
Organism Name
human (common): female
MCF7 cell line (cell_line): human breast adenocarcinoma cells
SkBr3 cell line (cell_line): human breast cancer cells
Taxa Notes
Animals, Chordates, Humans, Mammals, Primates, Vertebrates
REGISTRY NUMBER: 303-98-0 (coenzyme Q-10)
169592-56-7 (caspase 3)
169592-56-7 (EC 3.4.22.56)
180189-96-2 (caspase 9)
180189-96-2 (EC 3.4.22.62)
182372-15-2 (caspase 6)
182372-15-2 (EC 3.4.22.59)

L87 ANSWER 35 OF 37 BIOSIS COPYRIGHT (c) 2010 The Thomson Corporation on STN
ACCESSION NUMBER: 2008:488647 BIOSIS Full-text
DOCUMENT NUMBER: PREV200800488646
TITLE: Normalization of Bcl-2 family members in breast cancer by Coenzyme Q10.
AUTHOR(S): Narain, Niven R. [Reprint Author]; Sloan, Alexis; Pinto, Lizbeth; McCook, John P.; Persaud, Indushekhar
CORPORATE SOURCE: Univ Miami, Miller Sch Med, Miami, FL 33152 USA
SOURCE: Proceedings of the American Association for Cancer Research Annual Meeting, (APR 2008) Vol. 49, pp. 1043-1044.
Meeting Info.: 99th Annual Meeting of the American-Association-for-Cancer-Research. San Diego, CA, USA. April 12 -16, 2008. Amer Assoc Canc Res.
ISSN: 0197-016X.
DOCUMENT TYPE: Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)
LANGUAGE: English
ENTRY DATE: Entered STN: 3 Sep 2008
Last Updated on STN: 3 Sep 2008
CONCEPT CODE: General biology - Symposia, transactions and proceedings 00520
Cytology - Human 02508
Biochemistry studies - Proteins, peptides and amino acids 10064
Enzymes - General and comparative studies: coenzymes 10802
Pathology - Diagnostic 12504

Reproductive system - Physiology and biochemistry 16504
Reproductive system - Pathology 16506
Neoplasms - Diagnostic methods 24001
Neoplasms - Pathology, clinical aspects and systemic effects 24004

INDEX TERMS: Major Concepts
Enzymology (Biochemistry and Molecular Biophysics); Tumor Biology; Reproductive System (Reproduction)

INDEX TERMS: Parts, Structures, & Systems of Organisms
breast: reproductive system

INDEX TERMS: Diseases
breast cancer: neoplastic disease, reproductive system disease/female, diagnosis
Breast Neoplasms (MeSH)

INDEX TERMS: Chemicals & Biochemicals
p53; bcl-2; Bcl-2 protein family; bcl-xl; bad; bid; mcl-1; coenzyme Q 10; bak protein; caspase 3 [EC 3.4.22.56]; caspase 9 [EC 3.4.22.62]; caspase 6 [EC 3.4.22.59]

INDEX TERMS: Methods & Equipment
cancer therapy: therapeutic and prophylactic techniques, clinical techniques; Western blot analysis: laboratory techniques, genetic techniques

INDEX TERMS: Miscellaneous Descriptors
apoptosis; programmed cell death

ORGANISM: Classifier
Hominidae 86215
Super Taxa
Primates; Mammalia; Vertebrata; Chordata; Animalia
Organism Name
human (common)
Sk-Br-3 cell line (cell_line): human breast carcinoma cells
MCF 7 cell line (cell_line): human breast carcinoma cells
Taxa Notes
Animals, Chordates, Humans, Mammals, Primates, Vertebrates

REGISTRY NUMBER: 303-98-0 (coenzyme Q 10)
169592-56-7 (caspase 3)
169592-56-7 (EC 3.4.22.56)
180189-96-2 (caspase 9)
180189-96-2 (EC 3.4.22.62)
182372-15-2 (caspase 6)
182372-15-2 (EC 3.4.22.59)

L87 ANSWER 36 OF 37 BIOSIS COPYRIGHT (c) 2010 The Thomson Corporation on STN

ACCESSION NUMBER: 2008:486091 BIOSIS Full-text
DOCUMENT NUMBER: PREV200800486090
TITLE: Induction of p53 by Coenzyme Q10 via modulation of mdm2 and p14.
AUTHOR(S): Persaud, Indushekhar [Reprint Author]; Lindley, Linsey; Sloan, Alexis J.; McCook, John P.; Narain, Niven R.
CORPORATE SOURCE: Univ Miami, Sch Med, Miami, FL USA
SOURCE: Proceedings of the American Association for Cancer Research Annual Meeting, (APR 2008) Vol. 49, pp. 428.
Meeting Info.: 99th Annual Meeting of the American-Association-for-Cancer-Research. San Diego, CA, USA. April 12 -16, 2008. Amer Assoc Canc Res.

ISSN: 0197-016X.
DOCUMENT TYPE: Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)
LANGUAGE: English
ENTRY DATE: Entered STN: 3 Sep 2008
Last Updated on STN: 3 Sep 2008
CONCEPT CODE: General biology - Symposia, transactions and proceedings 00520
Cytology - Human 02508
Biochemistry studies - Proteins, peptides and amino acids 10064
Enzymes - General and comparative studies: coenzymes 10802
Pathology - Therapy 12512
Neoplasms - Pathology, clinical aspects and systemic effects 24004
Neoplasms - Therapeutic agents and therapy 24008
INDEX TERMS: Major Concepts
Enzymology (Biochemistry and Molecular Biophysics); Tumor Biology
INDEX TERMS: Diseases
tumor: neoplastic disease, drug therapy
Neoplasms (MeSH)
INDEX TERMS: Chemicals & Biochemicals
Bcl-2: expression; p53: expression; mdm2: expression; coenzyme Q10: antineoplastic-drug; p14ARF: expression; caspase-3 [EC 3.4.22.56]: expression
INDEX TERMS: Methods & Equipment
Western blot analysis: laboratory techniques, genetic techniques
ORGANISM: Classifier
Hominidae 86215
Super Taxa
Primates; Mammalia; Vertebrata; Chordata; Animalia
Organism Name
SK MEL-28 cell line (cell_line): human melanoma cells
Taxa Notes
Animals, Chordates, Humans, Mammals, Primates, Vertebrates
REGISTRY NUMBER: 303-98-0 (coenzyme Q10)
169592-56-7 (caspase-3)
169592-56-7 (EC 3.4.22.56)

L87 ANSWER 37 OF 37 BIOSIS COPYRIGHT (c) 2010 The Thomson Corporation on STN
ACCESSION NUMBER: 2005:406013 BIOSIS Full-text
DOCUMENT NUMBER: PREV200510197832
TITLE: Coenzyme Q10 enhances the proliferation and migration of fibroblasts and keratinocytes: a possible implication for wound healing.
AUTHOR(S): Woan, K. V. [Reprint Author]; Narain, N. R.; Persaud, I.; Ricotti, C. A.; Panchal, R. J.; Russell, K. J.; Malik, L. H.; Li, J.; Hsia, S. L.
CORPORATE SOURCE: Univ Miami, Miller Sch Med, Miami, FL 33152 USA
SOURCE: Journal of Investigative Dermatology, (APR 2005) Vol. 124, No. 4, Suppl. S, pp. A57.
Meeting Info.: 66th Annual Meeting of the Society-for-Investigative-Dermatology. St Louis, MO, USA. May 04 -07, 2005. Soc Investigat Dermatol.
CODEN: JIDEAE. ISSN: 0022-202X.

DOCUMENT TYPE: Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)
LANGUAGE: English
ENTRY DATE: Entered STN: 12 Oct 2005
Last Updated on STN: 12 Oct 2005
CONCEPT CODE: General biology - Symposia, transactions and proceedings 00520
Cytology - General 02502
Cytology - Animal 02506
Biochemistry studies - Nucleic acids, purines and pyrimidines 10062
Integumentary system - Physiology and biochemistry 18504
INDEX TERMS: Major Concepts
Integumentary System (Chemical Coordination and Homeostasis); Cell Biology
INDEX TERMS: Parts, Structures, & Systems of Organisms
skin: integumentary system; mitochondria; keratinocyte: integumentary system, migration, proliferation; fibroblast, migration, proliferation
INDEX TERMS: Chemicals & Biochemicals
coenzyme Q10: potent antioxidant, effect; ATP: production, oxidative phosphorylation
INDEX TERMS: Miscellaneous Descriptors
apoptosis; wound healing; cell protection
REGISTRY NUMBER: 303-98-0 (coenzyme Q10)
111839-44-2 (ATP)

```
=> file registry
FILE 'REGISTRY' ENTERED AT 12:18:59 ON 29 MAR 2010
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2010 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   28 MAR 2010  HIGHEST RN 1214990-69-8
DICTIONARY FILE UPDATES:  28 MAR 2010  HIGHEST RN 1214990-69-8

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 8, 2010.

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html
Uploading L15.str
```



```
chain nodes :
1  2  3  4  5  6  7  8  9  16  17  18  19  20  21  22  23  24  25  26  27  28  29
30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50
51  52  53  54
55  56  57  58  59  60  61
ring nodes :
10  11  12  13  14  15
chain bonds :
1-12  2-18  3-22  4-26  5-30  6-14  7-15  8-11  9-13  10-16  16-17  17-18  18-19
19-20  20-21  21-22  22-23  23-24  24-25  25-26  26-27  27-28  28-29  29-30  30-55
31-37  32-41
33-45  34-49  35-53  36-37  36-56  37-38  38-39  39-40  40-41  41-42  42-43  43-44
44-45  45-46  46-47
47-48  48-49  49-50  50-51  51-52  52-53  53-54  54-57  55-56  57-59  58-59  58-60
58-61
ring bonds :
10-11  10-12  11-13  12-14  13-15  14-15
exact/norm bonds :
6-14  8-11  10-11  10-12  11-13  12-14  13-15  14-15
exact bonds :
```

```
1-12  2-18  3-22  4-26  5-30  7-15  9-13  10-16  16-17  17-18  18-19  19-20  20-21
21-22  22-23  23-24  24-25  25-26  26-27  27-28  28-29  29-30  30-55  31-37  32-41
33-45  34-49
35-53  36-37  36-56  37-38  38-39  39-40  40-41  41-42  42-43  43-44  44-45  45-46
46-47  47-48
48-49  49-50  50-51  51-52  52-53  53-54  54-57  55-56  57-59  58-59  58-60  58-61


Match level :
1:CLASS  2:CLASS  3:CLASS  4:CLASS  5:CLASS  6:CLASS  7:CLASS  8:CLASS  9:CLASS
10:Atom  11:Atom  12:Atom  13:Atom  14:Atom  15:Atom  16:CLASS  17:CLASS  18:CLASS
19:CLASS  20:CLASS
21:CLASS  22:CLASS  23:CLASS  24:CLASS  25:CLASS  26:CLASS  27:CLASS  28:CLASS
29:CLASS  30:CLASS
31:CLASS  32:CLASS  33:CLASS  34:CLASS  35:CLASS  36:CLASS  37:CLASS  38:CLASS
39:CLASS  40:CLASS
41:CLASS  42:CLASS  43:CLASS  44:CLASS  45:CLASS  46:CLASS  47:CLASS  48:CLASS
49:CLASS  50:CLASS
51:CLASS  52:CLASS  53:CLASS  54:CLASS  55:CLASS  56:CLASS  57:CLASS  58:CLASS
59:CLASS  60:CLASS
61:CLASS



=> file zcaplus
FILE 'ZCAPLUS' ENTERED AT 12:19:03 ON 29 MAR 2010
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2010 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS is
strictly prohibited.

FILE COVERS 1907 - 29 Mar 2010  VOL 152 ISS 14
FILE LAST UPDATED: 28 Mar 2010  (20100328/ED)
REVISED CLASS FIELDS (/NCL) LAST RELOADED:  Dec 2009
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE:  Dec 2009

ZCAplus now includes complete International Patent Classification (IPC)
reclassification data for the first quarter of 2010.

CAS Information Use Policies apply and are available at:

http://www.cas.org/legal/infopolicy.html

This file contains CAS Registry Numbers for easy and accurate
substance identification.
'OBI' IS DEFAULT SEARCH FIELD FOR 'ZCAPLUS' FILE

=> d stat que L37
```

L15 STR



Structure attributes must be viewed using STN Express query preparation.

L17	83	SEA FILE=REGISTRY FAM FUL L15
L21	2380	SEA FILE=ZCAPLUS SPE=ON ABB=ON PLU=ON L17 (L) (THU OR DMA OR BAC OR PKT OR PAC OR FFD)/RL
L22	139854	SEA FILE=ZCAPLUS SPE=ON ABB=ON PLU=ON (?LEUKAEM?/BI OR ?LEUKEM?/BI)
L23	502215	SEA FILE=ZCAPLUS SPE=ON ABB=ON PLU=ON ?CANCER?/BI
L24	781886	SEA FILE=ZCAPLUS SPE=ON ABB=ON PLU=ON ?TUMOUR?/BI OR ?TUMOR?/BI
L25	62114	SEA FILE=ZCAPLUS SPE=ON ABB=ON PLU=ON ?SARCOMA?/BI
L26	645501	SEA FILE=ZCAPLUS SPE=ON ABB=ON PLU=ON ?NEOPLAS?/BI
L27	360843	SEA FILE=ZCAPLUS SPE=ON ABB=ON PLU=ON ?CARCINO?/BI
L28	28213	SEA FILE=ZCAPLUS SPE=ON ABB=ON PLU=ON ?MYELOM?/BI
L29	52342	SEA FILE=ZCAPLUS SPE=ON ABB=ON PLU=ON ?LYMPHOMA?/BI
L30	46413	SEA FILE=ZCAPLUS SPE=ON ABB=ON PLU=ON ?MELANOM?/BI
L31	66132	SEA FILE=ZCAPLUS SPE=ON ABB=ON PLU=ON ?ANGIOGEN?/BI
L32	200452	SEA FILE=ZCAPLUS SPE=ON ABB=ON PLU=ON CELL PROLIFER?/BI
L33	311	SEA FILE=ZCAPLUS SPE=ON ABB=ON PLU=ON L21 AND (L22 OR L23 OR L24 OR L25 OR L26 OR L27 OR L28 OR L29 OR L30 OR L31 OR L32)
L34	123	SEA FILE=ZCAPLUS SPE=ON ABB=ON PLU=ON L33 AND P/DT AND (PRD<20050121 OR PD<20050121 OR AD<20050121)
L35	166	SEA FILE=ZCAPLUS SPE=ON ABB=ON PLU=ON L33 AND PY<2006
L36	183	SEA FILE=ZCAPLUS SPE=ON ABB=ON PLU=ON (L34 OR L35)
L37	30	SEA FILE=ZCAPLUS SPE=ON ABB=ON PLU=ON L36 AND ?TOPICAL?/BI

=> file medline embase biosis
FILE 'MEDLINE' ENTERED AT 12:19:18 ON 29 MAR 2010

FILE 'EMBASE' ENTERED AT 12:19:18 ON 29 MAR 2010

FILE 'BIOSIS' ENTERED AT 12:19:18 ON 29 MAR 2010

=> d stat que L79

L15 STR




```
Structure attributes must be viewed using STN Express query preparation.
L17          83 SEA FILE=REGISTRY FAM FUL L15
L22      139854 SEA FILE=ZCAPLUS SPE=ON  ABB=ON  PLU=ON  (?LEUKAEM?/BI OR
                ?LEUKEM?/BI)
L23      502215 SEA FILE=ZCAPLUS SPE=ON  ABB=ON  PLU=ON  ?CANCER?/BI
L24      781886 SEA FILE=ZCAPLUS SPE=ON  ABB=ON  PLU=ON  ?TUMOUR?/BI OR
                ?TUMOR?/BI
L25       62114 SEA FILE=ZCAPLUS SPE=ON  ABB=ON  PLU=ON  ?SARCOMA?/BI
L26      645501 SEA FILE=ZCAPLUS SPE=ON  ABB=ON  PLU=ON  ?NEOPLAS?/BI
L27      360843 SEA FILE=ZCAPLUS SPE=ON  ABB=ON  PLU=ON  ?CARCINO?/BI
L28       28213 SEA FILE=ZCAPLUS SPE=ON  ABB=ON  PLU=ON  ?MYELOM?/BI
L29       52342 SEA FILE=ZCAPLUS SPE=ON  ABB=ON  PLU=ON  ?LYMPHOMA?/BI
L30       46413 SEA FILE=ZCAPLUS SPE=ON  ABB=ON  PLU=ON  ?MELANOM?/BI
L31       66132 SEA FILE=ZCAPLUS SPE=ON  ABB=ON  PLU=ON  ?ANGIOGEN?/BI
L32      200452 SEA FILE=ZCAPLUS SPE=ON  ABB=ON  PLU=ON  CELL PROLIFER?/BI
L38             SEL  PLU=ON  L17 1- CHEM :      120 TERMS
L39       10721 SEA L38
L40        1098 SEA L39 AND (L22 OR L23 OR L24 OR L25 OR L26 OR L27 OR L28 OR
                L29 OR L30 OR L31 OR L32)
L41          34 SEA L40 AND ?TOPICAL?
L79          11 SEA L41 AND PY<2006


=> dup rem L37 L79
FILE 'ZCAPLUS' ENTERED AT 12:19:26 ON 29 MAR 2010
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2010 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'EMBASE' ENTERED AT 12:19:26 ON 29 MAR 2010
Copyright (c) 2010 Elsevier B.V. All rights reserved.

FILE 'BIOSIS' ENTERED AT 12:19:26 ON 29 MAR 2010
Copyright (c) 2010 The Thomson Corporation
PROCESSING COMPLETED FOR L37
PROCESSING COMPLETED FOR L79
L88          41 DUP REM L37 L79 (0 DUPLICATES REMOVED)
```

```
                ANSWERS '1-30' FROM FILE ZCAPLUS
                ANSWERS '31-37' FROM FILE EMBASE
                ANSWERS '38-41' FROM FILE BIOSIS

=> d ibib abs hitind hitstr L88 1-30; d iall L88 31-41

L88  ANSWER 1 OF 41  ZCAPLUS  COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER:         2008:529977  ZCAPLUS  Full-text
DOCUMENT NUMBER:          148:479925
TITLE:                    Liposomally encapsulated reduced glutathione, combined
                          with other drugs, for oral, topical, or transmucosal
                          administration, for prevention of oxidation of
                          cholesterol and of low d. lipoprotein, in ameliorating
                          vascular diseases
INVENTOR(S):              Guilford, Timothy F.; Schumm, Brooke
PATENT ASSIGNEE(S):       USA
SOURCE:                   PCT Int. Appl., 63pp.
                          CODEN: PIXXD2
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   7
PATENT INFORMATION:

     PATENT NO.          KIND   DATE        APPLICATION NO.          DATE
     ----------          ----   --------    -------------------      --------
     WO 2008052184        A1    20080502    WO 2007-US82718          20071026
         W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA,
            CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI,
            GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG,
            KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME,
            MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL,
            PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN,
            TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
         RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
            IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF,
            BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW,
            GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
            BY, KG, KZ, MD, RU, TJ, TM
     US 20070065497       A1    20070322    US 2005-230277           20050920
     US 20060099244       A1    20060511    US 2005-163979           20051106 <--
PRIORITY APPLN. INFO.:                      US 2005-230277      A2 20050920
                                            US 2005-163979      A2 20051106
                                            US 2006-863015P     P  20061026
                                            US 2004-522785P     P  20041107 <--
                                            US 2005-597041P     P  20051106

AB   The invention proposes the use of reduced glutathione in a liposome (liposomal
     reduced glutathione) in form usable i.v., orally, dermally or mucosally, for
     administration of a therapeutically effective amount to ameliorate the
     progression of vascular disease, including atherosclerosis, diabetes,
     hypertension, narrowing of arteries leading to decreased blood flow, ischemic
     events, and the formation of blood clots, abnormal platelet aggregation, and
     thrombotic events, by reducing the amount and effect of oxidized cholesterol,
     oxidized HDL and oxidized LDL.  The invention also proposes combining
     liposomal encapsulated glutathione with statin drugs to improve the effect of
     lowering not only cholesterol but also the oxidized cholesterol as well as
     oxidized HDL and oxidized LDL.  The invention proposes a combination with a
     nitrous oxide enhancing substance such as arginine or lysine.  The invention
     also proposes combining liposomal encapsulated glutathione with CoQ10 and
     other hypertensive treatment drugs such as lisinopril and ACE inhibitors as a
     therapy for vascular disease and management of side effects of statin therapy.
```

Thus, a 60 yr old woman, with diabetes requiring insulin therapy also has a long history of elevated blood pressure, previously controlled using lisinopril 20 mg. Upon blood pressure further increase, she was started on one l-arginine 450 mg per capsule in combination with 800 mg liposomal glutathione in its liquid form; the next day her blood pressure was 130/74. The dose of lisinopril was lowered to 20 mg once a day; continuing the arginine and liposomal glutathione, the blood pressure remains stable at 130/74.

CC 63-6 (Pharmaceuticals)
Section cross-reference(s): 1

IT Platelet aggregation
(abnormal; liposomally encapsulated reduced glutathione, combined with other drugs, for oral, topical, or transmucosal administration, for prevention of oxidation of cholesterol and of low d. lipoprotein, in ameliorating vascular diseases)

IT Fatigue, biological
(chronic fatigue syndrome; liposomally encapsulated reduced glutathione, combined with other drugs, for oral, topical, or transmucosal administration, for prevention of oxidation of cholesterol and of low d. lipoprotein, in ameliorating vascular diseases)

IT Mucuna pruriens
Withania somnifera
(extract; liposomally encapsulated reduced glutathione, combined with other drugs, for oral, topical, or transmucosal administration, for prevention of oxidation of cholesterol and of low d. lipoprotein, in ameliorating vascular diseases)

IT Infusion drug delivery systems
(i.v. infusions; liposomally encapsulated reduced glutathione, combined with other drugs, for oral, topical, or transmucosal administration, for prevention of oxidation of cholesterol and of low d. lipoprotein, in ameliorating vascular diseases)

IT Pharmaceutical injections
(i.v. injections; liposomally encapsulated reduced glutathione, combined with other drugs, for oral, topical, or transmucosal administration, for prevention of oxidation of cholesterol and of low d. lipoprotein, in ameliorating vascular diseases)

IT Sexual disorders
(impotence; liposomally encapsulated reduced glutathione, combined with other drugs, for oral, topical, or transmucosal administration, for prevention of oxidation of cholesterol and of low d. lipoprotein, in ameliorating vascular diseases)

IT Lipid peroxidation
Oxidation
(inhibition; liposomally encapsulated reduced glutathione, combined with other drugs, for oral, topical, or transmucosal administration, for prevention of oxidation of cholesterol and of low d. lipoprotein, in ameliorating vascular diseases)

IT Amnesia
Angiotensin-converting enzyme inhibitors
Anticholesteremic agents
Antihypertensives
Atherosclerosis
Combination chemotherapy
Diabetes mellitus
Dyspnea
HMG-CoA reductase inhibitors
Human
Hypertension
Ischemia
Mucosal drug delivery systems
Myalgia

Oral drug delivery systems
Pharmaceutical liposomes
Prostate gland, neoplasm
Thrombosis
Topical drug delivery systems
Vascular disease
(liposomally encapsulated reduced glutathione, combined with other drugs, for oral, topical, or transmucosal administration, for prevention of oxidation of cholesterol and of low d. lipoprotein, in ameliorating vascular diseases)

IT Phosphatidylcholines
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(liposomally encapsulated reduced glutathione, combined with other drugs, for oral, topical, or transmucosal administration, for prevention of oxidation of cholesterol and of low d. lipoprotein, in ameliorating vascular diseases)

IT Encapsulation
(nanoencapsulation; liposomally encapsulated reduced glutathione, combined with other drugs, for oral, topical, or transmucosal administration, for prevention of oxidation of cholesterol and of low d. lipoprotein, in ameliorating vascular diseases)

IT Nerve, disease
(neuropathy; liposomally encapsulated reduced glutathione, combined with other drugs, for oral, topical, or transmucosal administration, for prevention of oxidation of cholesterol and of low d. lipoprotein, in ameliorating vascular diseases)

IT High-density lipoproteins
Low-density lipoproteins
RL: ADV (Adverse effect, including toxicity); PEP (Physical, engineering or chemical process); BIOL (Biological study); PROC (Process)
(oxidized; liposomally encapsulated reduced glutathione, combined with other drugs, for oral, topical, or transmucosal administration, for prevention of oxidation of cholesterol and of low d. lipoprotein, in ameliorating vascular diseases)

IT Low-density lipoproteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(oxidation; liposomally encapsulated reduced glutathione, combined with other drugs, for oral, topical, or transmucosal administration, for prevention of oxidation of cholesterol and of low d. lipoprotein, in ameliorating vascular diseases)

IT Drug interactions
(synergistic; liposomally encapsulated reduced glutathione, combined with other drugs, for oral, topical, or transmucosal administration, for prevention of oxidation of cholesterol and of low d. lipoprotein, in ameliorating vascular diseases)

IT 9015-82-1 9028-35-7
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(inhibitors; liposomally encapsulated reduced glutathione, combined with other drugs, for oral, topical, or transmucosal administration, for prevention of oxidation of cholesterol and of low d. lipoprotein, in ameliorating vascular diseases)

IT 10024-97-2, Nitrous oxide, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(liposomally encapsulated reduced glutathione, combined with other drugs, for oral, topical, or transmucosal administration, for prevention of oxidation of cholesterol and of low d. lipoprotein, in ameliorating vascular diseases)

IT 56-81-5, Glycerine, biological studies 56-87-1, Lysine, biological studies 70-18-8, Reduced glutathione, biological studies 74-79-3, L-Arginine, biological studies 146-48-5, Yohimbine 303-98-0,

CoQ10 7782-49-2, Selenium, biological studies 24634-61-5, Potassium sorbate 75330-75-5, Lovastatin 76547-98-3, Lisinopril 79902-63-9, Simvastatin 81093-37-0, Pravastatin 93957-54-1, Fluvastatin 134523-00-5, Atorvastatin 287714-41-4, Rosuvastatin
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(liposomally encapsulated reduced glutathione, combined with other drugs, for oral, topical, or transmucosal administration, for prevention of oxidation of cholesterol and of low d. lipoprotein, in ameliorating vascular diseases)

IT 57-88-5, Cholesterol, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(oxidation; liposomally encapsulated reduced glutathione, combined with other drugs, for oral, topical, or transmucosal administration, for prevention of oxidation of cholesterol and of low d. lipoprotein, in ameliorating vascular diseases)

IT 303-98-0, CoQ10
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(liposomally encapsulated reduced glutathione, combined with other drugs, for oral, topical, or transmucosal administration, for prevention of oxidation of cholesterol and of low d. lipoprotein, in ameliorating vascular diseases)

RN 303-98-0 ZCAPLUS

CN 2,5-Cyclohexadiene-1,4-dione, 2-[(2E,6E,10E,14E,18E,22E,26E,30E,34E)-3,7,11,15,19,23,27,31,35,39-decamethyl-2,6,10,14,18,22,26,30,34,38-tetracontadecaen-1-yl]-5,6-dimethoxy-3-methyl- (CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A



PAGE 1-B



PAGE 1-C

REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L88 ANSWER 2 OF 41 ZCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2008:978432 ZCAPLUS Full-text
DOCUMENT NUMBER: 149:259457
TITLE: Method of cancer screening; method of cancer treatment; and method of auto-immune disease treatment
INVENTOR(S): Woodward, John R.
PATENT ASSIGNEE(S): Les Medecins L.P., USA
SOURCE: U.S. Pat. Appl. Publ., 14 pp., Cont.-in-part of U.S. Ser. No. 533,805.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 7
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20080193482	A1	20080814	US 2008-100089	20080409 <--
US 20060063211	A1	20060323	US 2004-946213	20040921 <--
US 20060063212	A1	20060323	US 2004-3293	20041203 <--
US 20060062755	A1	20060323	US 2005-32399	20050110 <--
US 20060062757	A1	20060323	US 2005-133838	20050519 <--
US 7125836	B2	20061024		
US 20070014821	A1	20070118	US 2006-533805	20060921 <--
US 7507703	B2	20090324		
PRIORITY APPLN. INFO.:			US 2004-946213	B2 20040921 <--
			US 2004-3293	B2 20041203 <--
			US 2005-32399	B3 20050110 <--
			US 2005-133838	A1 20050519
			US 2006-533805	A2 20060921

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
AB A method of cancer screening comprising the steps of administering the Blood CA 27,29 testing procedure; if the result is pos. administering a mammogram; if the result is pos. administering a needle biopsy; if the result is pos. administering a PET scan; if the result is pos. administering a blood tumor cell count. If all of the foregoing steps are pos., the cancer is treated by selecting one or more treatments from a group of provided treatment according to the patient's body and condition. A method of treating auto-immune diseases comprises selecting one or more treatments from another group of provided treatments, the one or more treatments selected and administered according to the patient's body and condition.
INCL 424227100; 424009200; 424184100
CC 1-6 (Pharmacology)
Section cross-reference(s): 2, 9, 14, 15, 63
ST breast cancer screening Blood CA2729 test mammogram needle biopsy; PET scan blood tumor cell count breast cancer screening; cancer autoimmune disease multiple treatment selection
IT Immune system
(BCG vaccine and imiquimod cream for stimulation of T-cells and; cancer screening, cancer treatment, and autoimmune disease treatment with selected multiple therapies)
IT T cell
(BCG vaccine and imiquimod cream for stimulation of; cancer screening, cancer treatment, and autoimmune disease treatment with selected multiple therapies)
IT Blood analysis
(Blood CA 27,29 test or tumor cell count; cancer screening, cancer treatment, and autoimmune disease treatment with selected multiple therapies)

IT Natural products, pharmaceutical
(GinSeng, in Q-base cream; cancer screening, cancer treatment, and autoimmune disease treatment with selected multiple therapies)
IT Vaccines
(Mycobacterium BCG; cancer screening, cancer treatment, and autoimmune disease treatment with selected multiple therapies)
IT Imaging
(NMR; cancer screening, cancer treatment, and autoimmune disease treatment with selected multiple therapies)
IT Fats and Glyceridic oils
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(almond, bitter almond kernel oil, in H base cream; cancer screening, cancer treatment, and autoimmune disease treatment with selected multiple therapies)
IT Almond
(bitter, kernel oil, in H base cream; cancer screening, cancer treatment, and autoimmune disease treatment with selected multiple therapies)
IT Antidiabetic agents
Antioxidants
Antitumor agents
Autoimmune disease
Combination chemotherapy
Human
Mammary gland, neoplasm
Neoplasm
Oral drug delivery systems
Pharmaceutical capsules
Pharmaceutical creams
Pharmaceutical tablets
Positron-emission tomography
Therapy
Tomography
Topical drug delivery systems
Transdermal drug delivery systems
(cancer screening, cancer treatment, and autoimmune disease treatment with selected multiple therapies)
IT Diagnosis
(cancer; cancer screening, cancer treatment, and autoimmune disease treatment with selected multiple therapies)
IT Cyclosiloxanes
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(di-Me, in Q-base cream; cancer screening, cancer treatment, and autoimmune disease treatment with selected multiple therapies)
IT Metastasis
(diagnosis of; cancer screening, cancer treatment, and autoimmune disease treatment with selected multiple therapies)
IT Proteins
RL: FFD (Food or feed use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(diet low in; cancer screening, cancer treatment, and autoimmune disease treatment with selected multiple therapies)
IT Exercise
(directing plan for; cancer screening, cancer treatment, and autoimmune disease treatment with selected multiple therapies)

IT Mammary gland, neoplasm
(ductal carcinoma; cancer screening, cancer treatment, and autoimmune disease treatment with selected multiple therapies)
IT Ginkgo biloba
(extract of, in Q-base cream; cancer screening, cancer treatment, and autoimmune disease treatment with selected multiple therapies)
IT Fats and Glyceridic oils
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(fish, oral administration of tablets of; cancer screening, cancer treatment, and autoimmune disease treatment with selected multiple therapies)
IT Fats and Glyceridic oils
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(grape seed, in H base cream; cancer screening, cancer treatment, and autoimmune disease treatment with selected multiple therapies)
IT Tea products
(green, extract of, in Q-base cream; cancer screening, cancer treatment, and autoimmune disease treatment with selected multiple therapies)
IT Vaccines
(hepatitis B, recombinant hepatitis B, i.v. administration of; cancer screening, cancer treatment, and autoimmune disease treatment with selected multiple therapies)
IT Pharmaceutical injections
(i.v. injections; cancer screening, cancer treatment, and autoimmune disease treatment with selected multiple therapies)
IT Skin
(imiquimod-containing cream administration to various sites to avoid irritation to; cancer screening, cancer treatment, and autoimmune disease treatment with selected multiple therapies)
IT Aloe barbadensis
(in H base cream; cancer screening, cancer treatment, and autoimmune disease treatment with selected multiple therapies)
IT Canola oil
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(in H base cream; cancer screening, cancer treatment, and autoimmune disease treatment with selected multiple therapies)
IT Diabetes mellitus
(insulin-dependent; cancer screening, cancer treatment, and autoimmune disease treatment with selected multiple therapies)
IT T cell
(killer T-cell, DHEA sulfate cream for attracting and activating; cancer screening, cancer treatment, and autoimmune disease treatment with selected multiple therapies)
IT Diet
(low protein; cancer screening, cancer treatment, and autoimmune disease treatment with selected multiple therapies)
IT Carcinoma
(mammary ductal; cancer screening, cancer treatment, and autoimmune disease treatment with selected multiple therapies)
IT Radiography

(mammogram; cancer screening, cancer treatment, and autoimmune disease treatment with selected multiple therapies)
IT Controlled-release drug delivery systems
(oral, for niacin; cancer screening, cancer treatment, and autoimmune disease treatment with selected multiple therapies)
IT Fatty acids
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(polyunsatd., omega-3, oral administration of; cancer screening, cancer treatment, and autoimmune disease treatment with selected multiple therapies)
IT Hepatitis B virus
(recombinant, vaccine, i.v. administration of; cancer screening, cancer treatment, and autoimmune disease treatment with selected multiple therapies)
IT Mammary gland
(tissue needle biopsy; cancer screening, cancer treatment, and autoimmune disease treatment with selected multiple therapies)
IT Samples
(tissue; cancer screening, cancer treatment, and autoimmune disease treatment with selected multiple therapies)
IT Immunization
(vaccination; cancer screening, cancer treatment, and autoimmune disease treatment with selected multiple therapies)
IT Tumor necrosis factors
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); BIOL (Biological study)
(vaccine inducing production of; cancer screening, cancer treatment, and autoimmune disease treatment with selected multiple therapies)
IT Mycobacterium BCG
(vaccine; cancer screening, cancer treatment, and autoimmune disease treatment with selected multiple therapies)
IT Fats and Glyceridic oils
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(wheat germ, in H base cream; cancer screening, cancer treatment, and autoimmune disease treatment with selected multiple therapies)
IT Interferons
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); BIOL (Biological study)
(α, induction of production of; cancer screening, cancer treatment, and autoimmune disease treatment with selected multiple therapies)
IT 168273-06-1, Rimonabant
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(Acomplia, oral administration of; cancer screening, cancer treatment, and autoimmune disease treatment with selected multiple therapies)
IT 59-67-6, Niacin, biological studies
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(Niaspan, oral administration of extended release form of; cancer screening, cancer treatment, and autoimmune disease treatment with selected multiple therapies)
IT 50-99-7, D-Glucose, biological studies 62572-11-6, Hemoglobin A1c
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic

use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(cancer screening, cancer treatment, and autoimmune disease treatment with selected multiple therapies)

IT 36282-47-0, ULTRAM ER
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(cancer screening, cancer treatment, and autoimmune disease treatment with selected multiple therapies)

IT 150977-36-9, Bromelain
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(capsules of; cancer screening, cancer treatment, and autoimmune disease treatment with selected multiple therapies)

IT 56-81-5, Glycerin, biological studies 57-11-4, Stearic acid, biological studies 57-55-6, Propylene glycol, biological studies 58-95-7, Vitamin E acetate 64-02-8, Tetrasodium EDTA 79-81-2, Vitamin A palmitate 102-71-6, Triethanolamine, biological studies 1327-43-1, Magnesium aluminum silicate 7732-18-5, Water, biological studies 9004-99-3, PEG stearate 9005-67-8, Polysorbate 60 9006-65-9, Dimethicone 11099-07-3, Glyceryl stearate 11138-66-2, Xanthan gum 24634-61-5, Potassium sorbate 36653-82-4, Cetyl alcohol 64296-33-9, Vitamin C palmitate 78491-02-8, Diazolidinylurea
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(in H base cream; cancer screening, cancer treatment, and autoimmune disease treatment with selected multiple therapies)

IT 50-70-4, Sorbitol, biological studies 112-92-5, Stearyl alcohol 139-33-3, Edetate disodium 541-02-6, Cyclopentasiloxane 6829-55-6D, Tocotrienol, compds. 22047-49-0, Octyl stearate 55965-84-9 84750-06-1, Arlacel 165 314241-95-7, Dow Corning 5225C
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(in Q-base cream; cancer screening, cancer treatment, and autoimmune disease treatment with selected multiple therapies)

IT 124832-27-5, VALTREX
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(oral administration of combination of tramadol and; cancer screening, cancer treatment, and autoimmune disease treatment with selected multiple therapies)

IT 861006-80-6, Lovaza
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(oral administration of tablets of; cancer screening, cancer treatment, and autoimmune disease treatment with selected multiple therapies)

IT 303-98-0, Coenzyme Q10 443-48-1, FLAGYL 1783-84-2 9001-00-7 32222-06-3, Calcitriol 161973-10-0, NEXium 174882-69-0, Pycnogenol 186826-86-8, AVELOX
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(oral administration of; cancer screening, cancer treatment, and autoimmune disease treatment with selected multiple therapies)

IT 119141-88-7, Esomeprazole 151096-09-2, Moxifloxacin
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(oral of; cancer screening, cancer treatment, and autoimmune disease treatment with selected multiple therapies)

IT 53-43-0, DHEA 651-48-9, DHEA sulfate

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(topical administration of cream containing; cancer screening, cancer treatment, and autoimmune disease treatment with selected multiple therapies)

IT 99011-02-6, Imiquimod
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(transdermal administration of cream containing; cancer screening, cancer treatment, and autoimmune disease treatment with selected multiple therapies)

IT 506-26-3
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(γ-linolenic acid, oral administration of; cancer screening, cancer treatment, and autoimmune disease treatment with selected multiple therapies)

IT 303-98-0, Coenzyme Q10
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(oral administration of; cancer screening, cancer treatment, and autoimmune disease treatment with selected multiple therapies)

RN 303-98-0 ZCAPLUS

CN 2,5-Cyclohexadiene-1,4-dione, 2-[(2E,6E,10E,14E,18E,22E,26E,30E,34E)-3,7,11,15,19,23,27,31,35,39-decamethyl-2,6,10,14,18,22,26,30,34,38-tetracontadecaen-1-yl]-5,6-dimethoxy-3-methyl- (CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A



PAGE 1-B



PAGE 1-C

L88 ANSWER 3 OF 41 ZCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2008:349028 ZCAPLUS Full-text
DOCUMENT NUMBER: 148:338999
TITLE: Foamable vehicle and vitamin and flavonoid pharmaceutical compositions thereof for treatment of skin and other disorders
INVENTOR(S): Tamarkin, Dov; Friedman, Doron; Eini, Meir; Berman, Tal; Schuz, David
PATENT ASSIGNEE(S): Foamix Ltd., Israel
SOURCE: U.S. Pat. Appl. Publ., 57pp., Cont.-in-part of U.S. Ser. No. 430,599.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 35
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20080069779	A1	20080320	US 2007-900072	20070910 <--
US 20050031547	A1	20050210	US 2004-835505	20040428 <--
AU 2004313285	A1	20050929	AU 2004-313285	20041216 <--
ZA 2005007018	A	20080227	ZA 2005-7018	20041216 <--
US 20060275218	A1	20061207	US 2006-430599	20060509 <--
AU 2006298442	A1	20070412	AU 2006-298442	20060509
CA 2609953	A1	20070412	CA 2006-2609953	20060509
WO 2007039825	A2	20070412	WO 2006-IB3628	20060509
WO 2007039825	A3	20080306		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				
AU 2006313443	A1	20070518	AU 2006-313443	20060509
CA 2610662	A1	20070518	CA 2006-2610662	20060509
WO 2007054818	A2	20070518	WO 2006-IB3519	20060509
WO 2007054818	A3	20081023		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				
EP 1888032	A2	20080220	EP 2006-831721	20060509
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL,				

BA, HR, MK, YU
EP 1893396 A2 20080305 EP 2006-809259 20060509
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU
JP 2008540508 T 20081120 JP 2008-510676 20060509
JP 2008540511 T 20081120 JP 2008-510679 20060509
US 20070280891 A1 20071206 US 2006-645444 20061226 <--
ZA 2007010621 A 20090325 ZA 2007-10621 20070101
US 20080050317 A1 20080228 US 2007-894668 20070820 <--
MX 2007014106 A 20080829 MX 2007-14106 20071109
MX 2007014101 A 20090213 MX 2007-14101 20071109
IN 2007KN04432 A 20080125 IN 2007-KN4432 20071203
IN 2007KN04590 A 20080704 IN 2007-KN4590 20071203
ZA 2007010619 A 20090826 ZA 2007-10619 20071204
PRIORITY APPLN. INFO.: US 2003-492385P P 20030804 <--
US 2003-530015P P 20031216 <--
US 2004-835505 A2 20040428 <--
US 2005-679020P P 20050509
US 2006-784793P P 20060321
US 2006-430599 A2 20060509
US 2006-843140P P 20060908
WO 2006-IB3519 W 20060509
WO 2006-IB3628 W 20060509

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

AB Vitamin and flavonoid containing compns. are provided that are stable to degradation Stabilized compns. include one or more features including a hygroscopic solvent at a sufficient concentration to provide an Aw value of the hygroscopic vitamin and or flavonoid containing composition of less than 0.9, antioxidant flavonoids that are preferentially oxidized before the vitamin, preservatives, and hydrocarbon propellants selected to reduce the oxidation potential of the composition Thus, a foamable carrier was prepared containing propylene glycol 88.00, stearyl alc. 2.00, hydroxypropyl cellulose 2.00, Laureth-4 2.00, GMS NE 2.00, macrogol cetostearyl ether 1.00, and PPG-15 stearyl ether 3.00%, resp. Ascorbic acid and niacinamide were concurrently added to the carrier at 5.00% and 2.00%, resp. Following addition of a propellant, the foamable composition was obtained, which upon release from an aerosol pressurized container afforded foam of good quality. The foam was easily spread and immediately absorbed into the facial skin with no extensive rubbing.

INCL 424045000
CC 63-6 (Pharmaceuticals)
Section cross-reference(s): 1, 62
ST flavonoid vitamin topical foam microsponge skin disease
IT Alcohols
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(C16-18, ethoxylated, ethers; foamable vehicle for vitamin and flavonoid topical compns. for treatment of skin and other disorders)
IT Alcohols
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(C16-18, ethoxylated; foamable vehicle for vitamin and flavonoid topical compns. for treatment of skin and other disorders)
IT Alcohols
Glycosides
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(C16-18; foamable vehicle for vitamin and flavonoid topical compns. for treatment of skin and other disorders)
IT Glycerides
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(C8-10; foamable vehicle for vitamin and flavonoid topical compns. for treatment of skin and other disorders)
IT Disease, animal
(Dercum disease; foamable vehicle for vitamin and flavonoid topical compns. for treatment of skin and other disorders)
IT Skin, disease
(Hailey-Hailey disease; foamable vehicle for vitamin and flavonoid topical compns. for treatment of skin and other disorders)
IT Sarcoma
(Kaposi's; foamable vehicle for vitamin and flavonoid topical compns. for treatment of skin and other disorders)
IT Reproductive system, neoplasm
Viral infection
(acuminate wart; foamable vehicle for vitamin and flavonoid topical compns. for treatment of skin and other disorders)
IT Wart
(acuminate; foamable vehicle for vitamin and flavonoid topical compns. for treatment of skin and other disorders)
IT Lymph node disease
(acute lymphangitis; foamable vehicle for vitamin and flavonoid topical compns. for treatment of skin and other disorders)
IT Reproductive system disease
(adnexitis; foamable vehicle for vitamin and flavonoid topical compns. for treatment of skin and other disorders)
IT Skin, disease
(aging; foamable vehicle for vitamin and flavonoid topical compns. for treatment of skin and other disorders)
IT Intestinal neoplasm
(anal; foamable vehicle for vitamin and flavonoid topical compns. for treatment of skin and other disorders)
IT Dandruff
(antidandruff agents; foamable vehicle for vitamin and flavonoid topical compns. for treatment of skin and other disorders)
IT Intestinal disease
(anus; foamable vehicle for vitamin and flavonoid topical compns. for treatment of skin and other disorders)
IT Dermatitis
(atopic; foamable vehicle for vitamin and flavonoid topical compns. for treatment of skin and other disorders)
IT Skin, disease
(bacterial infection; foamable vehicle for vitamin and flavonoid topical compns. for treatment of skin and other disorders)
IT Vaginal disease
(bacterial; foamable vehicle for vitamin and flavonoid topical compns. for treatment of skin and other disorders)
IT Skin, neoplasm
(basal cell carcinoma; foamable vehicle for vitamin and flavonoid topical compns. for treatment of skin and other disorders)
IT Carcinoma
(basal cell; foamable vehicle for vitamin and flavonoid topical compns. for treatment of skin and other disorders)
IT Adhesives
(biol.; foamable vehicle for vitamin and flavonoid topical compns. for treatment of skin and other disorders)
IT Skin, disease
(bullous pemphigoid; foamable vehicle for vitamin and flavonoid topical compns. for treatment of skin and other disorders)
IT Skin
(callus; foamable vehicle for vitamin and flavonoid topical

compns. for treatment of skin and other disorders)
IT Foot
(calluses and corns; foamable vehicle for vitamin and flavonoid topical compns. for treatment of skin and other disorders)
IT Vinyl compounds
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(carboxy-containing, polymers; foamable vehicle for vitamin and flavonoid topical compns. for treatment of skin and other disorders)
IT Skin, disease
(carbuncle; foamable vehicle for vitamin and flavonoid topical compns. for treatment of skin and other disorders)
IT Inflammation
(cellulitis; foamable vehicle for vitamin and flavonoid topical compns. for treatment of skin and other disorders)
IT Sexually transmitted diseases
(chancroid; foamable vehicle for vitamin and flavonoid topical compns. for treatment of skin and other disorders)
IT Ear disease
(cholesteatoma; foamable vehicle for vitamin and flavonoid topical compns. for treatment of skin and other disorders)
IT Glycerides
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(coco; foamable vehicle for vitamin and flavonoid topical compns. for treatment of skin and other disorders)
IT Polyp
(colon polyp; foamable vehicle for vitamin and flavonoid topical compns. for treatment of skin and other disorders)
IT Colon disease
(colon polyps; foamable vehicle for vitamin and flavonoid topical compns. for treatment of skin and other disorders)
IT Dermatitis
(contact; foamable vehicle for vitamin and flavonoid topical compns. for treatment of skin and other disorders)
IT Skin, disease
(corn; foamable vehicle for vitamin and flavonoid topical compns. for treatment of skin and other disorders)
IT Injury
Ulcer
(cutaneous; foamable vehicle for vitamin and flavonoid topical compns. for treatment of skin and other disorders)
IT Pain
(dermatol.; foamable vehicle for vitamin and flavonoid topical compns. for treatment of skin and other disorders)
IT Cyclosiloxanes
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(di-Me; foamable vehicle for vitamin and flavonoid topical compns. for treatment of skin and other disorders)
IT Carboxylic acids
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(dicarboxylic; foamable vehicle for vitamin and flavonoid topical compns. for treatment of skin and other disorders)
IT Oviduct
(disease, salpingitis; foamable vehicle for vitamin and flavonoid topical compns. for treatment of skin and other disorders)
IT Urethra
(disease, urethritis, nongonococcal urethritis; foamable vehicle for vitamin and flavonoid topical compns. for treatment of skin and other disorders)
IT Vaginal disease
(dyspareunia; foamable vehicle for vitamin and flavonoid

topical compns. for treatment of skin and other disorders)
IT Cholesteatoma
(ear; foamable vehicle for vitamin and flavonoid topical compns. for treatment of skin and other disorders)
IT Skin, disease
(ecthyma; foamable vehicle for vitamin and flavonoid topical compns. for treatment of skin and other disorders)
IT Skin, disease
(epidermal necrolysis; foamable vehicle for vitamin and flavonoid topical compns. for treatment of skin and other disorders)
IT Skin, disease
(erysipelas; foamable vehicle for vitamin and flavonoid topical compns. for treatment of skin and other disorders)
IT Skin, disease
(erythema nodosum; foamable vehicle for vitamin and flavonoid topical compns. for treatment of skin and other disorders)
IT Skin, disease
(erythrasma; foamable vehicle for vitamin and flavonoid topical compns. for treatment of skin and other disorders)
IT Fatty acids
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(essential; foamable vehicle for vitamin and flavonoid topical compns. for treatment of skin and other disorders)
IT Polyoxyalkylenes
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(ethers; foamable vehicle for vitamin and flavonoid topical compns. for treatment of skin and other disorders)
IT Vitamins
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(fat-soluble; foamable vehicle for vitamin and flavonoid topical compns. for treatment of skin and other disorders)
IT Alcohols
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(fatty; foamable vehicle for vitamin and flavonoid topical compns. for treatment of skin and other disorders)
IT Intestinal disease
(fecal incontinence; foamable vehicle for vitamin and flavonoid topical compns. for treatment of skin and other disorders)
IT AIDS (disease)
Abscess
Acaricides
Allergy inhibitors
Alopecia
Analgesics
Anthelmintics
Anti-infective agents
Anti-inflammatory agents
Antiaging cosmetics
Antibacterial agents
Antibiotics
Antidepressants
Antihistamines
Antimicrobial agents
Antioxidants
Antitumor agents
Antiviral agents
Astringents
Beeswax
Behcet's syndrome
Candidiasis

Cervix, neoplasm
Constipation
Crohn disease
Cytotoxic agents
Dermatitis
Dermatological agents
Disinfectants
Drugs
Ectodermal dysplasia
Eczema
Endometritis
Fungicides
Gelation agents
Hemorrhoid
Hepatitis B
Herpes
Honey
Human
Human papillomavirus
Hypolipemic agents
Immunomodulators
Immunosuppressants
Insect repellents
Insecticides
Lupus erythematosus
Lymphadenitis
Melanoma
Mycosis
Natural products, pharmaceutical
Nonsteroidal anti-inflammatory drugs
Oxidizing agents
Pharmaceutical foams
Photosensitizers, pharmaceutical
Preservatives
Propellants (sprays and foams)
Pruritus
Psoriasis
Purpura (disease)
Reproductive system, neoplasm
Rhus diversiloba
Rhus toxicodendron
Scar
Scleroderma
Skin, neoplasm
Stabilizing agents
Sunburn
Sunless tanning products
Surfactants
Topical drug delivery systems
Urticaria
Vagina, neoplasm
Vasoconstrictors
Vasodilators
Vitiligo
Wound healing promoters
(foamable vehicle for vitamin and flavonoid topical compns. for treatment of skin and other disorders)

IT Alditols
Allergens
Anthocyanins

Carbohydrates
Carboxylic acids
Corticosteroids
Diglycerides
Disaccharides
Fatty acids
Flavanols
Flavones
Flavonoids
Gelatins
Glycols
Hormones, animal
Hydrocarbon oils
Lactams
Lanolin
Lecithins
Metals
Monoglycerides
Monosaccharides
Neuropeptides
Oligosaccharides
Ovalbumin
Oxides (inorganic)
Petrolatum
Polyamines
Polyoxyalkylenes
Proanthocyanidins
Retinoids
Vitamins
Waxes
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(foamable vehicle for vitamin and flavonoid topical compns. for treatment of skin and other disorders)

IT Hair, disease
Inflammation
(folliculitis; foamable vehicle for vitamin and flavonoid topical compns. for treatment of skin and other disorders)

IT Skin, disease
(furunculosis; foamable vehicle for vitamin and flavonoid topical compns. for treatment of skin and other disorders)

IT Necrosis
(gangrene; foamable vehicle for vitamin and flavonoid topical compns. for treatment of skin and other disorders)

IT Sexually transmitted diseases
(gonorrhea; foamable vehicle for vitamin and flavonoid topical compns. for treatment of skin and other disorders)

IT Skin, disease
(granuloma annulare; foamable vehicle for vitamin and flavonoid topical compns. for treatment of skin and other disorders)

IT Bacterial infection
(granuloma inguinale; foamable vehicle for vitamin and flavonoid topical compns. for treatment of skin and other disorders)

IT Hair
(growth regulators; foamable vehicle for vitamin and flavonoid topical compns. for treatment of skin and other disorders)

IT Feeding
Sweat
(gustatory sweating; foamable vehicle for vitamin and flavonoid topical compns. for treatment of skin and other disorders)

IT Dermatitis

(herpetiformis; foamable vehicle for vitamin and flavonoid topical compns. for treatment of skin and other disorders)
IT Disease, animal
(hidradenitis suppurativa; foamable vehicle for vitamin and flavonoid topical compns. for treatment of skin and other disorders)
IT Castor oil
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(hydrogenated; foamable vehicle for vitamin and flavonoid topical compns. for treatment of skin and other disorders)
IT Solvents
(hydrophilic; foamable vehicle for vitamin and flavonoid topical compns. for treatment of skin and other disorders)
IT Solvents
(hydrophobic; foamable vehicle for vitamin and flavonoid topical compns. for treatment of skin and other disorders)
IT Fatty acids
Flavones
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(hydroxy; foamable vehicle for vitamin and flavonoid topical compns. for treatment of skin and other disorders)
IT Sweat gland
(hyperhidrosis; foamable vehicle for vitamin and flavonoid topical compns. for treatment of skin and other disorders)
IT Skin, disease
(ichthyosis; foamable vehicle for vitamin and flavonoid topical compns. for treatment of skin and other disorders)
IT Skin, disease
(impetigo; foamable vehicle for vitamin and flavonoid topical compns. for treatment of skin and other disorders)
IT Chlamydia
Molluscum contagiosum virus
(infection; foamable vehicle for vitamin and flavonoid topical compns. for treatment of skin and other disorders)
IT Skin, disease
(injury; foamable vehicle for vitamin and flavonoid topical compns. for treatment of skin and other disorders)
IT Dermatological agents
(keratolytics; foamable vehicle for vitamin and flavonoid topical compns. for treatment of skin and other disorders)
IT Skin, disease
(lichen planus; foamable vehicle for vitamin and flavonoid topical compns. for treatment of skin and other disorders)
IT Anesthetics
(local; foamable vehicle for vitamin and flavonoid topical compns. for treatment of skin and other disorders)
IT Lymph node disease
(lymphogranuloma venereum; foamable vehicle for vitamin and flavonoid topical compns. for treatment of skin and other disorders)
IT Triglycerides
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(medium-chain; foamable vehicle for vitamin and flavonoid topical compns. for treatment of skin and other disorders)
IT Drug delivery systems
(microsponges; foamable vehicle for vitamin and flavonoid topical compns. for treatment of skin and other disorders)
IT Skin, disease
(miliaria; foamable vehicle for vitamin and flavonoid topical compns. for treatment of skin and other disorders)
IT Neoplasm
(mole; foamable vehicle for vitamin and flavonoid topical

compns. for treatment of skin and other disorders)
IT Mycosis
(moniliasis; foamable vehicle for vitamin and flavonoid topical compns. for treatment of skin and other disorders)
IT Uterine cervicitis
(mucopurulent cervicitis; foamable vehicle for vitamin and flavonoid topical compns. for treatment of skin and other disorders)
IT Erythema
(multiforme; foamable vehicle for vitamin and flavonoid topical compns. for treatment of skin and other disorders)
IT Joint disease
(nail-patella syndrome; foamable vehicle for vitamin and flavonoid topical compns. for treatment of skin and other disorders)
IT Skin, disease
(necrosis, ischemic necrosis; foamable vehicle for vitamin and flavonoid topical compns. for treatment of skin and other disorders)
IT Skin, disease
(necrotizing fasciitis; foamable vehicle for vitamin and flavonoid topical compns. for treatment of skin and other disorders)
IT Myositis
(necrotizing myositis; foamable vehicle for vitamin and flavonoid topical compns. for treatment of skin and other disorders)
IT Ovarian disease
(oophoritis; foamable vehicle for vitamin and flavonoid topical compns. for treatment of skin and other disorders)
IT Flavonoids
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(oxo dihydro; foamable vehicle for vitamin and flavonoid topical compns. for treatment of skin and other disorders)
IT Skin, disease
(pain; foamable vehicle for vitamin and flavonoid topical compns. for treatment of skin and other disorders)
IT Infection
(paronychial; foamable vehicle for vitamin and flavonoid topical compns. for treatment of skin and other disorders)
IT Insecticides
(pediculocides; foamable vehicle for vitamin and flavonoid topical compns. for treatment of skin and other disorders)
IT Parasitic infection
(pediculosis; foamable vehicle for vitamin and flavonoid topical compns. for treatment of skin and other disorders)
IT Body, anatomical
(pelvis, inflammation; foamable vehicle for vitamin and flavonoid topical compns. for treatment of skin and other disorders)
IT Skin, disease
(pemphigus; foamable vehicle for vitamin and flavonoid topical compns. for treatment of skin and other disorders)
IT Skin
(permeation through; foamable vehicle for vitamin and flavonoid topical compns. for treatment of skin and other disorders)
IT Biological transport
(permeation; foamable vehicle for vitamin and flavonoid topical compns. for treatment of skin and other disorders)
IT Skin, disease
(photosensitivity; foamable vehicle for vitamin and flavonoid topical compns. for treatment of skin and other disorders)
IT Keratosis
(pilaris; foamable vehicle for vitamin and flavonoid topical compns. for treatment of skin and other disorders)

IT Skin, disease
(pityriasis rosea; foamable vehicle for vitamin and flavonoid topical compns. for treatment of skin and other disorders)
IT Skin, disease
(pityriasis rubra pilaris; foamable vehicle for vitamin and flavonoid topical compns. for treatment of skin and other disorders)
IT Alcohols
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(polyhydric; foamable vehicle for vitamin and flavonoid topical compns. for treatment of skin and other disorders)
IT Hydrocarbons
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(propellants; foamable vehicle for vitamin and flavonoid topical compns. for treatment of skin and other disorders)
IT Skin, disease
(rash; foamable vehicle for vitamin and flavonoid topical compns. for treatment of skin and other disorders)
IT Intestinal neoplasm
(rectal polyp; foamable vehicle for vitamin and flavonoid topical compns. for treatment of skin and other disorders)
IT Intestinal disease
(rectum; foamable vehicle for vitamin and flavonoid topical compns. for treatment of skin and other disorders)
IT Wart
(removers; foamable vehicle for vitamin and flavonoid topical compns. for treatment of skin and other disorders)
IT Skin, disease
(rosacea; foamable vehicle for vitamin and flavonoid topical compns. for treatment of skin and other disorders)
IT Connective tissue disease
(s.c. necrotizing infection; foamable vehicle for vitamin and flavonoid topical compns. for treatment of skin and other disorders)
IT Inflammation
(salpingitis; foamable vehicle for vitamin and flavonoid topical compns. for treatment of skin and other disorders)
IT Skin, disease
(scabies, scabicides; foamable vehicle for vitamin and flavonoid topical compns. for treatment of skin and other disorders)
IT Skin, disease
(scalded skin syndrome; foamable vehicle for vitamin and flavonoid topical compns. for treatment of skin and other disorders)
IT Cydonia
(seed extract; foamable vehicle for vitamin and flavonoid topical compns. for treatment of skin and other disorders)
IT Necrosis
(skin, ischemic necrosis; foamable vehicle for vitamin and flavonoid topical compns. for treatment of skin and other disorders)
IT Caseins
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(sodium complexes; foamable vehicle for vitamin and flavonoid topical compns. for treatment of skin and other disorders)
IT Carcinoma
(squamous cell; foamable vehicle for vitamin and flavonoid topical compns. for treatment of skin and other disorders)
IT Connective tissue
(subcutaneous tissue, necrotizing infection; foamable vehicle for vitamin and flavonoid topical compns. for treatment of skin and other disorders)
IT Foot
(toe, disease, corn; foamable vehicle for vitamin and flavonoid

topical compns. for treatment of skin and other disorders)
IT Cardiovascular agents
(topical; foamable vehicle for vitamin and flavonoid topical compns. for treatment of skin and other disorders)
IT Sexually transmitted diseases
(trichomoniasis; foamable vehicle for vitamin and flavonoid topical compns. for treatment of skin and other disorders)
IT Alcohols
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(trihydric; foamable vehicle for vitamin and flavonoid topical compns. for treatment of skin and other disorders)
IT Skin, disease
(ulcer; foamable vehicle for vitamin and flavonoid topical compns. for treatment of skin and other disorders)
IT Inflammation
(urethritis, nongonococcal urethritis; foamable vehicle for vitamin and flavonoid topical compns. for treatment of skin and other disorders)
IT Vaginal disease
(vaginal dryness; foamable vehicle for vitamin and flavonoid topical compns. for treatment of skin and other disorders)
IT Acne
(vulgaris; foamable vehicle for vitamin and flavonoid topical compns. for treatment of skin and other disorders)
IT Female reproductive system
(vulva, neoplasm; foamable vehicle for vitamin and flavonoid topical compns. for treatment of skin and other disorders)
IT Reproductive system disease
(vulvar dystrophy; foamable vehicle for vitamin and flavonoid topical compns. for treatment of skin and other disorders)
IT Reproductive system, neoplasm
(vulvar intraepithelial neoplasia; foamable vehicle for vitamin and flavonoid topical compns. for treatment of skin and other disorders)
IT Reproductive system disease
(vulvar; foamable vehicle for vitamin and flavonoid topical compns. for treatment of skin and other disorders)
IT Pain
(vulvodynia; foamable vehicle for vitamin and flavonoid topical compns. for treatment of skin and other disorders)
IT Vitamins
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(water-soluble; foamable vehicle for vitamin and flavonoid topical compns. for treatment of skin and other disorders)
IT Skin
(wrinkles; foamable vehicle for vitamin and flavonoid topical compns. for treatment of skin and other disorders)
IT 13157-90-9
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(Benzquercin; foamable vehicle for vitamin and flavonoid topical compns. for treatment of skin and other disorders)
IT 9005-00-9
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(Brij 721; foamable vehicle for vitamin and flavonoid topical compns. for treatment of skin and other disorders)
IT 9003-01-4D, crosslinked
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(Carbomer; foamable vehicle for vitamin and flavonoid topical compns. for treatment of skin and other disorders)
IT 30851-76-4

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(ethoxazorutoside; foamable vehicle for vitamin and flavonoid topical compns. for treatment of skin and other disorders)

IT 50-02-2, Dexamethasone 50-03-3, Hydrocortisone acetate 50-14-6, Vitamin D2 50-21-5, Lactic acid, biological studies 50-23-7, Hydrocortisone 50-24-8, Prednisolone 50-70-4D, Sorbitol, esters 50-81-7, Vitamin C, biological studies 52-01-7, Spironolactone 53-03-2, Prednisone 53-06-5, Cortisone 53-33-8, Paramethasone 53-34-9, Fluprednisolone 53-36-1, Methylprednisolone acetate 56-47-3, Desoxycorticosterone acetate 56-81-5, Glycerin, biological studies 57-13-6, Urea, biological studies 57-50-1D, Sucrose, esters 57-55-6, Propylene glycol, biological studies 57-83-0, Progesterone, biological studies 58-08-2, Caffeine, biological studies 58-85-5, Vitamin B7 58-95-7, Tocopheryl acetate 59-02-9, α-Tocopherol 59-43-8, Vitamin B1, biological studies 59-67-6, Vitamin B5, biological studies 60-00-4, EDTA, biological studies 60-29-7, Ether, biological studies 67-68-5, Dimethyl sulfoxide, biological studies 67-73-2, Fluocinolone acetonide 67-97-0, Vitamin D3 68-04-2, Sodium citrate 68-19-9, Vitamin B12 68-26-8, Retinol 69-72-7, Salicylic acid, biological studies 76-25-5, Triamcinolone acetonide 76-47-1, Hydrocortamate 79-14-1, Glycolic acid, biological studies 79-83-4, Vitamin B3 81-13-0, Dexpanthenol 83-43-2, Methylprednisolone 83-88-5, Vitamin B2, biological studies 94-36-0, Benzoyl peroxide, biological studies 97-99-4, Tetrahydrofurfuryl alcohol 98-92-0, Niacinamide 106-69-4, 1,2,6-Hexanetriol 107-41-5, Hexylene glycol 110-27-0, Isopropyl myristate 111-46-6, Diethylene glycol, biological studies 112-27-6, Triethylene glycol 112-60-7, Tetraethylene glycol 112-72-1, Myristyl alcohol 112-92-5, Stearyl alcohol 117-39-5, Quercetin 123-31-9, Hydroquinone, biological studies 123-99-9, Azelaic acid, biological studies 124-94-7, Triamcinolone 126-30-7, Neopentyl glycol 127-19-5, Dimethylacetamide 127-31-1, Fludrocortisone 134-01-0, Peonidin 134-04-3, Pelargonidin 137-58-6, Lidocaine 137-66-6, Ascorbyl palmitate 139-33-3 143-28-2, Oleyl alcohol 145-13-1, Pregnenolone 150-13-0, PABA 152-58-9, Cortodoxone 152-97-6, Fluocortolone 153-18-4, Rutin 154-23-4, Catechin 302-79-4, Retinoic acid 303-98-0, Coenzyme Q 10 312-93-6, Dexamethasone phosphate 356-12-7, Flucetonide 378-44-9, Betamethasone 382-67-2, Desoxymethasone 426-13-1, Fluoromethalone 443-48-1, Metronidazole 480-17-1, Leucocianidol 480-41-1, Naringenin 490-46-0, Epicatechin 491-70-3, Luteolin 508-99-6, Hydrocortisone cyclopentylpropionate 511-28-4, Vitamin D4 520-18-3, Kaempferol 520-27-4, Diosmin 520-33-2, Hesperetin 520-36-5, Apigenin 520-91-2, Vitamin D1 528-53-0, Delphinidin 528-58-5, Cyanidin 529-44-2, Myricetin 552-58-9, Eriodictyol 616-45-5, Pyrrolidone 638-94-8, Desonide 643-84-5, Malvidin 661-19-8, Behenyl alcohol 807-38-5, Fluocinolone 872-50-4, N-Methyl-2-pyrrolidone, biological studies 970-73-0, Gallocatechin 970-74-1, Epigallocatechin 1247-42-3, Meprednisone 1255-35-2, Fluprednidene acetate 1338-39-2, Sorbitan monolaurate 1338-41-6, Span 60 1338-43-8, Sorbitan monooleate 1403-66-3, Gentamycin 1406-18-4, Vitamin E 1429-30-7, Petunidin 1524-88-5, Flurandrenolone acetonide 1569-02-4, Ethyl proxitol 2002-29-1, Flumethasone pivalate 2135-17-3, Flumethasone 2152-44-5, Betamethasone valerate 2163-42-0, 2-Methyl-1,3-propanediol 2668-66-8, Medrysone 3068-00-6, 1,2,4-Butanetriol 3093-35-4, Halcinonide 3385-03-3, Flunisolide 3403-82-5, Dibutylene glycol 3693-39-8, Flucloronide 3841-11-0, Fluperolone 3924-70-7, Amcinafal 4419-39-0, Beclomethasone 4435-50-1, 1,2,3-Butanetriol 4828-27-7, Clocortolone 5306-85-4, Dimethyl isosorbide 5534-09-8, Beclomethasone dipropionate 5593-20-4, Betamethasone dipropionate 6938-94-9, Diisopropyl adipate 7008-26-6, Dichlorisone 7332-27-6, Amcinafide 7681-57-4 8014-04-8, Sharonmix

824 8059-24-3, Vitamin B6 9000-07-1, Carrageenan 9000-30-0, Guar gum 9000-30-0D, Guar gum, cationic derivs. 9000-40-2, Locust bean gum 9000-65-1, Tragacanth gum 9002-18-0, Agar 9002-85-1, Polyvinylidene chloride 9002-86-2, Polyvinyl chloride 9002-89-5, Polyvinyl alcohol 9002-92-0, Laureth 4 9003-01-4, Polyacrylic acid 9003-20-7, Polyvinyl acetate 9003-39-8, Polyvinylpyrrolidone 9004-30-2, Hydroxyethyl carboxymethyl cellulose 9004-32-4, Carboxymethyl cellulose 9004-61-9, Hyaluronic acid 9004-62-0, Hydroxyethyl cellulose 9004-64-2, Hydroxypropyl cellulose 9004-65-3, Hydroxypropyl methyl cellulose 9004-67-5, Methyl cellulose 9004-95-9, Polyoxyethylene cetyl ether 9004-99-3, Myrj 45 9005-25-8, Starch, biological studies 9005-32-7, Alginic acid 9005-38-3, Sodium alginate 9005-64-5 9005-65-6 9005-67-8 9007-16-3, Carbopol 934 9012-76-4, Chitosan 9032-42-2, Methylhydroxyethyl cellulose 9062-04-8, Carbopol 941 9087-61-0, Aluminum starch octenyl succinate 11070-67-0, Butynediol 11096-55-2, Vitamin B9 11099-07-3, Glyceryl stearate 11103-57-4, Vitamin A 11138-66-2, Xanthan gum 12001-79-5, Vitamin K 12542-32-4, Butenediol 13609-67-1, Hydrocortisone butyrate 14066-79-6, Chlorprednisone acetate 15307-86-5, Diclofenac 18323-44-9, Clindamycin 20283-92-5, Rosmarinic acid 22298-29-9, Betamethasone benzoate 23593-75-1, Clotrimazole 23674-86-4, Difluprednate 23869-24-1, Monoxerutin 25087-26-7, Polymethacrylic acid 25122-41-2, Clobetasol 25122-46-7, Clobetasol propionate 25122-57-0, Clobetasone butyrate 25231-21-4, PPG-15 stearyl ether 25265-71-8, Dipropylene glycol 25265-75-2, Butanediol 25322-68-3, Polyethylene glycol 25322-68-3D, fatty acid esters 25655-41-8, Povidone iodine 26762-52-7, Hexanediol 26762-67-4, Octanediol 27195-16-0, Sucrose distearate 29342-05-0, Ciclopirox 29348-79-6, Pentanediol 29468-36-8, Methyl hydroxybenzoate 31566-31-1, Glyceryl monostearate 33564-31-7, Diflorasone diacetate 34406-66-1 34513-50-3, Octyldodecanol 37318-31-3 37470-13-6 37870-43-2, Propyl hydroxybenzoate 39421-75-5, Hydroxypropyl guar gum 41767-29-7, Fluocortin butyl ester 51022-69-6, Amcinonide 51333-22-3, Budesonide 51395-75-6, Avicel RC 581 52080-57-6, Chloroprednisone 54063-32-0, Clobetasone 56451-84-4, Sorbitan stearate 57524-89-7, Hydrocortisone valerate 59198-70-8, Diflucortolone valerate 59277-89-3, Acyclovir 66734-13-2, Alclometasone dipropionate 68936-95-8, Methyl glucose sesquistearate 69364-63-2, Isoceteth-20 71761-06-3, Vitamin D5 76050-42-5, Carbopol 940 78628-80-5, Terbinafine hydrochloride 83919-23-7, Mometasone furoate 90566-53-3, Fluticasone 98651-66-2, Halobetasol 99011-02-6, Imiquimod 104987-11-3, Tacrolimus 108910-78-7, Magnesium ascorbyl phosphate 120146-89-6, Micro Sponge 138757-67-2, Carbopol 980 138757-68-3, Carbopol 981 145687-02-1, Pemulen TR 2 156410-05-8, Montanov 68

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(foamable vehicle for vitamin and flavonoid topical compns. for treatment of skin and other disorders)

IT 194674-18-5, Simulsol 165 827596-80-5 916451-60-0 952676-80-1 1007319-03-0, Simusol 165 1011299-99-2

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(foamable vehicle for vitamin and flavonoid topical compns. for treatment of skin and other disorders)

IT 61641-74-5, Butane-propane mixture 102767-64-6, Propellant 1681 1011493-08-5, Propellant 5515

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(propellant; foamable vehicle for vitamin and flavonoid topical compns. for treatment of skin and other disorders)

IT 303-98-0, Coenzyme Q 10

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(foamable vehicle for vitamin and flavonoid topical compns. for treatment of skin and other disorders)

RN 303-98-0 ZCAPLUS
CN 2,5-Cyclohexadiene-1,4-dione, 2-[(2E,6E,10E,14E,18E,22E,26E,30E,34E)-3,7,11,15,19,23,27,31,35,39-decamethyl-2,6,10,14,18,22,26,30,34,38-tetracontadecaen-1-yl]-5,6-dimethoxy-3-methyl- (CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A



PAGE 1-B



PAGE 1-C

OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)

L88 ANSWER 4 OF 41 ZCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2007:1215784 ZCAPLUS Full-text
DOCUMENT NUMBER: 147:491621
TITLE: Nutraceutical composition comprising 2,3-dimethoxy-5-methyl-1,4-benzoquinone and method of use for treatment/prevention of cancer
INVENTOR(S): Mazzio, Elizabeth; Soliman, Karam
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 31pp., Cont.-in-part of U.S. Ser. No. 233,279.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20070248693	A1	20071025	US 2007-711883	20070227 <--
US 20060035981	A1	20060216	US 2005-233279	20050920 <--

PRIORITY APPLN. INFO.: US 2003-491841P P 20030802 <--
US 2004-540525P P 20040129 <--
US 2004-909590 B2 20040802 <--
US 2005-233279 A2 20050920

AB The invention describes a pharmaceutical composition and method for treating cancer comprising (a) 2,3-dimethoxy-5-methyl-1,4-benzoquinone, and/or (b) at least one of wild yam root, teasel root, balm of gilead bud, bakuchi seed, dichroa root, kochia seed, kanta kari, bushy knotweed rhizome, arjun, babul chall bark, opopanax and bhumy amalaki; optionally one or more of frankincense, garcinia fruit, vitex, dragons blood, mace, sage and red sandalwood with at least (c) one compound capable of maximizing oxidative mitochondrial function, preferably riboflavin or vitamin B2 derivs., FAD, FMN, 5-amino-6-(5'-phosphoribitylamino)uracil, 6,7-dimethyl-8-(1-D-ribityl)lumazine, ribitol, 5,6-dimethylbenzimidazole, tetrahydrobiopterin, vitamin B1, lipoic acid, biotin, vitamin B6, vitamin B12, folate, niacin, vitamin C and pantothenate, and/or (d) at least one lactic acid dehydrogenase inhibitor, preferably 2',3,4'5,7-pentahydroxyflavone and optionally (f) an alkalizing agent (Aloe vera, chlorella, wheat grass, sodium or potassium bicarbonate, potassium), (g) an antiproliferative herb (speranskia or goldenseal), and (h) a pharmaceutically acceptable carrier. A method for inhibiting cancer optionally comprises one or more chemotherapy drug(s), selected, among others, from acetogenins, actinomycin D, adriamycin, aminoglutethimide, asparaginase, bleomycin, bullatacin, busulfan, carmustine, carboplatin, chlorambucil, cisplatin, etc. Thus, a composition comprised rosemary (Rosmarinus officinalis) .apprx.1000, myrrh gum (Commiphora molmol) .apprx.500, 2,3-dimethoxy-5-methyl-1,4 benzoquinone .apprx.800, and riboflavin .apprx.300 mg/day, resp.

INCL 424725000
CC 63-6 (Pharmaceuticals)
Section cross-reference(s): 1, 17, 18
ST benzoquinone plant natural product nutraceutical cancer
IT Neoplasm
(AIDS-related; nutraceutical composition comprising 2,3-dimethoxy-5-methyl-1,4-benzoquinone for treatment/prevention of cancer)
IT Neuroglia, neoplasm
(astrocytoma; nutraceutical composition comprising 2,3-dimethoxy-5-methyl-1,4-benzoquinone for treatment/prevention of cancer)
IT Interferons
Polyketides
Quassinoids
Steroids
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(combination with; nutraceutical composition comprising 2,3-dimethoxy-5-methyl-1,4-benzoquinone for treatment/prevention of cancer)
IT Uterus, neoplasm
(endometrium; nutraceutical composition comprising 2,3-dimethoxy-5-methyl-1,4-benzoquinone for treatment/prevention of cancer)
IT Camellia sinensis
(green; nutraceutical composition comprising 2,3-dimethoxy-5-methyl-1,4-benzoquinone for treatment/prevention of cancer)
IT Commiphora molmol
(gum; nutraceutical composition comprising 2,3-dimethoxy-5-methyl-1,4-benzoquinone for treatment/prevention of cancer)
IT Neoplasm

(head and neck; nutraceutical composition comprising 2,3-dimethoxy-5-methyl-1,4-benzoquinone for treatment/prevention of cancer)
IT Beverages
(health; nutraceutical composition comprising 2,3-dimethoxy-5-methyl-1,4-benzoquinone for treatment/prevention of cancer)
IT Pharmaceutical injections
(i.a. injections; nutraceutical composition comprising 2,3-dimethoxy-5-methyl-1,4-benzoquinone for treatment/prevention of cancer)
IT Pharmaceutical injections
(i.m. injections; nutraceutical composition comprising 2,3-dimethoxy-5-methyl-1,4-benzoquinone for treatment/prevention of cancer)
IT Pharmaceutical injections
(i.p. injections; nutraceutical composition comprising 2,3-dimethoxy-5-methyl-1,4-benzoquinone for treatment/prevention of cancer)
IT Pharmaceutical injections
(i.v. injections; nutraceutical composition comprising 2,3-dimethoxy-5-methyl-1,4-benzoquinone for treatment/prevention of cancer)
IT Pharmaceutical injections
(intratumor; nutraceutical composition comprising 2,3-dimethoxy-5-methyl-1,4-benzoquinone for treatment/prevention of cancer)
IT Enzyme inhibitors
(lactic acid dehydrogenase inhibitors; nutraceutical composition comprising 2,3-dimethoxy-5-methyl-1,4-benzoquinone for treatment/prevention of cancer)
IT Respiration, animal
(mitochondrial, modulators; nutraceutical composition comprising 2,3-dimethoxy-5-methyl-1,4-benzoquinone for treatment/prevention of cancer)
IT Oxidative phosphorylation
(modulators; nutraceutical composition comprising 2,3-dimethoxy-5-methyl-1,4-benzoquinone for treatment/prevention of cancer)
IT Perfumes
(myrrh; nutraceutical composition comprising 2,3-dimethoxy-5-methyl-1,4-benzoquinone for treatment/prevention of cancer)
IT Astrocyte
(neoplasm, astrocytoma; nutraceutical composition comprising 2,3-dimethoxy-5-methyl-1,4-benzoquinone for treatment/prevention of cancer)
IT Connective tissue
(neoplasm; nutraceutical composition comprising 2,3-dimethoxy-5-methyl-1,4-benzoquinone for treatment/prevention of cancer)
IT Acacia nilotica
Acute lymphocytic leukemia
Acute myeloid leukemia
Adrenal gland, neoplasm
Aloe barbadensis
Antitumor agents
Bassia scoparia
Bile duct, neoplasm
Bladder, neoplasm

Bone neoplasm
Boswellia carterii
Brain, neoplasm
Bronchi, neoplasm
Burkitt lymphoma
  Carcinoma
Central nervous system, neoplasm
Cervix, neoplasm
Chlorella pyrenoidosa
Cinnamomum cassia
Colon neoplasm
Commiphora molmol
Coriandrum sativum
Cyamopsis tetragonolobus
Cytotoxic agents
Daemonorops draco
Dichroa febrifuga
Dietary supplements
Digestive tract, neoplasm
Dioscorea villosa
Dipsacus asper
Electrolytes
Enemas
Eye, neoplasm
Fallopia japonica
Gallbladder, neoplasm
Garcinia gummi-gutta
Glycyrrhiza glabra
Head and Neck, neoplasm
Health food
Hematopoietic neoplasm
Hodgkin's disease
Hydrastis canadensis
Hypothalamic neoplasm
Juglans nigra
Kidney, neoplasm
Liver, neoplasm
Lung, neoplasm
  Lymphoma
Mammary gland, neoplasm
Metastasis
Mouth, neoplasm
Myristica fragrans
Natural products, pharmaceutical
  Neoplasm
Neuroglia, neoplasm
Nose, neoplasm
Oral drug delivery systems
Ovary, neoplasm
Pancreas, neoplasm
Parathyroid gland, neoplasm
Parenteral drug delivery systems
Pharmaceutical aerosols
Pharmaceutical capsules
Pharmaceutical emulsions
Pharmaceutical foams
Pharmaceutical gels
Pharmaceutical granules
Pharmaceutical injections
Pharmaceutical liposomes

Pharmaceutical liquids
Pharmaceutical pastes
Pharmaceutical powders
Pharmaceutical solids
Pharmaceutical solutions
Pharmaceutical suppositories
Pharmaceutical suspensions
Pharmaceutical suspensions
Pharmaceutical tablets
Phyllanthus niruri
Pituitary gland, neoplasm
Populus balsamifera
Prophylaxis
Prostate gland, neoplasm
Pterocarpus santalinus
Rosmarinus officinalis
Salvia apiana
Skin, neoplasm
Solanum xanthocarpum
Speranskia tuberculata
Stomach, neoplasm
Syzygium aromaticum
Terminalia arjuna
Thyroid gland, neoplasm
Topical drug delivery systems
Triticum aestivum
Vitex agnus-castus
Wheat
Zingiber officinale
(nutraceutical composition comprising 2,3-dimethoxy-5-methyl-1,4-benzoquinone for treatment/prevention of cancer)

IT Hydroquinones
Ubiquinones
RL: FFD (Food or feed use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(nutraceutical composition comprising 2,3-dimethoxy-5-methyl-1,4-benzoquinone for treatment/prevention of cancer)

IT Resins
(opopanax; nutraceutical composition comprising 2,3-dimethoxy-5-methyl-1,4-benzoquinone for treatment/prevention of cancer)

IT Drug delivery systems
(packs; nutraceutical composition comprising 2,3-dimethoxy-5-methyl-1,4-benzoquinone for treatment/prevention of cancer)

IT Ubiquinones
RL: FFD (Food or feed use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(reduced; nutraceutical composition comprising 2,3-dimethoxy-5-methyl-1,4-benzoquinone for treatment/prevention of cancer)

IT Pharmaceutical injections
(s.c. injections; nutraceutical composition comprising 2,3-dimethoxy-5-methyl-1,4-benzoquinone for treatment/prevention of cancer)

IT Body, anatomical
(sinus, neoplasm; nutraceutical composition comprising 2,3-dimethoxy-5-methyl-1,4-benzoquinone for treatment/prevention of

cancer)

IT Pharmaceutical solutions
(syrups; nutraceutical composition comprising 2,3-dimethoxy-5-methyl-1,4-benzoquinone for treatment/prevention of cancer)

IT 50-18-0, Cyclophosphamide 50-28-2, Estradiol, biological studies 50-44-2, Mercaptopurine 50-76-0, Actinomycin D 50-91-9, Floxuridine 51-21-8, Fluorouracil 51-75-2, Mechlorethamine 52-24-4, Thiotepa 53-19-0, Mitotane 55-98-1, Busulfan 57-22-7, Vincristine 59-05-2, Methotrexate 125-84-8, Aminoglutethimide 127-07-1, Hydroxyurea 147-94-4, Cytarabine 148-82-3, Melphalan 154-42-7, Thioguanine 154-93-8, Carmustine 299-75-2, Treosulfan 305-03-3, Chlorambucil 645-05-6, Hexamethylmelamine 671-16-9, Procarbazine 865-21-4, Vinblastine 1404-00-8, Mitomycin 1990-01-8, Glaucarubolone 3778-73-2, Ifosfamide 4342-03-4, Dacarbazine 9015-68-3, Asparaginase 10540-29-1, Tamoxifen 11056-06-7, Bleomycin 13010-47-4, Lomustine 13311-84-7, Flutamide 13909-09-6, Semustine 15663-27-1, Cisplatin 18378-89-7, Plicamycin 18883-66-4, Streptozocin 20830-81-3, Daunorubicin 21679-14-1, Fludarabine 23214-92-8, Doxorubicin 24148-77-4, Simalikalactone A 25316-40-9, Adriamycin 29767-20-2, Teniposide 33069-62-4, Taxol 33419-42-0, Etoposide 41575-94-4, Carboplatin 53643-48-4, Vindesine 53714-56-0, Leuprolide 53910-25-1, Pentostatin 56420-45-2, Epirubicin 58957-92-9, Idarubicin 61825-94-3, Oxaliplatin 65271-80-9, Mitozantrone 71486-22-1, Vinorelbine 95058-81-4, Gemcitabine 97682-44-5, Irinotecan 112887-68-0, Tomudex 114977-28-5, Taxotere 123123-32-0, Bullatacin 123948-87-8, Topotecan
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(combination with; nutraceutical composition comprising 2,3-dimethoxy-5-methyl-1,4-benzoquinone for treatment/prevention of cancer)

IT 9001-60-9, Lactic acid dehydrogenase
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(inhibitors; nutraceutical composition comprising 2,3-dimethoxy-5-methyl-1,4-benzoquinone for treatment/prevention of cancer)

IT 50-81-7, Vitamin C, biological studies 58-85-5, Biotin 59-30-3, Folic acid, biological studies 59-43-8, Vitamin B1, biological studies 59-67-6, Niacin, biological studies 60-18-4, Tyrosine, biological studies 63-91-2, Phenylalanine, biological studies 68-19-9, Vitamin B12 77-92-9, Citric acid, biological studies 79-83-4, Pantothenic acid 83-88-5, Riboflavin, biological studies 83-88-5D, Vitamin B2, derivs. and salts 99-96-7, biological studies 99-96-7D, p-Hydroxybenzoic acid, polyprenyl esters 117-39-5, Quercetin 144-55-8, Sodium bicarbonate, biological studies 146-14-5, Flavin-adenine dinucleotide 146-17-8, Flavin mononucleotide 156-39-8 298-14-6, Potassium bicarbonate 303-98-0, Ubiquinone 50 306-23-0 358-71-4 480-16-0, 2',3,4'5,7-Pentahydroxyflavone 488-81-3, Ribitol 582-60-5, 5,6-Dimethylbenzimidazole 605-94-7, 2,3-Dimethoxy-5-methyl-1,4-benzoquinone 989-51-5, Epigallocatechin gallate 1200-22-2, Lipoic acid 2382-48-1D, Ubichromenol, derivs. 2535-20-8 6703-77-1D, Ubichromanol, derivs. 7400-08-0 7440-09-7, Potassium, biological studies 8059-24-3, Vitamin B6 17528-72-2, Tetrahydrobiopterin 71491-01-5
RL: FFD (Food or feed use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(nutraceutical composition comprising 2,3-dimethoxy-5-methyl-1,4-benzoquinone for treatment/prevention of cancer)

IT 303-98-0, Ubiquinone 50

RL: ~~FFD (Food or feed use)~~; ~~THU (Therapeutic use)~~;
BIOL (Biological study); USES (Uses)
(nutraceutical composition comprising
2,3-dimethoxy-5-methyl-1,4-benzoquinone for treatment/prevention of
cancer)
RN 303-98-0 ZCAPLUS
CN 2,5-Cyclohexadiene-1,4-dione, 2-[(2E,6E,10E,14E,18E,22E,26E,30E,34E)-
3,7,11,15,19,23,27,31,35,39-decamethyl-2,6,10,14,18,22,26,30,34,38-
tetracontadecaen-1-yl]-5,6-dimethoxy-3-methyl- (CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A



PAGE 1-B



PAGE 1-C

L88 ANSWER 5 OF 41 ZCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2006:544828 ZCAPLUS Full-text
DOCUMENT NUMBER: 145:33510
TITLE: Dermatological compositions using bio-activating organocatalysts
INVENTOR(S): Eberl, James, J.
PATENT ASSIGNEE(S): Ebersytes, LLC, USA
SOURCE: PCT Int. Appl., 49 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006060548	A2	20060608	WO 2005-US43434	20051201 <--

WO 2006060548 A3 20070111
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
US 20060120980 A1 20060608 US 2005-292227 20051201 <--
PRIORITY APPLN. INFO.: US 2004-632479P P 20041202 <--
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

AB The invention provides novel dermatol. compns. and related methods useful in the activation of skin growth factors and growth receptors. Compns. of the invention act upon follicle cells and other skin targets to induce hair growth, facilitate dermal cell repair, and enhance skin health. Compns. comprise a bio-activating organocatalyst in a pharmaceutically acceptable carrier, adapter for use on an animal's skin or hair. Thus, a composition contained Eucerin Renewal 33.00, ascorbyl palmitate 1.60, Coenzyme Q 0.6, and soybean il 1.15 g, and copper lactate 1.5 mL of a 1% solution

CC 62-4 (Essential Oils and Cosmetics)
Section cross-reference(s): 63

IT Acne
Antioxidants
Arnica
Brassica
Burn
Cardiovascular system, disease
Catalysts
Creosote
Drug delivery systems
Grindelia
Hair
Human
Irritants
Juniperus
Lytta vesicatoria
Neoplasm
Populus
Redox agents
Skin
Surfactants
Tar oils
Thymus (plant)
Wound
Wound healing
(dermatol. composition using bio-activating organocatalysts)

IT Drug delivery systems
(topical; dermatol. composition using bio-activating organocatalysts)

IT 50-21-5, Lactic acid, biological studies 50-81-7, L-Ascorbic acid, biological studies 52-90-4, Cysteine, biological studies 57-88-5, Cholest-5-en-3-ol (3β)-, biological studies 59-67-6, Nicotinic acid, biological studies 60-87-7, Promethazine 64-17-5, Ethanol, biological studies 64-18-6, Formic acid, biological studies 67-63-0, 2-Propanol, biological studies 69-72-7, biological studies 69-93-2,

Uric acid, biological studies 70-18-8, Reduced glutathione, biological studies 74-31-7 76-22-2, Camphor 89-78-1, Menthol 89-83-8, Thymol 94-62-2, Piperine 102-29-4, Resorcinol monoacetate 108-46-3, Resorcinol, biological studies 117-39-5, Quercetin 128-37-0, Butylated hydroxytoluene, biological studies 134-03-2, Sodium ascorbate 137-66-6 149-91-7, Gallic acid, biological studies 153-18-4, Rutin 303-98-0 315-30-0 331-39-5, Caffeic acid 404-86-4, Capsaicin 462-20-4, Dihydrolipoic acid 470-82-6 476-66-4, Ellagic acid 491-58-7, Chrysarobin 499-75-2, Carvacrol 526-84-1 616-91-1, N-Acetylcysteine 992-78-9 1143-38-0, Anthralin 1200-22-2 1406-18-4, Vitamin E 1948-33-0 6027-13-0, L-Homocysteine 7439-89-6, Iron, biological studies 7439-96-5, Manganese, biological studies 7440-48-4, Cobalt, biological studies 7440-50-8, Copper, biological studies 8001-71-6, Chrysarobin 8029-68-3, Ichthammol 10597-60-1, Hydroxytyrosol 13870-80-9 15651-72-6 16039-52-4, Copper lactate 23288-49-5 23661-48-5 25013-16-5, Butylated hydroxyanisole 51395-10-9, Copper EDTA 53188-07-1 137865-26-0 805241-13-8, Eucerin Renewal
RL: COS (Cosmetic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(dermatol. composition using bio-activating organocatalysts)

IT 303-98-0
RL: COS (Cosmetic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(dermatol. composition using bio-activating organocatalysts)

RN 303-98-0 ZCAPLUS

CN 2,5-Cyclohexadiene-1,4-dione, 2-[(2E,6E,10E,14E,18E,22E,26E,30E,34E)-3,7,11,15,19,23,27,31,35,39-decamethyl-2,6,10,14,18,22,26,30,34,38-tetracontadecaen-1-yl]-5,6-dimethoxy-3-methyl- (CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A



PAGE 1-B



PAGE 1-C

OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)
REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L88 ANSWER 6 OF 41 ZCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2006:238357 ZCAPLUS Full-text
DOCUMENT NUMBER: 144:318557
TITLE: Preparation, compositions and uses of mixtures of polypeptides
INVENTOR(S): Pinchasi, Irit; Dolitzky, Ben-Zion; Frenkel, Anton; Schwartz, Michal; Arnon, Ruth; Aharoni, Rina
PATENT ASSIGNEE(S): Teva Pharmaceutical Industries, Ltd., Israel; Teva Pharmaceuticals USA, Inc.; Yeda Research and Development Co. Ltd.
SOURCE: PCT Int. Appl., 197 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006029411	A2	20060316	WO 2005-US32553	20050909 <--
WO 2006029411	A3	20060803		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
US 20060122113	A1	20060608	US 2005-223408	20050909 <--
US 7560100	B2	20090714		
EP 1797109	A2	20070620	EP 2005-795337	20050909 <--
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU				
US 20070054857	A1	20070308	US 2006-541263	20060929 <--

PRIORITY APPLN. INFO.: US 2004-608844P P 20040909 <--
US 2005-223408 A1 20050909
WO 2005-US32553 W 20050909

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

AB The invention provides a composition comprising a mixture of polypeptides, wherein each polypeptide (a) is a copolymer of the amino acids L-glutamic acid, L-alanine, L-tyrosine, and L-lysine, and (b) may be in the form of a pharmaceutically acceptable salt. In the mixture (i) the polypeptides have an average mol. weight in the range 13,500 to 18,500 daltons, (ii) 13% to 38% of the polypeptides have a diethylamide group instead of a carboxyl group present at one end thereof, and (iii) 68% of the polypeptides have a mol. weight between 7000 and 41,000 daltons. The average mol. weight of polypeptides is 16,000 daltons. Processes for preparing the mixture of polypeptides and its

therapeutic uses are described. For example, an injection formulation containing the polypeptide mixture 5 mg, mannitol 50 mg, and water for injection to 1.0 mL was prepared and packaged in Hypak syringe. Also, the biol. activity of prepns. of different mol. weight (MW) was evaluated by their ability to block the induction of exptl. autoimmune encephalomyelitis (EAE) in mice by reducing the number of sick animals and lowering the severity of disease (clin. score). The results were compared to that of glatiramer acetate (GA). The effect of increase in MW on biol. activity was observed At the dose of 25 μg/mouse, GA blocking activity was suboptimal while prepns. with MW ranging between 15 and 20 KDa were more effective in inhibiting acute EAE. At the dose of 50 μg/mouse, GA (7.5 daltons) was not effective in inhibiting chronic myelin oligodendrocyte glycoprotein (MOG)-induced EAE, while the mixture of polypeptides of the invention (.apprx. 16.0 KD) had a significant inhibitory effect.

CC 63-6 (Pharmaceuticals)
Section cross-reference(s): 1

IT Antibodies and Immunoglobulins
Corticosteroids, biological studies
Glucocorticoids
Interferons
Steroids, biological studies
Tumor necrosis factors
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(therapeutic combinations containing mixts. of polypeptides comprising alanine, glutamic acid, lysine and tyrosine)

IT Drug delivery systems
(topical; preparation, compns. and therapeutic uses of mixts. of polypeptides comprising alanine, glutamic acid, lysine and tyrosine)

IT 50-02-2, Dexamethasone 50-18-0, Cyclophosphamide 50-23-7, Hydrocortisone 50-24-8, Prednisolone 50-44-2, 6-Mercaptopurine 50-47-5, Desipramine 50-48-6, Amitriptyline 50-49-7, Imipramine 50-53-3, biological studies 50-55-5, Reserpine 50-81-7, Vitamin C, biological studies 51-34-3, Scopolamine 51-43-4, Epinephrine 51-55-8, Atropine, biological studies 51-83-2, Carbachol 51-85-4, Cystamine 52-86-8, Haloperidol 53-03-2, Prednisone 54-85-3, Isoniazide 54-96-6, 3,4-Diaminopyridine 55-91-4, Isoflurophate 56-81-5, Glycerin, biological studies 56-94-0 57-00-1, Creatine 57-41-0, Phenytoin 58-38-8 58-73-1, Diphenhydramine 58-74-2, Papaverine 59-05-2, Methotrexate 59-30-3, Folic acid, biological studies 59-66-5, Acetazolamide 59-96-1, Phenoxybenzamine 67-20-9, Nitrofurantoin 68-88-2, Hydroxyzine 72-69-5, Nortriptyline 74-79-3, L-Arginine, biological studies 76-57-3, Codeine 79-43-6, biological studies 83-88-5, Riboflavin, biological studies 89-57-6, 5-Aminosalicylic acid 92-13-7, Pilocarpine 92-84-2, Phenothiazine 94-78-0, Phenazopyridine 98-92-0, Nicotinamide 99-20-7, Trehalose 100-97-0, Methenamine, biological studies 101-31-5, Hyoscyamine 113-53-1, Dothiepin 125-33-7, Primidone 130-95-0, Quinine 155-09-9, Tranylcypromine 298-46-4, Carbamazepine 298-50-0, Propantheline 302-79-4, Retinoic acid 303-98-0, Coenzyme Q10 438-60-8, Protriptyline 439-14-5, Diazepam 443-48-1, Metronidazole 446-86-6, Azathioprine 495-40-9D, Butyrophenone, derivs. 504-24-5, 4-Aminopyridine 523-87-5, Dimenhydrinate 541-15-1, Carnitine 569-65-3, Meclizine 578-68-7D, 4-Aminoquinoline, derivs. 599-79-1, Sulfasalazine 603-50-9, Bisacodyl 745-65-3, Alprostadil 768-94-5, Amantadine 846-50-4, Temazepam 915-30-0, Diphenoxylate 1134-47-0, Baclofen 1200-22-2, Lipoic acid 1309-42-8, Magnesium hydroxide 1406-16-2D, Vitamin D, derivs. 1406-18-4, Vitamin E 1622-61-3, Clonazepam 1668-19-5, Doxepin 2152-34-3, Pemoline 4205-90-7, Clonidine 4291-63-8, Cladribine 5633-20-5, Oxybutynin 6493-05-6, Pentoxifylline 7601-54-9, Sodium phosphate 7782-49-2, Selenium,

biological studies 8063-16-9, Psyllium mucilloid 10041-19-7, Docusate 10118-90-8, Minocycline 11000-17-2, Vasopressin 11103-57-4, Vitamin A 14605-22-2, Tauroursodeoxycholic acid 14663-23-1, Dantrolene sodium 15722-48-2, Olsalazine 16679-58-6, Desmopressin 18378-89-7, Mithramycin 19794-93-5, Trazodone 19982-08-2, Memantine 22664-55-7, Metipranolol 23047-25-8, Lofepramine 26921-17-5, Timolol maleate 28981-97-7, Alprazolam 30562-34-6, Geldanamycin 32222-06-3, Calcitriol 34911-55-2, Bupropion 36505-84-7, Buspirone 41294-56-8, Alphacalcidol 47141-42-4, Levobunolol 51322-75-9, Tizanidine 51781-06-7, Carteolol 52365-63-6, Dipivefrin 53123-88-9, Rapamycin 53179-11-6, Loperamide 54910-89-3, Fluoxetine 57308-51-7, Carbidopa-levodopa mixture 59277-89-3, Acyclovir 59729-33-8, Citalopram 59803-98-4, Brimonidine 59865-13-3, Cyclosporine 60142-96-3, Gabapentin 61869-08-7, Paroxetine 63590-64-7, Terazosin 63659-18-7, Betaxolol 65271-80-9, Mitoxantrone 66711-21-5, Apraclonidine 68291-97-4, Zonisamide 68693-11-8, Modafinil 71320-77-9, Moclobemide 79617-96-2, Sertraline 79902-63-9, Simvastatin 80573-04-2, Balsalazide 82626-48-0, Zolpidem 83366-66-9, Nefazodone 84057-84-1, Lamotrigine 85650-52-8, Mirtazapine 85721-33-1, Ciprofloxacin 91524-16-2, Timolol hemihydrate 93413-69-5, Venlafaxine 97240-79-4, Topiramate 107231-12-9, Botulinum toxin 107452-89-1, Ziconotide 119431-25-3, Eliprodil 120279-96-1, Dorzolamide 124937-51-5, Tolterodine 128298-28-2, Remacemide 130209-82-4, Latanoprost 136236-51-6, Rasagiline 138890-62-7, Brinzolamide 139755-83-2, Sildenafil 148553-50-8, Pregabalin 155206-00-1, Bimatoprost 157283-68-6, Travoprost 189261-10-7, Natalizumab 216503-57-0, Alemtuzumab 248281-84-7, Laquinimod
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(therapeutic combinations containing mixts. of polypeptides comprising alanine, glutamic acid, lysine and tyrosine)

IT 303-98-0, Coenzyme Q10
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(therapeutic combinations containing mixts. of polypeptides comprising alanine, glutamic acid, lysine and tyrosine)

RN 303-98-0 ZCAPLUS

CN 2,5-Cyclohexadiene-1,4-dione, 2-[(2E,6E,10E,14E,18E,22E,26E,30E,34E)-3,7,11,15,19,23,27,31,35,39-decamethyl-2,6,10,14,18,22,26,30,34,38-tetracontadecaen-1-yl]-5,6-dimethoxy-3-methyl- (CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A



PAGE 1-B



OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS)
REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L88 ANSWER 7 OF 41 ZCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2006:365124 ZCAPLUS Full-text
DOCUMENT NUMBER: 144:398343
TITLE: Methods and compositions for the treatment of diseases characterized by calcification and/or plaque formation
INVENTOR(S): Kajander, E. Olavi; Aho, K.; Ciftcioglu, Neva; Millican, H. B.; Maniscalco, B.
PATENT ASSIGNEE(S): Nanobac Pharmaceuticals, Inc., USA
SOURCE: U.S. Pat. Appl. Publ., 14 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
US 20060083727	A1	20060420	US 2005-182076		20050715 <--
US 20070048296	A1	20070301	US 2006-544048		20061006 <--
PRIORITY APPLN. INFO.:			US 2004-587871P	P	20040715 <--
			US 2005-182076	A1	20050715

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
AB The invention provides methods and compns. that include a nutraceutical supplement, antibiotic, and metal chelating agent that is administered to a patient to treat or prevent pathol. calcification and or plaque formation as associated with Nanobacteria Calcifying Nano-Particles and/or diseases caused there-from, The method includes the administration of a therapeutically effective nutraceutical supplement, tetracycline HCL, and EDTA calcium di-sodium salt to a patient in order to prevent and treat calcific disease.
INCL 424094100; 424094200; 424765000; 424766000; 514154000; 514566000; 514052000; 514251000; 514276000; 514350000
CC 63-6 (Pharmaceuticals)
IT Ovary, neoplasm
(adenocarcinoma, Serous; methods and compns. for treatment of diseases characterized by calcification and/or plaque formation)
IT Nervous system, neoplasm
(meningioma; methods and compns. for treatment of diseases characterized by calcification and/or plaque formation)
IT Addison's disease
Alzheimer's disease
Anemia (disease)
Anti-Alzheimer's agents
Anti-infective agents
Antiarteriosclerotics
Antiarthritics

Antibiotics
Anticoagulants
Antidiabetic agents
Antiphospholipid syndrome
Antirheumatic agents
Antitumor agents
Arteriosclerosis
Atherosclerosis
Autoimmune disease
Blood, disease
Calculi, biliary
Calculi, urinary
Cataract
Chelating agents
Cirrhosis
Curcuma longa
Ear, disease
Eczema
Eye, disease
Fruit and vegetable juices
Graves' disease
Hypothyroidism
Intestine, disease
Kidney
Liver, disease
Lupus erythematosus
Mammary gland, neoplasm
Multiple sclerosis
Osteoarthritis
Pancreas
Placenta, disease
Prostate gland, neoplasm
Psoriasis
Rheumatoid arthritis
Thrombosis
Thyroid gland, neoplasm
(methods and compns. for treatment of diseases characterized by calcification and/or plaque formation)

IT Meninges
(neoplasm, meningioma; methods and compns. for treatment of diseases characterized by calcification and/or plaque formation)

IT Angiogenesis
(neovascularization, retinal, -derived processes; methods and compns. for treatment of diseases characterized by calcification and/or plaque formation)

IT Drug delivery systems
(ointments, creams, topical; methods and compns. for treatment of diseases characterized by calcification and/or plaque formation)

IT Carcinoma
(ovarian adenocarcinoma, Serous; methods and compns. for treatment of diseases characterized by calcification and/or plaque formation)

IT Drug delivery systems
(topical, cream; methods and compns. for treatment of diseases characterized by calcification and/or plaque formation)

IT Neoplasm
(treatment of; methods and compns. for treatment of diseases characterized by calcification and/or plaque formation)

IT 50-81-7, Vitamin C, biological studies 56-87-1, L-Lysine, biological

studies 57-62-5, Chlortetracycline 59-30-3, biological studies 59-43-8, Vitamin B1, biological studies 59-67-6, Niacin, biological studies 60-54-8, Tetracycline 64-75-5, Tetracycline hydrochloride 67-42-5, EGTA 67-43-6 67-71-0, Methyl sulfonyl methane 68-19-9, Vitamin B12 68-26-8, Vitamin A 70-26-8, L-Ornithine 74-79-3, L-Arginine, biological studies 79-57-2, Oxytetracycline 83-88-5, Vitamin B2, biological studies 117-39-5, Quercetin 127-33-3, Demeclocycline 303-98-0, Co-Q10 564-25-0, Doxycycline 751-97-3, Rolitetracycline 808-26-4, Sancycline 914-00-1, Methacycline 1406-18-4, Vitamin E 6381-92-6 7779-25-1, Magnesium citrate 7782-49-2, Selenium, biological studies 8059-24-3, Vitamin B6 9001-73-4, Papain 9002-07-7, Trypsin 9004-65-3, Hydroxypropyl methylcellulose 10118-90-8, Minocycline 11103-57-4, Vitamin A 85233-19-8, BAPTA 95975-55-6, Gugulipid 150977-36-9, Bromelain 174882-69-0, Pycnogenol
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(methods and compns. for treatment of diseases characterized by calcification and/or plaque formation)

IT 303-98-0, Co-Q10
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(methods and compns. for treatment of diseases characterized by calcification and/or plaque formation)

RN 303-98-0 ZCAPLUS

CN 2,5-Cyclohexadiene-1,4-dione, 2-[(2E,6E,10E,14E,18E,22E,26E,30E,34E)-3,7,11,15,19,23,27,31,35,39-decamethyl-2,6,10,14,18,22,26,30,34,38-tetracontadecaen-1-yl]-5,6-dimethoxy-3-methyl- (CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A



PAGE 1-B



PAGE 1-C

OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD

(1 CITINGS)

L88 ANSWER 8 OF 41 ZCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2005:696614 ZCAPLUS Full-text
DOCUMENT NUMBER: 143:159636
TITLE: Topical Coenzyme Q10 formulations
INVENTOR(S): Hsia, Sung Lan; Narain, Niven Rajin; Li, Jie; Russell, Kathryn J.; Woan, Karrune V.; Persaud, Indushekhar
PATENT ASSIGNEE(S): University of Miami, USA
SOURCE: PCT Int. Appl., 86 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005069916	A2	20050804	WO 2005-US1581	20050121 <--
WO 2005069916	A3	20061019		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, SM				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2005206953	A1	20050804	AU 2005-206953	20050121 <--
CA 2553690	A1	20050804	CA 2005-2553690	20050121 <--
EP 1718283	A2	20061108	EP 2005-711599	20050121 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, BA, HR, IS, YU				
CN 1953743	A	20070425	CN 2005-80005626	20050121 <--
BR 2005007039	A	20070605	BR 2005-7039	20050121 <--
JP 2007518805	T	20070712	JP 2006-551208	20050121 <--
MX 2006008293	A	20070611	MX 2006-8293	20060721 <--
IN 2006KN02090	A	20070518	IN 2006-KN2090	20060725 <--
NO 2006003439	A	20061023	NO 2006-3439	20060726 <--
KR 2007012349	A	20070125	KR 2006-716800	20060822 <--
US 20080299100	A1	20081204	US 2008-597378	20080821 <--
PRIORITY APPLN. INFO.:			US 2004-538319P P	20040122 <--
			WO 2005-US1581 W	20050121

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

AB Topical formulations of CoQ10 reduce the rate of tumor growth in an animal subject. In the expts. described herein, CoQ10 was shown to increase the rate of apoptosis in a culture of skin cancer cells but not normal cells. Moreover, treatment of tumor-bearing animals with a topical formulation of CoQ10 was shown to dramatically reduce the rate of tumor growth in the animals. Thus, a kit comprised Coenzyme Q10, Phospholipon-90, glycerol, BHT, ethanol, medium chain triglycerides and lavender.

IC ICM A61K
CC 63-6 (Pharmaceuticals)
Section cross-reference(s): 1
ST topical coenzyme Q10
IT Glycerides, biological studies

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(medium-chain; topical Coenzyme Q10 formulations)
IT Drug delivery systems
(ointments, creams; topical Coenzyme Q10 formulations)
IT Phosphatidylcholines, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(soya; topical Coenzyme Q10 formulations)
IT Antitumor agents
Apoptosis
Human
Lavandula
Neoplasm
(topical Coenzyme Q10 formulations)
IT Taxanes
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(topical Coenzyme Q10 formulations)
IT Drug delivery systems
(topical; topical Coenzyme Q10 formulations)
IT 303-98-0, Coenzyme Q10
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(topical Coenzyme Q10 formulations)
IT 50-18-0, Cyclophosphamide 55-98-1, Busulfan 56-81-5, Glycerol, biological studies 57-22-7, Vincristine 59-05-2, Methotrexate 64-17-5, Ethanol, biological studies 128-37-0, Butylated hydroxytoluene, biological studies 148-82-3, Melphalan 305-03-3, Chlorambucil 865-21-4, Vinblastine 4291-63-8, Cladribine 15663-27-1, Cisplatin 20830-81-3, Daunorubicin 23214-92-8, Doxorubicin 33069-62-4, Paclitaxel 114977-28-5, Docetaxel 135945-29-8, Phospholipon 90 156259-71-1, Phospholipon 90H
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(topical Coenzyme Q10 formulations)
IT 303-98-0, Coenzyme Q10
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(topical Coenzyme Q10 formulations)
RN 303-98-0 ZCAPLUS
CN 2,5-Cyclohexadiene-1,4-dione, 2-[(2E,6E,10E,14E,18E,22E,26E,30E,34E)-3,7,11,15,19,23,27,31,35,39-decamethyl-2,6,10,14,18,22,26,30,34,38-tetracontadecaen-1-yl]-5,6-dimethoxy-3-methyl- (CA INDEX NAME)

Double bond geometry as shown.



PAGE 1-B



PAGE 1-C

OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)
REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L88 ANSWER 9 OF 41 ZCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2005:588633 ZCAPLUS Full-text
DOCUMENT NUMBER: 143:103253
TITLE: Drug-containing nanoparticle, process for producing the same and parenterally administered preparation from the nanoparticle
INVENTOR(S): Ishihara, Tsutomu; Mizushima, Yutaka; Suzuki, Jun; Sekine, Junzou; Yamaguchi, Yoko; Igarashi, Rie
PATENT ASSIGNEE(S): LTT Bio-Pharma Co., Ltd., Japan
SOURCE: PCT Int. Appl., 35 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005060935	A1	20050707	WO 2004-JP15026	20041012 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2549966	A1	20050707	CA 2004-2549966	20041012 <--
EP 1698329	A1	20060906	EP 2004-792270	20041012 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
CN 1917859	A	20070221	CN 2004-80041856	20041012 <--
JP 3903061	B2	20070411	JP 2005-516421	20041012 <--
KR 2006123384	A	20061201	KR 2006-712602	20060623 <--

US 20070077286 A1 20070405 US 2006-596828 20060626 <--
PRIORITY APPLN. INFO.: JP 2003-428462 A 20031224 <--
WO 2004-JP15026 W 20041012 <--

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

AB An external preparation or injectable solution that exerts the effect of enabling percutaneous or transmucous in vivo absorption of fat-soluble drugs and water-soluble drugs has not been satisfactorily attained hitherto. The injectable solution especially aims at sustained release and target effects. In particular, drug-containing nanoparticles (secondary nanoparticles) are provided by causing primary nanoparticles containing a fat-soluble drug or fat-solubilized water-soluble drug to act with a divalent or trivalent metal salt. Further, drug-containing nanoparticles (tertiary nanoparticles) are provided by first causing primary nanoparticles containing a fat-soluble drug or fat-solubilized water-soluble drug to act with a divalent or trivalent metal salt to thereby obtain secondary nanoparticles and thereafter causing a monovalent to trivalent basic salt to act on the secondary nanoparticles. Still further, there are provided a process for producing these nanoparticles, and a percutaneous or transmucous external preparation or injectable solution in which these nanoparticles are contained.

IC ICM A61K009-14
ICS A61K009-06; A61K009-08; A61K009-10; A61K009-20; A61K009-70; A61K009-72; A61K047-02; A61K047-04; A61K047-10; A61K047-12; A61K047-24; A61K047-34; A61K047-36; A61K031-07; A61K031-122; A61K031-198; A61P003-02

CC 63-6 (Pharmaceuticals)

ST nanoparticle metal salt topical parenteral bioavailability

IT Lipids, biological studies
Phosphatidylethanolamines, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(ethoxylated; manufacture of nanoparticles for topical and parenteral administration)

IT Vitamins
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(fat-soluble; manufacture of nanoparticles for topical and parenteral administration)

IT Drug delivery systems
(gels, topical; manufacture of nanoparticles for topical and parenteral administration)

IT Steroids, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(hormones; manufacture of nanoparticles for topical and parenteral administration)

IT Drug delivery systems
(hydrogels; manufacture of nanoparticles for topical and parenteral administration)

IT Castor oil
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(hydrogenated, ethoxylated; manufacture of nanoparticles for topical and parenteral administration)

IT Drug delivery systems
(inhalants; manufacture of nanoparticles for topical and parenteral administration)

IT Drug delivery systems
(injections; manufacture of nanoparticles for topical and parenteral administration)

IT Drug delivery systems
(lotions; manufacture of nanoparticles for topical and parenteral administration)

IT Antibiotics
Antihypertensives

Antipsychotics
Antitumor agents
Antiviral agents
Calcium channel blockers
Chemotherapy
Drug bioavailability
Immunomodulators
Immunosuppressants
(manufacture of nanoparticles for topical and parenteral administration)

IT Prostaglandins
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(manufacture of nanoparticles for topical and parenteral administration)

IT Drug delivery systems
(nanoparticles; manufacture of nanoparticles for topical and parenteral administration)

IT Anti-inflammatory agents
(nonsteroidal; manufacture of nanoparticles for topical and parenteral administration)

IT Drug delivery systems
(ointments; manufacture of nanoparticles for topical and parenteral administration)

IT Hormones, animal, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(steroid; manufacture of nanoparticles for topical and parenteral administration)

IT Drug delivery systems
(suspensions; manufacture of nanoparticles for topical and parenteral administration)

IT Drug delivery systems
(tablets, buccal; manufacture of nanoparticles for topical and parenteral administration)

IT Drug delivery systems
(tapes; manufacture of nanoparticles for topical and parenteral administration)

IT 64-17-5, Ethanol, uses 67-64-1, Acetone, uses 71-23-8, Propanol, uses 71-36-3, Butanol, uses
RL: NUU (Other use, unclassified); USES (Uses)
(manufacture of nanoparticles for topical and parenteral administration)

IT 50-28-2, Estradiol, biological studies 50-50-0, Estradiol benzoate 50-53-3, Chlorpromazine, biological studies 52-21-1, Prednisolone acetate 56-81-5, Glycerin, biological studies 57-10-3, Palmitic acid, biological studies 57-22-7, Vincristine 57-85-2, Testosterone propionate 58-22-0, Testosterone 59-05-2, Methotrexate 60-33-3, Linoleic acid, biological studies 68-26-8, Retinol 112-80-1, Oleic acid, biological studies 143-07-7, Lauric acid, biological studies 143-19-1, Sodium oleate 302-25-0, Prednisolone phosphate 303-98-0, Ubidecarenone 312-93-6, Dexamethasone phosphate 315-37-7, Testosterone enanthate 360-63-4, Betamethasone phosphate 363-24-6, Dinoprostone 378-44-9, Betamethasone 389-08-2, Nalidixic acid 439-14-5, Diazepam 463-40-1, Linolenic acid 544-63-8, Myristic acid, biological studies 745-65-3, Alprostadil 979-32-8, Estradiol valerate 1177-87-3, Dexamethasone acetate 1404-90-6, Vancomycin 1406-16-2, Vitamin D 1406-18-4, Vitamin E 2152-44-5, Betamethasone valerate 2203-97-6, Hydrocortisone succinate 2920-86-7, Prednisolone succinate 3544-94-3, Chloramphenicol succinate 5104-49-4, Flurbiprofen 5536-17-4, Vidarabine 5593-20-4, Betamethasone dipropionate 7646-85-7, Zinc chloride, biological studies 9005-64-5, Tween 20 9005-65-6, Tween

80 9005-66-7, Tween 40 9005-67-8, Tween 60 9005-70-3, Tween 85 9036-19-5, Polyoxyethylene octylphenyl ether 10043-52-4, Calcium chloride, biological studies 12001-79-5, Vitamin K 15663-27-1, Cisplatin 17902-23-7, Tegafur 21829-25-4, Nifedipine 22071-15-4, Ketoprofen 23214-92-8, Doxorubicin 24729-96-2, Clindamycin phosphate 27321-96-6, Polyoxyethylene cholesteryl ether 33069-62-4, Paclitaxel 59277-89-3, Acyclovir 59865-13-3, Cyclosporin 60299-11-8, Nifedipine hydrochloride 61422-45-5, Carmofur 64952-97-2, Latamoxef 70458-96-7, Norfloxacin 78110-38-0, Aztreonam 81103-11-9, Clarithromycin 82419-36-1, Ofloxacin 84957-29-9, Cefpirome 87638-04-8, Carumonam 91503-79-6, Flurbiprofen axetil 100286-90-6, Irinotecan hydrochloride 104987-11-3, Tacrolimus 111470-99-6, Amlodipine besylate 136470-78-5, Abacavir 145040-37-5, Candesartan cilexetil 154598-52-4, Efavirenz
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(manufacture of nanoparticles for topical and parenteral administration)

IT 303-98-0, Ubidecarenone
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(manufacture of nanoparticles for topical and parenteral administration)

RN 303-98-0 ZCAPLUS

CN 2,5-Cyclohexadiene-1,4-dione, 2-[(2E,6E,10E,14E,18E,22E,26E,30E,34E)-3,7,11,15,19,23,27,31,35,39-decamethyl-2,6,10,14,18,22,26,30,34,38-tetracontadecaen-1-yl]-5,6-dimethoxy-3-methyl- (CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A



PAGE 1-B



PAGE 1-C

REFERENCE COUNT: 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L88 ANSWER 10 OF 41 ZCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2005:96445 ZCAPLUS Full-text
DOCUMENT NUMBER: 142:170141
TITLE: Annatto extract compositions including tocotrienols and tocopherols and methods of use
INVENTOR(S): Tan, Barrie; Llobrera, Jose
PATENT ASSIGNEE(S): USA
SOURCE: PCT Int. Appl., 60 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005009135	A1	20050203	WO 2004-US11366	20040412 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2521020	A1	20050203	CA 2004-2521020	20040412 <--
EP 1617724	A1	20060125	EP 2004-750079	20040412 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
PRIORITY APPLN. INFO.:			US 2003-461932P	P 20030410 <--
			US 2003-488310P	P 20030718 <--
			WO 2004-US11366	W 20040412 <--

AB Compns. and methods of use of annatto exts. including tocotrienols and tocopherols with an appropriate spectrum. This spectrum includes but not limited to low alpha tocopherol, high delta- and gamma-tocols, and mixts. with other exts. and/or nutrients. These compns. may be used in metabolic, inflammatory, cardiovascular, fatty liver and other diseases.

IC ICM A01N065-00
ICS A61K035-78

CC 1-12 (Pharmacology)
Section cross-reference(s): 11

IT Allium sativum
Alzheimer's disease
Anti-Alzheimer's agents
Anti-inflammatory agents
Anticholesteremic agents
Antidiabetic agents
Antihypertensives
Antiparkinsonian agents
Antitumor agents
Arecaceae
Bixa orellana
Blood analysis
Bone resorption inhibitors
Cardiovascular system, disease
Central nervous system
Cottonseed

Dietary supplements
Glycine max
Human
Hypertension
Hypolipemic agents
Immunostimulants
Inflammation
Litchi
Neoplasm
Nervous system agents
Neurotoxicity
Oryza sativa
Osteoporosis
Parkinson's disease
Psoriasis
Skin, disease
Skin preparations (pharmaceutical)
Zea mays
(annatto extract compns. including tocotrienols and tocopherols for metabolic and other disorders)

IT Drug delivery systems
(topical; annatto extract compns. including tocotrienols and tocopherols for metabolic and other disorders)

IT 54-28-4P 59-02-9P 60-33-3P, α-Linoleic acid, biological studies 119-13-1P 303-98-0P, CoQ10 490-23-3P 541-15-1P, Carnitine 556-02-5P, D-Tyrosine 4547-24-4P, Corosolic acid 6217-54-5P, DHA 6829-55-6P, Tocotrienol 7439-95-4P, Magnesium, biological studies 7440-47-3P, Chromium, biological studies 7440-70-2P, Calcium, biological studies 9012-76-4P, Chitosan 10417-94-4P, EPA 12001-76-2P, Vitamin B 12738-23-7P, Oryzanol 14101-61-2P 16698-35-4P 16816-67-4P, Pantethine 25612-59-3P 57828-26-9P, Lipoic acid 58864-81-6P 95975-55-6P, Gugulipid 142583-61-7P, Policosanol
RL: NPO (Natural product occurrence); PUR (Purification or recovery); THU (Therapeutic use); BIOL (Biological study); OCCU (Occurrence); PREP (Preparation); USES (Uses)
(annatto extract compns. including tocotrienols and tocopherols for metabolic and other disorders)

IT 303-98-0P, CoQ10
RL: NPO (Natural product occurrence); PUR (Purification or recovery); THU (Therapeutic use); BIOL (Biological study); OCCU (Occurrence); PREP (Preparation); USES (Uses)
(annatto extract compns. including tocotrienols and tocopherols for metabolic and other disorders)

RN 303-98-0 ZCAPLUS

CN 2,5-Cyclohexadiene-1,4-dione, 2-[(2E,6E,10E,14E,18E,22E,26E,30E,34E)-3,7,11,15,19,23,27,31,35,39-decamethyl-2,6,10,14,18,22,26,30,34,38-tetracontadecaen-1-yl]-5,6-dimethoxy-3-methyl- (CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-B



PAGE 1-C

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L88 ANSWER 11 OF 41 ZCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2005:527199 ZCAPLUS Full-text
DOCUMENT NUMBER: 143:65418
TITLE: Water-based delivery systems comprising lipids
INVENTOR(S): Skold, Thomas
PATENT ASSIGNEE(S): Collagenex Pharmaceuticals, Inc., USA
SOURCE: U.S. Pat. Appl. Publ., 28 pp., Cont.-in-part of U.S. Ser. No. 388,371.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20050129722	A1	20050616	US 2004-957320	20040930 <--
WO 2003077861	A2	20030925	WO 2003-US7752	20030313 <--
WO 2003077861	A3	20050324		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 20040009213	A1	20040115	US 2003-388371	20030313 <--
WO 2006039667	A2	20060413	WO 2005-US35531	20050930 <--
WO 2006039667	A3	20060629		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ,

NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

AU 2007211879	A1	20070913	AU 2007-211879		20070822	<--
US 20090081139	A1	20090326	US 2008-82406		20080409	<--
US 20090226491	A1	20090910	US 2008-290455		20081030	<--
PRIORITY APPLN. INFO.:			US 2002-365059P	P	20020313	<--
			US 2003-388371	A2	20030313	<--
			WO 2003-US7752	A2	20030313	<--
			AU 2003-233396	A3	20030313	<--
			US 2004-957320	A	20040930	<--

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

AB The invention relates to a water-based delivery system for an active substance, characterized by enhancing skin barrier restoration in the stratum corneum comprising water, a fatty acid, cholesterol, a ceramide and at least one skin lipid precursor. For example, a topical cream formulation (without an active ingredient) contained water 79.5%, Epikuron 200SH 3.5%, palmitic acid 1.5%, cholesterol 1.5%, mevalonic acid 0.01% or 0.1%, triethanolamine 0.5%, Phenonip 0.4%, xanthan gum 2.0%, Skinflux 2.0%, 25-hydroxycholecalciferol 0.0015% or 0.015%, propylene glycol 4.0%, glycerol 3.0%, and polyvinylpyrrolidone 2.0%. Addition of nonionic adjuvants, such as Brij 30, and Brij 35 affected the characteristics of the formulation.

IC ICM A61K031-715
ICS A01N043-04; A61K007-42; A61K031-685; A01N057-26

INCL 424401000; 424059000; 514078000; 424405000; 514054000

CC 63-6 (Pharmaceuticals)
Section cross-reference(s): 1, 62

ST ceramide cholesterol fatty acid lipid precursor topical drug delivery

IT Ceramides
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(Ceramide 1, Ceramide 3; water-based topical delivery systems comprising fatty acid, cholesterol, ceramide and skin lipid precursor)

IT Ceramides
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(Ceramide 6A, Ceramide 6b; water-based topical delivery systems comprising fatty acid, cholesterol, ceramide and skin lipid precursor)

IT Fatty acids, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(C10-24; water-based topical delivery systems comprising fatty acid, cholesterol, ceramide and skin lipid precursor)

IT Fatty acids, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(C16-18; water-based topical delivery systems comprising fatty acid, cholesterol, ceramide and skin lipid precursor)

IT Acne
Alopecia
Dandruff
Eczema
Psoriasis
Skin, neoplasm
(agents for treatment of; water-based topical delivery systems comprising fatty acid, cholesterol, ceramide and skin lipid precursor)

IT Skin, disease

(aging, wrinkles, agents for treatment of; water-based topical delivery systems comprising fatty acid, cholesterol, ceramide and skin lipid precursor)

IT Polyoxyalkylenes, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(alkylphenol ethers; water-based topical delivery systems comprising fatty acid, cholesterol, ceramide and skin lipid precursor)

IT Agglutinins and Lectins
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(aloe-derived; water-based topical delivery systems comprising fatty acid, cholesterol, ceramide and skin lipid precursor)

IT Infection
(cutaneous, fungal, agents for treatment of; water-based topical delivery systems comprising fatty acid, cholesterol, ceramide and skin lipid precursor)

IT Skin, disease
(dry, agents for treatment of; water-based topical delivery systems comprising fatty acid, cholesterol, ceramide and skin lipid precursor)

IT Skin
(enhancement of barrier restoration of; water-based topical delivery systems comprising fatty acid, cholesterol, ceramide and skin lipid precursor)

IT Pimpinella anisum
(exts.; water-based topical delivery systems comprising fatty acid, cholesterol, ceramide and skin lipid precursor)

IT Hair preparations
(growth stimulants; water-based topical delivery systems comprising fatty acid, cholesterol, ceramide and skin lipid precursor)

IT Lecithins
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(hydrogenated; water-based topical delivery systems comprising fatty acid, cholesterol, ceramide and skin lipid precursor)

IT Skin, disease
(infection, fungal, agents for treatment of; water-based topical delivery systems comprising fatty acid, cholesterol, ceramide and skin lipid precursor)

IT Pediculus humanus corporis
(infections, agents for treatment of; water-based topical delivery systems comprising fatty acid, cholesterol, ceramide and skin lipid precursor)

IT Skin, disease
(lesion, agents for treatment of; water-based topical delivery systems comprising fatty acid, cholesterol, ceramide and skin lipid precursor)

IT Lysophosphatides
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(lysophosphatidylglycerols; water-based topical delivery systems comprising fatty acid, cholesterol, ceramide and skin lipid precursor)

IT Drug delivery systems
(ointments, creams; water-based topical delivery systems comprising fatty acid, cholesterol, ceramide and skin lipid precursor)

IT Biological transport
(permeation; water-based topical delivery systems comprising fatty acid, cholesterol, ceramide and skin lipid precursor)

IT Sphingosines
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(phytosphingosines; water-based topical delivery systems comprising fatty acid, cholesterol, ceramide and skin lipid precursor)

IT Lecithins
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(soya; water-based topical delivery systems comprising fatty acid, cholesterol, ceramide and skin lipid precursor)
IT Skin
(stratum corneum; water-based topical delivery systems comprising fatty acid, cholesterol, ceramide and skin lipid precursor)
IT Drug delivery systems
(topical; water-based topical delivery systems comprising fatty acid, cholesterol, ceramide and skin lipid precursor)
IT Analgesics
Particle size
Sunscreens
Suntanning agents
Vaccines
Zeta potential
(water-based topical delivery systems comprising fatty acid, cholesterol, ceramide and skin lipid precursor)
IT Catecholamines, biological studies
Ceramides
Cerebrosides
Estrogens
Hormones, animal, biological studies
Interferons
Lipids, biological studies
Lysophosphatidic acids
Lysophosphatidylcholines
Lysophosphatidylethanolamines
Lysophosphatidylinositols
Lysophosphatidylserines
Lysophospholipids
Peptides, biological studies
Phosphatidic acids
Phosphatidylcholines, biological studies
Phosphatidylethanolamines, biological studies
Phosphatidylglycerols
Phosphatidylinositols
Phosphatidylserines
Phospholipids, biological studies
Proteins
Vitamins
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(water-based topical delivery systems comprising fatty acid, cholesterol, ceramide and skin lipid precursor)
IT 75168-11-5, Acridine Orange 10-nonyl bromide
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(Acridine Orange 10-nonyl bromide; water-based topical delivery systems comprising fatty acid, cholesterol, ceramide and skin lipid precursor)
IT 9003-01-4D, crosslinked
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(Carbomer; water-based topical delivery systems comprising fatty acid, cholesterol, ceramide and skin lipid precursor)
IT 34354-88-6, Ceramide 3
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(Ceramide 3; water-based topical delivery systems comprising fatty acid, cholesterol, ceramide and skin lipid precursor)
IT 50-81-7, Ascorbic acid, biological studies 54-11-5, Nicotine 56-81-5, Glycerine, biological studies 57-10-3, Palmitic acid, biological studies 57-11-4, Stearic acid, biological studies 57-55-6, Propylene glycol,

biological studies 57-88-5, Cholesterol, biological studies 58-61-7, Adenosine, biological studies 58-85-5, Biotin 60-33-3, Linoleic acid, biological studies 64-17-5, Ethanol, biological studies 65-85-0, Benzoic acid, biological studies 79-81-2, Retinyl palmitate 112-80-1, Oleic acid, biological studies 112-85-6, Behenic acid 116-31-4, Retinal 121-44-8, Triethylamine, biological studies 123-78-4, Sphingosine 127-47-9, Retinyl acetate 137-58-6, Lidocaine 137-66-6, Ascorbyl palmitate 143-07-7, Lauric acid, biological studies 145-13-1, Pregnenolone 150-97-0, Mevalonic acid 302-79-4, Retinoic acid 303-98-0, Coenzyme Q10 373-49-9, Palmitoleic acid 434-16-2, Dehydrocholesterol 446-72-0, Genistein 463-40-1, Linolenic acid 464-92-6, Asiatic acid 490-83-5, Dehydroascorbic acid 496-65-1, Pantetheine 506-26-3, γ-Linolenic acid 506-30-9, Arachidic acid 506-32-1, Arachidonic acid 544-63-8, Myristic acid, biological studies 554-62-1, Phytosphingosine 557-59-5, Lignoceric acid 616-91-1, N-Acetylcysteine 631-89-0, Retinyl linoleate 674-26-0, Mevalonic acid lactone 816-94-4, DSPC 1071-28-9, 3-Aminopropyl dihydrogen phosphate 1200-22-2, Lipoic acid 1783-84-2, Homo-γ-linolenic acid 2237-36-7, 4-Methoxysalicylic acid 2441-53-4, Columbinic acid 5274-68-0, Tetraethylene glycol monododecyl ether 7069-42-3, Retinyl propionate 7732-18-5, Water, biological studies 9002-92-0 9003-39-8, PVP 10417-94-4, Timnodonic acid 11138-66-2, Xanthan gum 17364-18-0 19356-17-3, 25-Hydroxycholecalciferol 25322-68-3D, fatty acid esters and mercaptan complexes 42415-70-3, Sodium lauroyl lactate 57828-26-9, Lipoic acid 66176-93-0 68247-19-8, Inositol phosphate 72088-94-9, 5(6)-Carboxyfluorescein 89022-37-7, 6,9,13-Eicosatrienoic acid 106392-12-5, Polyethylene oxide-polypropylene oxide block copolymer 106685-40-9, Adapalene 110483-07-3 129983-52-4 170231-37-5 170231-40-0 178617-15-7 178617-16-8 189384-85-8 259150-85-1, SK-influx 264624-38-6 603950-78-3 603950-79-4 603950-80-7 603950-81-8 603950-82-9 603950-83-0 603950-84-1 603950-85-2 603950-86-3 603950-87-4 603950-88-5 603950-89-6 603950-90-9 603950-91-0 603950-92-1 603950-93-2 603950-94-3 603950-95-4 603950-96-5 603950-97-6 603950-98-7 603950-99-8 603951-00-4 603951-01-5 603951-02-6 603951-03-7 603951-04-8 603951-05-9 603951-06-0 603951-07-1 603951-08-2 603951-09-3 603951-10-6 603951-11-7 603951-12-8 603951-13-9 603951-14-0 603951-15-1 603951-16-2 603951-17-3 603951-18-4 603951-19-5 603951-20-8 603951-21-9 603951-22-0 603951-23-1 603951-24-2 603951-25-3 603951-26-4 603951-27-5 603951-28-6 603951-29-7 603951-30-0 603951-31-1 603951-32-2 603951-33-3 603951-34-4 603951-35-5 603951-36-6 603951-37-7 603951-38-8 603951-39-9 603951-40-2

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(water-based topical delivery systems comprising fatty acid, cholesterol, ceramide and skin lipid precursor)

IT 303-98-0, Coenzyme Q10

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(water-based topical delivery systems comprising fatty acid, cholesterol, ceramide and skin lipid precursor)

RN 303-98-0 ZCAPLUS

CN 2,5-Cyclohexadiene-1,4-dione, 2-[(2E,6E,10E,14E,18E,22E,26E,30E,34E)-3,7,11,15,19,23,27,31,35,39-decamethyl-2,6,10,14,18,22,26,30,34,38-tetracontadecaen-1-yl]-5,6-dimethoxy-3-methyl- (CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A



PAGE 1-B



PAGE 1-C

OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)

L88 ANSWER 12 OF 41 ZCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2005:303178 ZCAPLUS Full-text
DOCUMENT NUMBER: 142:349112
TITLE: Tocopherol treatment of diabetic microvascular and macrovascular complications
INVENTOR(S): Papas, Andreas M.; Papas, Konstantinos A.; Papas, Klearchos K.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 11 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20050074447	A1	20050407	US 2004-956538	20041001 <--
WO 2005032478	A2	20050414	WO 2004-US32210	20041001 <--
WO 2005032478	A3	20050602		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,

AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2003-507826P P 20031001 <--

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

AB Disclosed is a method of preventing or retarding the progression of diabetic microvascular and macrovascular complications by chronically administering a therapeutically effective amount of gamma-tocopherol to a diabetic patient. It is further disclosed that synergistic cytoprotectant activity is provided by administering a combination of gamma-tocopherol and alpha-tocopherol.

IC ICM A61K038-43
ICS A61K031-355

INCL 424094100; 514458000

CC 1-12 (Pharmacology)
Section cross-reference(s): 18

IT Pancreatic islet of Langerhans, neoplasm
(insulinoma, cells, cytoprotective activity of tocotrienols in; tocopherol treatment of diabetic microvascular and macrovascular complications)

IT Drug delivery systems
(topical; tocopherol treatment of diabetic microvascular and macrovascular complications)

IT 50-81-7, Vitamin C, biological studies 127-40-2, Lutein 144-68-3, Zeaxanthin 303-98-0, Coenzyme Q10 616-91-1, N-Acetylcysteine 1200-22-2, α-Lipoic acid 1721-51-3, α-Tocotrienol 6829-55-6, Tocotrienol 7235-40-7, Beta-carotene 7440-47-3, Chromium, biological studies 7440-50-8, Copper, biological studies 7440-66-6, Zinc, biological studies 7732-18-5, Water, biological studies 7782-49-2, Selenium, biological studies 14101-61-2, γ-Tocotrienol 14992-62-2, Acetyl carnitine 25612-59-3, δ-Tocotrienol
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(tocopherol treatment of diabetic microvascular and macrovascular complications)

IT 303-98-0, Coenzyme Q10
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(tocopherol treatment of diabetic microvascular and macrovascular complications)

RN 303-98-0 ZCAPLUS

CN 2,5-Cyclohexadiene-1,4-dione, 2-[(2E,6E,10E,14E,18E,22E,26E,30E,34E)-3,7,11,15,19,23,27,31,35,39-decamethyl-2,6,10,14,18,22,26,30,34,38-tetracontadecaen-1-yl]-5,6-dimethoxy-3-methyl- (CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A



PAGE 1-B



PAGE 1-C

L88 ANSWER 13 OF 41 ZCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2004:372848 ZCAPLUS Full-text
DOCUMENT NUMBER: 140:386058
TITLE: Methods using antioxidant flavonoid compounds for the treatment of peripheral neural and vascular ailments
INVENTOR(S): Rosenbloom, Richard A.
PATENT ASSIGNEE(S): The Quigley Corporation, USA
SOURCE: U.S. Pat. Appl. Publ., 11 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20040087516	A1	20040506	US 2002-288825	20021106 <--
US 7083813	B2	20060801		
US 20050239721	A1	20051027	US 2005-165151	20050623 <--
US 7410659	B2	20080812		

PRIORITY APPLN. INFO.: US 2002-288825 A3 20021106 <--
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
AB Compns. and methods for the treatment of peripheral neural and vascular ailments are disclosed. The method comprises administering a flavonoid compound with antioxidant properties, optionally formulated in a acceptable carrier. This compound or combination of compds. provides significant, effective relief of the symptoms of peripheral neural or vascular ailments. In addition, the compns., when used according to the methods of the invention, do not exhibit the severe side effects of many prior art compns. proposed for treatment of these ailments.
IC ICM A61K031-7048
ICS A61K031-353
INCL 514027000; X51-445.6
CC 1-12 (Pharmacology)
Section cross-reference(s): 63
IT Alopecia
Analgesics
Angiogenesis
Antioxidants
Cardiovascular agents
Circulation

Cosmetics
Human
Nervous system agents
Pain
Permeation enhancers
(antioxidant flavonoid compds. for treatment of peripheral neural and vascular ailments)

IT Drug delivery systems
(topical; antioxidant flavonoid compds. for treatment of peripheral neural and vascular ailments)

IT 50-81-7, Ascorbic acid, biological studies 58-95-7, Vitamin E acetate 60-81-1, Phloridzin 60-82-2, Phloretin 67-97-0, Vitamin D3 70-18-8, Glutathione, biological studies 79-81-2, Vitamin A palmitate 81-13-0, D-Panthenol 87-44-5, Caryophyllene 90-18-6, Quercetagetin 90-19-7, Rhamnetin 117-39-5, Quercetin 117-39-5D, Quercetin, derivs. 120-72-9, Indole, biological studies 134-04-3, Pelargonidin 137-66-6, Ascorbyl palmitate 152-95-4, Sophoricoside 153-18-4, Rutin 154-23-4, Catechin 303-98-0, Coenzyme Q10 446-72-0, Genistein 458-37-7, Curcumin 474-07-7, Brazilin 476-66-4, Ellagic acid 480-10-4, Astragalin 480-16-0, Morin 480-18-2, Dihydroquercetin 480-36-4, Linarin 480-40-0, Chrysin 480-40-0D, Chrysin, derivs. 480-41-1, Naringenin 480-44-4, Acacetin 482-36-0, Hyperin 482-39-3, Kaempferol-3-rhamnoside 489-35-0, Gossypetin 490-46-0, Epicatechin 491-50-9, Quercimeritrin 491-67-8, Baicalein 491-70-3, Luteolin 491-71-4, Chrysoeriol 506-26-3, Gamma linolenic acid 517-28-2, Haematoxylin 520-11-6, Nepetin 520-12-7, Pectolinarigenin 520-18-3, Kaempferol 520-26-3, Hesperidine 520-27-4, Diosmin 520-33-2, Hesperitin 520-34-3, Diosmetin 520-36-5, Apigenin 522-12-3, Quercitrin 528-48-3, Fisetin 528-58-5, Cyanidin 529-44-2, Myricetin 529-53-3, Scutellarein 529-53-3D, Scutellarein, derivs. 548-83-4, Galangin 549-17-7, Oxyayanin-a 549-32-6, Reynoutrin 569-90-4, Nepetrin 572-30-5, Aviculario 578-74-5, Cosmosiin 603-56-5, Chrysosplenol B 632-85-9, Wogonin 652-78-8, Gossypetin-8-glucoside 961-29-5, Isoliquiritigenin 970-74-1, (-)-Epigallocatechin 989-51-5, (-)-Epigallocatechin-gallate 1200-22-2, α-Lipoic acid 1340-08-5, Citrin 1406-18-4, Vitamin E 1406-18-4D, Vitamin E, esters 1617-49-8, 3,3',4-Tri-o-methyl-ellagic acid 1617-53-4, Amentoflavone 3416-24-8D, Glucosamine, ascorbic acid conjugates 3681-93-4, Vitexin 5041-67-8, Juglanin 5041-81-6, Isoliquiritin 5188-73-8, Axillarin 5373-11-5, Luteolin-7-glucoside 6601-54-3, Diacetylcirsimaritin 6980-20-7, TetraHER 7085-55-4, TriHER 7212-44-4, Nerolidol 10236-47-2, Naringin 11103-57-4, Vitamin A 16485-10-2, DL-Panthenol 17306-46-6, Rhoifolin 17680-84-1, Hispiduloside 18003-33-3, 6-Hydroxy-luteolin 18490-95-4, Brevifolin carboxylic acid 20229-56-5, Spiraeoside 21637-25-2, Isoquercitrin 22697-65-0, 6-Hydroxykaempferol-3,6-dimethyl ether 22888-70-6, Silibinin 23615-30-7, Chrysosplenoside-a 23627-87-4, Trifolin 23869-24-1, MonoHER 24512-68-3, Sorbarin 25321-00-0, Chrysosplenoside D 25694-72-8, Lonicerin 26544-34-3, Apiin 26854-07-9, DiHER 28978-02-1, Pectolinarin 29350-73-0D, Cadinene, derivs. 29741-10-4, Luteolin-7-glucuronide 29782-68-1, Silydianin 29913-71-1, Licuraside 32511-63-0, 1,25-Dihydroxyvitamin D3 32602-81-6, Kaempferol-3-neohesperidoside 33889-69-9, Silychristin 52225-20-4, DL-α-Tocopheryl acetate 53755-56-9, Linariin 61276-17-3, Acteoside 61360-94-9, Flavosativaside 62624-30-0, Ascorbic acid 64661-76-3, Flavocannabiside 65666-07-1, Silymarin 67255-34-9, Iridine 70360-12-2, Sideritoflavone 79886-50-3 84632-09-7, 6,3',4'-Trihydroxy-5,7,8-trimethoxyflavone 97560-11-7, Kolaviron 107646-82-2, Ethyl brevifolin carboxylate 123715-11-7D, derivs. 125712-75-6 132951-90-7, Macrocarpal-a 142628-53-3, Macrocarpal-g 142647-71-0, Macrocarpal D 142698-60-0, Macrocarpal-b 439217-49-9,

Dimethylmussaenoside 524727-65-9, Maniflavone 524729-83-7, Nelumboside 537684-20-1, Dosmetin 537684-31-4, Ebinin
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(antioxidant flavonoid compds. for treatment of peripheral neural and vascular ailments)

IT 303-98-0, Coenzyme Q10
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(antioxidant flavonoid compds. for treatment of peripheral neural and vascular ailments)

RN 303-98-0 ZCAPLUS

CN 2,5-Cyclohexadiene-1,4-dione, 2-[(2E,6E,10E,14E,18E,22E,26E,30E,34E)-3,7,11,15,19,23,27,31,35,39-decamethyl-2,6,10,14,18,22,26,30,34,38-tetracontadecaen-1-yl]-5,6-dimethoxy-3-methyl- (CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A



PAGE 1-B



PAGE 1-C

OS.CITING REF COUNT: 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (4 CITINGS)
REFERENCE COUNT: 127 THERE ARE 127 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L88 ANSWER 14 OF 41 ZCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2003:757479 ZCAPLUS Full-text
DOCUMENT NUMBER: 139:265779
TITLE: Water-based drug delivery systems
INVENTOR(S): Skoeld, Thomas
PATENT ASSIGNEE(S): Collagenex Pharmaceuticals, Inc., USA

SOURCE: PCT Int. Appl., 50 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003077861	A2	20030925	WO 2003-US7752	20030313 <--
WO 2003077861	A3	20050324		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2476859	A1	20030925	CA 2003-2476859	20030313 <--
AU 2003233396	A1	20030929	AU 2003-233396	20030313 <--
AU 2003233396	B2	20070524		
EP 1534213	A2	20050601	EP 2003-728242	20030313 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2005522463	T	20050728	JP 2003-575915	20030313 <--
NZ 534377	A	20080430	NZ 2003-534377	20030313 <--
US 20050129722	A1	20050616	US 2004-957320	20040930 <--
AU 2007211879	A1	20070913	AU 2007-211879	20070822 <--
US 20090226491	A1	20090910	US 2008-290455	20081030 <--

PRIORITY APPLN. INFO.:

US 2002-365059P	P	20020313 <--
AU 2003-233396	A3	20030313 <--
US 2003-388371	A2	20030313 <--
WO 2003-US7752	W	20030313 <--
US 2004-957320	A1	20040930 <--

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

AB The invention relates to a water-based drug delivery system, characterized by enhancing skin barrier restoration in the stratum corneum comprising water, a fatty acid, cholesterol, a ceramide and at least one skin lipid precursor. Thus, a formulation contained water 79.75, Epikuron 200SH 3.5, palmitic acid 1.5, cholesterol 1.5, mevalonic acid 0.01, triethanolamine 0.5, phenonip 0.4, xanthan gum 2.0, Skin-flux 2.0, 25-hydroxycholecalciferol 0.0015, propylene glycol 4.0, glycerol 3.0, and PVP 2.0%.

IC ICM A61K
CC 63-6 (Pharmaceuticals)
Section cross-reference(s): 62
IT Drug delivery systems
(liposomes, topical; water-based drug delivery systems)
IT Drug delivery systems
(topical; water-based drug delivery systems)
IT Alopecia
Analgesics
Antitumor agents
Cosmetics
Eczema
Pain
Pruritus
Psoriasis

Skin
Skin, neoplasm
Sunscreens
Suntanning agents
Vaccines
(water-based drug delivery systems)

IT 50-81-7, Ascorbic acid, biological studies 54-11-5, Nicotine 56-81-5, Glycerine, biological studies 57-10-3, Hexadecanoic acid, biological studies 57-11-4, Octadecanoic acid, biological studies 57-55-6, Propylene glycol, biological studies 57-88-5, Cholesterol, biological studies 58-61-7, Adenosine, biological studies 58-85-5, Biotin 60-33-3, Linoleic acid, biological studies 65-85-0D, Benzoic acid, derivs. 79-81-2, Retinyl palmitate 89-65-6, Erythorbic acid 102-71-6, Triethanolamine, biological studies 112-80-1, 9-Octadecenoic acid (9Z)-, biological studies 112-85-6, Docosanoic acid 116-31-4, Retinal 127-47-9, Retinyl acetate 137-66-6, Ascorbyl palmitate 143-07-7, Lauric acid, biological studies 145-13-1, Pregnenolone 150-97-0, Mevalonic acid 303-98-0, Coenzyme Q10 373-49-9, Palmitoleic acid 434-16-2, DehydroCholesterol 446-95-7, Genisteine 463-40-1, Linolenic acid 464-92-6, Asiatic acid 490-83-5, DehydroAscorbic acid 496-65-1, Pantetheine 506-26-3, γ-Linolenic acid 506-30-9, Eicosanoic acid 506-32-1, Arachidonic acid 544-63-8, Myristic acid, biological studies 554-62-1, Phytosphingosine 557-59-5, Tetracosanoic acid 616-91-1, N-Acetylcysteine 631-89-0, Retinyl linoleate 816-94-4, DSPC 1071-28-9 1783-84-2, Homo-γ-Linolenic acid 2237-36-7, 4-Methoxysalicylic acid 2441-53-4, Columbinic acid 7069-42-3, Retinyl propionate 9003-39-8, Polyvinylpyrrolidone 10417-94-4, Timnodonic acid 19356-17-3, 25-Hydroxycholecalciferol 57828-26-9, Lipoic acid 66176-93-0, Cimicifugoside 68247-19-8, Inositol phosphate 89022-37-7, 6,9,13-Eicosatrienoic acid 106685-40-9, Adapalene 110483-07-3 129983-52-4 170231-37-5 170231-40-0 178617-15-7 178617-16-8 189384-85-8 259150-85-1, SK-influx 264624-38-6, 27-Deoxyactein 603950-78-3 603950-79-4 603950-80-7 603950-81-8 603950-82-9 603950-83-0 603950-84-1 603950-85-2 603950-86-3 603950-87-4 603950-88-5 603950-89-6 603950-90-9 603950-91-0 603950-92-1 603950-93-2 603950-94-3 603950-95-4 603950-96-5 603950-97-6 603950-98-7 603950-99-8 603951-00-4 603951-01-5 603951-02-6 603951-03-7 603951-04-8 603951-05-9 603951-06-0 603951-07-1 603951-08-2 603951-09-3 603951-10-6 603951-11-7 603951-12-8 603951-13-9 603951-14-0 603951-15-1 603951-16-2 603951-17-3 603951-18-4 603951-19-5 603951-20-8 603951-21-9 603951-22-0 603951-23-1 603951-24-2 603951-25-3 603951-26-4 603951-27-5 603951-28-6 603951-29-7 603951-30-0 603951-31-1 603951-32-2 603951-33-3 603951-34-4 603951-35-5 603951-36-6 603951-37-7 603951-38-8 603951-39-9 603951-40-2
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(water-based drug delivery systems)

IT 303-98-0, Coenzyme Q10
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(water-based drug delivery systems)

RN 303-98-0 ZCAPLUS

CN 2,5-Cyclohexadiene-1,4-dione, 2-[(2E,6E,10E,14E,18E,22E,26E,30E,34E)-3,7,11,15,19,23,27,31,35,39-decamethyl-2,6,10,14,18,22,26,30,34,38-tetracontadecaen-1-yl]-5,6-dimethoxy-3-methyl- (CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A



PAGE 1-B



PAGE 1-C

OS.CITING REF COUNT: 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS)
REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L88 ANSWER 15 OF 41 ZCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2003:376557 ZCAPLUS Full-text
DOCUMENT NUMBER: 138:367907
TITLE: Nutritional supplements and methods for prevention, reduction and treatment of radiation injury
INVENTOR(S): Rosenbloom, Richard A.
PATENT ASSIGNEE(S): The Quigley Corporation, USA
SOURCE: PCT Int. Appl., 41 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 5
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003039452	A2	20030515	WO 2002-US13526	20020501 <--
WO 2003039452	A3	20041202		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,

CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 20030103953	A1	20030605	US 2001-993003	20011106	<--
US 6753325	B2	20040622			
US 20030103954	A1	20030605	US 2002-45790	20020114	<--
US 7435725	B2	20081014			
US 20030105027	A1	20030605	US 2002-132642	20020425	<--
CA 2465945	A1	20030515	CA 2002-2465945	20020501	<--
AU 2002309615	A1	20030519	AU 2002-309615	20020501	<--
AU 2002309615	B2	20071018			
EP 1505984	A2	20050216	EP 2002-736624	20020501	<--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR					
JP 2005510509	T	20050421	JP 2003-541744	20020501	<--
NZ 532774	A	20080829	NZ 2002-532774	20020501	<--
IN 2004DN01165	A	20060728	IN 2004-DN1165	20040430	<--
MX 2004004376	A	20040811	MX 2004-4376	20040506	<--

PRIORITY APPLN. INFO.:

US 2001-993003	A	20011106	<--
US 2002-45790	A	20020114	<--
US 2002-132642	A	20020425	<--
WO 2002-US13526	W	20020501	<--

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

AB A nutritional supplement composition for the prevention, reduction or treatment of radiation injury due to exposure to ionizing radiation, including one or more compds. that regulates cell differentiation and/or cell proliferation, and one or more antioxidants, optionally formulated in a pharmaceutically acceptable carrier for an oral composition The composition of the present invention may further include optional ingredients such as flavonoids, flavonoid derivs., selenium, selenium compds., anti-inflammatories, organic germanium, Korean ginseng, American ginseng, Siberian ginseng and B-complex vitamins. A method for the administration of an oral composition for the purpose of preventing, reducing or treating radiation injury involves orally administering an effective amount of a composition including one or more compds. that regulates cell differentiation and/or cell proliferation, and one or more antioxidants to a person before, during or after radiation exposure. A method for the topical administration of the composition in accordance with the present invention for the purpose of preventing, reducing or treating radiation injury involves topically administering an effective amount of the composition of the invention an area of skin, which has been or will be exposed to ionizing radiation. The compns. and methods can be employed to prevent, reduce or treat radiation injury caused by a wide variety of types of radiation exposure.

IC ICM A61K

CC 17-6 (Food and Feed Chemistry)
Section cross-reference(s): 62, 63

IT Anti-inflammatory agents
Antioxidants
Candy
Cell differentiation
Cell proliferation
Dentifrices
Food additives
Gamma ray
Ionizing radiation
Mouthwashes
Panax
Radiation
Radioprotectants
(nutritional supplements and methods for prevention, reduction and treatment of radiation injury)

IT 50-81-7, Vitamin C, biological studies 59-02-9, α-Tocopherol 67-97-0, Vitamin D3 67-97-0D, Vitamin D3, salts 70-18-8, Glutathione, biological studies 79-81-2, Vitamin A palmitate 87-44-5, Caryophyllene 90-18-6, Quercetagetin 90-19-7, Rhamnetin 117-39-5, Quercetin 120-72-9, Indole, biological studies 137-66-6, Ascorbyl palmitate 142-50-7, Nerolidol 152-95-4, Sophoricoside 153-18-4, Rutin 303-98-0, Coenzyme Q10 434-16-2, Provitamin D3 446-72-0, Genistein 458-37-7, Curcumin 458-37-7D, Curcumin, derivs. 474-07-7, Brazilin 476-66-4, Ellagic acid 480-10-4, Astragalin 480-16-0, Morin 480-36-4, Linarin 480-40-0 480-41-1, Naringenin 480-44-4, Acacetin 482-36-0, Hyperin 482-39-3, Kaempferol-3-rhamnoside 483-76-1, δ-Cadinene 490-83-5, Dehydroascorbic acid 491-50-9, Quercimeritrin 491-67-8, Baicalein 491-70-3, Luteolin 491-71-4, Chrysoeriol 517-28-2, Hematoxylin 520-11-6, Nepetin 520-12-7, Pectolinarigenin 520-26-3, Hesperidine 520-33-2, Hesperitin 520-34-3, Diosmetin 520-36-5, Apigenin 522-12-3, Quercitrin 528-48-3, Fisetin 528-58-5, Cyanidin 529-44-2, Myricetin 529-53-3, Scutellarein 548-83-4, Galangin 549-17-7, Oxyayanin-a 549-32-6, Reynoutrin 569-90-4, Nepetrin 572-30-5, Avicularin 578-74-5, Cosmosiin 632-85-9, Wogonin 652-78-8 961-29-5, Isoliquiritigenin 1200-22-2, α-Lipoic acid 1340-08-5, Citrin 1447-88-7 1617-49-8, 3,3',4-Tri-o-methylellagic acid 1617-53-4, Amentoflavone 3681-93-4, Vitexin 4172-43-4D, L-Lyxonic acid, salts 4172-44-5, L-Xylonic acid 4172-44-5D, L-Xylonic acid, salts 5041-67-8, Juglanin 5041-81-6, Isoliquiritin 5188-73-8, Axillarin 5373-11-5, Luteolin-7-glucoside 6601-54-3, Diacetylcirsmaritin 7235-40-7, β-Carotene 7306-96-9, L-Threonic acid 7306-96-9D, L-Threonic acid, salts 7440-56-4D, Germanium, organic derivs. 7782-49-2, Selenium, biological studies 7782-49-2D, Selenium, compds. 9054-89-1, Superoxide dismutase 10236-47-2, Naringin 11103-57-4, Vitamin A 11103-57-4D, Vitamin A, esters 12001-76-2, Vitamin B 12758-40-6 17306-46-6, Rhoifolin 17680-84-1, Hispiduloside 17912-87-7 18003-33-3, 6-Hydroxyluteolin 18490-95-4, Brevifolin carboxylic acid 19356-17-3, 25-Hydroxycholecalciferol 20229-56-5, Spiraeoside 21637-25-2, Isoquercitrin 22697-65-0, 6-Hydroxykaempferol-3,6-dimethyl ether 23615-30-7, Chrysosplenoside A 24512-68-3, Sorbarin 25321-00-0, Chrysosplenoside d 25694-72-8, Lonicerin 26544-34-3, Apiin 28978-02-1, Pectolinarin 29741-10-4, Luteolin-7-glucuronide 29913-71-1, Licuraside 32222-06-3, Calcitriol 32602-81-6, Kaempferol-3-neohesperidoside 33876-31-2, Trifolin 53755-56-9, Linariin 60534-79-4 61276-17-3, Acteoside 61360-94-9, Flavosativaside 61891-39-2 64661-76-3, Flavocannabiside 65666-07-1, Silymarin 67255-34-9, Iridine 70360-12-2, Sideritoflavone 79886-50-3, 1,2,3,6-Tetra-o-galloyl-β-D-glucose 82451-22-7 84632-09-7, 6,3',4'-Trihydroxy-5,7,8-trimethoxyflavone 97560-11-7, Kolaviron 107646-82-2, Ethyl brevifolin carboxylate 129932-47-4 132951-90-7, Macrocarpal-a 142628-53-3, Macrocarpal-g 142647-71-0, Macrocarpal D 142698-60-0, Macrocarpal-b 524689-97-2 524727-65-9, Maniflavone 524729-83-7, Nelumboside
RL: COS (Cosmetic use); FFD (Food or feed use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(nutritional supplements and methods for prevention, reduction and treatment of radiation injury)

IT 303-98-0, Coenzyme Q10
RL: COS (Cosmetic use); FFD (Food or feed use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(nutritional supplements and methods for prevention, reduction and treatment of radiation injury)

RN 303-98-0 ZCAPLUS

CN 2,5-Cyclohexadiene-1,4-dione, 2-[(2E,6E,10E,14E,18E,22E,26E,30E,34E)-3,7,11,15,19,23,27,31,35,39-decamethyl-2,6,10,14,18,22,26,30,34,38-tetracontadecaen-1-yl]-5,6-dimethoxy-3-methyl- (CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A



PAGE 1-B



PAGE 1-C

OS.CITING REF COUNT: 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD (4 CITINGS)
REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L88 ANSWER 16 OF 41 ZCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2003:334926 ZCAPLUS Full-text
DOCUMENT NUMBER: 138:343911
TITLE: Delivery system containing Shilajit for pharmaceuticals and nutrition and cosmetics
INVENTOR(S): Ghosal, Shibnath
PATENT ASSIGNEE(S): Natreon Inc., USA; Indian Herbs Research & Supply Company Ltd.
SOURCE: PCT Int. Appl., 34 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003035094	A1	20030501	WO 2002-US25683	20020813 <--

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,

CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
UA, UG, UZ, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF,
CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 6558712 B1 20030506 US 2001-957797 20010921 <--
AU 2002324690 A1 20030506 AU 2002-324690 20020813 <--
EP 1435982 A1 20040714 EP 2002-759348 20020813 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK
PRIORITY APPLN. INFO.: US 2001-957797 A 20010921 <--
WO 2002-US25683 W 20020813 <--

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

AB A stable, water-soluble delivery system which is a purified Shilajit composition obtained by extraction of native Shilajit, preferably containing at least 40% by weight of a carrier which is purified fulvic acid, characterized by having a sponge-like structure punctured by voids of about 200-1000 A in diameter, and a mol. weight of about 700-2500, and an effective amount of an active pharmaceutical, nutritional or cosmetic ingredient added to the carrier and filling voids therein. Thus, a tablet composition contained tamoxifen citrate 10.00, Shilajit/fulvic acid 100.00, lactose 50.00, microcryst. cellulose 50.00, Croscarmellose sodium 2.00, and Mg stearate 1.00 mg/tablet.

IC ICM A61K035-78
CC 63-6 (Pharmaceuticals)
Section cross-reference(s): 17, 62
IT Aging, animal
Analgesics
Anthelmintics
Anti-inflammatory agents
Antianginal agents
Antiarrhythmics
Antibacterial agents
Anticoagulants
Anticonvulsants
Antidepressants
Antidiabetic agents
Antihistamines
Antihypertensives
Antimalarials
Antimigraine agents
Antiobesity agents
Antioxidants
Antiparkinsonian agents
Antipsychotics
Antitumor agents
Antiviral agents
Anxiolytics
Cognition enhancers
Cosmetics
Diagnostic agents
Diuretics
Drug delivery systems
Fungicides
Hypnotics and Sedatives
Immunosuppressants

Inotropics
Muscarinic antagonists
Muscle relaxants
Nutrients
Nutrition, animal
Osteoporosis
Protozoacides
Sunscreens
β-Adrenoceptor antagonists
(delivery system containing Shilajit for pharmaceuticals and nutrition and cosmetics)

IT Drug delivery systems
(topical; delivery system containing Shilajit for pharmaceuticals and nutrition and cosmetics)

IT 59-05-2, Methotrexate 59-30-3, Folic acid, biological studies 303-98-0, Coenzyme Q10 359-83-1, Pentazocin 9004-10-8, Insulin, biological studies 10238-21-8, Glibenclamide 12001-76-2, Vitamin B complex 54965-24-1, Tamoxifen citrate
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(delivery system containing Shilajit for pharmaceuticals and nutrition and cosmetics)

IT 303-98-0, Coenzyme Q10
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(delivery system containing Shilajit for pharmaceuticals and nutrition and cosmetics)

RN 303-98-0 ZCAPLUS

CN 2,5-Cyclohexadiene-1,4-dione, 2-[(2E,6E,10E,14E,18E,22E,26E,30E,34E)-3,7,11,15,19,23,27,31,35,39-decamethyl-2,6,10,14,18,22,26,30,34,38-tetracontadecaen-1-yl]-5,6-dimethoxy-3-methyl- (CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A



PAGE 1-B



PAGE 1-C

OS.CITING REF COUNT: 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD (4 CITINGS)
REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L88 ANSWER 17 OF 41 ZCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2003:202513 ZCAPLUS Full-text
DOCUMENT NUMBER: 138:226402
TITLE: A topical water-in-oil emulsion composition
INVENTOR(S): Fischer, Andreas
PATENT ASSIGNEE(S): Lipocore Holding AB, Swed.
SOURCE: PCT Int. Appl., 33 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003020318	A1	20030313	WO 2002-SE1571	20020903 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002330820	A1	20030318	AU 2002-330820	20020903 <--
PRIORITY APPLN. INFO.:			SE 2001-2933 A	20010904 <--
			SE 2002-1667 A	20020603 <--
			WO 2002-SE1571 W	20020903 <--

AB The present invention refers to a topical water-in-oil (w/o)-emulsion composition for cosmetic or medical use, comprising an oil phase and an aqueous phase dispersed in the continuous oil phase in a w/o ratio of up to 80:20, resp. The oil phase contains 60-99.9% of at least one non-polar oil in combination with 0.1-40% of monoglycosylceramide, and optionally ethanol. The composition is able to form a macroscopically homogeneous and stable w/o emulsion. For example, to the oil phase prepared from 0.0591 g of monohexosylceramide mixed with 0.9992 g of evening primrose oil and 0.1209 g of ethanol, 0.7885 g of water was added to form the emulsion.

IC ICM A61K047-44
ICS A61K009-113
CC 62-4 (Essential Oils and Cosmetics)
Section cross-reference(s): 63
ST monoglycosylceramide oil topical emulsion cosmetic medical
IT Acne
Psoriasis
Seborrhea
(agents for treatment of; topical water-in-oil emulsions containing non-polar oil and monoglycosylceramide for cosmetic or medical use)
IT Cosmetics
(creams; topical water-in-oil emulsions containing non-polar oil and monoglycosylceramide for cosmetic or medical use)

IT Cerebrosides
RL: COS (Cosmetic use); THU (Therapeutic use); BIOL (Biological study);
USES (Uses)
(emulsifiers; topical water-in-oil emulsions containing non-polar oil and monoglycosylceramide for cosmetic or medical use)
IT Drug delivery systems
(emulsions, topical; topical water-in-oil emulsions containing non-polar oil and monoglycosylceramide for cosmetic or medical use)
IT Cosmetics
(emulsions; topical water-in-oil emulsions containing non-polar oil and monoglycosylceramide for cosmetic or medical use)
IT Fats and Glyceridic oils, biological studies
RL: COS (Cosmetic use); THU (Therapeutic use); BIOL (Biological study);
USES (Uses)
(evening primrose; topical water-in-oil emulsions containing non-polar oil and monoglycosylceramide for cosmetic or medical use)
IT Fats and Glyceridic oils, biological studies
RL: COS (Cosmetic use); THU (Therapeutic use); BIOL (Biological study);
USES (Uses)
(fish; topical water-in-oil emulsions containing non-polar oil and monoglycosylceramide for cosmetic or medical use)
IT Hair preparations
(growth stimulants; topical water-in-oil emulsions containing non-polar oil and monoglycosylceramide for cosmetic or medical use)
IT Cerebrosides
RL: COS (Cosmetic use); THU (Therapeutic use); BIOL (Biological study);
USES (Uses)
(hexose-containing; topical water-in-oil emulsions containing non-polar oil and monoglycosylceramide for cosmetic or medical use)
IT Cosmetics
Drug delivery systems
(lotions; topical water-in-oil emulsions containing non-polar oil and monoglycosylceramide for cosmetic or medical use)
IT Glycerides, biological studies
RL: COS (Cosmetic use); THU (Therapeutic use); BIOL (Biological study);
USES (Uses)
(medium-chain, oils; topical water-in-oil emulsions containing non-polar oil and monoglycosylceramide for cosmetic or medical use)
IT Milk
(monohexosylceramides from; topical water-in-oil emulsions containing non-polar oil and monoglycosylceramide for cosmetic or medical use)
IT Drug delivery systems
(ointments, creams; topical water-in-oil emulsions containing non-polar oil and monoglycosylceramide for cosmetic or medical use)
IT Drug delivery systems
(ointments; topical water-in-oil emulsions containing non-polar oil and monoglycosylceramide for cosmetic or medical use)
IT Fats and Glyceridic oils, biological studies
RL: COS (Cosmetic use); THU (Therapeutic use); BIOL (Biological study);
USES (Uses)
(sesame; topical water-in-oil emulsions containing non-polar oil and monoglycosylceramide for cosmetic or medical use)
IT Anesthetics
Anti-inflammatory agents
Antibiotics
Antimicrobial agents
Antitumor agents
Antiviral agents

Cosmetics
Emulsifying agents
Fungicides
Insecticides
(topical water-in-oil emulsions containing non-polar oil and monoglycosylceramide for cosmetic or medical use)

IT Coconut oil
Corn oil
Fats and Glyceridic oils, biological studies
Hydrocarbon oils
Soybean oil
Sunflower oil
RL: COS (Cosmetic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(topical water-in-oil emulsions containing non-polar oil and monoglycosylceramide for cosmetic or medical use)

IT Amino acids, biological studies
Hormones, animal, biological studies
Lipids, biological studies
Mineral elements, biological studies
Peptides, biological studies
Proteins
Steroids, biological studies
Vitamins
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(topical water-in-oil emulsions containing non-polar oil and monoglycosylceramide for cosmetic or medical use)

IT 50-21-5, Lactic acid, biological studies 50-81-7, Ascorbic acid, biological studies 56-81-5, Glycerol, biological studies 57-13-6, Carbamide, biological studies 59-02-9, α-Tocopherol 64-17-5, Ethanol, biological studies 303-98-0, Coenzyme Q10 443-48-1, Metronidazole 85305-87-9, Glucosylceramide 85305-88-0, Galactosylceramide
RL: COS (Cosmetic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(topical water-in-oil emulsions containing non-polar oil and monoglycosylceramide for cosmetic or medical use)

IT 55-16-3, Scopolamine hydrochloride 58-56-0, Pyridoxine hydrochloride 93-60-7, Methyl nicotinate 5451-09-2, Aminolevulinic acid hydrochloride 16090-09-8, Lithium succinate 22839-47-0, Aspartame
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(topical water-in-oil emulsions containing non-polar oil and monoglycosylceramide for cosmetic or medical use)

IT 303-98-0, Coenzyme Q10
RL: COS (Cosmetic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(topical water-in-oil emulsions containing non-polar oil and monoglycosylceramide for cosmetic or medical use)

RN 303-98-0 ZCAPLUS

CN 2,5-Cyclohexadiene-1,4-dione, 2-[(2E,6E,10E,14E,18E,22E,26E,30E,34E)-3,7,11,15,19,23,27,31,35,39-decamethyl-2,6,10,14,18,22,26,30,34,38-tetracontadecaen-1-yl]-5,6-dimethoxy-3-methyl- (CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A



PAGE 1-B



PAGE 1-C

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L88 ANSWER 18 OF 41 ZCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2003:454875 ZCAPLUS Full-text
DOCUMENT NUMBER: 139:38559
TITLE: Coated particles, their manufacture and use
INVENTOR(S): Anderson, David M.
PATENT ASSIGNEE(S): Lyotropic Therapeutics, Inc., USA
SOURCE: U.S. Pat. Appl. Publ., 65 pp., Cont.-in-part of U.S. Ser. No. 297,997.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20030108743	A1	20030612	US 2002-170237	20020613 <--
US 6638621	B2	20031028		
US 6482517	B1	20021119	US 2000-297997	20000816 <--
US 20040201117	A1	20041014	US 2003-624498	20030723 <--
US 6989195	B2	20060124		
US 20060073333	A1	20060406	US 2004-11956	20041215 <--
US 7105229	B2	20060912		
PRIORITY APPLN. INFO.:			US 2000-297997	A2 20000816 <--
			US 1997-58309P	P 19970909 <--
			WO 1998-US18639	W 19980908 <--
			US 2002-170237	A1 20020613 <--

US 2003-624498 A1 20030723 <--

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

AB A particle coated with a nonlamellar material such as a nonlamellar crystalline material, a nonlamellar amorphous material, or a nonlamellar semi-crystalline material includes an internal matrix core having ≥1 a nanostructured liquid phase or its dehydrated variant, or ≥1 nanostructured liquid crystalline phase or its dehydrated variant, or a combination of the 2 is used for the delivery of active agents such as pharmaceuticals, nutrients, pesticides, etc. The coated particle can be fabricated by a variety of different techniques where the exterior coating is a nonlamellar material such as a nonlamellar crystalline material, a nonlamellar amorphous material, or a nonlamellar semi-crystalline material.

IC ICM B32B005-16

INCL 428402240

CC 48-3 (Unit Operations and Processes)
Section cross-reference(s): 5, 18, 41, 60, 63

IT Antihypertensives
Antitumor agents
Drugs
Dyes
Herbicides
Pesticides
Rodenticides
(microencapsulated; coated particles for delivery or uptake of materials)

IT Drug delivery systems
(topical; coated particles for delivery or uptake of materials)

IT 58-27-5, Menadione 303-98-0, Coenzyme Q10
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(coated particles for delivery or uptake of materials)

IT 303-98-0, Coenzyme Q10
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(coated particles for delivery or uptake of materials)

RN 303-98-0 ZCAPLUS

CN 2,5-Cyclohexadiene-1,4-dione, 2-[(2E,6E,10E,14E,18E,22E,26E,30E,34E)-3,7,11,15,19,23,27,31,35,39-decamethyl-2,6,10,14,18,22,26,30,34,38-tetracontadecaen-1-yl]-5,6-dimethoxy-3-methyl- (CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A



PAGE 1-B



OS.CITING REF COUNT: 7 THERE ARE 7 CAPLUS RECORDS THAT CITE THIS RECORD (7 CITINGS)

L88 ANSWER 19 OF 41 ZCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2003:435298 ZCAPLUS Full-text
DOCUMENT NUMBER: 139:26624
TITLE: Nutritional supplements containing antioxidants and flavonoids for prevention, reduction and treatment of radiation injury
INVENTOR(S): Rosenbloom, Richard A.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 14 pp., Cont.-in-part of U.S. Ser. No. 45,790.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 5
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20030105027	A1	20030605	US 2002-132642	20020425 <--
US 20030103953	A1	20030605	US 2001-993003	20011106 <--
US 6753325	B2	20040622		
US 20030103954	A1	20030605	US 2002-45790	20020114 <--
US 7435725	B2	20081014		
CA 2465945	A1	20030515	CA 2002-2465945	20020501 <--
WO 2003039452	A2	20030515	WO 2002-US13526	20020501 <--
WO 2003039452	A3	20041202		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002309615	A1	20030519	AU 2002-309615	20020501 <--
AU 2002309615	B2	20071018		
EP 1505984	A2	20050216	EP 2002-736624	20020501 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2005510509	T	20050421	JP 2003-541744	20020501 <--
CN 1630521	A	20050622	CN 2002-822057	20020501 <--
NZ 532774	A	20080829	NZ 2002-532774	20020501 <--
US 20030105031	A1	20030605	US 2002-279315	20021024 <--
CA 2465888	A1	20030626	CA 2002-2465888	20021106 <--
US 20030118536	A1	20030626	US 2002-288761	20021106 <--

WO 2003051287	A2	20030626	WO 2002-US35701	20021106	<--
WO 2003051287	A3	20050414			
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW					
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
AU 2002365155	A1	20030630	AU 2002-365155	20021106	<--
AU 2002365155	B2	20071018			
EP 1536801	A2	20050608	EP 2002-803307	20021106	<--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY, TR, BG, CZ, EE, SK					
CN 1635907	A	20050706	CN 2002-826541	20021106	<--
JP 2005528333	T	20050922	JP 2003-552220	20021106	<--
NZ 532775	A	20061027	NZ 2002-532775	20021106	<--
IN 2004DN01160	A	20060728	IN 2004-DN1160	20040430	<--
IN 2004DN01165	A	20060728	IN 2004-DN1165	20040430	<--
MX 2004004376	A	20040811	MX 2004-4376	20040506	<--
MX 2004004377	A	20040811	MX 2004-4377	20040506	<--
PRIORITY APPLN. INFO.:			US 2001-993003	A2 20011106	<--
			US 2002-45790	A2 20020114	<--
			US 2002-132642	A 20020425	<--
			WO 2002-US13526	W 20020501	<--
			WO 2002-US35701	W 20021106	<--

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

AB A nutritional supplement composition for the prevention, reduction or treatment of radiation injury due to exposure to ionizing radiation, including one or more compds. that regulates cell differentiation and/or cell proliferation, and one or more antioxidants, optionally formulated in a pharmaceutically acceptable carrier for an oral composition is described. The composition of the present invention may further include optional ingredients such as flavonoids, flavonoid derivs., selenium, selenium compds., anti-inflammatories, organic germanium, Korean ginseng, American ginseng, Siberian ginseng and B-complex vitamins. A method for the administration of an oral composition for the purpose of preventing, reducing or treating radiation injury involves orally administering an effective amount of a composition including one or more compds. that regulates cell differentiation and/or cell proliferation, and one or more antioxidants to a person before, during or after radiation exposure. A method for the topical administration of the composition in accordance with the present invention for the purpose of preventing, reducing or treating radiation injury involves topically administering an effective amount of the composition of the invention an area of skin, which has been or will be exposed to ionizing radiation. The compns. and methods can be employed to prevent, reduce or treat radiation injury caused by a wide variety of types of radiation exposure. For example, an oral composition, e.g. a tablet, contained vitamin A palmitate 10,000 IU, vitamin D 400 IU, β-carotene 15,000 IU, vitamin E 400 IU, α-lipoic acid 150 mg, quercetin 1200 mg, ascorbyl palmitate 500 mg, curcumin 15 mg, green tea extract 20 mg, chlorophyllin 200 mg, carboxyethyl sesquioxide of germanium 100 mg, and superoxide dismutase 1125 μg. This oral composition can be administered 1-5 times daily for the prevention, reduction or treatment of radiation injury prior to, during or after radiation exposure.

IC ICM A61K038-05
ICS A61K031-7048; A61K031-59; A61K031-375; A61K031-353; A61K035-78; A61K031-07; A61K031-355

INCL 514018000; 424094100; 424729000; 514168000; 514456000; 514440000; 514474000; 514027000; 514458000; 514725000
CC 63-6 (Pharmaceuticals)
Section cross-reference(s): 8, 18, 62
IT Anti-inflammatory agents
Antioxidants
Cell differentiation
Cell proliferation
Radioprotectants
(nutritional supplements containing antioxidants and regulators of cell differentiation and/or proliferation for prevention, reduction and treatment of radiation injury)
IT Drug delivery systems
(topical; compns. containing antioxidants and regulators of cell differentiation and/or differentiation for prevention, reduction and treatment of radiation injury)
IT 50-81-7, L-Ascorbic acid, biological studies 58-95-7, Vitamin E acetate 70-18-8, Glutathione, biological studies 87-44-5, Caryophyllene 90-18-6, Quercetagetin 90-19-7, Rhamnetin 117-39-5, Quercetin 120-72-9, Indole, biological studies 137-66-6, Ascorbyl palmitate 142-50-7, Nerolidol 152-95-4, Sophoricoside 153-18-4, Rutin 303-98-0, Coenzyme Q10 446-72-0, Genistein 458-37-7, Curcumin 474-07-7, Brazilin 476-66-4, Ellagic acid 480-10-4, Astragalin 480-16-0, Morin 480-36-4, Linarin 480-40-0, Chrysin 480-41-1, Naringenin 480-44-4, Acacetin 482-36-0, Hyperin 482-39-3, Kaempferol-3-rhamnoside 483-76-1, δ-Cadinene 490-83-5, Dehydroascorbic acid 491-50-9, Quercimeritrin 491-67-8, Baicalein 491-70-3, Luteolin 491-71-4, Chrysoeriol 506-26-3, γ-Linolenic acid 517-28-2, Haematoxylin 520-11-6, Nepetin 520-12-7, Pectolinarigenin 520-18-3, Kaempferol 520-26-3, Hesperidine 520-33-2, Hesperitin 520-34-3, Diosmetin 520-36-5, Apigenin 522-12-3, Quercitrin 528-48-3, Fisetin 528-58-5, Cyanidin 529-44-2, Myricetin 548-83-4, Galangin 549-17-7, Oxyayanin-a 549-32-6, Reynoutrin 569-90-4, Nepetrin 572-30-5, Avicularin 578-74-5, Cosmosiin 603-56-5, Chrysosplenol B 632-85-9, Wogonin 652-78-8 961-29-5, Isoliquiritigenin 1200-22-2, α-Lipoic acid 1340-08-5, Citrin 1406-18-4, Vitamin E 1617-49-8, 3,3',4-Tri-O-methylellagic acid 1617-53-4, Amentoflavone 3681-93-4, Vitexin 4172-43-4, L-Lyxonic acid 4172-44-5, L-Xylonic acid 5041-67-8, Juglanin 5041-81-6, Isoliquiritin 5188-73-8, Axillarin 5373-11-5, Luteolin-7-glucoside 6601-54-3 7306-96-9, L-Threonic acid 7306-96-9D, L-Threonic acid, salts 7440-56-4, Germanium, biological studies 7782-49-2, Selenium, biological studies 9054-89-1, Superoxide dismutase 10236-47-2, Naringin 11103-57-4, Vitamin A 12001-76-2, Vitamin B 12758-40-6, Carboxyethylgermanium sesquioxide 17306-46-6, Rhoifolin 17680-84-1, Hispiduloside 17912-87-7 18003-33-3, 6-Hydroxyluteolin 18490-95-4, Brevifolin carboxylic acid 19356-17-3, 25-Hydroxycholecalciferol 20229-56-5, Spiraeoside 21637-25-2, Isoquercitrin 22697-65-0, 6-Hydroxykaempferol-3,6-dimethyl ether 23615-30-7, Chrysosplenoside-a 23627-87-4, Trifolin 24512-68-3, Sorbarin 25321-00-0, Chrysosplenoside d 25694-72-8, Lonicerin 26544-34-3, Apiin 28978-02-1, Pectolinarin 29741-10-4, Luteolin 7-glucuronide 29913-71-1, Licuraside 32222-06-3, Calcitriol 32602-81-6, Kaempferol-3-neohesperidoside 53755-56-9, Linariin 60534-79-4 61276-17-3, Acteoside 61360-94-9, Flavosativaside 61891-39-2 64661-76-3 65666-07-1, Silymarin 67255-34-9, Iridine 70360-12-2, Sideritoflavone 79886-50-3 84632-09-7, 6,3',4'-Trihydroxy-5,7,8-trimethoxyflavone 94492-24-7 97560-11-7, Kolaviron 107646-82-2, Ethyl brevifolin carboxylate 120444-60-2, Jionoside a1 125712-75-6 132951-90-7, Macrocarpal-a

142628-53-3, Macrocarpal-g 142647-71-0, Macrocarpal d 142698-60-0, Macrocarpal-b 439217-49-9 524689-97-2 524727-65-9, Maniflavone 524729-83-7, Nelumboside 536737-05-0 537684-20-1, Dosmetin 537684-31-4, Ebinin
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(nutritional supplements containing antioxidants and regulators of cell differentiation and/or differentiation for prevention, reduction and treatment of radiation injury)

IT 303-98-0, Coenzyme Q10
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(nutritional supplements containing antioxidants and regulators of cell differentiation and/or differentiation for prevention, reduction and treatment of radiation injury)

RN 303-98-0 ZCAPLUS

CN 2,5-Cyclohexadiene-1,4-dione, 2-[(2E,6E,10E,14E,18E,22E,26E,30E,34E)-3,7,11,15,19,23,27,31,35,39-decamethyl-2,6,10,14,18,22,26,30,34,38-tetracontadecaen-1-yl]-5,6-dimethoxy-3-methyl- (CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A



PAGE 1-B



PAGE 1-C

OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)

L88 ANSWER 20 OF 41 ZCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2003:435063 ZCAPLUS Full-text
DOCUMENT NUMBER: 139:26623
TITLE: Oral compositions containing antioxidants and flavonoids for prevention, reduction and treatment of radiation injury
INVENTOR(S): Rosenbloom, Richard A.

PATENT ASSIGNEE(S): The Quigly Corporation, USA
SOURCE: U.S. Pat. Appl. Publ., 13 pp., Cont.-in-part of U.S. Ser. No. 993,003.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 5
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20030103954	A1	20030605	US 2002-45790	20020114 <--
US 7435725	B2	20081014		
US 20030103953	A1	20030605	US 2001-993003	20011106 <--
US 6753325	B2	20040622		
US 20030105027	A1	20030605	US 2002-132642	20020425 <--
CA 2465945	A1	20030515	CA 2002-2465945	20020501 <--
WO 2003039452	A2	20030515	WO 2002-US13526	20020501 <--
WO 2003039452	A3	20041202		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002309615	A1	20030519	AU 2002-309615	20020501 <--
AU 2002309615	B2	20071018		
EP 1505984	A2	20050216	EP 2002-736624	20020501 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2005510509	T	20050421	JP 2003-541744	20020501 <--
CN 1630521	A	20050622	CN 2002-822057	20020501 <--
NZ 532774	A	20080829	NZ 2002-532774	20020501 <--
US 20030105031	A1	20030605	US 2002-279315	20021024 <--
CA 2465888	A1	20030626	CA 2002-2465888	20021106 <--
US 20030118536	A1	20030626	US 2002-288761	20021106 <--
WO 2003051287	A2	20030626	WO 2002-US35701	20021106 <--
WO 2003051287	A3	20050414		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002365155	A1	20030630	AU 2002-365155	20021106 <--
AU 2002365155	B2	20071018		
EP 1536801	A2	20050608	EP 2002-803307	20021106 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY, TR, BG, CZ, EE, SK				
CN 1635907	A	20050706	CN 2002-826541	20021106 <--
JP 2005528333	T	20050922	JP 2003-552220	20021106 <--
NZ 532775	A	20061027	NZ 2002-532775	20021106 <--
IN 2004DN01160	A	20060728	IN 2004-DN1160	20040430 <--

IN 2004DN01165	A	20060728	IN 2004-DN1165	20040430	<--
ZA 2004003364	A	20061025	ZA 2004-3364	20040504	<--
MX 2004004376	A	20040811	MX 2004-4376	20040506	<--
MX 2004004377	A	20040811	MX 2004-4377	20040506	<--
ZA 2004003365	A	20060531	ZA 2004-3365	20060328	<--
PRIORITY APPLN. INFO.:			US 2001-993003	A2 20011106	<--
			US 2002-45790	A2 20020114	<--
			US 2002-132642	A 20020425	<--
			WO 2002-US13526	W 20020501	<--
			WO 2002-US35701	W 20021106	<--

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

AB An oral composition for the prevention, reduction or treatment of radiation injury including one or more compds. that regulates cell differentiation and/or cell proliferation, and one or more antioxidants, optionally formulated in a pharmaceutically acceptable carrier for an oral composition The composition of the present invention may further include optional ingredients such as flavonoids, flavonoid derivs., selenium, selenium compds., anti-inflammatories, organic germanium, Korean ginseng, American ginseng, Siberian ginseng and B-complex vitamins. A method for the administration of an oral composition for the purpose of preventing, reducing or treating radiation injury involves orally administering an effective amount of a composition including one or more compds. that regulates cell differentiation and/or cell proliferation, and one or more antioxidants to a person before, during or after radiation exposure. The compns. and methods can be employed to prevent, reduce or treat radiation injury caused by a wide variety of types of radiation exposure. For example, an oral composition, e.g., a tablet, contained vitamin A palmitate and D3 in corn oil dispersion 10,000 IU of vitamin A, β-carotene 15,000 IU, vitamin E 400 IU, α-lipoic acid 150 mg, quercetin 1200 mg, ascorbyl palmitate 500 mg, curcumin 15 mg, green tea extract 20 mg, chlorophyllin 200 mg, germanium carboxyethyl sesquioxide 100 mg, and superoxide dismutase 1125 μg. This oral composition can be administered 1-5 times daily for the prevention, reduction or treatment of radiation injury prior to, during or after radiation exposure.

IC ICM A61K038-43
ICS A61K038-05; A61K031-355; A61K035-78; A61K031-59

INCL 424094100; X51-4 1.8; X42-472.9; X51-416.8; X51-445.6; X51-447.4; X51-445.8; X51-472.5; X51-441.0; X51-444.0

CC 63-6 (Pharmaceuticals)
Section cross-reference(s): 8, 62

ST antioxidant flavonoid germanium selenium ginseng oral radioprotection; cell differentiation proliferation regulation oral topical radiotherapy

IT Anti-inflammatory agents
Antioxidants
Cell differentiation
Cell proliferation
Radioprotectants
Radiotherapy
(oral compns. containing antioxidant, and regulator of cell differentiation and/or proliferation for prevention, reduction and treatment of radiation injury)

IT Drug delivery systems
(topical; compns. containing antioxidant, and regulator of cell differentiation and/or proliferation for prevention, reduction and treatment of radiation injury)

IT 50-81-7, L-Ascorbic acid, biological studies 50-81-7D, L-Ascorbic acid, glucosamine complexes 58-95-7, Vitamin E acetate 59-02-9, α-Tocopherol 67-97-0, Vitamin D3 70-18-8, Glutathione, biological studies 79-81-2, Vitamin A palmitate 87-44-5, Caryophyllene 90-18-6, Quercetagetin 90-19-7, Rhamnetin 117-39-5, Quercetin

120-72-9, Indole, biological studies 137-66-6, Ascorbyl palmitate 142-50-7, Nerolidol 152-95-4, Sophoricoside 153-18-4, Rutin 303-98-0, Coenzyme Q10 446-72-0, Genistein 458-37-7, Curcumin 474-07-7, Brazilin 476-66-4, Ellagic acid 480-10-4, Astragalin 480-16-0, Morin 480-36-4, Linarin 480-40-0, Chrysin 480-41-1, Naringenin 480-44-4, Acacetin 482-36-0, Hyperin 482-39-3, Kaempferol-3-rhamnoside 483-76-1, δ-Cadinene 491-50-9, Quercimeritrin 491-67-8, Baicalein 491-70-3, Luteolin 491-71-4, Chrysoeriol 506-26-3, γ-Linolenic acid 517-28-2, Haematoxylin 520-11-6, Nepetin 520-12-7, Pectolinarigenin 520-18-3, Kaempferol 520-26-3, Hesperidine 520-33-2, Hesperitin 520-34-3, Diosmetin 520-36-5, Apigenin 522-12-3, Quercitrin 528-48-3, Fisetin 528-58-5, Cyanidin 529-44-2, Myricetin 529-53-3, Scutellarein 548-83-4, Galangin 549-17-7, Oxyayanin-a 549-32-6, Reynoutrin 569-90-4, Nepetrin 572-30-5, Avicularin 578-74-5, Cosmosiin 603-56-5, Chrysosplenol b 632-85-9, Wogonin 652-78-8 961-29-5, Isoliquiritigenin 1200-22-2, α-Lipoic acid 1340-08-5, Citrin 1406-18-4, Vitamin E 1617-49-8, 3,3',4-Tri-o-methylellagic acid 1617-53-4, Amentoflavone 3416-24-8D, Glucosamine, ascorbic acid complexes 3681-93-4, Vitexin 5041-67-8, Juglanin 5041-81-6, Isoliquiritin 5188-73-8, Axillarin 5373-11-5, Luteolin-7-glucoside 6601-54-3, Diacetyl cirsmaritin 7235-40-7, β-Carotene 7782-49-2, Selenium, biological studies 9054-89-1, Superoxide dismutase 10236-47-2, Naringin 11103-57-4, Vitamin A 12001-76-2, Vitamin B 12758-40-6, Carboxyethylgermanium sesquioxide 17306-46-6, Rhoifolin 17680-84-1, Hispiduloside 17912-87-7 18003-33-3, 6-Hydroxyluteolin 18490-95-4, Brevifolin carboxylic acid 20229-56-5, Spiraeoside 21637-25-2, Isoquercitrin 22697-65-0, 6-Hydroxykaempferol-3,6-dimethyl ether 23615-30-7, Chrysosplenoside a 23627-87-4, Trifolin 24512-68-3, Sorbarin 25321-00-0, Chrysosplenoside d 25694-72-8, Lonicerin 26544-34-3, Apiin 28978-02-1, Pectolinarin 29741-10-4, Luteolin-7-glucuronide 29913-71-1, Licuraside 32222-06-3, 1,25-Dihydroxyvitamin D3 32602-81-6, Kaempferol-3-neohesperidoside 53755-56-9, Linariin 60534-79-4, 3-Acetylquercetin 7,3',4'-trisulfate 61276-17-3, Acteoside 61360-94-9, Flavosativaside 61891-39-2 64661-76-3, Flavocannabiside 65666-07-1, Silymarin 67255-34-9, Iridine 70360-12-2, Sideritoflavone 79886-50-3 84632-09-7, 6,3',4'-Trihydroxy-5,7,8-trimethoxyflavone 94492-24-7, 2'-Acetylacteoside 97560-11-7, Kolaviron 107646-82-2, Ethyl brevifolin carboxylate 120444-60-2, Jionoside a1 125712-75-6 132951-90-7, Macrocarpal-a 142628-53-3, Macrocarpal-g 142647-71-0, Macrocarpal d 142698-60-0, Macrocarpal-b 439217-49-9 524689-97-2 524727-65-9, Maniflavone 524729-83-7, Nelumboside 536737-05-0 537684-20-1, Dosmetin 537684-31-4, Ebinin

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(oral compns. containing antioxidant, and regulator of cell differentiation and/or proliferation for prevention, reduction and treatment of radiation injury)

IT 303-98-0, Coenzyme Q10

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(oral compns. containing antioxidant, and regulator of cell differentiation and/or proliferation for prevention, reduction and treatment of radiation injury)

RN 303-98-0 ZCAPLUS

CN 2,5-Cyclohexadiene-1,4-dione, 2-[(2E,6E,10E,14E,18E,22E,26E,30E,34E)-3,7,11,15,19,23,27,31,35,39-decamethyl-2,6,10,14,18,22,26,30,34,38-tetracontadecaen-1-yl]-5,6-dimethoxy-3-methyl- (CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A



PAGE 1-B



PAGE 1-C

OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)
REFERENCE COUNT: 202 THERE ARE 202 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L88 ANSWER 21 OF 41 ZCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2003:488554 ZCAPLUS Full-text
DOCUMENT NUMBER: 139:30864
TITLE: Coenzyme Q10 for the treatment of ocular diseases
INVENTOR(S): Brancato, Rosario; Lenaz, Giorgio; Capaccioli, Sergio; Schiavone, Nicola
PATENT ASSIGNEE(S): Simonelli, Giuseppe, Italy
SOURCE: Eur. Pat. Appl., 31 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1321138	A1	20030625	EP 2002-425777	20021217 <--
EP 1321138	B1	20060412		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
IT 2001RM0755	A1	20030620	IT 2001-RM755	20011220 <--
AT 322895	T	20060415	AT 2002-425777	20021217 <--
ES 2262777	T3	20061201	ES 2002-425777	20021217 <--

US 20030118576 A1 20030626 US 2002-323820 20021220 <--
US 7029672 B2 20060418
PRIORITY APPLN. INFO.: IT 2001-RM755 A 20011220 <--
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
AB The invention relates to the use of Coenzyme Q10 or functionally equivalent derivs. thereof, through topical or systemic administration, for the prevention, the treatment and/or attenuation of degenerative ocular pathologies, when said pathologies being of an heredofamilial, inflammatory, dysmetabolic, senile age-related nature, the degenerative process deriving from apoptotic events caused by hypoxia or other detrimental stimuli due to ischemia or to the lack of trophic factors.
IC ICM A61K031-122
ICS A61P027-02
CC 1-12 (Pharmacology)
Section cross-reference(s): 7, 14, 63
ST Coenzyme Q10 cytoprotectant topical systemic aging ocular neurodegenerative disease; heredofamilial inflammatory dysmetabolic senile ocular disease Coenzyme Q10 cytoprotectant; glaucoma topical CoenzymeQ10 hypoxia ischemia ocular neurodegenerative disease model
IT Eye, neoplasm
(retinoblastoma; treatment of ocular diseases with Coenzyme Q10)
IT Drug delivery systems
(solns., topical; treatment of ocular diseases with Coenzyme Q10)
IT 303-98-0, Coenzyme Q10 303-98-0D, Coenzyme Q10, deriv
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(treatment of ocular diseases with Coenzyme Q10)
IT 303-98-0, Coenzyme Q10 303-98-0D, Coenzyme Q10, deriv
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(treatment of ocular diseases with Coenzyme Q10)
RN 303-98-0 ZCAPLUS
CN 2,5-Cyclohexadiene-1,4-dione, 2-[(2E,6E,10E,14E,18E,22E,26E,30E,34E)-3,7,11,15,19,23,27,31,35,39-decamethyl-2,6,10,14,18,22,26,30,34,38-tetracontadecaen-1-yl]-5,6-dimethoxy-3-methyl- (CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A



PAGE 1-B



PAGE 1-C

RN 303-98-0 ZCAPLUS
CN 2,5-Cyclohexadiene-1,4-dione, 2-[(2E,6E,10E,14E,18E,22E,26E,30E,34E)-3,7,11,15,19,23,27,31,35,39-decamethyl-2,6,10,14,18,22,26,30,34,38-tetracontadecaen-1-yl]-5,6-dimethoxy-3-methyl- (CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A



PAGE 1-B



PAGE 1-C

OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)
REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L88 ANSWER 22 OF 41 ZCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2002:832565 ZCAPLUS Full-text
DOCUMENT NUMBER: 137:329452
TITLE: Compositions with a non-glucocorticoid steroid and/or a ubiquinone and kit for treatment of respiratory and lung disease

INVENTOR(S): Nyce, Jonathan W.
PATENT ASSIGNEE(S): Epigenesis Pharmaceuticals, Inc., USA
SOURCE: PCT Int. Appl., 51 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002085297	A2	20021031	WO 2002-US12555	20020422 <--
WO 2002085297	A3	20030403		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002303427	A1	20021105	AU 2002-303427	20020422 <--
US 20040082522	A1	20040429	US 2003-454061	20030603 <--
US 7456161	B2	20081125		
US 20080292709	A1	20081127	US 2008-172033	20080711 <--

PRIORITY APPLN. INFO.:
US 2001-286124P P 20010424 <--
WO 2002-US12555 W 20020422 <--
US 2003-454061 A3 20030603 <--

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OTHER SOURCE(S): MARPAT 137:329452

AB A pharmaceutical or veterinary composition comprises as the active agent (i) a non-glucocorticoid steroid or its analog, and (ii) a ubiquinone or their salts, in an amount effective for reducing levels of, or hypersensitivity to, adenosine, increasing levels of lung surfactant or ubiquinone, or for preventing or treating respiratory, lung and cancer diseases. The present treatment is useful for treating asthma, rhinitis, COPD, CF, RDS, pulmonary fibrosis, cancer and other diseases. For example, a metered dose inhaler contained ubiquinone 200 mg, dehydroepiandrosterone (DHEA) 200 mg, a stabilizer 5.0 μg, trichlorofluoromethane 23.70 mg, and dichlorodifluoromethane 61.25 mg.

IC ICM A61K
CC 63-6 (Pharmaceuticals)
Section cross-reference(s): 1, 2
ST steroid ubiquinone oral parenteral topical respiratory disease
IT Allergy
Antitumor agents
Asthma
Cell cycle
Cell proliferation
Cystic fibrosis
Freeze drying
Iontophoresis
Lung, disease
Neoplasm
Respiratory distress syndrome
Respiratory system, disease
(compns. with non-glucocorticoid steroid and/or ubiquinone and kits for treatment of respiratory diseases)

IT Drug delivery systems
(topical; compns. with non-glucocorticoid steroid and/or ubiquinone and kits for treatment of respiratory diseases)

IT 53-42-9, Etiocholanolone 53-43-0, Dehydroepiandrosterone 58-18-4, Methyltestosterone 303-98-0, CoQ 10 481-29-8, Epiandrosterone 651-48-9, Dehydroepiandrosterone sulfate 28507-02-0, 16α-Bromo-epiandrosterone 80724-82-9, 16α-Fluoro-epiandrosterone
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(compns. with non-glucocorticoid steroid and/or ubiquinone and kits for treatment of respiratory diseases)

IT 303-98-0, CoQ 10
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(compns. with non-glucocorticoid steroid and/or ubiquinone and kits for treatment of respiratory diseases)

RN 303-98-0 ZCAPLUS

CN 2,5-Cyclohexadiene-1,4-dione, 2-[(2E,6E,10E,14E,18E,22E,26E,30E,34E)-3,7,11,15,19,23,27,31,35,39-decamethyl-2,6,10,14,18,22,26,30,34,38-tetracontadecaen-1-yl]-5,6-dimethoxy-3-methyl- (CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A



PAGE 1-B



PAGE 1-C

OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L88 ANSWER 23 OF 41 ZCAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2002:315492 ZCAPLUS Full-text
DOCUMENT NUMBER: 136:330579
TITLE: Homeopathic preparations containing proteins
INVENTOR(S): Brewitt, Barbara A.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 10 pp., Cont.-in-part of U. S. Ser. No. 870,132.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 6
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20020049422	A1	20020425	US 2001-1367	20011030 <--
US 5629286	A	19970513	US 1996-710040	19960910 <--
US 6239105	B1	20010529	US 1999-251820	19990217 <--
US 20020071873	A1	20020613	US 2001-870132	20010529 <--
US 20030191061	A1	20031009	US 2002-304635	20021126 <--
US 20060088575	A1	20060427	US 2005-242988	20051004 <--
PRIORITY APPLN. INFO.:			US 1994-221365	B2 19940331 <--
			US 1995-488722	B1 19950608 <--
			US 1996-710040	A2 19960910 <--
			US 1997-855096	A2 19970513 <--
			US 1999-251820	A1 19990217 <--
			US 2000-255958P	P 20001215 <--
			US 2001-870132	A2 20010529 <--
			US 2000-499230	A2 20000207 <--
			US 2001-1367	A2 20011030 <--

AB The present invention comprises homeopathic prepns. of a purified protein, as well as methods and systems for delivery of such prepns. and treatment of disorders and conditions by administering such prepns. A homeopathic recombinant growth hormone (HrhGH) was formulated in a cosmetic eye gel formulation. Topical application of HrhGH decreased wrinkles and increased attractiveness of eyes.

IC ICM A61K038-00
ICS A61K038-43; A61K031-685; A61K035-78
INCL 604500000
CC 63-6 (Pharmaceuticals)
Section cross-reference(s): 2, 3
IT Drug delivery systems
(gels, topical; homeopathic prepns. containing proteins)
IT Amino acids, biological studies
Ciliary neurotrophic factor
Epidermal growth factor receptors
Hepatocyte growth factor
Interleukin 1
Interleukin 2
Minerals, biological studies
Neuregulin 1
Neuregulin 1
Phosphatidylserines
Platelet-derived growth factors
Proteins
Stem cell factor
Tumor necrosis factors
Vitamins
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(homeopathic prepns. containing proteins)

IT Drug delivery systems
(topical; homeopathic prepns. containing proteins)
IT 79-14-1, Glycolic acid, biological studies 302-79-4, Retinoic acid 303-98-0, CoQ10 541-15-1, Carnitine 1406-18-4, Vitamin E 6217-54-5, DHA 9061-61-4, NGF 12001-79-5, Vitamin K 61811-29-8, Apurinic endonuclease 61912-98-9, IGF 67763-96-6, IGF-1 81627-83-0, M-CSF 83869-56-1, GM-CSF 106096-92-8, FGF 1 106096-93-9, FGF 2 110098-88-9, Bombyxin 143011-72-7, G-CSF 148348-15-6, Fibroblast growth factor 7 161384-17-4, MT-MMP1 192230-91-4, Stress-activated protein kinase kinase-1
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(homeopathic prepns. containing proteins)
IT 303-98-0, CoQ10
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(homeopathic prepns. containing proteins)
RN 303-98-0 ZCAPLUS
CN 2,5-Cyclohexadiene-1,4-dione, 2-[(2E,6E,10E,14E,18E,22E,26E,30E,34E)-3,7,11,15,19,23,27,31,35,39-decamethyl-2,6,10,14,18,22,26,30,34,38-tetracontadecaen-1-yl]-5,6-dimethoxy-3-methyl- (CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A



PAGE 1-B



PAGE 1-C

OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)

L88 ANSWER 24 OF 41 ZCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2002:185691 ZCAPLUS Full-text
DOCUMENT NUMBER: 136:236872
TITLE: Epiandrosterones or ubiquinones for treatment of asthma and reduction of adenosine/adenosine receptor

levels
INVENTOR(S): Nyce, Jonathan W.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 10 pp., Cont.-in-part of U.S. Ser. No. 488,236.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20020032160	A1	20020314	US 2001-841426	20010424 <--
US 5660835	A	19970826	US 1995-393863	19950224 <--
EP 1555025	A2	20050720	EP 2005-4694	19960215 <--
EP 1555025	A3	20050803		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE				
US 6087351	A	20000711	US 1997-861962	19970522 <--
AU 9911317	A	19990304	AU 1999-11317	19990114 <--
AU 730453	B2	20010308		
US 6670349	B1	20031230	US 2000-488236	20000120 <--
US 20020119936	A1	20020829	US 2001-72010	20011025 <--
WO 2002085373	A1	20021031	WO 2002-US12489	20020422 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002254682	A1	20021105	AU 2002-254682	20020422 <--
JP 2005306880	A	20051104	JP 2005-162494	20050602 <--
US 20060111306	A1	20060525	US 2005-275327	20051222 <--
US 20090053143	A1	20090226	US 2008-196223	20080821 <--
US 20090054385	A1	20090226	US 2008-196233	20080821 <--

PRIORITY APPLN. INFO.:

US 1995-393863	A3	19950224 <--
US 1997-861962	A1	19970522 <--
US 2000-488236	A2	20000120 <--
AU 1996-48677	A3	19960215 <--
EP 1996-904622	A3	19960215 <--
JP 1996-525728	A3	19960215 <--
US 2001-841426	A3	20010424 <--
US 2001-72010	B1	20011025 <--
WO 2002-US12489	W	20020422 <--

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OTHER SOURCE(S): MARPAT 136:236872

AB A composition and various formulations comprise preventative or therapeutic amts. of an epiandrosterone, analog thereof or salt thereof, and/or a ubiquinone or salt thereof, and a pharmaceutically or veterinarily acceptable carrier or diluent. The composition and formulations are useful for treating bronchoconstriction, respiratory tract inflammation and allergies, asthma, and cancer. A method of treating diseases associated with low adenosine levels or adenosine depletion comprises administering folinic acid or a pharmaceutically acceptable salt hereof in a preventative or therapeutic amount, or an amount effective to treat adenosine depletion. For example, rats administered DHEA or methyltestosterone daily for two weeks showed multi-organ depletion of adenosine. Depletion was dramatic in brain (60% depletion for DHEA, 34% for

high dose methyltestosterone) and heart (37% depletion for DHEA, 22% depletion for high dose methyltestosterone). Coadministration of folinic acid completely abrogated steroid-mediated adenosine depletion. Folinic acid administered alone induce increase in adenosine levels for all organs studied. Also, both DHEA and ubiquinones inhibited NADPH levels in vitro by inhibiting the activity of glucose-6-phosphate dehydrogenase, an enzyme involved in the conversion of NADP to NADPH.

IC ICM A61K031-704
ICS A61K031-66; A61K031-56
INCL 514026000
CC 63-6 (Pharmaceuticals)
Section cross-reference(s): 1, 2
ST epiandrosterone ubiquinone folinic acid oral topical parenteral; adenosine receptor epiandrosterone ubiquinone antiasthmatic
IT Lung, neoplasm
(inhibitors; compns. containing epiandrosterones or ubiquinones for treatment of asthma and reduction of adenosine/adenosine receptor levels)
IT Analgesics
Anti-inflammatory agents
Antitumor agents
(lung; compns. containing epiandrosterones or ubiquinones for treatment of asthma and reduction of adenosine/adenosine receptor levels)
IT Drug delivery systems
(topical; compns. containing epiandrosterones or ubiquinones for treatment of asthma and reduction of adenosine/adenosine receptor levels)
IT 53-42-9, Etiocholanolone 53-43-0, Dehydroepiandrosterone 303-95-7, Ubiquinone 7 303-97-9, Ubiquinone 9 303-98-0, Ubiquinone 10 481-29-8D, Epiandrosterone, analogs and derivs. 606-06-4, Ubiquinone 2 651-48-9, Dehydroepiandrosterone sulfate 727-81-1, Ubiquinone 1 1065-31-2, Ubiquinone 6 1173-76-8, Ubiquinone 3 2394-68-5, Ubiquinone 8 4370-61-0, Ubiquinone 5 4370-62-1, Ubiquinone 4 28507-02-0, 16α-Bromoepiandrosterone 80724-81-8 80724-82-9, 16α-Fluoroepiandrosterone
RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(compns. containing epiandrosterones or ubiquinones for treatment of asthma and reduction of adenosine/adenosine receptor levels)
IT 303-98-0, Ubiquinone 10
RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(compns. containing epiandrosterones or ubiquinones for treatment of asthma and reduction of adenosine/adenosine receptor levels)
RN 303-98-0 ZCAPLUS
CN 2,5-Cyclohexadiene-1,4-dione, 2-[(2E,6E,10E,14E,18E,22E,26E,30E,34E)-3,7,11,15,19,23,27,31,35,39-decamethyl-2,6,10,14,18,22,26,30,34,38-tetracontadecaen-1-yl]-5,6-dimethoxy-3-methyl- (CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A



PAGE 1-B



PAGE 1-C

L88 ANSWER 25 OF 41 ZCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2002:944466 ZCAPLUS Full-text
DOCUMENT NUMBER: 138:16617
TITLE: Tocopherol derivatives for stabilizing nano-sized emulsion particles containing lecithin and their topical application to the skin
INVENTOR(S): Yoo, Byung Hee; Kim, Joong Soo; Kang, Young Byung; Kim, Joong Kil; Han, Hoon Sang
PATENT ASSIGNEE(S): Pacific Corporation, S. Korea
SOURCE: Eur. Pat. Appl., 21 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1264595	A1	20021211	EP 2002-8705	20020418 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
KR 2002092622	A	20021212	KR 2001-31360	20010605 <--
US 20030078238	A1	20030424	US 2002-120389	20020412 <--
US 6780430	B2	20040824		
JP 2003026604	A	20030129	JP 2002-121331	20020423 <--
JP 4237446	B2	20090311		

PRIORITY APPLN. INFO.: KR 2001-31360 A 20010605 <--
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OTHER SOURCE(S): MARPAT 138:16617
AB A stabilization method of nano-sized emulsion by using lecithin and tocopheryl derivs. and an topical application for skin containing the stabilized nano-sized emulsions are disclosed. 3-Aminopropyl-α-tocopherol phosphate (I) was prepared by the reaction of POCl3 with α-tocopherol in THF followed by the addition of 3-amino-1-propanol in the presence of Et3N to the resulting tocopherol dichlorophosphate. HCl treatment gave I. Nano-sized emulsion particles were prepared with varying amts. of lecithin and the tocopheryl derivative

IC ICM A61K009-107
CC 63-6 (Pharmaceuticals)
Section cross-reference(s): 30
ST tocopherol phosphate stabilization emulsion lecithin prepn; topical skin lecithin tocopherol phosphate prepn
IT Drug delivery systems
(emulsions; tocopherol derivs. for stabilizing nano-sized emulsion particles containing lecithin for topical application to skin)
IT Edema
(inhibitors; tocopherol derivs. for stabilizing nano-sized emulsion particles containing lecithin for topical application to skin)
IT Allergy inhibitors
Analgesics
Anti-inflammatory agents
Antiarrhythmics
Antibiotics
Anticonvulsants
Antihypertensives
Antioxidants
Antipyretics
Antitumor agents
Antitussives
Antiulcer agents
Cardiotonics
Expectorants
Hemostatics
Muscle relaxants
Skin
Stability
Vasodilators
(tocopherol derivs. for stabilizing nano-sized emulsion particles containing lecithin for topical application to skin)
IT Enzymes, biological studies
Hormones, animal, biological studies
Lecithins
Peptides, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(tocopherol derivs. for stabilizing nano-sized emulsion particles containing lecithin for topical application to skin)
IT Drug delivery systems
(topical; tocopherol derivs. for stabilizing nano-sized emulsion particles containing lecithin for topical application to skin)
IT 59-02-9, α-Tocopherol 156-87-6, 3-Amino-1-propanol
RL: RCT (Reactant); RACT (Reactant or reagent)
(tocopherol derivs. for stabilizing nano-sized emulsion particles containing lecithin for topical application to skin)
IT 61893-39-8P 429682-32-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(tocopherol derivs. for stabilizing nano-sized emulsion particles containing lecithin for topical application to skin)
IT 429682-33-7P
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(tocopherol derivs. for stabilizing nano-sized emulsion particles containing lecithin for topical application to skin)
IT 68-26-8, Retinol 303-98-0, Coenzyme Q10 501-36-0, Resveratrol
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(tocopherol derivs. for stabilizing nano-sized emulsion particles containing lecithin for topical application to skin)

IT 303-98-0, Coenzyme Q10
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(tocopherol derivs. for stabilizing nano-sized emulsion particles containing lecithin for topical application to skin)

RN 303-98-0 ZCAPLUS

CN 2,5-Cyclohexadiene-1,4-dione, 2-[(2E,6E,10E,14E,18E,22E,26E,30E,34E)-3,7,11,15,19,23,27,31,35,39-decamethyl-2,6,10,14,18,22,26,30,34,38-tetracontadecaen-1-yl]-5,6-dimethoxy-3-methyl- (CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A



PAGE 1-B



PAGE 1-C

OS.CITING REF COUNT: 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (4 CITINGS)
REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L88 ANSWER 26 OF 41 ZCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2002:961423 ZCAPLUS Full-text
DOCUMENT NUMBER: 138:16475
TITLE: Use of ascorbic acid and bioquinones for the production of angiogenetically active topical preparations
INVENTOR(S): Sauermann, Kirsten; Schimpf, Ralph; Filbry, Alexander; Wepf, Roger; Schreiner, Volker; Jaspers, Soeren; Schoenrock, Uwe; Ennen, Joachim; Sauermann, Gerhard
PATENT ASSIGNEE(S): Beiersdorf AG, Germany
SOURCE: Ger. Offen., 8 pp.
CODEN: GWXXBX

DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 10128818	A1	20021219	DE 2001-10128818	20010615 <--
PRIORITY APPLN. INFO.:			DE 2001-10128818	20010615 <--

AB The invention concerns angiogenetically active cosmetic and dermatol. prepns. that contain ascorbic acid and bioquinones. Thus a W/O lotion contained (weight/weight%): paraffin oil 20.00; petrolatum 4.00; glucose sesquiisostearate 2.00; aluminum stearate 0.40, ascorbic acid 1.50; Coenzyme Q10 0.10; Vitamin E acetate 2.00; Vitamin C palmitate 0.20; glycerin 5.00; water, preservative, perfume to 100.

IC ICM A61K007-00
ICS C07D307-33

CC 62-4 (Essential Oils and Cosmetics)
Section cross-reference(s): 63

ST ascorbate bioquinone Coenzyme Q10 cream skin aging angiogenetic activity

IT Skin, disease
(aging; use of ascorbic acid and bioquinones for production of angiogenetically active topical prepns.)

IT Quinones
RL: COS (Cosmetic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(bioquinones; use of ascorbic acid and bioquinones for production of angiogenetically active topical prepns.)

IT Cosmetics
(creams; use of ascorbic acid and bioquinones for production of angiogenetically active topical prepns.)

IT Cosmetics
(gels; use of ascorbic acid and bioquinones for production of angiogenetically active topical prepns.)

IT Cosmetics
(lotions; use of ascorbic acid and bioquinones for production of angiogenetically active topical prepns.)

IT Drug delivery systems
(topical; use of ascorbic acid and bioquinones for production of angiogenetically active topical prepns.)

IT 50-81-7, L-Ascorbic acid, biological studies 303-98-0, Coenzyme Q10
RL: COS (Cosmetic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(use of ascorbic acid and bioquinones for production of angiogenetically active topical prepns.)

IT 303-98-0, Coenzyme Q10
RL: COS (Cosmetic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(use of ascorbic acid and bioquinones for production of angiogenetically active topical prepns.)

RN 303-98-0 ZCAPLUS

CN 2,5-Cyclohexadiene-1,4-dione, 2-[(2E,6E,10E,14E,18E,22E,26E,30E,34E)-3,7,11,15,19,23,27,31,35,39-decamethyl-2,6,10,14,18,22,26,30,34,38-tetracontadecaen-1-yl]-5,6-dimethoxy-3-methyl- (CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A



PAGE 1-B



PAGE 1-C

REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L88 ANSWER 27 OF 41 ZCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2001:396644 ZCAPLUS Full-text
DOCUMENT NUMBER: 135:24671
TITLE: Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
INVENTOR(S): Patel, Manesh V.; Chen, Feng-jing
PATENT ASSIGNEE(S): Lipocine, Inc., USA
SOURCE: PCT Int. Appl., 107 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 13
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001037808	A1	20010531	WO 2000-US32255	20001122 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6248363	B1	20010619	US 1999-447690	19991123 <--

CA 2391923 A1 20010531 CA 2000-2391923 20001122 <--
EP 1233756 A1 20020828 EP 2000-980761 20001122 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
JP 2003517470 T 20030527 JP 2001-539423 20001122 <--
PRIORITY APPLN. INFO.: US 1999-447690 A 19991123 <--
WO 2000-US32255 W 20001122 <--
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

AB The present invention provides solid pharmaceutical compns. for improved delivery of a wide variety of pharmaceutical active ingredients contained therein or sep. administered. In one embodiment, the solid pharmaceutical composition includes a solid carrier, the solid carrier including a substrate and an encapsulation coat on the substrate. The encapsulation coat can include different combinations of pharmaceutical active ingredients, hydrophilic surfactant, lipophilic surfactants and triglycerides. In another embodiment, the solid pharmaceutical composition includes a solid carrier, the solid carrier being formed of different combinations of pharmaceutical active ingredients, hydrophilic surfactants, lipophilic surfactants and triglycerides. The compns. of the present invention can be used for improved delivery of hydrophilic or hydrophobic pharmaceutical active ingredients, such as drugs, nutritionals, cosmeceuticals and diagnostic agents. A composition contained glyburide 1, PEG 40 stearate 33, glycerol monolaurate 17, and nonpareil seed 80 g.

IC ICM A61K009-14
ICS A61K009-16; A61K009-20; A61K009-46; A61K009-48; A61K009-50; A61K009-54
CC 63-6 (Pharmaceuticals)
IT Analgesics
Anti-inflammatory agents
Anticoagulants
Anticonvulsants
Antidepressants
Antidiabetic agents
Antihistamines
Antihypertensives
Antimalarials
Antipsychotics
Antitumor agents
Anxiolytics
Fungicides
Hypnotics and Sedatives
Immunosuppressants
Muscarinic antagonists
Muscle relaxants
Plasticizers
Protozoacides
Sweetening agents
Tranquilizers
Vaccines
(solid carriers for improved delivery of active ingredients in pharmaceutical compns.)
IT Drug delivery systems
(topical; solid carriers for improved delivery of active ingredients in pharmaceutical compns.)
IT Fusion proteins (chimeric proteins)
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(tumor necrosis factor receptor:Fc region; solid carriers for improved delivery of active ingredients in pharmaceutical compns.)
IT 50-14-6, Ergocalciferol 50-24-8, Prednisolone 50-28-2, Estradiol, biological studies 50-34-0, Propantheline bromide 50-56-6, Oxytocin,

biological studies 51-15-0, Pralidoxime chloride 51-43-4, Epinephrine 51-48-9, L-Thyroxine, biological studies 51-55-8, Atropine, biological studies 51-60-5, Neostigminemethyl sulfate 52-01-7, Spironolactone 52-24-4, Thiotepa 53-43-0, Dehydroepiandrosterone 55-98-1, Busulphan 57-13-6, Urea, biological studies 57-22-7, Vincristine 57-64-7, Physostigmine salicylate 57-83-0, Progesterone, biological studies 57-94-3, Tubocurarine chloride 59-05-2, Methotrexate 60-31-1, Acetylcholine chloride 62-31-7, Dopamine hydrochloride 63-91-2, L-Phenylalanine, biological studies 65-28-1, Phentolamine mesylate 66-76-2, Dicoumarol 67-20-9, Nitrofurantoin 67-45-8, Furazolidone 67-96-9, Dihydrotachysterol 67-97-0, Cholecalciferol 68-19-9, Vitamin b12 69-65-8, D-Mannitol 70-51-9, Deferoxamine 71-27-2, Suxamethonium chloride 74-89-5, Methanamine, biological studies 76-57-3, Codeine 76-90-4, Mepenzolate bromide 76-99-3, Methadone 77-19-0, Dicyclomine 87-33-2, Isosorbide dinitrate 89-57-6, Mesalamine 90-82-4, Pseudoephedrine 101-26-8, Pyridostigmine bromide 104-31-4, Benzonatate 113-15-5, Ergotamine 113-92-8, Chlorpheniramine 114-07-8, Erythromycin 114-80-7, Neostigmine bromide 125-84-8, Aminoglutethimide 126-07-8, Griseofulvin 127-40-2, Lutein 129-06-6, Warfarin sodium 131-49-7, Diatrizoate meglumine 140-64-7, Pentamidine isethionate 147-94-4, Cytarabine 154-21-2, Lincomycin 155-97-5, Pyridostigmine 298-46-4, Carbamazepine 298-57-7, Cinnarizine 298-81-7, Methoxsalen 299-42-3, Ephedrine 300-62-9, Amphetamine 302-79-4, Tretinoin 303-49-1, Clomipramine 303-53-7, Cyclobenzaprine 303-98-0, Coenzyme Q10 321-64-2, Tacrine 359-83-1, Pentazocine 378-44-9, Betamethasone 404-86-4, Capsaicin 437-38-7, Fentanyl 443-48-1, Metronidazole 502-65-8, Lycopene 511-12-6, Dihydroergotamine 520-85-4, Medroxyprogesteron 577-11-7, Sodium docusate 595-33-5 596-51-0, Glycopyrrolate 616-91-1, Acetylcysteine 665-66-7, Amantadine hydrochloride 737-31-5, Diatrizoate sodium 865-21-4, Vinblastine 911-45-5, Clomiphene 1115-70-4, Metformin hydrochloride 1134-47-0, Baclofen 1264-72-8, Colistin sulfate 1319-82-0, Aminocaproic acid 1397-89-3, Amphotericin b 1403-66-3, Gentamycin 1404-90-6, Vancomycin 1405-20-5, Polymyxin B sulfate 1405-37-4, Capreomycin sulfate 1405-87-4, Bacitracin 1406-16-2, Vitamin D 1406-18-4, Vitamin E 1492-18-8, Leucovorin calcium 1501-84-4, Rimantadine hydrochloride 1684-40-8, Tacrine hydrochloride 1695-77-8, Spectinomycin 1951-25-3, Amiodarone 1972-08-3, Tetrahydrocannabinol 2016-88-8, Amiloride hydrochloride 3056-17-5, Stavudine 3485-62-9, Clidinium bromide 3778-73-2, Isofosfamide 3930-20-9, Sotalol 4291-63-8, Cladribine 4419-39-0, Beclomethasone 4759-48-2, Isotretinoin 5104-49-4, Flurbiprofen 5534-95-2, Pentagastrin 6493-05-6, Pentoxifylline 7261-97-4, Dantrolene 7414-83-7, Disodium etidronate 7481-89-2, Zalcitabine 7648-98-8, Ambenonium 7689-03-4, Camptothecin 8068-28-8, Colistimethate sodium 9001-27-8, Factor VIII 9001-28-9, Factor IX 9002-01-1, Streptokinase 9002-60-2, Corticotropin, biological studies 9002-61-3, Chorionic gonadotropin 9004-17-5, NPH insulin 9004-99-3, Polyethylene glycol stearate 9005-63-4D, Polyoxyethylene sorbitan, fatty acid esters 9007-92-5, Glucagon, biological studies 9015-68-3, Asparaginase 9034-40-6, Gonadotropin-releasing hormone 9039-53-6, Urokinase 9041-08-1, Dalteparin sodium 9041-93-4, Bleomycin sulfate 9087-70-1, Aprotinin 10238-21-8, Glibenclamide 10540-29-1, Tamoxifen 10596-23-3, Clodronic acid 11000-17-2, Vasopressin 11061-68-0, Insulin (human) 11103-57-4, Vitamin A 12001-79-5, Vitamin K 12584-58-6, Porcine insulin 13265-10-6, Methscopolamine 15307-86-5, Diclofenac 15500-66-0, Pancuronium bromide 15574-96-6, Pizotifen 15663-27-1, Cisplatin 15686-51-8, Clemastine 15686-71-2, Cephalexin 15687-27-1, Ibuprofen 15826-37-6, Cromolyn sodium 16679-58-6, Desmopressin 16960-16-0, Cosyntropin 17230-88-5, Danazol 18323-44-9, Clindamycin 18559-94-9, Albuterol 18883-66-4, Streptozocin 19356-17-3, Calcifediol

20537-88-6, Amifostine 20594-83-6, Nalbuphine 20830-75-5, Digoxin 21215-62-3, Human calcitonin 21256-18-8, Oxaprozin 21679-14-1, Fludarabine 21829-25-4, Nifedipine 22254-24-6, Ipratropium bromide 22916-47-8, Miconazole 23031-32-5, Terbutaline sulfate 23214-92-8, Doxorubicin 23288-49-5, Probucol 24356-60-3, Cephapirin sodium 25126-32-3, Sincalide 25322-68-3D, PEG, esters 25523-97-1, Dexchlorpheniramine 25618-55-7D, Polyglycerol, fatty acid esters 25812-30-0, Gemfibrozil 26839-75-8, Timolol 27164-46-1, Cefazolin sodium 27203-92-5, Tramadol 27215-38-9, Glycerol monolaurate 29094-61-9, Glipizide 29122-68-7, Atenolol 29767-20-2, Teniposide 30516-87-1, Zidovudine 32222-06-3, Calcitriol 33069-62-4, Paclitaxel 33419-42-0, Etoposide 33515-09-2, Gonadorelin 33564-30-6, Cefoxitin sodium 34787-01-4, Ticarcillin 34911-55-2, Bupropion 35607-66-0, Cefoxitin 36791-04-5, Ribavirin 38304-91-5, Minoxidil 41340-25-4, Etodolac 41575-94-4, Carboplatin 42057-22-7, Mezlocillin sodium 42540-40-9, Cefamandole nafate 42924-53-8, Nabumetone 43200-80-2, Zopiclone 47931-85-1, Salmon calcitonin 49562-28-9, Fenofibrate 49697-38-3, Rimexolone 50700-72-6, Vecuronium bromide 51110-01-1, Somatostatin 51322-75-9, Tizanidine 51333-22-3, Budesonide 51384-51-1, Metoprolol 51481-61-9, Cimetidine 53123-88-9, Sirolimus 53179-11-6, Loperamide 53230-10-7, Mefloquine 53910-25-1, Pentostatin 54063-53-5, Propafenone 54910-89-3, Fluoxetine 54965-21-8, Albendazole 55142-85-3, Ticlopidine 56180-94-0, Acarbose 57248-88-1, Pamidronate disodium 59277-89-3, Acyclovir 59467-70-8, Midazolam 59703-84-3, Piperacillin sodium 59865-13-3, Cyclosporine 60142-96-3, Neurontin 61270-78-8, Cefonicid sodium 61379-65-5, Rifapentine 61869-08-7, Paroxetine 62013-04-1, Dirithromycin 62893-19-0, Cefoperazone 63585-09-1, Foscarnet sodium 63612-50-0, Nilutamide 63675-72-9, Nisoldipine 64228-81-5, Atracurium besylate 64544-07-6, Cefuroxime axetil 65271-80-9, Mitoxantrone 65277-42-1, Ketoconazole 66376-36-1, Alendronate 68099-86-5, Bepridil hydrochloride 68401-81-0, Ceftizoxime

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(solid carriers for improved delivery of active ingredients in pharmaceutical compns.)

IT 303-98-0, Coenzyme Q10

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(solid carriers for improved delivery of active ingredients in pharmaceutical compns.)

RN 303-98-0 ZCAPLUS

CN 2,5-Cyclohexadiene-1,4-dione, 2-[(2E,6E,10E,14E,18E,22E,26E,30E,34E)-3,7,11,15,19,23,27,31,35,39-decamethyl-2,6,10,14,18,22,26,30,34,38-tetracontadecaen-1-yl]-5,6-dimethoxy-3-methyl- (CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A



PAGE 1-B



PAGE 1-C

OS.CITING REF COUNT: 19 THERE ARE 19 CAPLUS RECORDS THAT CITE THIS RECORD (19 CITINGS)
REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L88 ANSWER 28 OF 41 ZCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2001:300492 ZCAPLUS Full-text
DOCUMENT NUMBER: 134:316129
TITLE: Microcapsules for stabilizing cosmetic, pharmaceutical or food products
INVENTOR(S): Parente Duena, Antonio; Bonilla Munoz, Angel; Garces Garces, Josep
PATENT ASSIGNEE(S): Lipotec, S.A., Spain
SOURCE: PCT Int. Appl., 18 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Spanish
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001028530	A1	20010426	WO 2000-ES403	20001019 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
ES 2162746	A1	20020101	ES 1999-2323	19991021 <--
ES 2162746	B1	20030216		
CA 2388166	A1	20010426	CA 2000-2388166	20001019 <--
AU 2001010305	A	20010430	AU 2001-10305	20001019 <--
BR 2000014836	A	20020611	BR 2000-14836	20001019 <--
EP 1222918	A1	20020717	EP 2000-971451	20001019 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
JP 2003535032	T	20031125	JP 2001-531360	20001019 <--
MX 2002003933	A	20030922	MX 2002-3933	20020419 <--

US 20060051408 A1 20060309 US 2005-265467 20051102 <--
PRIORITY APPLN. INFO.: ES 1999-2323 A 19991021 <--
WO 2000-ES403 W 20001019 <--
US 2002-111333 A3 20020418 <--

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

AB Microcapsules for stabilizing cosmetic, pharmaceutical or food products, having a size which is smaller than 500 μm, said microcapsules being comprised of a core of adsorbent material which can be a water insol. natural or modified polysaccharide or an inorg. adsorbent material, wherein are included the active ingredients and is coated with polymer material (natural polymer or natural modified polymer or synthetic polymer which is appropriate to be used in cosmetic, pharmaceutical or food industries, and is capable of forming films). The microcapsules are incorporated into cosmetic products such as gels, creams, lotions, emulsions, bath gels, shampoos and the like; the microcapsules can also be incorporated into pharmaceutical and veterinary products through topical, oral or parenteral means; the microcapsules can also be incorporated into products for human or animal food and into dietetic products.

IC ICM A61K009-50
ICS A61K007-00; A23P001-04

CC 63-6 (Pharmaceuticals)
Section cross-reference(s): 2, 8, 15, 17, 62

IT Anti-inflammatory agents
Antibacterial agents
Antiglaucoma agents
Antitumor agents
Antiviral agents
Anxiolytics
Arnica
Calendula
Cardiovascular agents
Cosmetics
Drugs
Dyes
Fluorescent substances
Food
Fungicides
Ginseng (Panax)
Immunomodulators
Microcapsules
Narcotics
Nervous system stimulants
Parasiticides
Particle size distribution
Psychotropics
Saccharomyces cerevisiae
Shampoos
Stabilizing agents
Vasodilators
(microcapsules for stabilizing cosmetic and pharmaceutical and food products)

IT Drug delivery systems
(topical; microcapsules for stabilizing cosmetic and pharmaceutical and food products)

IT 52-90-4, Cysteine, biological studies 58-08-2, Caffeine, biological studies 58-95-7, Vitamin e acetate 79-81-2, Vitamin a palmitate 303-98-0, Ubidecarenone 1406-18-4D, Vitamin e, derivs. 1668-00-4, Arsenazo iii 7439-89-6D, Iron, salts, biological studies 7440-66-6D, Zinc, salts, biological studies 7631-86-9, Silica, biological studies 7782-49-2D, Selenium, salts, biological studies

9001-05-2, Catalase 9004-34-6, Cellulose, biological studies
9004-38-0, Cellulose acetophthalate 9004-57-3, Ethylcellulose
9004-61-9, Hyaluronic acid 9004-65-3, Hydroxypropylmethylcellulose
9005-25-8, Starch, biological studies 9005-79-2, Glycogen, biological studies 9012-36-6, Agarose 9050-31-1 14807-96-6, Talc, biological studies 24938-16-7, Eudragit e 26589-39-9, Eudragit S 33434-24-1, Eudragit RL 34346-01-5, Glycolic acid-lactic acid copolymer 51822-44-7, Eudragit L
RL: BUU (Biological use, unclassified); FFD (Food or feed use); PEP (Physical, engineering or chemical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(microcapsules for stabilizing cosmetic and pharmaceutical and food products)

IT 303-98-0, Ubidecarenone
RL: BUU (Biological use, unclassified); FFD (Food or feed use); PEP (Physical, engineering or chemical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(microcapsules for stabilizing cosmetic and pharmaceutical and food products)

RN 303-98-0 ZCAPLUS

CN 2,5-Cyclohexadiene-1,4-dione, 2-[(2E,6E,10E,14E,18E,22E,26E,30E,34E)-3,7,11,15,19,23,27,31,35,39-decamethyl-2,6,10,14,18,22,26,30,34,38-tetracontadecaen-1-yl]-5,6-dimethoxy-3-methyl- (CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A



PAGE 1-B



PAGE 1-C

OS.CITING REF COUNT: 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD (5 CITINGS)
REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L88 ANSWER 29 OF 41 ZCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2000:645846 ZCAPLUS Full-text
DOCUMENT NUMBER: 133:242652
TITLE: Pharmaceutical, dietetic and cosmetic compositions based on tioctic acid and cysteine
INVENTOR(S): Dall'aglio, Roberto; Borgonovo, Margherita; Introini, Carlo; Melegari, Pierangelo
PATENT ASSIGNEE(S): Uni-Ci S.R.L., Italy
SOURCE: PCT Int. Appl., 48 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000053176	A1	20000914	WO 2000-EP1637	20000228 <--
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
IT 1312377	B1	20020415	IT 1999-MI460	19990305 <--
EP 1156802	A1	20011128	EP 2000-907644	20000228 <--
EP 1156802	B1	20051207		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY				
AT 311874	T	20051215	AT 2000-907644	20000228 <--
ES 2254145	T3	20060616	ES 2000-907644	20000228 <--
EP 1072310	A3	20030108	EP 2000-113660	20000628 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				

PRIORITY APPLN. INFO.: IT 1999-MI460 A 19990305 <--
WO 2000-EP1637 W 20000228 <--

AB Novel pharmaceutic, dietetic and cosmetic compns., based on tioctic acid and cysteine and/or a pharmaceutically, dietetically or cosmetically acceptable derivative thereof, useful for the prevention and treatment of conditions caused by oxidative stresses and alterations of both aerobic and anaerobic energetic metabolism by activation of mitochondrial energetic enzyme systems (glycolysis and lipolysis) are described. Capsules were filled with N-acetylcysteine (I) 200, magnesium hydroxide 150, and tioctic acid (II) 200 mg. Capsules were orally administered to athletes for 60 days at 10 mg/kg/day of I and II. There was a decrease of 4% in body weight and 7% in body fat and an improvement of 3% proteic mass of muscles.

IC ICM A61K031-385
ICS A61K031-385; A61K031-195

CC 63-6 (Pharmaceuticals)
Section cross-reference(s): 1, 17, 62

IT Dermatitis
(atopical; pharmaceutical, dietetic and cosmetic compns. based on tioctic acid and cysteine)

IT AIDS (disease)
Aging, animal
Alopecia
Alzheimer's disease

Antiasthmatics
Antidiabetic agents
Antiobesity agents
Cataract
Cosmetics
Down's syndrome
Erythema
Heart, disease
Human herpesvirus
Inflammation
Influenza
Ischemia
Keloid
Liver, disease
Menopause
Neoplasm
Oxidative stress, biological
Pain
Preeclampsia
Psoriasis
Rheumatoid arthritis
Soybean (Glycine max)
Tarchonanthus camphoratus
(pharmaceutical, dietetic and cosmetic compns. based on tioctic acid and cysteine)

IT 52-90-4, Cysteine, biological studies 56-84-8, Aspartic acid, biological studies 56-85-9, Glutamine, biological studies 56-86-0, Glutamic acid, biological studies 58-61-7, Adenosine, biological studies 58-61-7D, Adenosine, derivs., biological studies 59-30-3, Folic acid, biological studies 73-31-4, Melatonin 79-83-4, Pantothenic acid 97-59-6, Allantoin 303-98-0, Coenzyme q10 501-36-0, Resveratrol 541-15-1D, Carnitine, derivs. 616-91-1, N-Acetylcysteine 638-23-3 1077-28-7, Thioctic acid 1406-18-4, Vitamin e 7440-50-8, Copper, biological studies 7440-66-6, Zinc, biological studies 7782-49-2, Selenium, biological studies 12001-76-2, Vitamin b 87259-20-9 142959-59-9 292819-47-7
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmaceutical, dietetic and cosmetic compns. based on tioctic acid and cysteine)

IT 303-98-0, Coenzyme q10
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmaceutical, dietetic and cosmetic compns. based on tioctic acid and cysteine)

RN 303-98-0 ZCAPLUS

CN 2,5-Cyclohexadiene-1,4-dione, 2-[(2E,6E,10E,14E,18E,22E,26E,30E,34E)-3,7,11,15,19,23,27,31,35,39-decamethyl-2,6,10,14,18,22,26,30,34,38-tetracontadecaen-1-yl]-5,6-dimethoxy-3-methyl- (CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A



PAGE 1-B



PAGE 1-C

OS.CITING REF COUNT: 13 THERE ARE 13 CAPLUS RECORDS THAT CITE THIS RECORD (13 CITINGS)
REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L88 ANSWER 30 OF 41 ZCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2000:573651 ZCAPLUS Full-text
DOCUMENT NUMBER: 133:159948
TITLE: Ubiquinone Qn for pain treatment
INVENTOR(S): Enzmann, Franz
PATENT ASSIGNEE(S): MSE Pharmazeutika G.m.b.H., Germany
SOURCE: PCT Int. Appl., 7 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000047192	A2	20000817	WO 2000-EP1011	20000209 <--
WO 2000047192	A3	20010412		
W: CA, JP, US				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
DE 19905879	A1	20000817	DE 1999-19905879	19990211 <--
CA 2362577	A1	20000817	CA 2000-2362577	20000209 <--
EP 1150682	A2	20011107	EP 2000-914075	20000209 <--
EP 1150682	B1	20050817		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				

IE, FI

AT 302009	T	20050915	AT 2000-914075		20000209 <--
ES 2243243	T3	20051201	ES 2000-914075		20000209 <--
US 20040034107	A1	20040219	US 2003-424987		20030429 <--
PRIORITY APPLN. INFO.:			DE 1999-19905879	A	19990211 <--
			WO 2000-EP1011	W	20000209 <--
			US 2001-890276	B1	20010810 <--

AB Ubiquinone Qn and its precursors can be used in the oral, parenteral, local, inhalative, or intranasal treatment of neurogenic pain, migraine, or pain resulting from dialysis, herpes zoster, cancer, etc. (no data).

IC ICM A61K031-00

CC 1-11 (Pharmacology)

IT Drug delivery systems
(topical; ubiquinone Qn for pain treatment)

IT Analgesics
Neoplasm
(ubiquinone Qn for pain treatment)

IT 303-98-0, Ubiquinone Q10
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(ubiquinone Qn for pain treatment)

IT 303-98-0, Ubiquinone Q10
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(ubiquinone Qn for pain treatment)

RN 303-98-0 ZCAPLUS

CN 2,5-Cyclohexadiene-1,4-dione, 2-[(2E,6E,10E,14E,18E,22E,26E,30E,34E)-3,7,11,15,19,23,27,31,35,39-decamethyl-2,6,10,14,18,22,26,30,34,38-tetracontadecaen-1-yl]-5,6-dimethoxy-3-methyl- (CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A



PAGE 1-B



OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)
REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L88 ANSWER 31 OF 41 EMBASE COPYRIGHT (c) 2010 Elsevier B.V. All rights reserved on STN
ACCESSION NUMBER: 2004297788 EMBASE Full-text
TITLE: [Free radicals: Oxidative stress makes the skin look old].
Freie Radikale: Oxidativer stress lasst die haut alt aussehen.
AUTHOR: Stolzing, Alexandra (correspondence); Grune, Tilman
AUTHOR: Grune, Tilman
AUTHOR: Stolzing, Alexandra (correspondence)
CORPORATE SOURCE: Neurowissenschaft. Forschungszentrum, Medizinische Fakultat (Charite), Schumannstrasse 20/21, 10089 Berlin, Germany.
AUTHOR: Grune, Tilman
CORPORATE SOURCE: Inst. F Umweltmedizinische Forschung, Heinrich-Heine-Universitat, Auf'm Hennekamp 50, 40225 Dusseldorf, Germany.
SOURCE: Pharmazeutische Zeitung, (24 Jun 2004) Vol. 149, No. 26, pp. 16-21.
ISSN: 0031-7136 CODEN: PZSED5
COUNTRY: Germany
DOCUMENT TYPE: Journal; Article
FILE SEGMENT: 013 Dermatology and Venereology
029 Clinical and Experimental Biochemistry
030 Clinical and Experimental Pharmacology
037 Drug Literature Index
005 General Pathology and Pathological Anatomy
LANGUAGE: German
ENTRY DATE: Entered STN: 12 Aug 2004
Last Updated on STN: 12 Aug 2004
CONTROLLED TERM: Medical Descriptors:
aging
article
cell proliferation
*cutaneous parameters
dermis
DNA damage
DNA repair
drug effect
drug mechanism
epidermis
human
keratinocyte
light exposure
lipid peroxidation
melanocyte

metabolism
oxidation reduction reaction
*oxidative stress
protein degradation
signal transduction
skin carcinogenesis
skin fibroblast
skin protection
stratum corneum
subcutaneous tissue
ultraviolet A radiation
ultraviolet B radiation
ultraviolet C radiation

CONTROLLED TERM: Drug Descriptors:
adenosine triphosphate: EC, endogenous compound
alpha tocopherol: PD, pharmacology
antioxidant: PD, pharmacology
antioxidant: TP, topical drug administration
ascorbic acid: PD, pharmacology
ascorbic acid: TP, topical drug administration
beta carotene: PD, pharmacology
bgp 15m
catalase: EC, endogenous compound
DNA: EC, endogenous compound
endonuclease: EC, endogenous compound
epigallocatechin: PD, pharmacology
epigallocatechin: TP, topical drug administration
*free radical: EC, endogenous compound
glutathione reductase: EC, endogenous compound
heat shock protein 70: EC, endogenous compound
malonaldehyde: EC, endogenous compound
melatonin: PD, pharmacology
melatonin: TP, topical drug administration
messenger RNA: EC, endogenous compound
nicotinamide adenine dinucleotide: EC, endogenous compound
nicotinamide adenine dinucleotide adenosine diphosphate ribosyltransferase: EC, endogenous compound
nicotinamide adenine dinucleotide adenosine diphosphate ribosyltransferase inhibitor: PD, pharmacology
nitric oxide synthase: EC, endogenous compound
oxidoreductase: EC, endogenous compound
polydeoxyribonucleotide synthase: PD, pharmacology
polydeoxyribonucleotide synthase: TP, topical drug administration
polyphenol: PO, oral drug administration
polyphenol: PD, pharmacology
polyphenol: TP, topical drug administration
protein: EC, endogenous compound
reactive oxygen metabolite: EC, endogenous compound
retinol: PD, pharmacology
selenium: PD, pharmacology
superoxide dismutase: EC, endogenous compound
ubidecarenone: PD, pharmacology
ubidecarenone: TP, topical drug administration
ubiquinone: PD, pharmacology
ubiquinone: TP, topical drug administration
unindexed drug

CAS REGISTRY NO.: (adenosine triphosphate) 15237-44-2, 56-65-5, 987-65-5; (alpha tocopherol) 1406-18-4, 1406-70-8, 52225-20-4, 58-95-7, 59-02-9; (ascorbic acid) 134-03-2, 15421-15-5,

50-81-7; (beta carotene) 7235-40-7; (catalase) 9001-05-2; (DNA) 9007-49-2; (endonuclease) 9055-11-2; (epigallocatechin) 970-74-1; (glutathione reductase) 9001-48-3; (malonaldehyde) 542-78-9; (melatonin) 73-31-4; (nicotinamide adenine dinucleotide adenosine diphosphate ribosyltransferase) 58319-92-9; (nicotinamide adenine dinucleotide) 53-84-9; (nitric oxide synthase) 125978-95-2; (oxidoreductase) 9035-73-8, 9035-82-9, 9037-80-3, 9055-15-6; (polydeoxyribonucleotide synthase) 9015-85-4; (polyphenol) 37331-26-3; (protein) 67254-75-5; (retinol) 68-26-8, 82445-97-4; (selenium) 7782-49-2; (superoxide dismutase) 37294-21-6, 9016-01-7, 9054-89-1; (ubidecarenone) 303-98-0; (ubiquinone) 1339-63-5

CHEMICAL NAME: bgp 15m

L88 ANSWER 32 OF 41 EMBASE COPYRIGHT (c) 2010 Elsevier B.V. All rights reserved on STN

ACCESSION NUMBER: 2003466982 EMBASE Full-text

TITLE: Topical vitamins, minerals and botanical ingredients as modulators of environmental and chronological skin damage.

AUTHOR: Chiu, A.; Kimball, A.B. (correspondence)

CORPORATE SOURCE: Department of Dermatology, Stanford Univ. School of Medicine, RM W0024, 900 Blake Wilbur Drive, Stanford, CA 94305-5334, United States. akimball@leland.stanford.edu

SOURCE: British Journal of Dermatology, (Oct 2003) Vol. 149, No. 4, pp. 681-691.
Refs: 107
ISSN: 0007-0963 CODEN: BJDEAZ

COUNTRY: United Kingdom

DOCUMENT TYPE: Journal; General Review; (Review)

FILE SEGMENT: 013 Dermatology and Venereology
020 Gerontology and Geriatrics
037 Drug Literature Index
039 Pharmacy

LANGUAGE: English

SUMMARY LANGUAGE: English

ENTRY DATE: Entered STN: 30 Dec 2003
Last Updated on STN: 30 Dec 2003

ABSTRACT: Ageing skin is characterized by fine lines, wrinkles, lentigines, dyspigmentation and increased coarseness. Topical preparations alleged to combat these changes abound in the over-the-counter market. Some of the most popular ingredients used in these products are vitamins, minerals and botanical extracts. Proposed mechanisms for antiageing effects on skin range from antioxidant properties to improved collagen synthesis or protection from collagen breakdown. Despite the media attention and consumer popularity that these ingredients have generated, there have been few scientific studies to support these claims. In this report, we review recent published studies on the most common of these ingredients for the topical photoprotection and the treatment of ageing skin.

CONTROLLED TERM: Medical Descriptors:
acne vulgaris: DT, drug therapy
*aging
alga
antiinflammatory activity
antineoplastic activity
antioxidant activity
clinical trial
coarse skin: DT, drug therapy
coarse skin: PC, prevention

collagen synthesis
drug effect
drug efficacy
drug formulation
drug mechanism
drug penetration
drug stability
ginseng
grape
herbal medicine
human
lemon
lentigo: DT, drug therapy
lentigo: PC, prevention
*light damage: DT, drug therapy
*light damage: PC, prevention
nonhuman
pigment disorder: DT, drug therapy
pigment disorder: PC, prevention
priority journal
radiation injury: DT, drug therapy
radiation injury: ET, etiology
radiation injury: PC, prevention
review
rosemary
seaweed
*skin defect: DT, drug therapy
*skin defect: ET, etiology
*skin defect: PC, prevention
skin protection
skin surface
tea
ultraviolet radiation

CONTROLLED TERM: Drug Descriptors:
Aloe vera extract
alpha tocopherol: CT, clinical trial
alpha tocopherol: CB, drug combination
alpha tocopherol: CM, drug comparison
alpha tocopherol: DT, drug therapy
alpha tocopherol: PD, pharmacology
alpha tocopherol: TP, topical drug administration
ascorbic acid: CT, clinical trial
ascorbic acid: CB, drug combination
ascorbic acid: CM, drug comparison
ascorbic acid: DT, drug therapy
ascorbic acid: PR, pharmaceutics
ascorbic acid: PD, pharmacology
ascorbic acid: TP, topical drug administration
ascorbyl palmitate: CM, drug comparison
ascorbyl palmitate: PK, pharmacokinetics
ascorbyl palmitate: PD, pharmacology
ascorbyl palmitate: TP, topical drug administration
ascorbyl phosphate: PD, pharmacology
ascorbyl phosphate: TP, topical drug administration
black tea extract: CT, clinical trial
black tea extract: DT, drug therapy
black tea extract: PD, pharmacology
black tea extract: TP, topical drug administration
cellex c
cosmetic

cucumber extract
dexpanthenol
essential oil: PD, pharmacology
essential oil: TP, topical drug administration
flavonoid: PD, pharmacology
Ginkgo biloba extract: CB, drug combination
Ginkgo biloba extract: PD, pharmacology
grape seed extract: PD, pharmacology
grape seed extract: TP, topical drug administration
green tea extract: CT, clinical trial
green tea extract: DT, drug therapy
green tea extract: PD, pharmacology
green tea extract: TP, topical drug administration
green tea polyphenol: CT, clinical trial
green tea polyphenol: DT, drug therapy
green tea polyphenol: PD, pharmacology
green tea polyphenol: TP, topical drug administration
Hamamelis extract
*mineral: CT, clinical trial
*mineral: DT, drug therapy
*mineral: PD, pharmacology
*mineral: TP, topical drug administration
nicotinamide: CT, clinical trial
nicotinamide: DT, drug therapy
nicotinamide: PD, pharmacology
nicotinamide: TP, topical drug administration
non prescription drug: DT, drug therapy
non prescription drug: PD, pharmacology
non prescription drug: TP, topical drug administration
peppermint extract
*plant extract: CT, clinical trial
*plant extract: DT, drug therapy
*plant extract: PD, pharmacology
*plant extract: TP, topical drug administration
retinol: CT, clinical trial
retinol: CM, drug comparison
retinol: DT, drug therapy
retinol: PD, pharmacology
retinol: TP, topical drug administration
retinol palmitate: DT, drug therapy
retinol palmitate: PD, pharmacology
retinol palmitate: TP, topical drug administration
soybean protein: CT, clinical trial
soybean protein: DT, drug therapy
soybean protein: PD, pharmacology
soybean protein: TP, topical drug administration
trolox C: PD, pharmacology
trolox C: TP, topical drug administration
ubidecarenone: CT, clinical trial
ubidecarenone: DT, drug therapy
ubidecarenone: PD, pharmacology
ubidecarenone: TP, topical drug administration
ubiquinone: CT, clinical trial
ubiquinone: DT, drug therapy
ubiquinone: PD, pharmacology
ubiquinone: TP, topical drug administration
unclassified drug
unindexed drug
*vitamin: CT, clinical trial
*vitamin: DT, drug therapy

*vitamin: PD, pharmacology
*vitamin: TP, topical drug administration
wheat protein
CAS REGISTRY NO.: (alpha tocopherol) 1406-18-4, 1406-70-8, 52225-20-4, 58-95-7, 59-02-9; (ascorbic acid) 134-03-2, 15421-15-5, 50-81-7; (ascorbyl palmitate) 137-66-6; (dexpanthenol) 81-13-0; (nicotinamide) 11032-50-1, 98-92-0; (retinol palmitate) 79-81-2; (retinol) 68-26-8, 82445-97-4; (soybean protein) 9010-10-0; (trolox C) 56305-04-5; (ubidecarenone) 303-98-0; (ubiquinone) 1339-63-5
CHEMICAL NAME: cellex c

L88 ANSWER 33 OF 41 EMBASE COPYRIGHT (c) 2010 Elsevier B.V. All rights reserved on STN
ACCESSION NUMBER: 2003246099 EMBASE Full-text
TITLE: Coenzyme Q10: One antioxidant, many promising applications.
AUTHOR: Horowitz, Sala
SOURCE: Alternative and Complementary Therapies, (Jun 2003) Vol. 9, No. 3, pp. 111-116.
Refs: 34
ISSN: 1076-2809 CODEN: ACTHFZ
COUNTRY: United States
DOCUMENT TYPE: Journal; Article
FILE SEGMENT: 030 Clinical and Experimental Pharmacology
037 Drug Literature Index
038 Adverse Reactions Titles
LANGUAGE: English
ENTRY DATE: Entered STN: 3 Jul 2003
Last Updated on STN: 3 Jul 2003
CONTROLLED TERM: Medical Descriptors:
acquired immune deficiency syndrome: DT, drug therapy
Alzheimer disease: DT, drug therapy
*antioxidant activity
article
asthma: DT, drug therapy
biochemistry
cancer
cardiotoxicity: SI, side effect
diabetes mellitus: DT, drug therapy
disorders of mitochondrial functions: DT, drug therapy
drug cross reactivity
drug formulation
*enzyme structure
heart disease: DT, drug therapy
human
male infertility: DT, drug therapy
muscle disease: DT, drug therapy
myopathy: SI, side effect
nerve cell lesion: SI, side effect
Parkinson disease: DT, drug therapy
periodontal disease: DT, drug therapy
side effect: SI, side effect
sinusitis: SI, side effect
skin disease: DT, drug therapy
sore throat: SI, side effect
structure activity relation
treatment indication
virus infection: SI, side effect
CONTROLLED TERM: Drug Descriptors:

acetohexamide: IT, drug interaction
alpha tocopherol: IT, drug interaction
alpha tocopherol succinate: PD, pharmacology
antidepressant agent: IT, drug interaction
antidiabetic agent: IT, drug interaction
antineoplastic agent: IT, drug interaction
ascorbic acid: PD, pharmacology
beta adrenergic receptor blocking agent: IT, drug interaction
beta carotene: PD, pharmacology
carnitine: IT, drug interaction
cholinergic receptor blocking agent: AE, adverse drug reaction
cholinergic receptor blocking agent: DT, drug therapy
dermatological agent: PD, pharmacology
dermatological agent: TP, topical drug administration
dopamine receptor stimulating agent: AE, adverse drug reaction
dopamine receptor stimulating agent: DT, drug therapy
doxorubicin: AE, adverse drug reaction
doxorubicin: IT, drug interaction
entacapone: AE, adverse drug reaction
entacapone: DT, drug therapy
glibenclamide: IT, drug interaction
hydroxymethylglutaryl coenzyme A reductase inhibitor: AE, adverse drug reaction
hydroxymethylglutaryl coenzyme A reductase inhibitor: IT, drug interaction
hypocholesterolemic agent: IT, drug interaction
olive oil: PD, pharmacology
olive oil: TP, topical drug administration
pergolide mesilate: AE, adverse drug reaction
pergolide mesilate: DT, drug therapy
phenothiazine derivative: IT, drug interaction
pramipexole: AE, adverse drug reaction
pramipexole: DT, drug therapy
ropinirole: AE, adverse drug reaction
ropinirole: DT, drug therapy
selegiline: AE, adverse drug reaction
selegiline: DT, drug therapy
selenium: PD, pharmacology
sulfonylurea derivative: IT, drug interaction
tolazamide: IT, drug interaction
*ubidecarenone: AE, adverse drug reaction
*ubidecarenone: AN, drug analysis
*ubidecarenone: IT, drug interaction
*ubidecarenone: PD, pharmacology
ubiqgel
unindexed drug
warfarin: IT, drug interaction

CAS REGISTRY NO.: (acetohexamide) 968-81-0; (alpha tocopherol succinate) 17407-37-3, 4345-03-3; (alpha tocopherol) 1406-18-4, 1406-70-8, 52225-20-4, 58-95-7, 59-02-9; (ascorbic acid) 134-03-2, 15421-15-5, 50-81-7; (beta carotene) 7235-40-7; (carnitine) 461-06-3, 541-15-1, 56-99-5; (doxorubicin) 23214-92-8, 25316-40-9; (entacapone) 116314-67-1; (glibenclamide) 10238-21-8; (olive oil) 8001-25-0; (pergolide mesilate) 66104-23-2; (pramipexole) 104632-26-0; (ropinirole) 91374-21-9; (selegiline) 14611-51-9, 14611-52-0, 2079-54-1, 2323-36-6; (selenium) 7782-49-2;

(tolazamide) 1156-19-0; (ubidecarenone) 303-98-0; (warfarin) 129-06-6, 2610-86-8, 3324-63-8, 5543-58-8, 81-81-2
CHEMICAL NAME: (1) ubiqgel; coumadin; diabeta; dymelor; panwarfin; sofarin; tolinase
COMPANY NAME: (1) Tishcon (United States)

L88 ANSWER 34 OF 41 EMBASE COPYRIGHT (c) 2010 Elsevier B.V. All rights reserved on STN
ACCESSION NUMBER: 2003380391 EMBASE Full-text
TITLE: Cosmeceuticals: A review of the science behind the claims.
AUTHOR: Farris, Patricia K., Dr. (correspondence)
CORPORATE SOURCE: Department of Dermatology, Tulane University School of Medicine, New Orleans, LA, United States.
AUTHOR: Draelos, Zoe Diana; Elson, Melvin L.
SOURCE: Cosmetic Dermatology, (1 Mar 2003) Vol. 16, No. 3, pp. 59-60+64-66+69-70.
Refs: 64
ISSN: 1041-3766 CODEN: CDOEBQ
COUNTRY: United States
DOCUMENT TYPE: Journal; General Review; (Review)
FILE SEGMENT: 013 Dermatology and Venereology
030 Clinical and Experimental Pharmacology
037 Drug Literature Index
LANGUAGE: English
SUMMARY LANGUAGE: English
ENTRY DATE: Entered STN: 9 Oct 2003
Last Updated on STN: 9 Oct 2003
ABSTRACT: As dermatologists, we have the task of sorting through the little scientific information that is available to provide sound advice regarding skin-care products. This review describes some cosmeceuticals that have been subjected to well-designed clinical studies; however, more studies are needed to validate the claims of other products. Cosmeceuticals have indeed become an important part of our armamentarium, and we rely on continued research, development, and clinical testing to provide us with innovative and effective topical therapies for aging skin.

CONTROLLED TERM: Medical Descriptors:
*aging
antiinflammatory activity
antioxidant activity
cell damage
clinical trial
drug formulation
drug mechanism
food and drug administration
human
review
*skin care
*skin defect: DT, drug therapy
skin penetration
sun exposure
ultraviolet radiation
CONTROLLED TERM: Drug Descriptors:
alpha tocopherol: DT, drug therapy
alpha tocopherol: EC, endogenous compound
alpha tocopherol: TP, topical drug administration
*antioxidant: CT, clinical trial
*antioxidant: DT, drug therapy
*antioxidant: EC, endogenous compound

*antioxidant: PD, pharmacology
*antioxidant: TP, topical drug administration
ascorbic acid: DT, drug therapy
ascorbic acid: EC, endogenous compound
ascorbic acid: TP, topical drug administration
catalase: EC, endogenous compound
collagen: EC, endogenous compound
*copper peptide: CT, clinical trial
*copper peptide: DT, drug therapy
*copper peptide: PD, pharmacology
*copper peptide: TP, topical drug administration
*cosmetic: CT, clinical trial
*cosmetic: DT, drug therapy
*cosmetic: PD, pharmacology
*cosmetic: TP, topical drug administration
*deanol: CT, clinical trial
*deanol: DT, drug therapy
*deanol: TP, topical drug administration
elastin: EC, endogenous compound
free radical: EC, endogenous compound
glucose 6 phosphate dehydrogenase: EC, endogenous compound
glutathione: EC, endogenous compound
glutathione peroxidase: EC, endogenous compound
glycosaminoglycan: EC, endogenous compound
*growth factor: CT, clinical trial
*growth factor: DT, drug therapy
*growth factor: PD, pharmacology
*growth factor: TP, topical drug administration
immunoglobulin enhancer binding protein: EC, endogenous compound
interleukin 1: EC, endogenous compound
interleukin 6: EC, endogenous compound
interleukin 8: EC, endogenous compound
kinetin: CT, clinical trial
kinetin: DT, drug therapy
kinetin: TP, topical drug administration
*nicotinamide: CT, clinical trial
*nicotinamide: DT, drug therapy
*nicotinamide: PD, pharmacology
*nicotinamide: TP, topical drug administration
non prescription drug: CT, clinical trial
non prescription drug: DT, drug therapy
non prescription drug: TP, topical drug administration
protein lysine 6 oxidase: EC, endogenous compound
retinoid: DT, drug therapy
retinoid: TP, topical drug administration
superoxide dismutase: EC, endogenous compound
thioctic acid: CT, clinical trial
thioctic acid: DT, drug therapy
thioctic acid: PD, pharmacology
thioctic acid: TP, topical drug administration
transcription factor AP 1: EC, endogenous compound
tumor necrosis factor alpha: EC, endogenous compound
ubidecarenone: CT, clinical trial
ubidecarenone: DT, drug therapy
ubidecarenone: PD, pharmacology
ubidecarenone: TP, topical drug administration
unclassified drug
unindexed drug

CAS REGISTRY NO.: (alpha tocopherol) 1406-18-4, 1406-70-8, 52225-20-4,

58-95-7, 59-02-9; (ascorbic acid) 134-03-2, 15421-15-5, 50-81-7; (catalase) 9001-05-2; (collagen) 9007-34-5; (deanol) 108-01-0, 2498-25-1; (elastin) 9007-58-3; (glucose 6 phosphate dehydrogenase) 37259-83-9, 9001-40-5; (glutathione peroxidase) 9013-66-5; (glutathione) 70-18-8; (interleukin 8) 114308-91-7; (kinetin) 525-79-1; (nicotinamide) 11032-50-1, 98-92-0; (protein lysine 6 oxidase) 99676-44-5; (superoxide dismutase) 37294-21-6, 9016-01-7, 9054-89-1; (thioctic acid) 1077-29-8, 1200-22-2, 2319-84-8, 62-46-4; (ubidecarenone) 303-98-0

L88 ANSWER 35 OF 41 EMBASE COPYRIGHT (c) 2010 Elsevier B.V. All rights reserved on STN

ACCESSION NUMBER: 2003033641 EMBASE Full-text
TITLE: Cutaneous photodamage, oxidative stress, and topical antioxidant protection.
AUTHOR: Pinnell, Sheldon R.
CORPORATE SOURCE: pinne002@mc.duke.edu
SOURCE: Journal of the American Academy of Dermatology, (1 Jan 2003) Vol. 48, No. 1, pp. 1-19.
Refs: 271
ISSN: 0190-9622 CODEN: JAADDB
COUNTRY: United States
DOCUMENT TYPE: Journal; General Review; (Review)
FILE SEGMENT: 013 Dermatology and Venereology
016 Cancer
037 Drug Literature Index
LANGUAGE: English
SUMMARY LANGUAGE: English
ENTRY DATE: Entered STN: 30 Jan 2003
Last Updated on STN: 30 Jan 2003

ABSTRACT: New methods to protect skin from photodamage from sun exposure are necessary if we are to conquer skin cancer and photoaging. Sunscreens are useful, but their protection is not ideal because of inadequate use, incomplete spectral protection, and toxicity. Skin naturally uses antioxidants (AOs) to protect itself from photodamage. This scientific review summarizes what is known about how photodamage occurs; why sunscreens - the current gold standard of photoprotection - are inadequate; and how topical AOs help protect against skin cancer and photoaging changes. This review is intended to be a reference source, including pertinent comprehensive reviews whenever available. Although not all AOs are included, an attempt has been made to select those AOs for which sufficient information is available to document their potential topical uses and benefits. Reviewed are the following physiologic and plant AOs: vitamin C, vitamin E, selenium, zinc, silymarin, soy isoflavones, and tea polyphenols. Their topical use may favorably supplement sunscreen protection and provide additional anticarcinogenic protection.

CONTROLLED TERM: Medical Descriptors:
aging
chromatophore
clinical trial
drug effect
human
nonhuman
*oxidative stress
*photodermatosis: DT, drug therapy
*photodermatosis: ET, etiology
*photodermatosis: TH, therapy
pollution
priority journal

review
*skin cancer: DT, drug therapy
*skin cancer: ET, etiology
*skin cancer: PC, prevention
skin carcinogenesis
skin protection
smoking
soybean
sun exposure
tea
technique
treatment indication
ultraviolet A radiation
ultraviolet B radiation

CONTROLLED TERM: Drug Descriptors:
alpha tocopherol: CB, drug combination
alpha tocopherol: DO, drug dose
alpha tocopherol: IT, drug interaction
alpha tocopherol: DT, drug therapy
alpha tocopherol: PO, oral drug administration
alpha tocopherol: PD, pharmacology
alpha tocopherol: TP, topical drug administration
*antioxidant: CT, clinical trial
*antioxidant: DT, drug therapy
*antioxidant: PD, pharmacology
*antioxidant: TP, topical drug administration
ascorbic acid: CB, drug combination
ascorbic acid: DO, drug dose
ascorbic acid: IT, drug interaction
ascorbic acid: DT, drug therapy
ascorbic acid: PO, oral drug administration
ascorbic acid: PD, pharmacology
ascorbic acid: TP, topical drug administration
daidzein: CM, drug comparison
daidzein: PO, oral drug administration
daidzein: PD, pharmacology
daidzein: TP, topical drug administration
DNA: EC, endogenous compound
epigallocatechin gallate: PO, oral drug administration
epigallocatechin gallate: PD, pharmacology
epigallocatechin gallate: TP, topical drug administration
estradiol: CM, drug comparison
estradiol: PD, pharmacology
estrogen: CM, drug comparison
estrogen: PO, oral drug administration
estrogen: PD, pharmacology
estrogen: TP, topical drug administration
estrogen receptor: EC, endogenous compound
free radical: EC, endogenous compound
genistein: CM, drug comparison
genistein: PO, oral drug administration
genistein: PD, pharmacology
genistein: TP, topical drug administration
glutathione: EC, endogenous compound
glutathione peroxidase: EC, endogenous compound
glutathione reductase: EC, endogenous compound
immunoglobulin enhancer binding protein: EC, endogenous compound
isoflavone: CM, drug comparison
isoflavone: DT, drug therapy

isoflavone: PD, pharmacology
isoflavone: TP, topical drug administration
matrix metalloproteinase: EC, endogenous compound
phytoestrogen: PD, pharmacology
polyphenol: DT, drug therapy
polyphenol: PD, pharmacology
polyphenol: TP, topical drug administration
reactive oxygen metabolite: EC, endogenous compound
selenium: CT, clinical trial
selenium: DO, drug dose
selenium: DT, drug therapy
selenium: PO, oral drug administration
selenium: PD, pharmacology
selenium: TP, topical drug administration
silymarin: CT, clinical trial
silymarin: DO, drug dose
silymarin: DT, drug therapy
silymarin: PD, pharmacology
silymarin: TP, topical drug administration
sodium selenite: PO, oral drug administration
sodium selenite: PD, pharmacology
sunscreen
superoxide dismutase: EC, endogenous compound
ubidecarenone: EC, endogenous compound
urocanic acid: EC, endogenous compound
zinc: DT, drug therapy
zinc: PD, pharmacology
zinc: TP, topical drug administration

CAS REGISTRY NO.: (alpha tocopherol) 1406-18-4, 1406-70-8, 52225-20-4, 58-95-7, 59-02-9; (ascorbic acid) 134-03-2, 15421-15-5, 50-81-7; (daidzein) 486-66-8; (DNA) 9007-49-2; (epigallocatechin gallate) 989-51-5; (estradiol) 50-28-2; (genistein) 446-72-0; (glutathione peroxidase) 9013-66-5; (glutathione reductase) 9001-48-3; (glutathione) 70-18-8; (isoflavone) 574-12-9; (polyphenol) 37331-26-3; (selenium) 7782-49-2; (silymarin) 65666-07-1; (sodium selenite) 10102-18-8; (superoxide dismutase) 37294-21-6, 9016-01-7, 9054-89-1; (ubidecarenone) 303-98-0; (urocanic acid) 104-98-3; (zinc) 7440-66-6

L88 ANSWER 36 OF 41 EMBASE COPYRIGHT (c) 2010 Elsevier B.V. All rights reserved on STN

ACCESSION NUMBER: 1999391294 EMBASE Full-text
TITLE: Antioxidants in cancer therapy; their actions and interactions with oncologic therapies.
AUTHOR: Lamson, Davis W. (correspondence); Brignall, Matthew S.
CORPORATE SOURCE: Tahoma Clinic, Kent, WA, United States. mattandmolly@w-link.net
AUTHOR: Lamson, Davis W. (correspondence)
CORPORATE SOURCE: Bastyr University, Kenmore, WA, United States.
AUTHOR: Lamson, Davis W. (correspondence)
CORPORATE SOURCE: 9803 17th Ave. NE, Seattle, WA 98115, United States.
AUTHOR: Brignall, Matthew S.
CORPORATE SOURCE: Bastyr University. mattandmolly@w-link.net
SOURCE: Alternative Medicine Review, (1999) Vol. 4, No. 5, pp. 304-329.
Refs: 180
ISSN: 1089-5159 CODEN: ALMRFP
COUNTRY: United States
DOCUMENT TYPE: Journal; General Review; (Review)

FILE SEGMENT: 016 Cancer
030 Clinical and Experimental Pharmacology
037 Drug Literature Index
038 Adverse Reactions Titles
LANGUAGE: English
SUMMARY LANGUAGE: English
ENTRY DATE: Entered STN: 2 Dec 1999
Last Updated on STN: 2 Dec 1999

ABSTRACT: There is a concern that antioxidants might reduce oxidizing free radicals created by radiotherapy and some forms of chemotherapy, and thereby decrease the effectiveness of the therapy. The question has arisen whether concurrent administration of oral antioxidants is contraindicated during cancer therapeutics. Evidence reviewed here demonstrates exogenous antioxidants alone produce beneficial effects in various cancers, and except for a few specific cases, animal and human studies demonstrate no reduction of efficacy of chemotherapy or radiation when given with antioxidants. In fact, considerable data exists showing increased effectiveness of many cancer therapeutic agents, as well as a decrease in adverse effects, when given concurrently with antioxidants.

CONTROLLED TERM: Medical Descriptors:
alternative medicine
*antioxidant activity
bone marrow toxicity: SI, side effect
breast cancer: DR, drug resistance
breast cancer: DT, drug therapy
*cancer: DT, drug therapy
*cancer chemotherapy
cancer combination chemotherapy
cancer radiotherapy
cardiotoxicity: SI, side effect
diet supplementation
drug efficacy
gastrointestinal toxicity: SI, side effect
head and neck cancer: DT, drug therapy
human
intraperitoneal drug administration
intravenous drug administration
lung cancer: DT, drug therapy
melanoma: DT, drug therapy
nephrotoxicity: ET, etiology
nephrotoxicity: SI, side effect
nonhuman
oral drug administration
review
topical drug administration
uterine cervix cancer: DT, drug therapy
uterine cervix cancer: RT, radiotherapy
*vitamin intake

CONTROLLED TERM: Drug Descriptors:
acetylcysteine: AE, adverse drug reaction
acetylcysteine: CB, drug combination
acetylcysteine: DO, drug dose
acetylcysteine: IT, drug interaction
acetylcysteine: DT, drug therapy
*alpha tocopherol: AD, drug administration
*alpha tocopherol: CB, drug combination
*alpha tocopherol: DO, drug dose
*alpha tocopherol: IT, drug interaction
*alpha tocopherol: DT, drug therapy

*alpha tocopherol: PD, pharmacology
alpha2a interferon: CB, drug combination
alpha2a interferon: DT, drug therapy
*antineoplastic agent: AE, adverse drug reaction
*antineoplastic agent: CB, drug combination
*antineoplastic agent: IT, drug interaction
*antineoplastic agent: DT, drug therapy
*antineoplastic agent: TO, drug toxicity
antineoplastic alkaloid: CB, drug combination
antineoplastic alkaloid: IT, drug interaction
antineoplastic alkaloid: DT, drug therapy
antineoplastic antibiotic: AE, adverse drug reaction
antineoplastic antibiotic: CB, drug combination
antineoplastic antibiotic: IT, drug interaction
antineoplastic antibiotic: DT, drug therapy
antineoplastic antimetabolite: CB, drug combination
antineoplastic antimetabolite: IT, drug interaction
antineoplastic antimetabolite: DT, drug therapy
*antioxidant: AD, drug administration
*antioxidant: CB, drug combination
*antioxidant: DO, drug dose
*antioxidant: IT, drug interaction
*antioxidant: DT, drug therapy
*antioxidant: PD, pharmacology
*ascorbic acid: AD, drug administration
*ascorbic acid: CB, drug combination
*ascorbic acid: DO, drug dose
*ascorbic acid: IT, drug interaction
*ascorbic acid: DT, drug therapy
*ascorbic acid: PD, pharmacology
*beta carotene: AD, drug administration
*beta carotene: CB, drug combination
*beta carotene: DO, drug dose
*beta carotene: IT, drug interaction
*beta carotene: DT, drug therapy
*beta carotene: PD, pharmacology
bleomycin: CB, drug combination
bleomycin: IT, drug interaction
bleomycin: DT, drug therapy
camptothecin derivative: CB, drug combination
camptothecin derivative: IT, drug interaction
camptothecin derivative: DT, drug therapy
*carotenoid: AD, drug administration
*carotenoid: CB, drug combination
*carotenoid: DO, drug dose
*carotenoid: IT, drug interaction
*carotenoid: DT, drug therapy
*carotenoid: PD, pharmacology
cisplatin: AE, adverse drug reaction
cisplatin: CB, drug combination
cisplatin: IT, drug interaction
cisplatin: DT, drug therapy
cisplatin: TO, drug toxicity
doxorubicin: AE, adverse drug reaction
doxorubicin: CB, drug combination
doxorubicin: IT, drug interaction
doxorubicin: DT, drug therapy
ebselen: CB, drug combination
ebselen: DO, drug dose
ebselen: IT, drug interaction

ebselen: DT, drug therapy
epirubicin: AE, adverse drug reaction
epirubicin: CB, drug combination
epirubicin: IT, drug interaction
epirubicin: DT, drug therapy
etoposide: CB, drug combination
etoposide: IT, drug interaction
etoposide: DT, drug therapy
flavonoid: CB, drug combination
flavonoid: DO, drug dose
flavonoid: IT, drug interaction
flavonoid: DT, drug therapy
fluorouracil: CB, drug combination
fluorouracil: IT, drug interaction
fluorouracil: DT, drug therapy
glutathione: CB, drug combination
glutathione: DO, drug dose
glutathione: IT, drug interaction
glutathione: DT, drug therapy
melatonin: CB, drug combination
melatonin: DO, drug dose
melatonin: IT, drug interaction
melatonin: DT, drug therapy
methotrexate: CB, drug combination
methotrexate: IT, drug interaction
methotrexate: DT, drug therapy
paclitaxel: CB, drug combination
paclitaxel: IT, drug interaction
paclitaxel: DT, drug therapy
platinum derivative: AE, adverse drug reaction
platinum derivative: CB, drug combination
platinum derivative: IT, drug interaction
platinum derivative: DT, drug therapy
*retinoic acid: AD, drug administration
*retinoic acid: DO, drug dose
*retinoic acid: DT, drug therapy
*retinoic acid: PD, pharmacology
selenium: CB, drug combination
selenium: DO, drug dose
selenium: IT, drug interaction
selenium: DT, drug therapy
tamoxifen: CB, drug combination
tamoxifen: IT, drug interaction
tamoxifen: DT, drug therapy
ubidecarenone: CB, drug combination
ubidecarenone: DO, drug dose
ubidecarenone: IT, drug interaction
ubidecarenone: DT, drug therapy
unindexed drug

CAS REGISTRY NO.: (acetylcysteine) 616-91-1; (alpha tocopherol) 1406-18-4, 1406-70-8, 52225-20-4, 58-95-7, 59-02-9; (alpha2a interferon) 76543-88-9; (ascorbic acid) 134-03-2, 15421-15-5, 50-81-7; (beta carotene) 7235-40-7; (bleomycin) 11056-06-7; (cisplatin) 15663-27-1, 26035-31-4, 96081-74-2; (doxorubicin) 23214-92-8, 25316-40-9; (ebselen) 60940-34-3; (epirubicin) 56390-09-1, 56420-45-2; (etoposide) 33419-42-0; (fluorouracil) 51-21-8; (glutathione) 70-18-8; (melatonin) 73-31-4; (methotrexate) 15475-56-6, 59-05-2, 7413-34-5; (paclitaxel) 33069-62-4; (retinoic acid) 302-79-4; (selenium) 7782-49-2; (tamoxifen) 10540-29-1;

(ubidecarenone) 303-98-0

L88 ANSWER 37 OF 41 EMBASE COPYRIGHT (c) 2010 Elsevier B.V. All rights reserved on STN

ACCESSION NUMBER: 1987006106 EMBASE Full-text
TITLE: An analytical study on the mechanism of Coenzyme Q10 enhancement of the effect of adriamycin in cultured mouse sarcoma cells.
AUTHOR: Toda, K.
SOURCE: Practica Otologica, (1986) Vol. 79, No. 9, pp. 1515-1529. CODEN: JIBIAG
COUNTRY: Japan
DOCUMENT TYPE: Journal
FILE SEGMENT: 037 Drug Literature Index
LANGUAGE: Japanese
SUMMARY LANGUAGE: English
ENTRY DATE: Entered STN: 11 Dec 1991
Last Updated on STN: 11 Dec 1991
CONTROLLED TERM: Medical Descriptors:
animal cell
*dna synthesis
*dose response
drug response
*flow cytometry
in vitro study
mouse
nonhuman
pharmacokinetics
topical drug administration
CONTROLLED TERM: Drug Descriptors:
*doxorubicin
radioisotope
*ubidecarenone
CAS REGISTRY NO.: (doxorubicin) 23214-92-8, 25316-40-9; (ubidecarenone) 303-98-0

L88 ANSWER 38 OF 41 BIOSIS COPYRIGHT (c) 2010 The Thomson Corporation on STN

ACCESSION NUMBER: 2005:319512 BIOSIS Full-text
DOCUMENT NUMBER: PREV200510114907
TITLE: Topical formulation of coenzyme Q10 inhibits the growth of melanoma tumors.
AUTHOR(S): Narain, N. R. [Reprint Author]; Li, J.; He, J.; Malik, L. H.; Russell, K. J.; Woan, K. V.; Persaud, I.; Hsia, S. L.
CORPORATE SOURCE: Univ Miami, Sch Med, Miami, FL USA
SOURCE: Journal of Investigative Dermatology, (MAR 2004) Vol. 122, No. 3, pp. A160.
Meeting Info.: 65th Annual Meeting of the Society-for-Investigative-Dermatology. Providence, RI, USA. April 28 -May 01, 2004. Soc Investigat Dermatol.
CODEN: JIDEAE. ISSN: 0022-202X.
DOCUMENT TYPE: Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)
LANGUAGE: English
ENTRY DATE: Entered STN: 25 Aug 2005
Last Updated on STN: 25 Aug 2005
CONCEPT CODE: General biology - Symposia, transactions and proceedings 00520
Cytology - Animal 02506
Cytology - Human 02508

Pathology - Therapy 12512
Pharmacology - General 22002
Pharmacology - Clinical pharmacology 22005
Neoplasms - Pathology, clinical aspects and systemic effects 24004
Neoplasms - Therapeutic agents and therapy 24008

INDEX TERMS: Major Concepts
Pharmacology; Tumor Biology

INDEX TERMS: Diseases
melanoma: neoplastic disease
Melanoma (MeSH)

INDEX TERMS: Chemicals & Biochemicals
coenzyme Q10; liposome-encapsulated Q10 cream: antineoplastic-drug, topical administration

INDEX TERMS: Methods & Equipment
transfection: laboratory techniques, genetic techniques; histological examination: laboratory techniques, histology and cytology techniques

ORGANISM: Classifier
Hominidae 86215
Super Taxa
Primates; Mammalia; Vertebrata; Chordata; Animalia
Organism Name
SKMEL28 cell line (cell_line)
Taxa Notes
Animals, Chordates, Humans, Mammals, Primates, Vertebrates

ORGANISM: Classifier
Muridae 86375
Super Taxa
Rodentia; Mammalia; Vertebrata; Chordata; Animalia
Organism Name
mouse (common)
Taxa Notes
Animals, Chordates, Mammals, Nonhuman Vertebrates, Nonhuman Mammals, Rodents, Vertebrates

REGISTRY NUMBER: 303-98-0 (coenzyme Q10)

L88 ANSWER 39 OF 41 BIOSIS COPYRIGHT (c) 2010 The Thomson Corporation on STN

ACCESSION NUMBER: 2003:369491 BIOSIS Full-text
DOCUMENT NUMBER: PREV200300369491
TITLE: Topical coenzyme Q10: comparative absorption and long-term antioxidant effects in human skin of two products with young and older subjects.
AUTHOR(S): Vinson, Joe Allen [Reprint Author]; Anamandla, Sunil
CORPORATE SOURCE: Chemistry, University of Scranton, Linden and Monroe Streets, Scranton, PA, 18510, USA
vinson@uofs.edu; amandlas2@uofs.edu
SOURCE: FASEB Journal, (March 2003) Vol. 17, No. 4-5, pp. Abstract No. 694.4. http://www.fasebj.org/. e-file. Meeting Info.: FASEB Meeting on Experimental Biology: Translating the Genome. San Diego, CA, USA. April 11-15, 2003. FASEB.
ISSN: 0892-6638 (ISSN print).
DOCUMENT TYPE: Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)
LANGUAGE: English
ENTRY DATE: Entered STN: 13 Aug 2003
Last Updated on STN: 13 Aug 2003

Ordered 4/22/10

ABSTRACT:Skin cancer is the fastest growing cancer in the US, and is primarily caused by excessive sun exposure. UV radiation produces free radicals in skin that damage the DNA, initiating the cancer process. Wrinkles are a result of the aging process and are accelerated with sun exposure. Antioxidants in the skin, such as ascorbate, tocopherol, and Coenzyme Q10H2 react with the free radicals and detoxify them before they can cause damage and ultimately cancer. CoQ10 (Q10) is the form contained in cosmetics and capsules for human consumption. The elderly have lower levels of endogenous Q10 than younger subjects. We tested the absorption of two forms of Q10, the pure USP form and yeast (Q10+ from Pharmachem Laboratories). A lotion was prepared that was 1% by weight Q10. 75 mg of lotion was applied to the inner wrist of 9 subjects aged 50 or over, and 9 subjects aged < 30. After 1 hour the lotion was removed and Q10 extracted from the stratum corneum with ethanol and measured by HPLC. Elderly absorbed significantly more Q10 than did the young subjects. For both groups Q10+ was significantly more absorbed than USP. A 1-month study was begun with an initial ethanol extraction followed by twice-daily application of 75 mg of lotion. The two forms of Q10 were made into two lotions that were applied on opposite arms. After 1 month the ethanol extraction was performed. A washout period of one month ensued, followed by another extraction. Both forms significantly increased skin lipids, and significantly decreased skin hydrogen peroxide plus lipid hydroperoxides. Only the Q10+ significantly increased skin antioxidants. Q10+ was significantly more efficacious than USP Q10.

CONCEPT CODE: General biology - Symposia, transactions and proceedings 00520
Pathology - Therapy 12512
Integumentary system - Physiology and biochemistry 18504
Integumentary system - Pathology 18506
Pharmacology - General 22002
Pharmacology - Clinical pharmacology 22005

INDEX TERMS: Major Concepts
Dermatology (Human Medicine, Medical Sciences); Pharmacology

INDEX TERMS: Parts, Structures, & Systems of Organisms
skin: integumentary system

INDEX TERMS: Chemicals & Biochemicals
coenzyme Q10: USP form, comparative absorption, long-term antioxidant effects, topical administration, yeast form

ORGANISM: Classifier
Hominidae 86215
Super Taxa
Primates; Mammalia; Vertebrata; Chordata; Animalia
Organism Name
human (common)
Taxa Notes
Animals, Chordates, Humans, Mammals, Primates, Vertebrates

REGISTRY NUMBER: 303-98-0 (coenzyme Q10)

L88 ANSWER 40 OF 41 BIOSIS COPYRIGHT (c) 2010 The Thomson Corporation on STN

ACCESSION NUMBER: 1987:424327 BIOSIS Full-text
DOCUMENT NUMBER: PREV198784090989; BA84:90989
TITLE: TOPICAL COENZYME Q10 COQ 10 IN A PATIENT WITH RADIATION ULCERS.
AUTHOR(S): SUGAI T [Reprint author]; ASOH S
CORPORATE SOURCE: DEP DERMATOL, OSAKA KAISEI HOSP, OHYODO, OSAKA, JPN 531
SOURCE: Hifu, (1987) Vol. 29, No. 2, pp. 326-329.
CODEN: HIFUAG. ISSN: 0018-1390.

Ordered 4/22/10

DOCUMENT TYPE: Article
FILE SEGMENT: BA
LANGUAGE: JAPANESE
ENTRY DATE: Entered STN: 9 Oct 1987
Last Updated on STN: 9 Oct 1987

ABSTRACT:A 78-year-old woman had been treated due to late radiodermatitis on the hypogastric and gluteal regions these 11 years. She had received 60Co-radiation nine times over a period of 3 years, following an operation of uterus cancer in her 50 years of age. The total amount of radiation was unknown. She had been suffering from ulcers on the gluteal regions since 55 years in age. Since May, 1985, 0.5% ubiquinone (CoQ 10) ointment has been applied topically to the intractable ulcers, which were getting smaller and cleared 1 year later. The ointment seems to possess a specific effect on radiation ulcer, because it is found to be ineffective on the other ulcers, such as leg ulcers and decubital ulcers.

CONCEPT CODE: Radiation biology - Radiation effects and protective measures 06506
Biochemistry studies - Proteins, peptides and amino acids 10064
Enzymes - General and comparative studies: coenzymes 10802
Pathology - Inflammation and inflammatory disease 12508
Pathology - Therapy 12512
Integumentary system - Pathology 18506
Pharmacology - Clinical pharmacology 22005
Pharmacology - Integumentary system, dental and oral biology 22020

INDEX TERMS: Major Concepts
Biochemistry and Molecular Biophysics; Dermatology (Human Medicine, Medical Sciences); Enzymology (Biochemistry and Molecular Biophysics); Pathology; Pharmacology

INDEX TERMS: Miscellaneous Descriptors
HUMAN DERMATOLOGICAL-DRUG RADIOTHERAPY

ORGANISM: Classifier
Hominidae 86215
Super Taxa
Primates; Mammalia; Vertebrata; Chordata; Animalia
Taxa Notes
Animals, Chordates, Humans, Mammals, Primates, Vertebrates

REGISTRY NUMBER: 303-98-0 (COENZYME Q10)
303-98-0 (COQ 10)

L88 ANSWER 41 OF 41 BIOSIS COPYRIGHT (c) 2010 The Thomson Corporation on STN

ACCESSION NUMBER: 1984:284579 BIOSIS Full-text
DOCUMENT NUMBER: PREV198478021059; BA78:21059
TITLE: DOXORUBICIN INDUCED SKIN ULCER IN THE PIGLET.
AUTHOR(S): OKANO T [Reprint author]; OHNUMA T; EFREMIDIS A; HOLLAND J F
CORPORATE SOURCE: DEP OF NEOPLASTIC DISEASES, MOUNT SINAI SCH OF MED, 1 GUSTAVE L LEVY P1, NEW YORK, NY 10029, USA
SOURCE: Cancer Treatment Reports, (1983) Vol. 67, No. 12, pp. 1075-1078.
CODEN: CTRRDO. ISSN: 0361-5960.
DOCUMENT TYPE: Article
FILE SEGMENT: BA
LANGUAGE: ENGLISH

ABSTRACT:Skin ulceration produced by inadvertently extravasated doxorubicin is

characterized by a prolonged course accompanied by severe morbidity, and it has proven to be notoriously difficult to treat. In attempts to identify possible antidotes, 11 different pharmacologic agents [carnitine, coenzyme Q10, deferoxamine mesylate, dimethyl sulfoxide (DMSO), dopamine, DNA type V, human serum albumin, iron dextran, isoproterenol, NaHCO3, α-tocopherol] were tested using piglets, because their skin is anatomically similar to that of man. Among the agents studied, topical application of DMSO daily for 7 days tended to decrease the maximal diameter and accelerate healing of skin ulcers produced by intradermal doxorubicin. α-Tocopherol appeared to worsen the ulceration. None of the 11 agents studied prevented the development of ulcerations completely.

CONCEPT CODE: Biochemistry studies - General 10060
Biochemistry studies - Nucleic acids, purines and pyrimidines 10062
Biochemistry studies - Vitamins 10063
Biochemistry studies - Proteins, peptides and amino acids 10064
Biochemistry studies - Lipids 10066
Biochemistry studies - Carbohydrates 10068
Biochemistry studies - Minerals 10069
Enzymes - General and comparative studies: coenzymes 10802
Pathology - Inflammation and inflammatory disease 12508
Pathology - Therapy 12512
Blood - Blood and lymph studies 15002
Integumentary system - General and methods 18501
Integumentary system - Pathology 18506
Pharmacology - Integumentary system, dental and oral biology 22020
Routes of immunization, infection and therapy 22100
Toxicology - Pharmacology 22504
Toxicology - Antidotes and prevention 22505
Neoplasms - Therapeutic agents and therapy 24008
Chemotherapy - General, methods and metabolism 38502

INDEX TERMS: Major Concepts
Integumentary System (Chemical Coordination and Homeostasis); Pathology; Pharmacology; Toxicology; Tumor Biology

INDEX TERMS: Miscellaneous Descriptors
CARNITINE COENZYME Q-10 DEFEROXAMINE MESYLATE DI METHYL SULFOXIDE DOPAMINE DNA HUMAN SERUM ALBUMIN IRON DEXTRAN ISOPROTERENOL SODIUM BI CARBONATE ALPHA TOCOPHEROL ANTIDOTE ANTINEOPLASTIC-DRUG DRUG EXTRAVASATION/

ORGANISM: Classifier
Suidae 85740
Super Taxa
Artiodactyla; Mammalia; Vertebrata; Chordata; Animalia
Taxa Notes
Animals, Artiodactyls, Chordates, Mammals, Nonhuman Vertebrates, Nonhuman Mammals, Vertebrates

REGISTRY NUMBER: 23214-92-8 (DOXORUBICIN)
541-15-1 (CARNITINE)
303-98-0 (COENZYME Q-10)
138-14-7 (DEFEROXAMINE MESYLATE)
67-68-5 (DIMETHYL SULFOXIDE)
51-61-6 (DOPAMINE)
9004-66-4 (IRON DEXTRAN)
7683-59-2 (ISOPROTERENOL)
144-55-8 (SODIUM BICARBONATE)
59-02-9 (ALPHA-TOCOPHEROL)

```
=> d his full

     (FILE 'HOME' ENTERED AT 11:17:49 ON 29 MAR 2010)

     FILE 'ZCAPLUS' ENTERED AT 11:20:47 ON 29 MAR 2010
                E US2008-597378/APPS
L1             1 SEA SPE=ON  ABB=ON  PLU=ON  US2008-597378/AP
                D SCA

     FILE 'REGISTRY' ENTERED AT 11:22:03 ON 29 MAR 2010
L2             2 SEA SPE=ON  ABB=ON  PLU=ON  COENZYME Q/CN OR 303-98-0
                D SCA
                D IDE 1
L3             0 SEA SPE=ON  ABB=ON  PLU=ON  UBIQUINONE/CN
                E UBIQUINONE/CN
L4            15 SEA SPE=ON  ABB=ON  PLU=ON  UBIQUINONE###/CN
                D SCA
                D SCA L2
                D IDE L2 1-2
                E UBIQUINONE/CN
L5             2 SEA SPE=ON  ABB=ON  PLU=ON  UBIQUINONE 10/CN
                D SCA
                D IDE 1-2
                E COENZYMEQ10/CN
                E COENZYME Q10/CN
L6             1 SEA SPE=ON  ABB=ON  PLU=ON  COENZYME Q10/CN
L7             5 SEA SPE=ON  ABB=ON  PLU=ON  COENZYME Q10?/CN
                D SCA L6
                D SCA L7
                D SCA L6
L8             2 SEA SPE=ON  ABB=ON  PLU=ON  L7 AND C59 H90 O4/MF
                D SCA
L9             3 SEA SPE=ON  ABB=ON  PLU=ON  L7 NOT L8
                D SCA
                D SCA L2
L10            3 SEA SPE=ON  ABB=ON  PLU=ON  L2 OR L8
L11           17 SEA SPE=ON  ABB=ON  PLU=ON  (L4 OR L5 OR L6 OR L7) NOT L8
                D SCA
L12            1 SEA SPE=ON  ABB=ON  PLU=ON  L11 AND ?DIOL?/CNS
                D SCA
L13           16 SEA SPE=ON  ABB=ON  PLU=ON  L11 NOT L12
                D SCA
                SEL RN L8
L14           58 SEA SPE=ON  ABB=ON  PLU=ON  (27696-12-4/CRN OR 303-98-0/CRN)
                D RN L8 1
                D IDE L8 1
                D IDE L8 2
L15               STRUCTURE UPLOADED
L16            5 SEA FAM SAM L15
                D SCA
L17           83 SEA FAM FUL L15
L18           81 SEA SPE=ON  ABB=ON  PLU=ON  L17 NOT L8
L19            0 SEA SPE=ON  ABB=ON  PLU=ON  L18 AND L12

     FILE 'ZCAPLUS' ENTERED AT 11:50:03 ON 29 MAR 2010
L20         5712 SEA SPE=ON  ABB=ON  PLU=ON  L17
L21         2380 SEA SPE=ON  ABB=ON  PLU=ON  L17 (L) (THU OR DMA OR BAC OR PKT
                 OR PAC OR FFD)/RL
```

```
L22      139854 SEA SPE=ON  ABB=ON  PLU=ON  (?LEUKAEM?/BI OR ?LEUKEM?/BI)
L23      502215 SEA SPE=ON  ABB=ON  PLU=ON  ?CANCER?/BI
L24      781886 SEA SPE=ON  ABB=ON  PLU=ON  ?TUMOUR?/BI OR ?TUMOR?/BI
L25       62114 SEA SPE=ON  ABB=ON  PLU=ON  ?SARCOMA?/BI
L26      645501 SEA SPE=ON  ABB=ON  PLU=ON  ?NEOPLAS?/BI
L27      360843 SEA SPE=ON  ABB=ON  PLU=ON  ?CARCINO?/BI
L28       28213 SEA SPE=ON  ABB=ON  PLU=ON  ?MYELOM?/BI
L29       52342 SEA SPE=ON  ABB=ON  PLU=ON  ?LYMPHOMA?/BI
L30       46413 SEA SPE=ON  ABB=ON  PLU=ON  ?MELANOM?/BI
L31       66132 SEA SPE=ON  ABB=ON  PLU=ON  ?ANGIOGEN?/BI
L32      200452 SEA SPE=ON  ABB=ON  PLU=ON  CELL PROLIFER?/BI
L33         311 SEA SPE=ON  ABB=ON  PLU=ON  L21 AND (L22 OR L23 OR L24 OR L25
                OR L26 OR L27 OR L28 OR L29 OR L30 OR L31 OR L32)
L34         123 SEA SPE=ON  ABB=ON  PLU=ON  L33 AND P/DT AND (PRD<20050121 OR
                PD<20050121 OR AD<20050121)
L35         166 SEA SPE=ON  ABB=ON  PLU=ON  L33 AND PY<2006
L*** DEL    131 S L33 AND PY<2005
L36         183 SEA SPE=ON  ABB=ON  PLU=ON  (L34 OR L35)
L37          30 SEA SPE=ON  ABB=ON  PLU=ON  L36 AND ?TOPICAL?/BI

     FILE 'MEDLINE, EMBASE, BIOSIS' ENTERED AT 11:59:53 ON 29 MAR 2010

     FILE 'REGISTRY' ENTERED AT 11:59:59 ON 29 MAR 2010
                SET SMARTSELECT ON
L38             SEL PLU=ON  L17 1- CHEM :     120 TERMS
                SET SMARTSELECT OFF

     FILE 'MEDLINE, EMBASE, BIOSIS' ENTERED AT 12:00:12 ON 29 MAR 2010
L39       10721 SEA SPE=ON  ABB=ON  PLU=ON  L38
L40        1098 SEA SPE=ON  ABB=ON  PLU=ON  L39 AND (L22 OR L23 OR L24 OR L25
                OR L26 OR L27 OR L28 OR L29 OR L30 OR L31 OR L32)
L41          34 SEA SPE=ON  ABB=ON  PLU=ON  L40 AND ?TOPICAL?
L42          23 SEA SPE=ON  ABB=ON  PLU=ON  L39 (L) TP/CT
L43          14 SEA SPE=ON  ABB=ON  PLU=ON  L40 AND ?TOPICAL?/AB,TI
L44          11 SEA SPE=ON  ABB=ON  PLU=ON  L40 AND L42
L45          21 SEA SPE=ON  ABB=ON  PLU=ON  (L43 OR L44)
L46          13 SEA SPE=ON  ABB=ON  PLU=ON  L41 NOT L45
L47          27 SEA SPE=ON  ABB=ON  PLU=ON  L40 AND TOPICAL DRUG ADMINISTRATION
                /CT

     FILE 'ZCAPLUS' ENTERED AT 12:08:06 ON 29 MAR 2010
                SET NOTICE OFF DISPLAY
                SET NOTICE OFF SEARCH
L48         228 SEA SPE=ON  ABB=ON  PLU=ON  HSIA S?/AU,AUTH
L49          89 SEA SPE=ON  ABB=ON  PLU=ON  NARAIN N?/AU,AUTH
L50       81413 SEA SPE=ON  ABB=ON  PLU=ON  LI J?/AU,AUTH
L51         704 SEA SPE=ON  ABB=ON  PLU=ON  RUSSELL K?/AU,AUTH
L52           5 SEA SPE=ON  ABB=ON  PLU=ON  WOAN K?/AU,AUTH
L53           9 SEA SPE=ON  ABB=ON  PLU=ON  PERSAUD I?/AU,AUTH
L54           1 SEA SPE=ON  ABB=ON  PLU=ON  L48 AND L49 AND L50 AND L51 AND
                L52 AND L53
L55           2 SEA SPE=ON  ABB=ON  PLU=ON  L48 AND (L49 OR L50 OR L51 OR L52
                OR L53)
L56           6 SEA SPE=ON  ABB=ON  PLU=ON  L49 AND (L50 OR L51 OR L52 OR L53)

L57           6 SEA SPE=ON  ABB=ON  PLU=ON  L50 AND (L51 OR L52 OR L53)
L58           1 SEA SPE=ON  ABB=ON  PLU=ON  L51 AND (L52 OR L53)
L59           1 SEA SPE=ON  ABB=ON  PLU=ON  L52 AND L53
L60          11 SEA SPE=ON  ABB=ON  PLU=ON  L55 OR L56 OR L57 OR L58 OR L59
```

```
     FILE 'MEDLINE, EMBASE, BIOSIS, WPIX' ENTERED AT 12:09:06 ON 29 MAR 2010
L61          862 SEA SPE=ON  ABB=ON  PLU=ON  HSIA S?/AU,AUTH
L62          107 SEA SPE=ON  ABB=ON  PLU=ON  NARAIN N?/AU,AUTH
L63        92982 SEA SPE=ON  ABB=ON  PLU=ON  LI J?/AU,AUTH
L64         1996 SEA SPE=ON  ABB=ON  PLU=ON  RUSSELL K?/AU,AUTH
L65           16 SEA SPE=ON  ABB=ON  PLU=ON  WOAN K?/AU,AUTH
L66           28 SEA SPE=ON  ABB=ON  PLU=ON  PERSAUD I?/AU,AUTH
L67            8 SEA SPE=ON  ABB=ON  PLU=ON  L61 AND L62 AND L63 AND L64 AND
                 L65 AND L66
L68           11 SEA SPE=ON  ABB=ON  PLU=ON  L61 AND (L62 OR L63 OR L64 OR L65
                 OR L66)
L69           19 SEA SPE=ON  ABB=ON  PLU=ON  L62 AND (L63 OR L64 OR L65 OR L66)

L70           28 SEA SPE=ON  ABB=ON  PLU=ON  L63 AND (L64 OR L65 OR L66)
L71           10 SEA SPE=ON  ABB=ON  PLU=ON  L64 AND (L65 OR L66)
L72            8 SEA SPE=ON  ABB=ON  PLU=ON  L65 AND L66
L73           38 SEA SPE=ON  ABB=ON  PLU=ON  L68 OR L69 OR L70 OR L71 OR L72
L74           11 SEA SPE=ON  ABB=ON  PLU=ON  L68 AND (L69 OR L70 OR L71 OR L72)

L75           10 SEA SPE=ON  ABB=ON  PLU=ON  L69 AND (L70 OR L71 OR L72)
L76            9 SEA SPE=ON  ABB=ON  PLU=ON  L70 AND (L71 OR L72)
L77            8 SEA SPE=ON  ABB=ON  PLU=ON  L71 AND L72
L78           11 SEA SPE=ON  ABB=ON  PLU=ON  L74 OR L75 OR L76 OR L77
                 SET NOTICE LOGIN DISPLAY
                 SET NOTICE LOGIN SEARCH

     FILE 'MEDLINE, EMBASE, BIOSIS' ENTERED AT 12:09:50 ON 29 MAR 2010
L79           11 SEA SPE=ON  ABB=ON  PLU=ON  L41 AND PY<2006
L80            2 SEA SPE=ON  ABB=ON  PLU=ON  L41 AND (L61 OR L62 OR L63 OR L64
                 OR L65 OR L66)
L81           29 SEA SPE=ON  ABB=ON  PLU=ON  L39 AND (L61 OR L62 OR L63 OR L64
                 OR L65 OR L66)
L82           12 SEA SPE=ON  ABB=ON  PLU=ON  L40 AND (L61 OR L62 OR L63 OR L64
                 OR L65 OR L66)

     FILE 'ZCAPLUS' ENTERED AT 12:12:55 ON 29 MAR 2010
L83           18 SEA SPE=ON  ABB=ON  PLU=ON  (L48 OR L49 OR L50 OR L51 OR L52
                 OR L53) AND L17
L84            4 SEA SPE=ON  ABB=ON  PLU=ON  (L48 OR L49 OR L50 OR L51 OR L52
                 OR L53) AND L33

     FILE 'REGISTRY' ENTERED AT 12:14:21 ON 29 MAR 2010

     FILE 'ZCAPLUS' ENTERED AT 12:14:24 ON 29 MAR 2010
                 D STAT QUE L60
                 D STAT QUE L83
                 D STAT QUE L84
L85           24 SEA SPE=ON  ABB=ON  PLU=ON  L60 OR L83 OR L84

     FILE 'MEDLINE, EMBASE, BIOSIS, WPIX' ENTERED AT 12:15:03 ON 29 MAR 2010
                 D STAT QUE L78

     FILE 'MEDLINE, EMBASE, BIOSIS' ENTERED AT 12:16:16 ON 29 MAR 2010
                 D STAT QUE L80
                 D STAT QUE L82
L86           12 SEA SPE=ON  ABB=ON  PLU=ON  L80 OR L82

     FILE 'MEDLINE, EMBASE, BIOSIS, WPIX' ENTERED AT 12:17:03 ON 29 MAR 2010
                 D STAT QUE L78
```

```
     FILE 'ZCAPLUS, BIOSIS, WPIX' ENTERED AT 12:17:18 ON 29 MAR 2010
L87            37 DUP REM L85 L86 L78 (10 DUPLICATES REMOVED)
                      ANSWERS '1-24' FROM FILE ZCAPLUS
                      ANSWERS '25-37' FROM FILE BIOSIS
                  D IBIB ABS HITIND HITSTR L87 1-24
                  D IALL L87 25-37

     FILE 'REGISTRY' ENTERED AT 12:18:59 ON 29 MAR 2010

     FILE 'ZCAPLUS' ENTERED AT 12:19:03 ON 29 MAR 2010
                  D STAT QUE L37

     FILE 'MEDLINE, EMBASE, BIOSIS' ENTERED AT 12:19:18 ON 29 MAR 2010
                  D STAT QUE L79

     FILE 'ZCAPLUS, EMBASE, BIOSIS' ENTERED AT 12:19:26 ON 29 MAR 2010
L88            41 DUP REM L37 L79 (0 DUPLICATES REMOVED)
                      ANSWERS '1-30' FROM FILE ZCAPLUS
                      ANSWERS '31-37' FROM FILE EMBASE
                      ANSWERS '38-41' FROM FILE BIOSIS
                  D IBIB ABS HITIND HITSTR L88 1-30
                  D IALL L88 31-41


     FILE HOME

     FILE ZCAPLUS

     Copyright of the articles to which records in this database refer is
     held by the publishers listed in the PUBLISHER (PB) field (available
     for records published or updated in Chemical Abstracts after December
     26, 1996), unless otherwise indicated in the original publications.
     The CA Lexicon is the copyrighted intellectual property of the
     American Chemical Society and is provided to assist you in searching
     databases on STN.  Any dissemination, distribution, copying, or storing
     of this information, without the prior written consent of CAS is
     strictly prohibited.

     FILE COVERS 1907 - 29 Mar 2010  VOL 152 ISS 14
     FILE LAST UPDATED: 28 Mar 2010  (20100328/ED)
     REVISED CLASS FIELDS (/NCL) LAST RELOADED:  Dec 2009
     USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE:  Dec 2009

     ZCAplus now includes complete International Patent Classification (IPC)
     reclassification data for the first quarter of 2010.

     CAS Information Use Policies apply and are available at:

     http://www.cas.org/legal/infopolicy.html

     This file contains CAS Registry Numbers for easy and accurate
     substance identification.

     FILE REGISTRY
     Property values tagged with IC are from the ZIC/VINITI data file
     provided by InfoChem.

     STRUCTURE FILE UPDATES:   28 MAR 2010  HIGHEST RN 1214990-69-8
     DICTIONARY FILE UPDATES:  28 MAR 2010  HIGHEST RN 1214990-69-8
```

```
New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 8, 2010.

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

FILE MEDLINE
 FILE LAST UPDATED: 27 Mar 2010 (20100327/UP).  FILE COVERS 1949 TO DATE.

 MEDLINE and LMEDLINE have been updated with the 2010 Medical Subject
 Headings (MeSH) vocabulary and tree numbers from the U.S.  National Libra
 of Medicine (NLM).  Additional information is available at

 http://www.nlm.nih.gov/pubs/techbull/nd09/nd09_medline_data_changes_2010.

 The Medline file has been reloaded effective January 24, 2010.  See HELP
 RLOAD for details.

 This file contains CAS Registry Numbers for easy and accurate
 substance identification.

 See HELP RANGE before carrying out any RANGE search.

FILE EMBASE
 FILE COVERS 1974 TO 26 Mar 2010 (20100326/ED)

 EMBASE is now updated daily.  SDI frequency remains weekly (default)
 and biweekly.

 This file contains CAS Registry Numbers for easy and accurate
 substance identification.

 For further assistance, please contact your local helpdesk.

FILE BIOSIS
FILE COVERS 1926 TO DATE.
CAS REGISTRY NUMBERS AND CHEMICAL NAMES (CNs) PRESENT
FROM JANUARY 1926 TO DATE.

RECORDS LAST ADDED: 24 March 2010 (20100324/ED)

BIOSIS has been augmented with 1.8 million archival records from 1926
through 1968.  These records have been re-indexed to match current
BIOSIS indexing.

FILE WPIX
FILE LAST UPDATED:          26 MAR 2010   <20100326/UP>
MOST RECENT UPDATE:          201021       <201021/DW>
DERWENT WORLD PATENTS INDEX SUBSCRIBER FILE, COVERS 1963 TO DATE
>>> Now containing more than 1.5 million chemical structures in DCR <<<

>>> IPC, ECLA, US National Classifications and Japanese F-Terms
```

and FI-Terms have been updated with reclassifications to
end of December 2009.
No update date (UP) has been created for the reclassified
documents, but they can be identified by
specific update codes (see HELP CLA for details) <<<

>>> FOR THE LATEST DERWENT WORLD PATENTS INDEX (DWPI)
STN USER DOCUMENTATION, PLEASE VISIT:
http://www.stn-international.com/stn_dwpi.html <<<

>>> HELP for European Patent Classifications see HELP ECLA, HELP ICO <<<

>>> Japanese FI-TERM thesaurus in field /FCL added <<<

>>> New display format ALLSTR available - see NEWS <<<

>>> US National Patent Classification thesaurus added - see NEWS <<<

=>
Uploading L15.str



chain nodes :
1 2 3 4 5 6 7 8 9 16 17 18 19 20 21 22 23 24 25 26 27 28 29
30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50
51 52 53 54
55 56 57 58 59 60 61
ring nodes :
10 11 12 13 14 15
chain bonds :
1-12 2-18 3-22 4-26 5-30 6-14 7-15 8-11 9-13 10-16 16-17 17-18 18-19
19-20 20-21 21-22 22-23 23-24 24-25 25-26 26-27 27-28 28-29 29-30 30-55
31-37 32-41
33-45 34-49 35-53 36-37 36-56 37-38 38-39 39-40 40-41 41-42 42-43 43-44
44-45 45-46 46-47
47-48 48-49 49-50 50-51 51-52 52-53 53-54 54-57 55-56 57-59 58-59 58-60
58-61
ring bonds :
10-11 10-12 11-13 12-14 13-15 14-15
exact/norm bonds :
6-14 8-11 10-11 10-12 11-13 12-14 13-15 14-15
exact bonds :
1-12 2-18 3-22 4-26 5-30 7-15 9-13 10-16 16-17 17-18 18-19 19-20 20-21
21-22 22-23 23-24 24-25 25-26 26-27 27-28 28-29 29-30 30-55 31-37 32-41
33-45 34-49
35-53 36-37 36-56 37-38 38-39 39-40 40-41 41-42 42-43 43-44 44-45 45-46
46-47 47-48
48-49 49-50 50-51 51-52 52-53 53-54 54-57 55-56 57-59 58-59 58-60 58-61

```
Match level :
1:CLASS  2:CLASS  3:CLASS  4:CLASS  5:CLASS  6:CLASS  7:CLASS  8:CLASS  9:CLASS
10:Atom  11:Atom  12:Atom  13:Atom  14:Atom  15:Atom  16:CLASS  17:CLASS  18:CLASS
19:CLASS  20:CLASS
21:CLASS  22:CLASS  23:CLASS  24:CLASS  25:CLASS  26:CLASS  27:CLASS  28:CLASS
29:CLASS  30:CLASS
31:CLASS  32:CLASS  33:CLASS  34:CLASS  35:CLASS  36:CLASS  37:CLASS  38:CLASS
39:CLASS  40:CLASS
41:CLASS  42:CLASS  43:CLASS  44:CLASS  45:CLASS  46:CLASS  47:CLASS  48:CLASS
49:CLASS  50:CLASS
51:CLASS  52:CLASS  53:CLASS  54:CLASS  55:CLASS  56:CLASS  57:CLASS  58:CLASS
59:CLASS  60:CLASS
61:CLASS
```